{"id":"F2024L00589","name":"Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024","slug":"therapeutic-goods-poisons-standard-june-2024-instrument-2024","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":442399,"registerId":"F2024L00589-fast-fetch-1775957406907","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"Part 1","sectionType":"part","heading":"Preliminary and interpretation","content":"Part 1—Preliminary and interpretation\n\n1  Name \n\n2  Commencement\n\n3  Authority\n\n4  Repeal and transitional provisions\n\n5  Reader’s guide and Index\n\n6  Definitions\n\n7  References to substances\n\n8  References to concentration, strength or quantity of substances\n\n9  References to boiling or distillation temperatures\n\n10  References to standards\n\nPart 2—Controls on substances\n\nDivision 1—Preliminary\n\n11  Application of Part 2\n\n12  Preparations containing poisons included in different schedules\n\nDivision 2—Labels\n\nSubdivision A—General\n\n","sortOrder":0},{"sectionNumber":"13","sectionType":"section","heading":"General requirements","content":"13  General requirements\n\n","sortOrder":1},{"sectionNumber":"14","sectionType":"section","heading":"Immediate wrapper","content":"14  Immediate wrapper\n\nSubdivision B—Primary packs and immediate containers\n\n15  Primary packs and immediate containers\n\n16  Signal words\n\n17  Cautionary statement—possession without authority illegal\n\n18  Cautionary statement—keep out of reach of children\n\n19  Cautionary statement—fire and explosion hazard\n\n20  Cautionary statement—burns skin and throat\n\n21  Cautionary statements for aqueous solution of paraquat\n\n22  Cautionary statement—read safety directions\n\n23  Cautionary statement—flammable\n\n24  Cautionary statement—for animal treatment only\n\n25  Cautionary statement—do not swallow\n\n26  Approved name and quantity, proportion or strength\n\n27  Statement—an anticholinesterase compound\n\n28  Directions for use\n\n29  Safety directions\n\n30  Warning statements\n\n31  First aid\n\n32  Name and address of manufacturer or distributor\n\n33  Warning statements and sedation warnings for certain medicines for human use\n\nSubdivision C—Statements of quantity, proportion or strength\n\n","sortOrder":2},{"sectionNumber":"34","sectionType":"section","heading":"Statements of quantity, proportion or strength","content":"34  Statements of quantity, proportion or strength\n\nSubdivision D—Exemptions from labelling requirements\n\n35  Selected containers and measure packs\n\n36  Ampoules, pre‑filled syringes and injection vials\n\n37  Transport containers and wrappings\n\n38  Dispensary, industrial, laboratory and manufacturing poisons\n\n39  Exemptions from label requirements in certain circumstances\n\n40  Dispensed medicines\n\n41  Gas cylinders\n\n42  Paints\n\n43  Camphor and naphthalene\n\nSubdivision E—Prohibitions\n\n44  Prohibitions\n\nDivision 3—Containers\n\n45  General requirements\n\n46  Containers for poisons other than poisons included in Schedule 5\n\n47  Containers for poisons included in Schedule 5\n\n48  Approved containers\n\n49  Child‑resistant closures\n\n50  Poisons included in Schedule 8\n\n51  Exemptions\n\n52  Camphor and naphthalene\n\n53  Prohibitions—use of containers for poisons\n\nDivision 4—Storage\n\n54  General storage requirements\n\nDivision 5—Disposal\n\n55  General disposal requirements\n\nDivision 6—Record keeping\n\n56  General record‑keeping requirements\n\nDivision 7—Advertising\n\n57  General advertising requirements\n\nDivision 8—Supply, prescribing, possession or use\n\n58  Poisons included in Schedule 2\n\n59  Poisons included in Schedule 3\n\n60  Poisons included in Schedule 4\n\n61  Poisons included in Schedules 5 and 6\n\n62  Poisons included in Schedule 7\n\n63  Poisons included in Schedule 10\n\n64  Poisons included in Schedule 4 or 8 and Appendix D\n\n65  Hawking\n\nDivision 9—Paints and tinters\n\n66  General requirements\n\n67  Definition of first group paint\n\n68  Definition of second group paint\n\nSchedule 1—Blank\n\nSchedule 2—Pharmacy medicines\n\nSchedule 3—Pharmacist only medicines\n\nSchedule 4—Prescription only medicines and prescription animal remedies\n\nSchedule 5—Caution\n\nSchedule 6—Poisons\n\nSchedule 7—Dangerous poisons\n\nSchedule 8—Controlled drugs\n\nSchedule 9—Prohibited substances\n\nSchedule 10—Substances of such danger to health as to warrant prohibition of supply and use\n\nAppendix A—General exemptions\n\n","sortOrder":3},{"sectionNumber":"1","sectionType":"section","heading":"Exempt preparations and products","content":"1  Exempt preparations and products\n\nAppendix B—Substances considered not to require control by scheduling\n\n1  Reasons for including substances in the table in clause 3\n\n2  Areas of use in relation to substances included in the table in clause 3\n\n3  Substances exempt in certain uses\n\nAppendix C—Blank\n\nAppendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8\n\n1  Poisons available for human use only from or on the prescription or order of an authorised medical practitioner\n\n","sortOrder":4},{"sectionNumber":"2","sectionType":"section","heading":"Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist","content":"2  Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist\n\n3  Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act\n\n4  Poisons available only from or on the order of a specialist physician\n\n5  Poisons for which possession without authority is illegal\n\n6  Poisons available for human use only from or on the prescription or order of a specialist physician\n\n7  Poisons available for human use only from or on the prescription or order of a dermatologist\n\n8  Poisons available for initial treatment of a patient only if authorised by certain health practitioners\n\n9  Poisons which must be stored in a locked container to prevent unauthorised access\n\n10  Poisons available only when prescribed or authorised in certain circumstances\n\nAppendix E—First aid instructions for poisons\n\n1  Standard statements for first aid instructions\n\n2  Poisons information centre contact information in statements\n\n3  First aid instructions for poisons\n\nAppendix F—Warning statements and general safety directions for poisons\n\n1  Warning statements\n\n2  Safety directions—general\n\n3  Poisons information centre contact information in statements\n\n4  Poisons that must be labelled with warning statements and safety directions\n\nAppendix G—Dilute preparations\n\n1  Substances exempt at or below certain concentrations\n\nAppendix H—Schedule 3 medicines permitted to be advertised\n\n1  Schedule 3 medicines permitted to be advertised\n\nAppendix I—Blank\n\nAppendix J—Conditions for availability and use of certain poisons included in Schedule 7\n\n1  Conditions for supply of certain poisons included in Schedule 7\n\nAppendix K—Human medicines required to be labelled with a sedation warning\n\n1  Human medicines required to be labelled with a sedation warning\n\nAppendix L—Requirements for dispensing labels for medicines\n\n1  General\n\n2  Additional warning statements for certain human medicines\n\nAppendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist\n\nIndex  363\n\nReader’s guide\n\n \n\nIntroduction\n\nThis instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989 (the Act), and is a compilation of decisions made under section 52D of the Act. This instrument should be read in conjunction with the Scheduling Policy Framework (the SPF) of the Australian Health Ministers’ Advisory Council. Further information on the scheduling amendments and the SPF can be viewed on the Therapeutic Goods Administration’s website (www.tga.gov.au). Refer to section 6 for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine).\n\nThis instrument serves 2 key purposes.\n\nFirstly, this instrument contains the decisions of the Secretary of the Department of Health and Aged Care or the Secretary’s delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes.\n\nSecondly, this instrument includes provisions for labelling, containers, storage, disposal, record‑keeping, supply and possession of poisons in general which are intended to be adopted for use in each jurisdiction of Australia. Other government agencies may also impose controls on certain products.\n\nThe requirements for labelling and containers in this instrument are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation.\n\nPoisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in this instrument as they are covered by labelling requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time. Note, however that this exemption does not extend to controls on supply of these poisons.\n\nThis instrument is presented with a view to promoting uniform:\n\n- scheduling of poisons throughout Australia; and\n- signal headings on labels for poisons throughout Australia; and\n- labelling and packaging requirements for poisons throughout Australia; and\n- additional controls on the availability and use of poisons in Australia.\n\nThe various Commonwealth Acts, legislative instruments and other documents, which integrate with this instrument include the following:\n\n- the Act;\n- the Agricultural and Veterinary Chemicals Code Act 1994;\n- the Agricultural and Veterinary Chemicals Code Regulations 1995;\n- the Therapeutic Goods Order No. 91 ‑ Standard for labels of prescription and related medicines;\n- the Therapeutic Goods Order No. 92 ‑ Standard for labels of non‑prescription medicines;\n- the Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017;\n- the Therapeutic Goods Order No. 95 ‑ Child‑resistant packaging requirements for medicines 2017 (TGO 95);\n- the Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021;\n- the Therapeutic Goods (Medicines Advisory Statements) Specification 2021 – Schedule 1 Required Advisory Statements for Medicine Labels No. 6 (RASML).\n\nClassification\n\nPoisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with each relevant State or Territory authority.\n\n \n\n| Schedule | Title | Description |\n| --- | --- | --- |\n| Schedule 1 | Blank | This Schedule is intentionally blank. |\n| Schedule 2 | Pharmacy medicines | Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person. |\n| Schedule 3 | Pharmacist only medicines | Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription. |\n| Schedule 4 | Prescription only medicines and prescription animal remedies | Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription. |\n| Schedule 5 | Caution | Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label. |\n| Schedule 6 | Poisons | Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label. |\n| Schedule 7 | Dangerous poisons | Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply. |\n| Schedule 8 | Controlled drugs | Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence. |\n| Schedule 9 | Prohibited substances | Substances which may be abused or misused, the manufacture, possession, supply or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. |\n| Schedule 10 (previously Appendix C) | Substances of such danger to health as to warrant prohibition of supply and use | Substances which are prohibited for the purpose or purposes listed for each poison. |\n\nPrinciples of scheduling\n\nPoisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.\n\nThis instrument lists poisons in 10 Schedules according to the degree of control recommended to be exercised over their availability to the public.\n\nPoisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls.\n\nFor some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7. Products for domestic use must not include poisons listed in Schedule 7.\n\n","sortOrder":5},{"sectionNumber":"Sch 9","sectionType":"schedule","heading":"contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this instrument, the method by which it is implemented in the States and Territories may vary.","content":"Schedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this instrument, the method by which it is implemented in the States and Territories may vary.\n\n","sortOrder":6},{"sectionNumber":"Sch 10","sectionType":"schedule","heading":"(previously Appendix C) contains a list of substances or preparations, the supply or use of which should be prohibited because of their known dangerous properties.","content":"Schedule 10 (previously Appendix C) contains a list of substances or preparations, the supply or use of which should be prohibited because of their known dangerous properties.\n\nSubstances in products which have been considered for scheduling, but have been exempted from this instrument, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).\n\nReading the schedules\n\nSchedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result, they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.\n\nFirstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned below. Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.\n\nSecondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the 2 different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.\n\nWhere exceptions are included in an entry, these have been emphasised by printing the word “except” in bold type.\n\nWhere the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this instrument do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply.\n\nWhere a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (“reverse scheduling”), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.\n\nWhere a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.\n\nIt is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise (see section 7).\n\nIt is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, and toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison. However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply.\n\nFinally, when using this instrument to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A, B and the Index. In this process, if the poison is not found under its “approved name” it may be shown under a group term such as:\n\n \n\n| Group | Example |\n| the parent acid of salts | “oxalic acid” to find sodium oxalate |\n| the radical of a salt | “chromates” to find potassium chromate |\n| the element | “arsenic” to find arsenic trioxide |\n| a chemical group with similar toxicological or pharmacological activity | “hydrocarbons, liquid” to find kerosene |\n| a pharmacological group | “anabolic steroidal agents” to find “androsterone” |\n\nAvailability of poisons\n\nThe purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability.\n\nThese Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons. Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.\n\nInclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It does not:\n\n- indicate that the poison is available; or\n- indicate that it is has been approved or is efficacious for any use that may be specified in a Schedule; or\n- negate any obligation for registration of therapeutic goods, or agricultural or veterinary chemical product containing that poison.\n\nAppendices\n\nSome substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this instrument. The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them.\n\n \n\n| Appendix | Title | Purpose/controls imposed |\n| --- | --- | --- |\n| Appendix A | General exemptions | List of preparations and products exempted from this instrument. |\n| Appendix B | Substances considered not to require control by scheduling | List of poisons exempted from scheduling. |\n| Appendix C | Appendix is intentionally left blank | See Schedule 10. |\n| Appendix D | Additional controls on possession or supply of poisons included in Schedule 4 or 8 | List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply. |\n| Appendix E | First aid instructions for poisons | First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |\n| Appendix F | Warning statements and general safety directions for poisons | Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |\n| Appendix G | Dilute preparations | Concentration cut‑offs for specified poisons, below which the requirements of this instrument do not apply |\n| Appendix H | Schedule 3 medicines permitted to be advertised | List of medicines included in Schedule 3 that are permitted to be advertised to the public. |\n| Appendix I | Appendix is intentionally left blank |  |\n| Appendix J | Conditions for availability and use of Schedule 7 poisons | List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use. |\n| Appendix K | Human medicines required to be labelled with a sedation warning | List of poisons in medicines for human use required to be labelled with a warning regarding their sedation potential. |\n| Appendix L | Requirements for dispensing labels for medicines | Requirements applying to labels attached to medicines at the time of dispensing. |\n| Appendix M | Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist<br>Appendix is intentionally left blank and is reserved for future use. |  |\n\nAppendix A (General exemptions)\n\nAppendix A lists preparations and products that are exempted from this instrument.\n\nAppendix B (Substances considered not to require control by scheduling)\n\nSubstances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times.\n\nInclusion in Appendix B indicates that a decision has been taken not to include substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list (that is, there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non‑hazardous, but have not been considered in relation to the need for scheduling).\n\nSubstances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:\n\n- the toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;\n- the use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or\n- the public access was limited such that scheduling was inappropriate or unnecessary.\n\nThe list of substances included in Appendix B was developed from scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”.\n\nInclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.\n\nApplications are considered for scheduling. Applications for inclusion in Appendix B will not be accepted.\n\nAppendix C (blank)\n\nAppendix C is intentionally blank.\n\nAppendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8)\n\nAppendix D lists poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply.\n\nAppendix E (First aid instructions for poisons)\n\nUnder poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. Standard statements have been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in Appendix E may be varied provided that the intent is not changed.\n\nThe directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non‑toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.\n\nThe First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self‑evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.\n\nAppendix F (Warning statements and general safety directions for poisons)\n\nIt is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.\n\nUnder poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. Warning statements and safety directions have been prepared as a guide for this purpose.\n\nThe wording of warning statements and safety directions specified in Appendix F may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.\n\nAppendix G (Dilute preparations)\n\nAppendix G lists concentration cut‑offs for specified substances, below which the requirements of this instrument do not apply.\n\nAppendix H (Schedule 3 medicines permitted to be advertised)\n\nAppendix H lists medicines included in Schedule 3 that are permitted to be advertised to the public.\n\nAppendix I (blank)\n\nAppendix I is intentionally blank.\n\nAppendix J (Conditions for availability and use of certain poisons included in Schedule 7)\n\nAll poisons included in Appendix J are not to be available except to authorised or licensed persons.\n\nThe use of a poison may be restricted for a particular purpose. Controls recommended for the Schedule 7 poisons included in Appendix J may be implemented through poisons controls or other State or Territory legislation.\n\nAppendix K (Human medicines required to be labelled with a sedation warning)\n\nMedicines for human use that contain a poison included in Appendix K are required to be labelled with a warning regarding their sedation potential.\n\nAppendix L (Requirements for dispensing labels for medicines)\n\nAppendix L sets out the requirements for labels attached to medicines at the time of dispensing.\n\nAppendix M (blank)\n\nAppendix M is intentionally blank and is reserved for future use.\n\nPoisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons\n\nCompanies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.\n\nCompanies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:\n\n1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and\n\n2. calls must be logged and submitted for incorporation into the official collection of poisoning data.\n\nPart 1—Preliminary and interpretation\n\n \n\n \n\n1  Name\n\n (1) This instrument is the Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024.\n\n (2) This instrument may also be cited as the Standard for the Uniform Scheduling of Medicines and Poisons No. 44.\n\nNote: This instrument is the current Poisons Standard for the purposes of the Act until a document is prepared in substitution for it (see sections 52A and 52D of the Act).\n\n2  Commencement\n\n (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.\n\n \n\n- Commencement information\n- Column 1 Column 2 Column 3\n- Provisions Commencement Date/Details\n- 1. The whole of this instrument 1 June 2024. 1 June 2024\n\nNote: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.\n\n (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.\n\n","sortOrder":7},{"sectionNumber":"3","sectionType":"section","heading":"Authority","content":"3  Authority\n\n  This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989.\n\n","sortOrder":8},{"sectionNumber":"4","sectionType":"section","heading":"Repeal and transitional provisions","content":"4  Repeal and transitional provisions\n\nRepeal\n\n (1) The Therapeutic Goods (Poisons Standard—February 2024) Instrument 2024 is repealed.\n\nSaving—things done under the repealed instrument\n\n (2) If:\n\n (a) a thing was done for a particular purpose under the Therapeutic Goods (Poisons Standard—February 2024) Instrument 2024 as in force immediately before that instrument was repealed; and\n\n (b) the thing could be done for that purpose under this instrument;\n\nthe thing has effect for the purposes of this instrument as if it had been done for that purpose under this instrument.\n\n (3) Without limiting subsection (2), a reference in that subsection to a thing being done includes a reference to an approval, authorisation, certificate, exemption, requirement or other instrument being given, made, granted or issued.\n\n","sortOrder":9},{"sectionNumber":"5","sectionType":"section","heading":"Reader’s guide and Index","content":"5  Reader’s guide and Index\n\n (1) The Reader’s guide is not part of this instrument.\n\n (2) The Index is not part of this instrument.\n\n","sortOrder":10},{"sectionNumber":"6","sectionType":"section","heading":"Definitions","content":"6  Definitions\n\nNote 1: The following expressions used in this instrument are defined in the Act:\n\n(a) current Poisons Standard;\n\n(b) poison;\n\n(c) Register;\n\n(d) Secretary;\n\n(e) supply;\n\n(f) therapeutic goods.\n\nNote 2: The definition of poison in the Act is as follows:\n\n poison means an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury and includes any ingredient, compound, material or preparation referred to in a schedule to the current Poisons Standard.\n\n  In this instrument:\n\nAct means the Therapeutic Goods Act 1989.\n\nagricultural chemical means:\n\n (a) a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly:\n\n (i) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing; or\n\n (ii) destroying a plant; or\n\n (iii) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity; or\n\n (iv) modifying an effect of another agricultural chemical; or\n\n (v) attracting a pest for the purpose of destroying it; or\n\n (b) an active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be an agricultural chemical product;\n\nbut does not include a veterinary chemical.\n\nagricultural chemical product has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.\n\nanimal means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs.\n\nanimal feed premix means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.\n\nappropriate authority: each of the following is an appropriate authority:\n\n (a) each person who is the head of the body (however described) in a State or Territory that is responsible for the administration of matters relating to health in that State or Territory;\n\n (b) the Deputy Secretary of the Department with responsibility for the part of the Department known as the Therapeutic Goods Administration, or their delegate;\n\n (c) the Chief Executive Officer of the Australian Pesticides and Veterinary Medicines Authority, or their delegate.\n\napproved name means:\n\n (a) for a poison that is for human therapeutic use—the name for the poison in the Australian Approved Names List within the meaning of the Therapeutic Goods Regulations 1990; or\n\n (b) for a poison that is for animal or agricultural use—the name approved for use by the Australian Pesticides and Veterinary Medicines Authority under the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994; or\n\n (c) for any other poison—the name for the poison mentioned in the first‑occurring of the following paragraphs that applies to the poison:\n\n (i) the name used for the poison in this instrument;\n\n (ii) the name recommended by Standards Australia as the common name for the poison;\n\n (iii) the English name given to the poison by the International Organization for Standardization;\n\n (iv) the name given to the poison by the British Standards Institution;\n\n (v) the English name given to the poison by the European Committee for Standardization (CEN);\n\n (vi) the international non‑proprietary name recommended for the poison by the World Health Organization;\n\n (vii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the International Cosmetic Ingredient Dictionary & Handbook published by the Personal Care Products Council of America;\n\n (viii) the accepted scientific name or the name descriptive of the true nature and origin of the poison.\n\nAustralian Dangerous Goods Code means the Australian Code for the Transport of Dangerous Goods by Road & Rail, published by the National Transport Commission, as existing from time to time.\n\nNote: The Australian Dangerous Goods Code could in 2022 be viewed on the Commission’s website (www.ntc.gov.au).\n\nauthorised prescriber means any of the following:\n\n (a) a dental practitioner;\n\n (b) a medical practitioner;\n\n (c) a veterinarian;\n\n (d) a person for whom an authorisation, given for the purposes of this paragraph by an appropriate authority, is in effect.\n\nblood means whole blood extracted from human donors.\n\nblood components means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.\n\nchild‑resistant closure means:\n\n (a) a closure that complies with the requirements for a child‑resistant closure in Australian Standard AS 1928‑2007, Child‑resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD); or\n\n (b) a closure that complies with the requirements for child‑resistant closures specified in Therapeutic Goods Order No. 95 ‑ Child‑resistant packaging requirements for medicines 2017 (TGO 95); or\n\n (c) a closure that is taken to comply with the requirements mentioned in paragraph (b) under Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021; or\n\n (d) in the case of a can fitted with a press‑on lid, a lid of the design known as “double tight” or “triple tight”.\n\nNote: See also the definition of non‑access packaging.\n\nchild‑resistant packaging means packaging that:\n\n (a) complies with the requirements of Australian Standard AS 1928‑2007, Child resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD); or\n\n (b) is reclosable and complies with the requirements of at least one of the following:\n\n (i) the International Organization for Standardization Standard ISO 8317:2015, Child‑resistant packaging—Requirements and testing procedures for reclosable packages;\n\n (ii) the British Standards Institution Standard BS EN ISO 8317:2004, Child‑resistant packaging—Requirements and testing procedures for reclosable packages;\n\n (iii) the Canadian Standards Association Standard CSA Z76.1‑06, Reclosable Child‑Resistant Packages;\n\n (iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, Poison prevention packaging standards and Section 1700.20, Testing procedure for special packaging, as in force from time to time; or\n\n (c) a closure that complies with the requirements for child‑resistant packaging specified in Therapeutic Goods Order No. 95 ‑ Child‑resistant packaging requirements for medicines 2017 (TGO 95); or\n\n (d) a closure that is taken to comply with the requirements mentioned in paragraph (c) under Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021; or\n\n (e) is in the form of blister or strip packaging:\n\n (i) in which a unit of use is individually protected until the time of release; and\n\n (ii) that complies with section 3 (Requirements for non‑reclosable packages) of Australian Standard AS 1928‑2001, Child‑resistant packages.\n\nNote: See also the definition of non‑access packaging.\n\ncompounded in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.\n\ncosmetic means a substance or preparation intended for placement in contact with any external part of the human body, including:\n\n (a) the mucous membranes of the oral cavity; and\n\n (b) the teeth;\n\nwith a view to:\n\n (c) altering the odours of the body; or\n\n (d) changing its appearance; or\n\n (e) cleansing it; or\n\n (f) maintaining it in good condition; or\n\n (g) perfuming it; or\n\n (h) protecting it.\n\ndebitterised neem seed oil means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.\n\ndental practitioner means a person who is registered, in a State or internal Territory, as a dental practitioner (other than a dental therapist, dental hygienist, dental prosthetist or oral health therapist).\n\ndermal use means application to the skin primarily for localised effect.\n\ndesignated solvent means the following:\n\n (a) acetone;\n\n (b) dimethylformamide;\n\n (c) N‑(N‑dodecyl)‑2‑pyrrolidone;\n\n (d) hydrocarbons, liquid;\n\n (e) methanol when included in Schedule 5;\n\n (f) methyl ethyl ketone;\n\n (g) methyl isoamyl ketone;\n\n (h) methyl isobutyl ketone;\n\n (i) N‑methyl‑2‑pyrrolidone;\n\n (j) N‑(N‑octyl)‑2‑pyrrolidone;\n\n (k) phenyl methyl ketone;\n\n (l) styrene;\n\n (m) tetrachloroethylene;\n\n (n) 1,1,1‑trichloroethane.\n\ndispensing label, for a substance for therapeutic use, means the label attached to the immediate container of the substance at the time of dispensing.\n\nNote: See section 40 and Appendix L.\n\ndistributor means a person who imports or supplies a poison.\n\ndivided preparation means a preparation manufactured and packed as discrete pre‑measured dosage units prior to supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.\n\ndosage unit means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.\n\ndrug means a poison intended for human or animal therapeutic use.\n\nessential oils means:\n\n (a) products obtained from natural raw materials by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation; or\n\n (b) oils of equivalent composition to products mentioned in paragraph (a) that are derived through synthetic means; or\n\n (c) prepared mixtures of oils of equivalent composition to products mentioned in paragraph (a) that comprise a mixture of synthetic and natural components.\n\nexternal in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.\n\nfirst group paint: see section 67.\n\nfree formaldehyde includes all hydrated and non‑hydrated formaldehyde present in aqueous solution, including methylene glycol and formaldehyde released from formaldehyde donors.\n\ngraphic material means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.\n\nhand sanitiser preparation means an antimicrobial skin care product that:\n\n (a) consists of, contains or generates one or more antimicrobial active substances; and\n\n (b) is represented in any way to be, or is likely to be taken to be (whether because of the way in which it is presented or for any other reason):\n\n (i) for use on hands when soap and water are not available; and\n\n (ii) applied to the hands without rinsing off; and\n\n (iii) intended to destroy, deter, render harmless, prevent the action of, or otherwise exert a controlling effect on any microbes on the skin.\n\nhawking means to supply (including peddle or distribute or cause to be distributed) in a public place.\n\nheight in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.\n\nhemp seed oil means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa.\n\nimmediate container includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.\n\nimmediate wrapper means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.\n\ninternal use means administration:\n\n (a) orally, except for topical effect in the mouth; or\n\n (b) for absorption and the production of a systemic effect:\n\n (i) by way of a body orifice other than the mouth; or\n\n (ii) parenterally, other than by application to unbroken skin.\n\nlabel:\n\n (a) means a written statement on a container of a poison; and\n\n (b) in relation to therapeutic goods, includes a display of printed information about the product:\n\n (i) on, or attached to, the goods; or\n\n (ii) on, or attached to, a container or primary pack in which the goods are supplied; or\n\n (iii) supplied with such a container or pack.\n\nmain label, for a container of poison, means:\n\n (a) the part of the label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and\n\n (b) if there are 2 or more labels:\n\n (i) the label or the part of the label where the product name is more or most conspicuously shown; or\n\n (ii) if the product name is equally more or most conspicuously displayed on more than one of those labels—each of the labels on which the product name is equally more or most conspicuously displayed.\n\nmanufacturer of a poison means a person who manufactures, produces, or packs a poison.\n\nmarker dyes or pigments means any product that is added to a liquid used in agricultural or veterinary chemicals to identify or distinguish treated from untreated objects, land or organisms by temporarily imparting colour on the relevant object, land or organism through, for example, spot‑ or boom‑spraying.\n\nmeasure pack means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.\n\nmedical practitioner means a person who is registered, in a State or internal Territory, as a medical practitioner.\n\nmedicine means any poison for therapeutic use.\n\nmidwife means a person who is registered, in a State or internal Territory, as a midwife.\n\nnon‑access packaging, for a product that is not intended for human therapeutic use, means packaging that complies with the requirements of AS 4710‑2001, Packages for chemicals not intended for access or contact with their contents by humans.\n\nNote: See also the definitions of child‑resistant closure and child‑resistant packaging.\n\nnon‑volatile content in relation to a paint or tinter means that portion of a paint or tinter determined to be the non‑volatile content by Method 301.1 of Australian Standard AS 1580‑301.1‑2005, Paints and related materials – Methods of test – Non‑volatile content by mass.\n\nnurse means a person who is registered, in a State or internal Territory, as a nurse.\n\noromucosal use means administration to the oral mucosa, specifically the oral cavity and/or the pharynx.\n\npaint includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use.\n\npesticide means any substance or mixture of substances used or intended to be used:\n\n (a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or\n\n (b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non‑agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.\n\npharmacist means a person who is registered, in a State or internal Territory, as a pharmacist.\n\nprimary pack, in relation to a poison, means the pack in which the poison and its immediate container or immediate wrapper or measure pack are presented for supply.\n\nproduct sample means a packed poison supplied directly to a consumer:\n\n (a) free of charge or for a nominal charge; and\n\n (b) as a mechanism to promote the supply of the product; and\n\n (c) in the form of:\n\n (i) a small pack produced specifically for the purposes of promotion; or\n\n (ii) a normal commercial pack that in other circumstances could be purchased by the consumer.\n\npublic place means any place where members of the public are lawfully entitled, invited or permitted to be present in their capacity as members of the public.\n\nNote: Examples of a public place include a street, road, footway, court, alley or thoroughfare that the public may use in any residential premises or to get from door to door, place to place or house to house.\n\nrequired advisory statements for medicine labels means the Therapeutic Goods (Medicines Advisory Statements) Specification 2021.\n\nrestricted flow insert means a restriction:\n\n (a) that is fitted or moulded in the neck of a container; and\n\n (b) that cannot readily be removed from the container by manual force; and\n\n (c) that limits the delivery of the contents of the container to drops each of which is not more than 200 microlitres.\n\nsecond group paint: see section 68.\n\nselected container means:\n\n (a) an injection vial having a nominal capacity of 10 ml or less; or\n\n (b) a single use syringe; or\n\n (c) any other container for substances for therapeutic use having a nominal capacity of 10 ml or less.\n\nsolid includes powder.\n\nsubstance has the same meaning as in Part 6‑3 of the Act.\n\nNote 1: In general terms, that definition covers an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury to persons or animals.\n\nNote 2: See also section 7.\n\ntherapeutic use means use in or in connection with:\n\n (a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals; or\n\n (b) influencing, inhibiting or modifying a physiological process in human beings or animals; or\n\n (c) testing the susceptibility of human beings or animals to a disease or ailment; or\n\n (d) influencing, controlling or preventing conception in human beings or animals; or\n\n (e) testing for pregnancy in human beings or animals; or\n\n (f) the replacement or modification of parts of the anatomy in human beings or animals.\n\ntinter means any pigment or admixture of pigment with other substances, in powder, semi‑solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.\n\ntopical use means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.\n\ntoy means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of 14 years.\n\ntransdermal use means application to the skin primarily for systemic effect.\n\nveterinarian means a person who is registered under the law of a State or Territory as a veterinarian, a veterinary practitioner or a veterinary surgeon.\n\nveterinary chemical means:\n\n (a) a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly:\n\n (i) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest; or\n\n (ii) curing or alleviating an injury suffered by the animal; or\n\n (iii) modifying the physiology of the animal:\n\n (A) so as to alter its natural development, productivity, quality or reproductive capacity; or\n\n (B) so as to make it more manageable; or\n\n (iv) modifying the effect of another veterinary chemical; or\n\n (b) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a); or\n\n (c) any active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be a veterinary chemical product;\n\nbut does not include an agricultural chemical.\n\nveterinary chemical product has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.\n\n","sortOrder":11},{"sectionNumber":"7","sectionType":"section","heading":"References to substances","content":"7  References to substances\n\n  In this instrument, unless the contrary intention appears, a reference to a substance includes the following:\n\n (a) that substance prepared from natural sources or artificially;\n\n (b) if the substance is a plant (other than a plant included in Schedule 8 or 9)—that plant or any part of that plant when packed or prepared for therapeutic use;\n\n (c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative;\n\n (d) every alkaloid of the substance and every salt of such an alkaloid;\n\n (e) every stereoisomer of the substance and every salt of such a stereoisomer;\n\n (f) every recombinant form of the substance;\n\n (g) a preparation or admixture containing any proportion of the substance.\n\nNote: Part 2 (controls on substances) does not apply in relation to certain substances (see section 11).\n\n","sortOrder":12},{"sectionNumber":"8","sectionType":"section","heading":"References to concentration, strength or quantity of substances","content":"8  References to concentration, strength or quantity of substances\n\n  In this instrument, for a reference to a concentration, strength or quantity of a substance:\n\n (a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance; and\n\n (b) the expression “1%” means:\n\n (i) in the case of a liquid preparation, 1 g of the substance per 100 mL of the preparation; or\n\n (ii) in the case of a solid, semi‑solid or pressurised spray aerosol preparation, 1 g of the substance per 100 g of the preparation; and\n\n (iii) any expression of greater or lesser percentages shall have a corresponding meaning; and\n\n (c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine.\n\n","sortOrder":13},{"sectionNumber":"9","sectionType":"section","heading":"References to boiling or distillation temperatures","content":"9  References to boiling or distillation temperatures\n\n  In this instrument, a reference to a boiling or distillation temperature means that temperature at an atmospheric pressure of 101.325 kPa (760 mm of mercury).\n\n","sortOrder":14},{"sectionNumber":"10","sectionType":"section","heading":"References to standards","content":"10  References to standards\n\n  A reference in this instrument to an Australian standard, an international standard or a standard of a foreign country is a reference to that standard as it exists from time to time.\n\nPart 2—Controls on substances\n\nDivision 1—Preliminary\n\n11  Application of Part 2\n\n  This Part applies to a substance or preparation included in a schedule to this instrument, other than the following:\n\n (a) a preparation or product included in the table in clause 1 of Appendix A;\n\n (b) a substance included in the table in clause 3 of Appendix B when used in an area, sub‑area or sub‑sub‑area of use specified in the table in relation to that substance;\n\n (c) a substance included in the table in clause 1 of Appendix G at a concentration not exceeding the concentration specified in that table in relation to that substance;\n\n (d) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8;\n\n (e) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022, published by the Australian Pesticides and Veterinary Medicines Authority, as existing from time to time.\n\nNote: For paragraph (e), the Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022 is a legislative instrument that could in 2023 be accessed at www.legislation.gov.au.\n\n","sortOrder":15},{"sectionNumber":"12","sectionType":"section","heading":"Preparations containing poisons included in different schedules","content":"12  Preparations containing poisons included in different schedules\n\n (1) If a preparation contains 2 or more poisons, the provisions relating to each of the schedules in which those poisons are included apply to the preparation.\n\n (2) However, if it is not possible to comply both with a provision relating to one of those schedules and with a provision relating to another of those schedules, the provision relating to the more restrictive schedule applies, unless a contrary intention is indicated in the schedules or relevant State or Territory legislation.\n\n (3) The Schedules listed in order of greatest to least restrictiveness are 9, 10, 8, 4, 7, 3, 2, 6, 5.\n\nNote: Schedule 1 is not currently in use.\n\n","sortOrder":16},{"sectionNumber":"Div 2","sectionType":"division","heading":"Labels","content":"Division 2—Labels\n\nSubdivision A—General\n\n13  General requirements\n\n (1) A poison must not be supplied unless it is labelled in accordance with this Division.\n\n (2) Any word, expression or statement required by this instrument to be written on a label or container must be written:\n\n (a) on the outside face of the label or container; and\n\n (b) in English; and\n\n (c) in durable characters; and\n\n (d) in a colour or colours to provide a distinct contrast to the background colour; and\n\n (e) in letters at least 1.5 mm in height.\n\n (3) Paragraph (2)(e) does not apply to a word, expression or statement on a container which has a capacity of 20 ml or less, or on the label of such a container if:\n\n (a) an appropriate authority approves the use of smaller letters; and\n\n (b) the letters are at least 1 mm in height.\n\n (4) The label must be printed on, or securely attached to:\n\n (a) the outside of the immediate container; and\n\n (b) if the immediate container is enclosed in a primary pack—the outside of that primary pack.\n\n14  Immediate wrapper\n\n  If a poison is enclosed in an immediate wrapper:\n\n (a) the poison must be contained in a primary pack labelled in accordance with section 15; and\n\n (b) the immediate wrapper must be conspicuously labelled with:\n\n (i) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and\n\n (ii) the approved name of the poison; and\n\n (iii) a statement of the quantity, proportion or strength of the poison in accordance with section 34.\n\nSubdivision B—Primary packs and immediate containers\n\n","sortOrder":17},{"sectionNumber":"15","sectionType":"section","heading":"Primary packs and immediate containers","content":"15  Primary packs and immediate containers\n\n  This Subdivision sets out how the primary pack and immediate container of a poison must be labelled.\n\n","sortOrder":18},{"sectionNumber":"16","sectionType":"section","heading":"Signal words","content":"16  Signal words\n\n (1) The signal word or words for the poison, as shown in the following table, must be written:\n\n (a) on the first line or lines of the main label; and\n\n (c) subject to subsection (3), in letters at least half the height of the largest letter or numeral on the label; and\n\n (d) with nothing else other than the following written on the same line or lines:\n\n (i) if the poison is included in Schedule 5—a class label as specified in the Australian Dangerous Goods Code or a statement of the principal hazard of the poison;\n\n (ii) if the poison is not included in Schedule 5—a class label as specified in the Australian Dangerous Goods Code.\n\n \n\n- Signal word or words for poisons\n- Item For a poison included in the following schedule … that is to be used for the following purpose … the signal word or words are …\n- 1 Schedule 2 for any purpose PHARMACY MEDICINE\n- 2 Schedule 3 for any purpose PHARMACIST ONLY MEDICINE\n- 3 Schedule 4 for human use PRESCRIPTION ONLY MEDICINE\n- 4 Schedule 4 for animal use PRESCRIPTION ANIMAL REMEDY\n- 5 Schedule 5 for any purpose CAUTION\n- 6 Schedule 6 for any purpose POISON\n- 7 Schedule 7 for any purpose DANGEROUS POISON\n- 8 Schedule 8 for any purpose CONTROLLED DRUG\n\n (2) For the purposes of paragraph (1)(c), the largest letter or numeral does not include:\n\n (a) a single letter or numeral which is larger than other lettering on the label; or\n\n (b) an affix forming part of the trade name for the poison; or\n\n (c) in the case of a poison for therapeutic use—numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.\n\n (3) For the purposes of paragraph (1)(c), the letters need not be larger than:\n\n (a) 6 mm on labels for packages having a nominal capacity of 2 L or less; or\n\n (b) 15 mm on labels for packages having a nominal capacity of more than 2 L.\n\n","sortOrder":19},{"sectionNumber":"17","sectionType":"section","heading":"Cautionary statement—possession without authority illegal","content":"17  Cautionary statement—possession without authority illegal\n\n  If the poison is included in Schedule 8, the cautionary statement:\n\nPOSSESSION WITHOUT AUTHORITY ILLEGAL\n\n (a) on a separate line or lines immediately below the signal words required by section 16; and\n\n (c) in letters at least four‑tenths the height of the letters used for the signal words; and\n\n (d) with no other statement written on the same line or lines.\n\n","sortOrder":20},{"sectionNumber":"18","sectionType":"section","heading":"Cautionary statement—keep out of reach of children","content":"18  Cautionary statement—keep out of reach of children\n\n  The cautionary statement:\n\nKEEP OUT OF REACH OF CHILDREN\n\n (a) on a separate line or lines:\n\n (i) immediately below the signal word or words required by section 16; or\n\n (ii) if the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by section 17—immediately below that statement; and\n\n (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.\n\n","sortOrder":21},{"sectionNumber":"19","sectionType":"section","heading":"Cautionary statement—fire and explosion hazard","content":"19  Cautionary statement—fire and explosion hazard\n\n (1) If the poison is a dry chlorinating compound containing more than 10% of available chlorine, the cautionary statement:\n\nFIRE AND EXPLOSION HAZARD\n\n (a) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and\n\n (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.\n\n (2) This section does not apply to a preparation certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code.\n\n","sortOrder":22},{"sectionNumber":"20","sectionType":"section","heading":"Cautionary statement—burns skin and throat","content":"20  Cautionary statement—burns skin and throat\n\n  If the poison is an alkaline salt in a dishwashing machine product, the cautionary statement:\n\nBURNS SKIN AND THROAT\n\n (a) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and\n\n (c) in letters at least four‑tenths the height of the letters used for the signal word; and\n\n (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines of the main label.\n\n","sortOrder":23},{"sectionNumber":"21","sectionType":"section","heading":"Cautionary statements for aqueous solution of paraquat","content":"21  Cautionary statements for aqueous solution of paraquat\n\n  If the poison is an aqueous solution of paraquat, the cautionary statements:\n\nCAN KILL IF SWALLOWED\n\nDO NOT PUT IN DRINK BOTTLES\n\nKEEP LOCKED UP\n\n (a) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and\n\n (c) in letters at least four‑tenths the height of the letters used for the signal words; and\n\n (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same lines of the main label.\n\n","sortOrder":24},{"sectionNumber":"22","sectionType":"section","heading":"Cautionary statement—read safety directions","content":"22  Cautionary statement—read safety directions\n\n (1) If safety directions are required on the label by section 29, the following cautionary statement:\n\nREAD SAFETY DIRECTIONS BEFORE OPENING OR USING\n\nor the following cautionary statement:\n\nREAD SAFETY DIRECTIONS\n\n (a) on a separate line or lines:\n\n (i) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; or\n\n (ii) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and\n\n (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.\n\n (2) This section does not apply to a medicine for human use that is labelled in accordance with the required advisory statements for medicine labels.\n\n","sortOrder":25},{"sectionNumber":"23","sectionType":"section","heading":"Cautionary statement—flammable","content":"23  Cautionary statement—flammable\n\n  If the poison meets the criteria for a “flammable liquid” in the Australian Dangerous Goods Code, the cautionary statement:\n\nFLAMMABLE\n\nmust be written on the main label in bold‑face sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the Australian Dangerous Goods Code.\n\n","sortOrder":26},{"sectionNumber":"24","sectionType":"section","heading":"Cautionary statement—for animal treatment only","content":"24  Cautionary statement—for animal treatment only\n\n  If the poison is only for the treatment of animals, the cautionary statement:\n\nmust be written on the main label in bold‑face sans serif capital letters of uniform thickness.\n\n","sortOrder":27},{"sectionNumber":"25","sectionType":"section","heading":"Cautionary statement—do not swallow","content":"25  Cautionary statement—do not swallow\n\n  If the poison is included in Schedule 5 and is intended for any purpose other than internal or pesticidal use, the cautionary statement:\n\nDO NOT SWALLOW\n\nmust be written in sans serif capital letters on the main label or as part of the directions for use.\n\n","sortOrder":28},{"sectionNumber":"26","sectionType":"section","heading":"Approved name and quantity, proportion or strength","content":"26  Approved name and quantity, proportion or strength\n\n (1) The approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with section 34 must be:\n\n (a) if the poison is for human therapeutic use—written on the main label in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or\n\n (b) if the poison is not for human therapeutic use—written in bold‑face sans serif capital letters on the main label, unless:\n\n (i) a list of approved names is required; and\n\n (ii) it is impractical to include the list on the main label; and\n\n (iii) it is included on another part of the label in accordance with an authorisation given by an appropriate authority.\n\n (2) If the poison is included in Schedule 5 and is referred to in column 1 of an item of the following table, the appropriate name in column 2 of that item may be used as the approved name.\n\n \n\n- Appropriate names for poisons\n- Item Column 1 Poison Column 2 Appropriate name\n- 1 Alkaline salts Alkaline salts\n- 2 Amines for use as curing agents for epoxy resins (unless separately specified in the Schedules) Aliphatic amines or aromatic amines\n- 3 Epoxy resins, liquid Liquid epoxy resins\n- 4 Hydrocarbons, liquid Liquid hydrocarbons\n- 5 Quaternary ammonium compounds Quaternary ammonium compound(s)\n\n (3) If a poison contains a mixture of designated solvents in excess of 25% of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25%, the approved names of those solvents may be expressed as follows:\n\n (a) where the designated solvent is a liquid hydrocarbon—as “liquid hydrocarbons”;\n\n (b) where the designated solvent is a ketone—as “ketones”;\n\n (c) in any other case—as “solvents” or “other solvents”.\n\n","sortOrder":29},{"sectionNumber":"27","sectionType":"section","heading":"Statement—an anticholinesterase compound","content":"27  Statement—an anticholinesterase compound\n\n (1) If the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, the following expression:\n\nAN ANTICHOLINESTERASE COMPOUND\n\nmust be written immediately below the approved name or the list of declared contents on the label.\n\n (2) This section does not apply to:\n\n (a) dazomet, mancozeb, metiram, propineb, thiram, tri‑allate, zineb or ziram; or\n\n (b) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or\n\n (c) an organophosphorus compound or carbamate contained in a pressurised spray pack for household use.\n\n","sortOrder":30},{"sectionNumber":"28","sectionType":"section","heading":"Directions for use","content":"28  Directions for use\n\n  If the poison is prepared, packed or sold for a specific purpose, it must be labelled with clear and adequate directions for use, unless:\n\n (a) it is a medicine for human use that is labelled in accordance with:\n\n (i) Therapeutic Goods Order No. 91 ‑ Standard for labels of prescription and related medicines; or\n\n (ii) Therapeutic Goods Order No. 92 ‑ Standard for labels of non‑prescription medicines; or\n\n (b) it is in an agricultural or veterinary chemical product labelled in compliance with the Agricultural and Veterinary Chemicals Code Act 1994; or\n\n (c) it is included in Schedule 4 or 8; or\n\n (d) all of the following apply:\n\n (i) it is impractical to include such directions on the label;\n\n (ii) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”;\n\n (iii) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label;\n\n (iv) the insert is enclosed in the primary pack.\n\n","sortOrder":31},{"sectionNumber":"29","sectionType":"section","heading":"Safety directions","content":"29  Safety directions\n\n (1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each safety direction required for the poison by that clause, grouped together as a distinct section of the label and prefaced by the words:\n\nSAFETY DIRECTIONS\n\nwritten in bold‑face capital letters.\n\n (ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.\n\n","sortOrder":32},{"sectionNumber":"30","sectionType":"section","heading":"Warning statements","content":"30  Warning statements\n\n (1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each warning statement required for the poison by that clause, grouped together:\n\n (a) if safety directions are included on the label—immediately after the words “SAFETY DIRECTIONS”; or\n\n (b) if there are no safety directions—immediately preceding the directions for use.\n\n (ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.\n\n","sortOrder":33},{"sectionNumber":"31","sectionType":"section","heading":"First aid","content":"31  First aid\n\n (1) If the poison is included in the table in clause 3 of Appendix E, it must be labelled with each statement required for the poison by clause 3 of Appendix E:\n\n (a) grouped together and prefaced by the following words:\n\nFIRST AID\n\n  written in bold‑face capital letters; or\n\n (b) if a primary pack contains 2 or more immediate containers of poisons each requiring different first aid instructions:\n\n (i) written on each immediate container as specified in paragraph (a); and\n\n (ii) replaced on the primary pack with the statement:\n\nFIRST AID: See inner packs.\n\n (i) is for human internal use; and\n\n (ii) is included in Schedule 3, 4 or 8;\n\n (c) a poison that:\n\n (ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.\n\n","sortOrder":34},{"sectionNumber":"32","sectionType":"section","heading":"Name and address of manufacturer or distributor","content":"32  Name and address of manufacturer or distributor\n\n (1) The poison must be labelled with the name and address of its manufacturer or distributor. The address:\n\n (a) must be a physical address in Australia; and\n\n (b) must not be a post office, cable, telegraphic or code address.\n\n (2) However, if the manufacturer or distributor is a company incorporated under the law of a State or Territory, or a firm registered under a law of a State or Territory dealing with business names, the name and address may be:\n\n (a) the registered name of the corporation or firm, or its branch or division; and\n\n (b) the city or town in which a registered office of the company or firm is situated.\n\n","sortOrder":35},{"sectionNumber":"33","sectionType":"section","heading":"Warning statements and sedation warnings for certain medicines for human use","content":"33  Warning statements and sedation warnings for certain medicines for human use\n\nWarning statements for certain medicines\n\n (1) A dispensed medicine for human use containing a poison included in column 1 of the table in clause 2 of Appendix L must be clearly labelled with each warning statement required for the poison by that clause.\n\nSedation warning for certain medicines\n\n (2) A dispensed medicine for human use containing a poison included in Appendix K must be clearly labelled with a warning statement set out in item 39, 40 or 90 of the table in clause 1 of Appendix F.\n\nSubdivision C—Statements of quantity, proportion or strength\n\n34  Statements of quantity, proportion or strength\n\n (1) The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:\n\n (a) if the poison is for human therapeutic use—the manner required by the standards for the goods specified in orders made under subsection 10(1) of the Act;\n\n (b) if the poison is for a purpose or purposes other than human therapeutic use—as follows:\n\n (i) if the poison is in a pressurised spray aerosol preparation—as the mass of the poison per stated mass of the preparation;\n\n (ii) if the poison is a liquid in a liquid preparation—as the mass or volume of the poison per stated volume of the preparation;\n\n (iii) if the poison is a liquid in a solid or semi‑solid preparation—as the mass or volume of the poison per stated mass of the preparation;\n\n (iv) if the poison is a solid or semi‑solid in a liquid preparation—as the mass of the poison per stated volume of the preparation;\n\n (v) if the poison is a solid or semi‑solid in a solid or semi‑solid preparation—as the mass of the poison per stated mass of the preparation;\n\n (vi) if the poison is a gas in a liquid preparation—as the mass of the poison per stated volume of the preparation;\n\n (vii) if the poison is a gas in a solid or semi‑solid preparation—as the mass of the poison per stated mass of the preparation;\n\n (viii) if the poison is a gas in a gaseous preparation—as the mass of the poison per stated mass of the preparation;\n\n (c) if the poison is a solution of a mineral acid, the proportion of the acid (un‑neutralised by any bases present in the preparation) in a preparation may be expressed as the un‑neutralised mass of the acid per stated mass of the preparation;\n\n (d) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:\n\n (i) “contains not more than 10 per cent of (insert name of the metal)”;\n\n (ii) “contains not more than 30 per cent of (insert name of the metal)”;\n\n (iii) “contains more than 30 per cent of (insert name of the metal)”;\n\n (e) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5% of the product;\n\n (f) if the poison is a lead‑based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non‑volatile content of the paint;\n\n (g) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.\n\n (2) In paragraph (1)(g):\n\nderivative includes alkaloid.\n\nNote: For requirements to state the quantity, proportion or strength of a poison, see subparagraph 14(b)(iii), section 26 and sub‑subparagraphs 35(b)(ii)(B) and 36(1)(b)(ii)(A) and (2)(b)(iii)(B).\n\nSubdivision D—Exemptions from labelling requirements\n\n","sortOrder":36},{"sectionNumber":"35","sectionType":"section","heading":"Selected containers and measure packs","content":"35  Selected containers and measure packs\n\n  The requirements of Subdivision B do not apply to an immediate container of poison that is a measure pack or a selected container (other than an ampoule, a pre‑filled syringe or an injection vial to which subsections 36(1) or (2) applies) if:\n\n (a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or\n\n (b) the immediate container is:\n\n (i) packed in a primary pack labelled in accordance with Subdivision B; and\n\n (ii) labelled with:\n\n (A) the signal word or words for the poison as shown in the table in subsection 16(1); and\n\n (B) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and\n\n (C) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and\n\n (D) if the poison is only for the treatment of animals—the cautionary statement:\n\n  written in sans serif capital letters.\n\n","sortOrder":37},{"sectionNumber":"36","sectionType":"section","heading":"Ampoules, pre‑filled syringes and injection vials","content":"36  Ampoules, pre‑filled syringes and injection vials\n\n (1) The requirements of Subdivision B do not apply to a selected container of poison or an ampoule of poison (other than an ampoule to which subsection (2) applies) when:\n\n (a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or\n\n (b) the selected container or ampoule is:\n\n (i) packed in a primary pack labelled in accordance with Subdivision B; and\n\n (ii) labelled with:\n\n (A) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and\n\n (B) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and\n\n (C) if the poison is only for the treatment of animals—the cautionary statement:\n\n  written in sans serif capital letters.\n\n (2) The requirements of Subdivision B do not apply to a selected container of poison that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:\n\n (a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or\n\n (b) the poison is not therapeutic goods and all of the following apply:\n\n (i) the ampoule is packed in a primary pack labelled in accordance with Subdivision B;\n\n (ii) the strip is labelled in accordance with this section;\n\n (iii) the ampoule is labelled with:\n\n (A) the approved name of the poison or the trade name of the poison; and\n\n (B) the quantity, proportion or strength of the poison in accordance with section 34.\n\n","sortOrder":38},{"sectionNumber":"37","sectionType":"section","heading":"Transport containers and wrappings","content":"37  Transport containers and wrappings\n\n  The labelling requirements of this instrument do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.\n\n","sortOrder":39},{"sectionNumber":"38","sectionType":"section","heading":"Dispensary, industrial, laboratory and manufacturing poisons","content":"38  Dispensary, industrial, laboratory and manufacturing poisons\n\n  The labelling requirements of this instrument do not apply to a poison that:\n\n (a) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and\n\n (b) is labelled in accordance with requirements under applicable jurisdictional work health and safety laws, as in force from time to time.\n\n","sortOrder":40},{"sectionNumber":"39","sectionType":"section","heading":"Exemptions from label requirements in certain circumstances","content":"39  Exemptions from label requirements in certain circumstances\n\n (1) A requirement specified in Subdivision B or section 35 or 37 does not apply to a poison if an appropriate authority has granted a labelling exemption under this subsection in relation to that requirement for the poison.\n\n (2) A labelling exemption granted by an appropriate authority under subsection (1) remains in force:\n\n (a) if the exemption relates to a product that is indicated for the treatment or prevention of the coronavirus known as COVID‑19:\n\n (i) for the period specified in the exemption; or\n\n (ii) if no period is specified—until revoked by the appropriate authority; or\n\n (b) in any other case:\n\n (i) for the period, specified in the exemption, that is 12 months or less from the date of commencement of the exemption; or\n\n (ii) if no period is specified—12 months from the date of commencement of the exemption.\n\n (3) For the avoidance of doubt, this section does not apply to an authorisation given under subparagraph 28(d)(iii).\n\n","sortOrder":41},{"sectionNumber":"40","sectionType":"section","heading":"Dispensed medicines","content":"40  Dispensed medicines\n\n  Unless otherwise specified in relevant State or Territory legislation and subject to section 33, the labelling requirements of this instrument do not apply to a medicine that:\n\n (a) is:\n\n (i) supplied by an authorised prescriber; or\n\n (ii) supplied on and in accordance with a prescription written by an authorised prescriber; or\n\n (iii) prepared and supplied by a pharmacist for an individual patient; and\n\n (b) is labelled in accordance with the requirements of clause 1 of Appendix L.\n\n","sortOrder":42},{"sectionNumber":"41","sectionType":"section","heading":"Gas cylinders","content":"41  Gas cylinders\n\n  The requirements of paragraph 16(1)(d) and paragraphs 18(d) and 22(1)(d) do not apply to a cylinder containing a poison that is a compressed gas.\n\n","sortOrder":43},{"sectionNumber":"42","sectionType":"section","heading":"Paints","content":"42  Paints\n\n  The requirements of Subdivision B do not apply to:\n\n (a) a paint (other than a paint for therapeutic or cosmetic use) that contains only poisons included in Schedule 5; or\n\n (b) a first group paint or second group paint that is labelled with:\n\n (i) the word “WARNING”, written in bold‑face sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and\n\n (ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold‑face sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and\n\n (iii) the appropriate warnings required for the paint by clause 4 of Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and\n\n (iv) the name and proportion of the first group or second group poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non‑volatile content” or “in the dried film” of the paint; or\n\n (c) a tinter which contains only poisons included in Schedule 5; or\n\n (d) a tinter that contains a poison mentioned in a table in section 67 or 68, if:\n\n (i) the tinter is labelled with the name and proportion of the poison; and\n\n (ii) if the poison is a metal or metal salt—the proportion is expressed as the metallic element present as “calculated on the non‑volatile content” or “in the dried film”.\n\n","sortOrder":44},{"sectionNumber":"43","sectionType":"section","heading":"Camphor and naphthalene","content":"43  Camphor and naphthalene\n\n  The labelling requirements of paragraph 13(2)(d) and Subdivision B do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:\n\n (a) complies with section 52; and\n\n (b) is sold or supplied in a primary pack labelled in accordance with section 13 and Subdivision B.\n\nSubdivision E—Prohibitions\n\n","sortOrder":45},{"sectionNumber":"44","sectionType":"section","heading":"Prohibitions","content":"44  Prohibitions\n\n (1) A label used in connection with a poison must not include:\n\n (a) any reference to this instrument, or any comment on, reference to, or explanation of any expression required by this instrument that directly or by implication contradicts, qualifies or modifies such expression; or\n\n (b) any expression or device suggesting or implying that the poison is safe, harmless, non‑toxic, non‑poisonous, or is recommended or approved by a government or government authority unless required by legislation; or\n\n (c) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or\n\n (d) any trade name or description that:\n\n (i) represents any single constituent of a compound preparation; or\n\n (ii) misrepresents the composition or any property or quality of the poison; or\n\n (iii) gives any false or misleading indication of origin or place of manufacture of the poison.\n\n (2) A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure any of the ribs or any expression required by this instrument to be written or embossed on the container or pack.\n\n","sortOrder":46},{"sectionNumber":"Div 3","sectionType":"division","heading":"Containers","content":"Division 3—Containers\n\n","sortOrder":47},{"sectionNumber":"45","sectionType":"section","heading":"General requirements","content":"45  General requirements\n\n  A poison must not be supplied unless the requirements of this Division for the immediate container for the poison are met.\n\n","sortOrder":48},{"sectionNumber":"46","sectionType":"section","heading":"Containers for poisons other than poisons included in Schedule 5","content":"46  Containers for poisons other than poisons included in Schedule 5\n\n (1) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of 2 L or less, the container must comply with Australian Standard AS 2216‑1997, Packaging for poisonous substances.\n\n (2) Despite subsection (1), a poison included in Schedule 6 that is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216‑1997, Packaging for poisonous substances, if:\n\n (a) other safety factors are not diminished; and\n\n (b) the container has a restricted flow insert and a child‑resistant closure.\n\n (3) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of more than 2 L:\n\n (a) the container must comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216‑1997, Packaging for poisonous substances; and\n\n (b) the word “POISON” must be embossed, or indelibly written in a colour in distinct contrast to the background colour, on the side or shoulder of the container, in sans serif capital letters the height of which is at least one thirty‑second part of the length, height or width of the container, whichever is the greatest.\n\n","sortOrder":49},{"sectionNumber":"47","sectionType":"section","heading":"Containers for poisons included in Schedule 5","content":"47  Containers for poisons included in Schedule 5\n\n (1) The container in which a poison included in Schedule 5 is supplied must:\n\n (a) comply with the container requirements of subsection 46(1) or (3); or\n\n (b) comply with subsection (2).\n\n (2) A container complies with this subsection if:\n\n (a) it is readily distinguishable from a container in which food (including a condiment) or drink is sold; and\n\n (b) it complies with subsection 1.4 (General Requirements) of Australian Standard AS 2216‑1997, Packaging for poisonous substances, excluding paragraph 1.4.3; and\n\n (c) it is securely closed and, except when containing a preparation for use on one occasion only, is capable of being re‑closed to prevent spillage of its contents; and\n\n (d) the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” is:\n\n (i) embossed or indelibly written on the container; or\n\n (ii) printed on a label that complies with subsection (3) that is attached to the container.\n\n (3) For the purposes of subparagraph (2)(d)(ii), the label must be a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.\n\n (4) Despite subsection (1), the following poisons included in Schedule 5:\n\n (a) methylated spirit(s);\n\n (b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;\n\n (c) petrol;\n\n (d) toluene;\n\n (e) xylene;\n\nmust not be supplied in a bottle or jar having a nominal capacity of 2 L or less, unless the immediate container complies with the container requirements of subsection 46(1).\n\n","sortOrder":50},{"sectionNumber":"48","sectionType":"section","heading":"Approved containers","content":"48  Approved containers\n\n  Despite subsections 46(1) and (3) and section 47, a poison may be packed in a container that does not comply with the tactile identification requirements of AS2216‑1997 (Packaging for poisonous substances) or the requirements of paragraph 46(3)(b) or 47(2)(d) if:\n\n (a) other safety factors are not diminished; and\n\n (b) the container is for a specific purpose; and\n\n (c) an appropriate authority has approved the use of the container for that purpose.\n\n","sortOrder":51},{"sectionNumber":"49","sectionType":"section","heading":"Child‑resistant closures","content":"49  Child‑resistant closures\n\n (1) If a poison specified in column 1 of an item of the following table is supplied in a container having a nominal capacity specified in column 2 of the item, it must be closed with a child‑resistant closure that:\n\n (a) is appropriate for the container and the poison; and\n\n (b) will retain its child‑resistant properties for the expected life of the poison.\n\n \n\n- Poisons that must be closed with a child‑resistant closure\n- Item Column 1 Poison Column 2 Nominal capacity of container\n- 1 Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine tablets All sizes\n- 2 Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine liquids, solids or gels 5 L/kg or less\n- 3 Alkaline salts included in Schedule 5, when packed and labelled as a food additive 2.5 L or less\n- 4 Anise oil when included in Schedule 5 200 mL or less\n- 5 Basil oil when included in Schedule 5 200 mL or less\n- 6 Bay oil when included in Schedule 6 200 mL or less\n- 7 Cajuput oil when included in Schedule 6 200 mL or less\n- 8 Cassia oil when included in Schedule 5 200 mL or less\n- 9 Cineole when included in Schedule 6 2 L or less\n- 10 Cinnamon bark oil when included in Schedule 5 200 mL or less\n- 11 Cinnamon leaf oil when included in Schedule 6 200 mL or less\n- 12 Clove oil when included in Schedule 6 200 mL or less\n- 13 CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) when included in Schedule 6, when presented in a wipe All sizes\n- 14 Essential oils when included in Schedule 6 because of their natural camphor component 200 mL or less\n- 15 Ethylene glycol when included in Schedule 6 5 L or less\n- 16 Ethylene glycol when included in Schedule 5 in preparations containing more than 50% of ethylene glycol 5 L or less\n- 17 Eucalyptus oil when included in Schedule 6 2 L or less\n- 18 Eugenol when included in Schedule 6 200 mL or less\n- 19 Fennel oil when included in Schedule 5 200 mL or less\n- 20 Hydrocarbons, liquid, when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid 5 L or less\n- 21 Hydrochloric acid when included in Schedule 6 5 L or less\n- 22 Leptospermum scoparium oil (manuka oil) when included in Schedule 6 200 mL or less\n- 23 Marjoram oil when included in Schedule 5 200 mL or less\n- 24 Melaleuca oil (tea‑tree oil) when included in Schedule 6 200 mL or less\n- 25 Methylated spirit excluding preparations or admixtures 5 L or less\n- 26 Methyl salicylate and preparations containing more than 50% of methyl salicylate 200 mL or less\n- 27 Nicotine in liquid preparations when included in Schedule 4. All sizes\n- 28 Nutmeg oil when included in Schedule 5 200 mL or less\n- 29 Oil of turpentine 5 L or less\n- 30 Paracetamol included in Schedule 4, when packed and labelled for the treatment of animals All sizes\n- 31 Pennyroyal oil when included in Schedule 6 200 mL or less\n- 32 Potassium hydroxide as such 2.5 L or less\n- 33 Potassium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs 5 L or less\n- 34 D‑Pulegone when included in Schedule 6 200 mL or less\n- 35 Sage oil (Dalmatian) when included in Schedule 6 200 mL or less\n- 36 Sodium hydroxide as such 2.5 L or less\n- 37 Sodium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs 5 L or less\n- 38 Thujone when included in Schedule 6 200 mL or less\n- 39 Thyme oil when included in Schedule 5 200 mL or less\n\n (2) This section does not apply to a poison included in therapeutic goods that are packaged in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act.\n\n","sortOrder":52},{"sectionNumber":"50","sectionType":"section","heading":"Poisons included in Schedule 8","content":"50  Poisons included in Schedule 8\n\n (1) If a poison included in Schedule 8 is supplied, it must be packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.\n\n (2) This paragraph does not apply to the supply of a poison included in Schedule 8:\n\n (a) by an authorised prescriber or other authorised supplier; or\n\n (b) by a pharmacist on the prescription of an authorised prescriber; or\n\n (c) by a pharmacist employed at a hospital, on the written requisition of:\n\n (i) a medical practitioner or dental practitioner; or\n\n (ii) the nurse or midwife in charge of the ward in which the poison is to be used or stored; or\n\n (d) by a nurse or midwife on the direction in writing of an authorised prescriber.\n\n","sortOrder":53},{"sectionNumber":"51","sectionType":"section","heading":"Exemptions","content":"51  Exemptions\n\n (1) Subsections 46(1) and (3) and section 47 do not apply to the immediate container of a poison prepared, packed and sold:\n\n (a) for human internal or animal internal use; or\n\n (b) as a solid or semi‑solid preparation for human external or animal external use; or\n\n (c) as a paint, other than a paint for therapeutic or cosmetic use; or\n\n (d) in containers having a nominal capacity of 15 mL or less; or\n\n (e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or\n\n (f) solely for dispensary, industrial, laboratory or manufacturing purposes.\n\n (2) Section 49 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.\n\n (3) The tactile identification or embossing required by subsections 46(1) and (3) and section 47 or Australian Standard AS 2216‑1997, Packaging for poisonous substances, do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.\n\n","sortOrder":54},{"sectionNumber":"52","sectionType":"section","heading":"Camphor and naphthalene","content":"52  Camphor and naphthalene\n\n (1) The container requirements of subsection 46(1) do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device:\n\n (a) in normal use, prevents removal or ingestion of its contents; and\n\n (b) is incapable of reacting with the poison; and\n\n (c) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and\n\n (d) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it.\n\n (2) Camphor or naphthalene must not be supplied in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents.\n\n","sortOrder":55},{"sectionNumber":"53","sectionType":"section","heading":"Prohibitions—use of containers for poisons","content":"53  Prohibitions—use of containers for poisons\n\n (1) A poison must not be supplied in a container that is embossed or indelibly marked with the name of another poison.\n\n (2) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply a poison for internal use.\n\n (3) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply food (including a condiment) or drink.\n\n (4) A poison must not be supplied in a container that is not readily distinguishable from a container in which food (including a condiment) or drink is sold.\n\n","sortOrder":56},{"sectionNumber":"Div 4","sectionType":"division","heading":"Storage","content":"Division 4—Storage\n\n","sortOrder":57},{"sectionNumber":"54","sectionType":"section","heading":"General storage requirements","content":"54  General storage requirements\n\nPoisons included in Schedule 2\n\n (1) A poison included in Schedule 2 that is stored at premises for supply to the public must be stored in such a way that public access to advice from a pharmacist is available if required.\n\nPoisons included in Schedules 3 and 4\n\n (2) A poison included in Schedule 3 or 4 that is stored at premises for supply to the public must be stored in a part of the premises to which the public does not have access.\n\nPoisons included in Schedule 6\n\n (3) A poison included in Schedule 6 that is stored at premises for supply by way of retail sale must be stored in such a way as to prevent access by children.\n\nPoisons included in Schedule 7\n\n (4) A poison included in Schedule 7 that is stored at premises for supply by retail sale must be stored in an area of the premises, and in a manner, that allows physical access only by the following:\n\n (a) the owner of the retail establishment;\n\n (b) an employee of the owner;\n\n (c) a person who is legally permitted to purchase the poison and is under the supervision of the owner or an employee of the owner.\n\n","sortOrder":58},{"sectionNumber":"Div 5","sectionType":"division","heading":"Disposal","content":"Division 5—Disposal\n\n","sortOrder":59},{"sectionNumber":"55","sectionType":"section","heading":"General disposal requirements","content":"55  General disposal requirements\n\n  A poison included in Schedule 5, 6 or 7 must not be disposed of in any place or manner that constitutes or is likely to constitute a risk to public health or safety.\n\nNote: Controls on the disposal of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.\n\n","sortOrder":60},{"sectionNumber":"Div 6","sectionType":"division","heading":"Record keeping","content":"Division 6—Record keeping\n\n","sortOrder":61},{"sectionNumber":"56","sectionType":"section","heading":"General record‑keeping requirements","content":"56  General record‑keeping requirements\n\n (1) If a poison included in Schedule 7 is supplied, a record of the following must be kept:\n\n (a) the name and address of the supplier and of the purchaser;\n\n (b) the date of the order and supply;\n\n (c) the approved name or trade name of the poison;\n\n (d) the quantity supplied or sold;\n\n (e) if an authorisation is required for purchase of the poison under the law of the jurisdiction in which the purchaser purchases the poison—proof that the purchaser has the required authorisation.\n\n (2) The records mentioned in subsection (1) must be kept for at least 5 years.\n\nNote: Controls on record keeping for the supply of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.\n\n","sortOrder":62},{"sectionNumber":"Div 7","sectionType":"division","heading":"Advertising","content":"Division 7—Advertising\n\n","sortOrder":63},{"sectionNumber":"57","sectionType":"section","heading":"General advertising requirements","content":"57  General advertising requirements\n\nPoisons included in Schedule 3, 4 and 8\n\n (1) A reference to a poison included in:\n\n (a) Schedule 3, unless included in Appendix H; or\n\n (b) Schedule 4; or\n\n (c) Schedule 8;\n\nmust not be included in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.\n\nPoisons included in Schedules 9 and 10\n\n (2) A reference to a poison included in Schedule 9 or Schedule 10 must not be included in any advertisement.\n\nNote: Schedule 10 includes poisons previously listed in Appendix C.\n\n","sortOrder":64},{"sectionNumber":"Div 8","sectionType":"division","heading":"Supply, prescribing, possession or use","content":"Division 8—Supply, prescribing, possession or use\n\n","sortOrder":65},{"sectionNumber":"58","sectionType":"section","heading":"Poisons included in Schedule 2","content":"58  Poisons included in Schedule 2\n\n (1) A poison included in Schedule 2 must not be supplied by a person other than:\n\n (a) a person who:\n\n (i) is a pharmacist (or an assistant under the direction of a pharmacist) or a medical practitioner, dental practitioner or veterinarian; and\n\n (ii) is acting in the lawful practice of the person’s profession; or\n\n (b) a person who is licensed to supply the poison under the law of the jurisdiction from which the person will supply the poison.\n\n (2) A person is not eligible to be granted a licence to supply a poison included in Schedule 2 unless:\n\n (a) the person is carrying on the business of supplying goods by retail sale; and\n\n (b) the premises from which the poison will be supplied is more than 25 km by the shortest practicable route from the nearest pharmacy; and\n\n (c) if required by the law of the jurisdiction from which the person will supply the poison—the person produces evidence that the person is a fit and proper person to be so licensed.\n\n (3) Subsection (1) does not apply to the supply of a poison included in Schedule 2 by way of wholesale dealing to:\n\n (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.\n\n","sortOrder":66},{"sectionNumber":"59","sectionType":"section","heading":"Poisons included in Schedule 3","content":"59  Poisons included in Schedule 3\n\n (1) A poison included in Schedule 3 must not be supplied by a person other than a person who:\n\n (a) is a pharmacist, medical practitioner, dental practitioner or veterinarian; and\n\n (b) is acting in the lawful practice of the person’s profession.\n\n (2) The following requirements apply if a poison included in Schedule 3 is supplied:\n\n (a) adequate instructions for use, either written or verbal, must be provided at the time of supply;\n\n (b) the container of the poison must be labelled with:\n\n (i) the name of the supplier or the name of the pharmacy (as applicable); and\n\n (ii) the address from which it was supplied;\n\n (c) if required by the law of the jurisdiction from which the supplier supplies the poison—a record of the transaction must be made in a prescription book or other approved recording system.\n\n (3) This section does not apply to the supply of a poison included in Schedule 3 by way of wholesale dealing to:\n\n (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.\n\n","sortOrder":67},{"sectionNumber":"60","sectionType":"section","heading":"Poisons included in Schedule 4","content":"60  Poisons included in Schedule 4\n\n (1) A poison included in Schedule 4 must not be supplied by a person other than:\n\n (a) a person who:\n\n (i) is a medical practitioner, dental practitioner or veterinarian; and\n\n (ii) is acting in the lawful practice of the person’s profession; or\n\n (b) a pharmacist dispensing a legal prescription for the poison; or\n\n (c) a pharmacist supplying the poison without a prescription as permitted by subsection (2).\n\n (2) A poison included in Schedule 4 may be supplied to a person (the patient) by a pharmacist without a prescription if:\n\n (a) the poison is not excepted from this provision by the law of the jurisdiction from which the pharmacist supplies the poison; and\n\n (b) the patient is under medical treatment with the poison and continuation of medication is essential; and\n\n (c) the quantity supplied does not exceed 3 days’ medication; and\n\n (d) the pharmacist is satisfied that an emergency exists.\n\n (3) Subsection (1) does not apply to the supply of a poison included in Schedule 4 by way of wholesale dealing to:\n\n (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.\n\n","sortOrder":68},{"sectionNumber":"61","sectionType":"section","heading":"Poisons included in Schedules 5 and 6","content":"61  Poisons included in Schedules 5 and 6\n\n (1) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in any manner unless the recipient has the opportunity to refuse at the time of supply.\n\n (2) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in an unsolicited manner (for example by post or by attaching the sample to another product).\n\n (3) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in a manner that does not promote disposal in accordance with Division 5.\n\n","sortOrder":69},{"sectionNumber":"62","sectionType":"section","heading":"Poisons included in Schedule 7","content":"62  Poisons included in Schedule 7\n\nPossession or use for domestic or domestic garden purposes prohibited\n\n (1) A poison included in Schedule 7 must not be possessed or used for domestic or domestic garden purposes.\n\nSupply for domestic or domestic garden purposes prohibited\n\n (2) A poison included in Schedule 7 must not be supplied for domestic or domestic garden purposes.\n\nSupply of liquid preparations containing paraquat\n\n (3) A poison included in Schedule 7 that is a liquid preparation containing paraquat must not be supplied unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell.\n\nSupply if authorisation required by appropriate authority\n\n (4) A poison included in Schedule 7 for which an authorisation to purchase, possess or use is required by the appropriate authority must not be supplied unless the purchaser produces the required authorisation.\n\nProduct samples prohibited\n\n (5) A product sample containing a poison included in Schedule 7 must not be supplied.\n\nSupply of poisons included in Appendix J\n\n (6) A poison included in Schedule 7 that is included in the table in clause 1 of Appendix J may be supplied only in accordance with that clause.\n\n","sortOrder":70},{"sectionNumber":"63","sectionType":"section","heading":"Poisons included in Schedule 10","content":"63  Poisons included in Schedule 10\n\n  A poison included in Schedule 10 must not be possessed, supplied or used for a purpose indicated in relation to that poison in Schedule 10.\n\nNote: Schedule 10 includes poisons previously listed in Appendix C.\n\n","sortOrder":71},{"sectionNumber":"64","sectionType":"section","heading":"Poisons included in Schedule 4 or 8 and Appendix D","content":"64  Poisons included in Schedule 4 or 8 and Appendix D\n\n (1) This section applies to a poison included in Schedule 4 or 8.\n\nSupply or prescribing\n\n (2) A poison included in a table in clause 1, 2, 3, 4, 6 or 7 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with the clause that contains the table.\n\n (3) A poison referred to in clause 8 or 10 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with clause 8 or 10 (as applicable) of Appendix D.\n\nPossession\n\n (4) A poison included in the table in clause 5 of Appendix D must not be possessed by a person without authority under the law of the jurisdiction in which the possession occurs.\n\nStorage\n\n (5) A poison included in the table in clause 9 of Appendix D must be stored in a locked container to prevent unauthorised access.\n\n","sortOrder":72},{"sectionNumber":"65","sectionType":"section","heading":"Hawking","content":"65  Hawking\n\n  A poison included in Schedule 7 must not be supplied by way of hawking.\n\nNote: Controls on supply by way of hawking of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.\n\n","sortOrder":73},{"sectionNumber":"Div 9","sectionType":"division","heading":"Paints and tinters","content":"Division 9—Paints and tinters\n\nNote: Paints and tinters are poisons that were previously listed in Appendix I.\n\n","sortOrder":74},{"sectionNumber":"66","sectionType":"section","heading":"General requirements","content":"66  General requirements\n\n (1) A first group paint must not be manufactured, supplied or used for application to:\n\n (a) a roof or any surface to be used for the collection or storage of potable water; or\n\n (b) furniture; or\n\n (c) any fence, wall, post, gate or building (interior or exterior) other than a building that is used exclusively for industrial purposes or mining or as an oil terminal; or\n\n (d) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.\n\n (2) An anti‑fouling paint containing more than 0.1% lead (the proportion of lead for the purposes of this section is calculated as a percentage of the element present in the non‑volatile content of the paint) must not be manufactured, supplied or used.\n\n (3) A paint (other than an anti‑fouling paint) or tinter containing more than 0.009% lead (calculated as a percentage of the element present in the non‑volatile content of the paint) must not be manufactured, supplied or used.\n\n (4) A paint for application to toys must not be manufactured, supplied or used unless it complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012, Safety of toys Part 3: Migration of certain elements (ISO 8124‑03:2010, MOD), published jointly by, or on behalf of, Standards Australia and Standards New Zealand.\n\n (5) A paint or tinter containing a pesticide other than a fungicide, algaecide, bactericide or antifouling agent must not be manufactured, supplied or used.\n\n","sortOrder":75},{"sectionNumber":"67","sectionType":"section","heading":"Definition of first group paint","content":"67  Definition of first group paint\n\n  A paint containing a substance mentioned in column 1 of an item in the following table in the proportion (calculated as a percentage of the element present in the non‑volatile content of the paint) specified in column 2 of the item is a first group paint.\n\n \n\n- First group paints\n- Item Column 1 Substance Column 2 Proportion\n- 1 ANTIMONY or antimony compounds other than antimony titanate pigments more than 5%\n- 2 BARIUM salts except barium sulfate or barium metaborate more than 5%\n- 3 CADMIUM or cadmium compounds more than 0.1%\n- 4 CHROMIUM as chromates of ammonia, barium, potassium sodium, strontium or zinc more than 5%\n- 5 SELENIUM or selenium compounds more than 0.1%\n\n","sortOrder":76},{"sectionNumber":"68","sectionType":"section","heading":"Definition of second group paint","content":"68  Definition of second group paint\n\n  A paint containing a substance mentioned in column 1 of an item in the following table in the proportion specified in column 2 of the item is a second group paint.\n\n \n\n- Second group paints\n- Item Column 1 Substance Column 2 Proportion\n- 1 DICHLOROMETHANE (methylene chloride) more than 5% by weight\n- 2 ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates more than 10% by volume\n- 3 HEXYLOXYETHANOL more than 10% by volume\n- 4 TOLUENE more than 50% by volume\n- 5 XYLENE more than 50% by volume\n\n","sortOrder":77},{"sectionNumber":"Sch 1","sectionType":"schedule","heading":"Blank","content":"Schedule 1—Blank\n\n \n\n \n\nNote: Schedule 1 is intentionally blank.\n\n","sortOrder":78},{"sectionNumber":"Sch 2","sectionType":"schedule","heading":"Pharmacy medicines","content":"Schedule 2—Pharmacy medicines\n\n \n\n \n\nNote: See section 16, subsection 54(1) and section 58.\n\nACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) for therapeutic use.\n\nACETYLCYSTEINE in preparations for oral use except when labelled with a recommended daily dose of 1 g or less of acetylcysteine.\n\nACONITUM spp. for therapeutic use in adults:\n\n (a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids; or\n\n (b) in preparations for dermal use containing 0.02% or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids.\n\nALIMEMAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:\n\n (b) in a day‑night pack containing alimemazine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;\n\nALOXIPRIN.\n\nAMOROLFINE in preparations for topical use except in preparations for the treatment of tinea pedis.\n\nANTAZOLINE in eye drops.\n\nASPIRIN except when:\n\n (a) included in Schedule 4, 5 or 6; or\n\n (b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:\n\n (i) enclosed in a primary pack that contains 12 or less individually wrapped powders or sachets of granules; and\n\n (ii) compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in tablets or capsules containing aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:\n\n (i) either:\n\n (A) packed in blister or strip packing; or\n\n (B) in a container with a child-resistant closure; and\n\n (ii) either:\n\n (A) in a primary pack that contains not more than 25 tablets or capsules, each containing 325 mg or less of aspirin; or\n\n (B) in a primary pack that contains not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; or\n\n (C) in a primary pack that contains not more than 100 tablets or capsules, each containing 100 mg or less of aspirin, and that is labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and\n\n (iii) compliant with the requirements of the required advisory statements for medicine labels.\n\nASTODRIMER SODIUM when used in a nasal spray.\n\nATROPA BELLADONNA (belladonna):\n\n (a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or\n\n (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.\n\nATROPINE (excluding atropine methonitrate) for oral use:\n\n (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.\n\nAZELAIC ACID in dermal preparations.\n\nAZELASTINE:\n\n (a) in preparations for nasal use; or\n\n (b) in topical eye preparations containing 0.05% or less of azelastine.\n\nBECLOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of beclometasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.\n\nBENZOCAINE in preparations for topical use other than eye drops:\n\n (a) containing 10% or less of total local anaesthetic substances, except in dermal preparations containing 2% or less of total local anaesthetic substances; or\n\n (b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.\n\nBENZOYL PEROXIDE in preparations for human external therapeutic use containing 10% or less of benzoyl peroxide except in preparations containing 5% or less of benzoyl peroxide.\n\nBENZYDAMINE in preparations for topical use, except:\n\n (a) in preparations for dermal use; or\n\n (b) in divided topical oral preparations containing 3 mg or less of benzydamine; or\n\n (c) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.\n\nBEPHENIUM SALTS.\n\nBIFONAZOLE in preparations for dermal use except:\n\n (a) in preparations containing 1% or less of bifonazole for the treatment of the scalp; or\n\nBILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 20 mg bilastine for the treatment of adults and children aged 12 years and over.\n\nBRIMONIDINE in ophthalmic preparations for adult use containing not more than 0.025% of brimonidine.\n\nBROMHEXINE.\n\nBROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:\n\n (b) in a day‑night pack containing brompheniramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;\n\nBUDESONIDE in aqueous nasal sprays delivering 64 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.\n\nCARBETAPENTANE except in preparations containing 0.5% or less of carbetapentane.\n\nCARBOCISTEINE.\n\nCETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:\n\n (a) in a primary pack containing not more than 10 days’ supply; and\n\n (b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.\n\nCHLOPHEDIANOL.\n\nCHLORBUTANOL for human use in topical preparations containing 5% or less of chlorbutanol except in preparations containing 0.5% or less of chlorbutanol.\n\nCHLOROFORM in preparations for therapeutic use except:\n\n (b) in preparations containing 0.5% or less of chloroform.\n\nCHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:\n\n (b) in a day‑night pack containing chlorphenamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;\n\nCHOLINE SALICYLATE in preparations for oromucosal use.\n\nCICLOPIROX:\n\n (a) in preparations for dermal use containing 2% or less of ciclopirox except in preparations for the treatment of tinea pedis; or\n\n (b) in preparations for application to the nails containing 8% or less of ciclopirox.\n\nCINCHOCAINE in preparations for topical use other than eye drops, containing 0.5% or less of total local anaesthetic substances.\n\nCINNAMEDRINE.\n\nCLOTRIMAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.\n\nCREOSOTE derived from wood other than beechwood for human therapeutic use, except in preparations containing 10% or less of creosote derived from wood other than beechwood.\n\nDATURA spp. for oral use:\n\n (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or\n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;\n\n except when separately specified in these Schedules.\n\nDATURA STRAMONIUM (stramonium) for oral use when:\n\n (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;\n\n except for smoking or burning.\n\nDATURA TATULA (stramonium) for oral use:\n\n (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;\n\n except for smoking or burning.\n\nDELPHINIUM STAPHISAGRIA except in preparations containing 0.2% or less of Delphinium staphisagria.\n\nDESLORATADINE in preparations for oral use.\n\nDEXCHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:\n\n (b) in a day‑night pack containing dexchlorphenamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;\n\nDEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.\n\nDIBROMOPROPAMIDINE for ophthalmic use.\n\nDICLOFENAC when:\n\n (a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac; or\n\n (b) in preparations for dermal use containing 4% or less of diclofenac except in preparations for dermal use containing 2% or less of diclofenac or for the treatment of solar keratosis; or\n\n (c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.\n\nDIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.\n\nDIPHENHYDRAMINE in oral preparations:\n\n (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or\n\n (b) when combined with one or more other therapeutically active substances when:\n\n (ii) in a day‑night pack containing diphenhydramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;\n\nDOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:\n\n (b) in a day‑night pack containing doxylamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;\n\nDUBOISIA LEICHHARDTII for oral use:\n\n (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.\n\nDUBOISIA MYOPOROIDES for oral use:\n\n (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.\n\nECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis.\n\nESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply.\n\nETAFEDRINE.\n\nETHER for therapeutic use except:\n\n (b) in preparations containing 10% or less of ether.\n\nETHYLMORPHINE when:\n\n (a) compounded with one or more other therapeutically active substances:\n\n (i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or\n\n (ii) in undivided preparations containing 0.25% or less of ethylmorphine; and\n\n (b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.\n\nETOFENAMATE in preparations for external use.\n\nFAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply.\n\nFELBINAC in preparations for external use.\n\nFEXOFENADINE in preparations for oral use except in divided preparations:\n\n (a) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n (ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or\n\n (b) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n (i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and\n\n (ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or\n\n (c) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:\n\n (ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.\n\nFLUORIDES for human use:\n\n (a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or\n\n (b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child‑resistant closure:\n\n (i) for therapeutic use when compliant with the requirements of the required advisory statements for medicine labels except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child‑resistant closure and compliant with the requirements of required advisory statements for medicine labels; or\n\n (ii) for non‑therapeutic use when labelled with warnings to the following effect:\n\n (A) Do not swallow; and\n\n (B) Do not use [this product/insert name of product] in children 6 years of age or less;\n\n  except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child‑resistant closure and labelled with warnings to the following effect:\n\n (C) Do not swallow; and\n\n (D) Do not use [this product/insert name of product] in children 6 years of age or less;\n\n except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.\n\nFLURBIPROFEN in preparations for topical oral use when:\n\n (a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit except when:\n\n (i) in a primary pack containing not more than 16 dosage units; and\n\n (ii) labelled only for the treatment of adults and children over 12 years; or\n\n (b) in undivided preparations containing either:\n\n (i) 0.25% or less of flurbiprofen per dose; or\n\n (ii) 10 mg or less of flurbiprofen per dose;\n\n (iii) in a primary pack containing not more than 15 mL; and\n\n (iv) labelled only for the treatment of adults 18 years and over.\n\nFLUTICASONE PROPIONATE (excluding derivatives) in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.\n\nFOLIC ACID for human therapeutic use except:\n\n (b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.\n\nFOLINIC ACID for human therapeutic use except:\n\n (b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.\n\nFORMALDEHYDE (excluding its derivatives) for human therapeutic use except:\n\n (a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or\n\n (b) in other preparations containing 0.2% or less of free formaldehyde.\n\nGELSEMIUM SEMPERVIRENS.\n\nGLUTARAL for human therapeutic use.\n\nGUAIFENESIN in a modified release dosage form of 1200 mg or less of guaifenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.\n\nHEXACHLOROPHENE in preparations for human use containing 3% or less of hexachlorophene except:\n\n (a) in preparations for use on infants, as specified in Schedule 4; or\n\n (b) in preparations for cosmetic use, as specified in Schedule 6; or\n\n (c) in other preparations containing 0.75% or less of hexachlorophene.\n\nHYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use:\n\n (a) for dermal use in preparations containing 0.5% or less of hydrocortisone, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or\n\n (b) for dermal use in preparations containing 1% or less of hydrocortisone, in packs containing 15 g or less of such preparations, containing an antifungal substance and no other therapeutically active constituent:\n\n (i) for the treatment of tinea (tinea pedis, tinea cruris, tinea corporis) and other fungal skin infections; and\n\n (ii) not labelled for the treatment of children under 12 years of age; or\n\n (c) for rectal use in preparations containing 0.5% or less of hydrocortisone, when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:\n\n (i) in undivided preparations in packs of 35 g or less; or\n\n (ii) in packs containing 12 or less suppositories.\n\nHYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2% or less of hydroquinone except:\n\n (a) in hair preparations containing 0.3% or less of hydroquinone; or\n\n (b) in cosmetic nail preparations containing 0.02% or less of hydroquinone.\n\nHYOSCINE:\n\n (a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or\n\n (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.\n\nHYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.\n\nHYOSCYAMINE:\n\n (a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or\n\n (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.\n\nHYOSCYAMUS NIGER for oral use:\n\n (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n (b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;\n\n except in a pack containing 0.03 mg or less of total solanaceous alkaloids.\n\nIBUPROFEN in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen, when:\n\n (a) in liquid preparations that are sold in the manufacturer’s original pack containing 8 g or less of ibuprofen; or\n\n (b) in divided immediate release preparations:\n\n (i) each containing 400 mg or less of ibuprofen in a primary pack containing not more than 12 dosage units; and\n\n (ii) that are labelled not for the treatment of children under 12 years; or\n\n (c) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units except when:\n\n (i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and\n\n (ii) packed in blister or strip packaging or in a container with a child-resistant closure; and\n\n (v) not labelled for the treatment of children 6 years or under; and\n\n (vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.\n\nINDANAZOLINE.\n\nINDOMETACIN in preparations for external use containing 1% or less of indometacin.\n\nIODINE:\n\n (a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or\n\n (b) in preparations for human external therapeutic use containing more than 2.5% of available iodine (excluding salts, derivatives or iodophors);\n\n except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.\n\nIPRATROPIUM in preparations for nasal use.\n\nIRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1% or less of total iron oxides) for human internal use except:\n\n (b) when labelled with a recommended daily dose of 24 mg or less of iron:\n\n (i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or\n\n (ii) in divided preparations:\n\n (A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or\n\n (B) containing 5 mg or less of iron per dosage unit.\n\nISOCONAZOLE for human use in dermal preparations.\n\nISOPROPAMIDE in preparations for dermal use containing 2% or less of isopropamide.\n\nKETOCONAZOLE in preparations for dermal use except:\n\n (a) in preparations containing 1% or less of ketoconazole for the treatment of the scalp; or\n\nKETOTIFEN for ophthalmic use in preparations containing 0.025% or less of ketotifen.\n\nLANSOPRAZOLE in oral preparations 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.\n\nLEVOCABASTINE in topical eye or nasal preparations.\n\nLEVOCETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n (a) in a primary pack containing not more than 5 days’ supply; and\n\n (b) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.\n\nLIDOCAINE in preparations for topical use other than eye drops:\n\n (a) containing 10% or less of total local anaesthetic substances, except:\n\n (i) in dermal preparations containing 2% or less of total local anaesthetic substances; or\n\n (ii) in aqueous sprays for oromucosal use containing 0.6% or less of total local anaesthetic substances; or\n\n (b) in divided preparations containing 200 mg or less of total local anaesthetic substances, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.\n\nLINDANE in preparations for human external therapeutic use containing 2% or less of lindane.\n\nLITHIUM in preparations for dermal use containing 1% or less of lithium except:\n\n (a) when present as an excipient at 0.25% or less of lithium; or\n\n (b) in preparations containing 0.01% or less of lithium.\n\nLOBELIA INFLATA except for smoking or burning.\n\nLOBELINE except in preparations for smoking or burning.\n\nLODOXAMIDE in preparations for ophthalmic use.\n\nLOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less except in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.\n\nLORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis when:\n\n (a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and\n\n (b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.\n\nMACROGOLS in preparations for oral use as a liquid concentrate for laxative use.\n\nMEBENDAZOLE for human therapeutic use.\n\nMECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.\n\nMEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.\n\nMEPYRAMINE for dermal use.\n\nMERCUROCHROME in preparations for external use containing 2% or less of mercurochrome except when included in Schedule 6.\n\nMERCURY for external use in preparations containing 0.5% or less of mercury.\n\nMETHOXAMINE in preparations for external use except in preparations containing 1% or less of methoxamine.\n\nMETHOXYPHENAMINE.\n\nMETHYLEPHEDRINE.\n\nMICONAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.\n\nMINOXIDIL in preparations for dermal use containing 5% or less of minoxidil.\n\nMOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.\n\nNAPHAZOLINE.\n\nNAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.\n\nNICLOSAMIDE for human therapeutic use.\n\nNIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply.\n\nNOSCAPINE.\n\nNYSTATIN in dermal preparations.\n\nOLOPATADINE in preparations for nasal use delivering 600 micrograms or less of olopatadine per dose when the maximum recommended daily dose is no greater than 4,800 micrograms for the treatment of allergic rhinitis or rhinoconjunctivitis for up to 6 months in adults and children 12 years of age and over.\n\nOMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.\n\nOXETACAINE (oxethazaine) in preparations for internal use.\n\nOXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis.\n\nOXYMETAZOLINE.\n\nOXYQUINOLINE and its non‑halogenated derivatives for human therapeutic use, except in preparations for external use containing 1% or less of such substances.\n\nPAPAVERINE except when included in Schedule 4.\n\nPANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.\n\nPARACETAMOL for therapeutic use:\n\n (a) in liquid preparations for oral use containing a maximum of 10 g of paracetamol per container; or\n\n (b) when combined with ibuprofen in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided doses in a primary pack containing no more than 12 dosage units per pack; or\n\n (c) in tablets or capsules enclosed in a primary pack containing not more than 100 tablets or capsules; or\n\n (d) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine pack and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or\n\n (e) in individually wrapped powders or sachets of granules enclosed in a primary pack containing not more than 50 wrapped powders or sachets of granules; or\n\n (f) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules intended only as a bulk medicine pack and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or\n\n (g) in other preparations except:\n\n (i) when included in Schedule 3 or 4; or\n\n (ii) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:\n\n (A) enclosed in a primary pack that contains not more than 10 such powders or sachets of granules;\n\n (B) compliant with the requirements of the required advisory statements for medicine labels;\n\n (C) not labelled for the treatment of children 6 years of age or less; and\n\n (D) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin; or\n\n (iii) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:\n\n (A) packed in blister or strip packaging or in a container with a child‑resistant closure;\n\n (B) in a primary pack containing not more than 20 tablets or capsules;\n\n (C) compliant with the requirements of the required advisory statements for medicine labels;\n\n (D) not labelled for the treatment of children 6 years of age or less; and\n\n (E) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin.\n\nPARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use except:\n\n (a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or\n\n (b) in other preparations containing 0.2% or less of free formaldehyde.\n\nPHEDRAZINE.\n\nPHENAZONE for human external use.\n\nPHENIRAMINE:\n\n (a) in eye drops; or\n\n (b) when combined with one or more other therapeutically active substances in oral preparations when:\n\n (ii) in a day‑night pack containing pheniramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;\n\nPHENOL, or any homologue boiling below 220°C, for human therapeutic use except:\n\n (b) in preparations for external use containing 1% or less of phenol and in preparations for external use containing 3% or less of cresols and xylenols and other homologues of phenol.\n\nPHENYLEPHRINE except:\n\n (b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or\n\n (c) in topical eye or nasal preparations containing 1% or less of phenylephrine.\n\nPHOLCODINE:\n\n (a) in liquid preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or\n\n (b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.\n\nPIPERAZINE for human therapeutic use.\n\nPODOPHYLLOTOXIN in preparations containing 0.5% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.\n\nPODOPHYLLUM EMODI (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.\n\nPODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.\n\nPOTASSIUM CHLORATE for therapeutic use except in preparations containing 10% or less of potassium chlorate.\n\nPRILOCAINE in preparations for dermal use containing 10% or less of total local anaesthetic substances.\n\nPROCYCLIDINE in preparations containing 5% or less of procyclidine for dermal use.\n\nPROMETHAZINE in oral preparations:\n\n (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or\n\n (b) when combined with one or more other therapeutically active substances when:\n\n (ii) in a day‑night pack containing promethazine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;\n\nPROPAMIDINE for ophthalmic use.\n\nPYRANTEL for human therapeutic use.\n\nPYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10% of such substances.\n\nPYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels.\n\nRABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.\n\nRANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days’ supply except:\n\n (a) in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units; or\n\n (b) in divided preparations for oral use containing 300 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units.\n\nSALICYLAMIDE except when included in Schedule 4.\n\nSELENIUM in preparations for human therapeutic use except:\n\n (a) for topical use containing 3.5% or less of selenium sulfide;\n\n (b) when included in Schedule 4; or\n\n (c) for oral use with a recommended daily dose of 150 micrograms or less.\n\nSILVER for therapeutic use except:\n\n (a) in solutions for human oral use containing 0.3% or less of silver when compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in other preparations containing 1% or less of silver.\n\nSODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.\n\nSODIUM NITRITE for therapeutic use (excluding when present as an excipient).\n\nSQUILL except in preparations containing 1% or less of squill.\n\nSULCONAZOLE in preparations for dermal use.\n\nTERBINAFINE for dermal use except in preparations for the treatment of tinea pedis.\n\nTETRACAINE in preparations for topical use other than eye drops, containing 10% or less of total local anaesthetic substances except in dermal preparations containing 2% or less of total local anaesthetic substances.\n\nTETRACHLOROETHYLENE for human therapeutic use.\n\nTETRYZOLINE.\n\nTHIABENDAZOLE for human therapeutic use.\n\nTIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.\n\nTRAMAZOLINE.\n\nTRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.\n\nTRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:\n\n (b) in a day‑night pack containing triprolidine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;\n\nTUAMINOHEPTANE.\n\nTYMAZOLINE.\n\nXYLOMETAZOLINE.\n\nZINC CHLORIDE for human dermal use except in preparations containing 5% or less of zinc chloride.\n\n","sortOrder":79},{"sectionNumber":"Sch 3","sectionType":"schedule","heading":"Pharmacist only medicines","content":"Schedule 3—Pharmacist only medicines\n\n \n\n \n\nNote: See sections 16 and 31, subsections 54(2) and 57(1) and section 59.\n\nADAPALENE in topical preparations containing 0.1% or less of adapalene for the treatment of acne vulgaris in adults and in children over 12 years of age.\n\nADRENALINE in preparations containing 1% or less of adrenaline except in preparations that are not for injection containing 0.02% or less of adrenaline.\n\nALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of alclometasone in packs containing 30 g or less of the preparation.\n\nALIMEMAZINE:\n\n (a) in solid oral preparations except when included in Schedule 2; or\n\n (b) in liquid oral preparations containing 10 mg or less of alimemazine per 5 mL;\n\nAMINOPHYLLINE in liquid oral preparations containing 2% or less of aminophylline.\n\nAMYL NITRITE when in preparations for human therapeutic use and packaged in containers with child‑resistant closures.\n\nASTODRIMER SODIUM except:\n\n (b) in a condom lubricant.\n\nAZATADINE in oral preparations.\n\nBILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 10 mg of bilastine for the treatment of children 6-11 years of age except when included in Schedule 2.\n\nBROMPHENIRAMINE in oral preparations except:\n\nBUCLIZINE in oral preparations.\n\nBUTOCONAZOLE in preparations for vaginal use.\n\nCANNABIDIOL in oral, oromucosal and sublingual preparations included in the Register when:\n\n (a) the cannabidiol is either plant derived or, when synthetic, only contains the (‑)‑CBD enantiomer; and\n\n (b) the cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and\n\n (c) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation and of which tetrahydrocannabinol (THC) can only comprise 1% of the total cannabinoid content; and\n\n (d) the maximum recommended daily dose is 150 mg or less of cannabidiol; and\n\n (e) packed in blister or strip packaging or in a container fitted with a child‑resistant closure; and\n\n (f) in packs containing not more than 30 days’ supply; and\n\n (g) for persons aged 18 years and over.\n\nCELECOXIB in tablets or capsules each containing 200 mg or less of celecoxib, in a primary pack containing not more than 10 dosage units for the short‑term treatment of acute pain due to primary dysmenorrhea or musculoskeletal or soft tissue injuries in adults.\n\nCHLORAMPHENICOL for ophthalmic use only.\n\nCHLORBUTANOL in preparations for human use except:\n\n (b) in preparations containing 0.5% or less of chlorbutanol.\n\nCHLORPHENAMINE in oral preparations except:\n\nCICLOPIROX in preparations for dermal use and for application to the nails except:\n\nCIMETIDINE in a primary pack containing not more than 14 days’ supply.\n\nCLEMASTINE in preparations for oral use.\n\nCLOBETASONE (clobetasone‑17‑butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of clobetasone in packs containing 30 g or less of the preparation.\n\nCLOTRIMAZOLE in preparations for vaginal use.\n\nCYCLIZINE in divided preparations for oral use in primary packs containing 6 dosage units or less.\n\nCYPROHEPTADINE in oral preparations.\n\nDEXCHLORPHENAMINE in oral preparations except:\n\nDICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units except when included in Schedule 2.\n\nDIHYDROCODEINE when indicated for cough suppression and compounded with one or more other therapeutically active substances:\n\n (a) in divided preparations containing 10 mg or less of dihydrocodeine per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or\n\n (b) in undivided preparations containing 0.25% or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine.\n\nDIIODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.\n\nDIMENHYDRINATE in oral preparations except when included in Schedule 2.\n\nDIMETHINDENE in oral preparations.\n\nDIPHENHYDRAMINE in oral preparations except:\n\nDIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate.\n\nDITHRANOL for therapeutic use.\n\nDOXYLAMINE in oral preparations except:\n\nECONAZOLE in preparations for vaginal use.\n\nELETRIPTAN for oral use in tablets containing 40 mg or less per tablet and when in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.\n\nERYTHRITYL TETRANITRATE for therapeutic use.\n\nFAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).\n\nFLAVOXATE.\n\nFLUCONAZOLE in single‑dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.\n\nFLUORIDES for human topical use:\n\n (a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child‑resistant closure except when included in or expressly excluded from Schedule 2; or\n\n (b) in non‑liquid preparations containing 5500 mg/kg or less of fluoride ion except:\n\n (i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the required advisory statements for medicine labels; or\n\n (ii) in preparations for non‑therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:\n\n (A) Do not swallow; and\n\n (B) Do not use [this product/name of product] in children six years of age or less; or\n\n (iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.\n\nGLUCAGON.\n\nGLYCERYL TRINITRATE:\n\n (a) in preparations for oral use; or\n\n (b) in preparations for rectal use.\n\nGLYCOPYRRONIUM except when included in Schedule 4.\n\nHYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1% or less of hydrocortisone:\n\n (a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or\n\n (b) for dermal use, in packs containing 2 g or less of such preparations, containing no other therapeutically active constituent other than aciclovir (5% w/w or less) in adults and adolescents (12 years of age and older); or\n\n (c) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:\n\n (i) in undivided preparations, in packs of 35 g or less; or\n\n (ii) in packs containing 12 or less suppositories;\n\nHYOSCINE BUTYLBROMIDE in undivided preparations for oral use with a recommended single dose not exceeding 20 mg of hyoscine butylbromide in a pack containing 100 mg or less of hyoscine butylbromide when labelled for adults and children 6 years and over.\n\nIBUPROFEN when:\n\n (a) either:\n\n (i) in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units; or\n\n (ii) in a modified release dosage form, each containing 600 mg of ibuprofen, in a primary pack containing not more than 32 dosage units; and\n\n (b) labelled:\n\n (i) with a recommended daily dose of 1200 mg or less of ibuprofen; and\n\n (ii) not for the treatment of children under 12 years;\n\n (c) included in Schedule 2; or\n\n (d) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:\n\n (i) ibuprofen is the only therapeutically active constitutent, other than phenylephrine or when combined with an effervescent agent; and\n\n (ii) packed in a blister or strip packaging or in a container with a child-resistant closure; and\n\n (v) not labelled for the treatment of children 6 years or under; and\n\n (vi) when combined with phenylephrine—not labelled for the treatment of children under 12 years.\n\nINOSITOL NICOTINATE.\n\nISOCONAZOLE in preparations for vaginal use.\n\nISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.\n\nKETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.\n\nLANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.\n\nLEVONORGESTREL for emergency post‑coital contraception.\n\nMACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.\n\nMAGNESIUM SULFATE for human therapeutic use in divided oral preparations except when containing 1.5 g or less of magnesium sulfate per recommended daily dose.\n\nMALATHION in preparations for human external use except in preparations containing 2% or less of malathion.\n\nMANNITYL HEXANITRATE for therapeutic use.\n\nMELATONIN in:\n\n (a) modified release tablets containing 2 mg or less of melatonin for monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep for adults aged 55 or over, in packs containing not more than 30 tablets; or\n\n (b) immediate release preparations containing 5 mg or less of melatonin for the treatment of jet lag in adults 18 years and over, in a primary pack containing no more than 10 dosage units.\n\nMEPYRAMINE in oral preparations.\n\nMETHDILAZINE in oral preparations.\n\nMETOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.\n\nMICONAZOLE for human use in topical preparations:\n\n (a) for the treatment of oral candidiasis; or\n\n (b) for vaginal use.\n\nMOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.1% or less of mometasone in packs containing 15 g or less.\n\nNALOXONE when used for the treatment of opioid overdose.\n\nNAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment of children under 12 years of age.\n\nNARATRIPTAN when in divided oral preparations containing 2.5 mg or less of naratriptan per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.\n\nNICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit except:\n\n (a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or\n\n (b) nicotinamide.\n\nNICOTINYL ALCOHOL except in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.\n\nNYSTATIN in preparations for topical use except when included in Schedule 2.\n\nOMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.\n\nORLISTAT in oral preparations for weight‑control purposes containing 120 mg or less of orlistat per dosage unit.\n\nOXICONAZOLE in preparations for vaginal use.\n\nPANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.\n\nPARACETAMOL:\n\n (a) when combined with ibuprofen in a primary pack containing 30 dosage units or less except when included in Schedule 2; or\n\n (b) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing not more than 100 tablets or capsules; or\n\n (c) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or\n\n (d) in liquid preparations for oral use except when in Schedule 2.\n\nPHENIRAMINE in oral preparations except:\n\nPODOPHYLLOTOXIN in preparations containing 1% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.\n\nPODOPHYLLUM EMODI (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.\n\nPODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.\n\nPROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.\n\nPROMETHAZINE in oral preparations except:\n\n (b) in preparations for the treatment of children under 2 years of age.\n\nPSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight‑control purposes) when supplied in a primary pack:\n\n (a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or\n\n (b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).\n\nRABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.\n\nRIZATRIPTAN when in divided oral preparations containing 5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of migraine symptoms.\n\nSALBUTAMOL as the only therapeutically active substance:\n\n (a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or\n\n (b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.\n\nSALICYLIC ACID in preparations for dermal use except in preparations containing 40% or less of salicylic acid.\n\nSANTONIN.\n\nSODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.\n\nSODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.\n\nSULFACETAMIDE in preparations for ophthalmic use containing 10% or less of sulfacetamide.\n\nSUMATRIPTAN when in divided oral preparations containing 50 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.\n\nTERBUTALINE as the only therapeutically active substance:\n\n (a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or\n\n (b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.\n\nTHEOPHYLLINE in liquid oral preparations containing 2% or less of theophylline.\n\nTIOCONAZOLE in preparations for vaginal use.\n\nTRIAMCINOLONE for buccal use in preparations containing 0.1% or less of triamcinolone in a pack of 5 g or less.\n\nTRIPROLIDINE in oral preparations except:\n\nULIPRISTAL for emergency post‑coital contraception.\n\nVITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose except in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.\n\nZOLMITRIPTAN when in divided oral preparations containing 2.5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.\n\n","sortOrder":80},{"sectionNumber":"Sch 4","sectionType":"schedule","heading":"Prescription only medicines and prescription animal remedies","content":"Schedule 4—Prescription only medicines and prescription animal remedies\n\n \n\n \n\nNote 1: See sections 16, 28, 31 and 49, subsections 54(2) and 57(1) and section 60.\n\nNote 2: Substances marked # are listed in Appendix D.\n\nABACAVIR.\n\nABATACEPT.\n\nABIRATERONE ACETATE.\n\nABCIXIMAB.\n\nABEMACICLIB.\n\nABROCITINIB.\n\nACALABRUTINIB.\n\nACAMPROSATE CALCIUM.\n\nACARBOSE.\n\nACEBUTOLOL.\n\nACEPROMAZINE.\n\nACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.\n\nACETARSOL.\n\nACETAZOLAMIDE.\n\nACETOHEXAMIDE.\n\nACETYL ISOVALERYLTYLOSIN.\n\nACETYLCARBROMAL.\n\nACETYLCHOLINE.\n\nACETYLCYSTEINE except:\n\n (b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.\n\nACETYLDIGITOXIN.\n\nACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.\n\nACETYLSTROPHANTHIDIN.\n\nACICLOVIR except in preparations containing 5% or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.\n\nACIPIMOX.\n\n# ACITRETIN.\n\nACLIDINIUM BROMIDE.\n\nACOKANTHERA OUABAIO.\n\nACOKANTHERA SCHIMPERI.\n\nACONITUM spp. except:\n\n (b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or\n\n (c) in preparations for dermal use in adults containing 0.02% or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.\n\nACRIVASTINE.\n\nADALIMUMAB.\n\nADAPALENE except when included in Schedule 3.\n\nADEFOVIR.\n\nADENOSINE for human therapeutic use in preparations for injection.\n\nADIPHENINE.\n\nADONIS VERNALIS.\n\nADRAFINIL.\n\nADRENALINE in:\n\n (a) topical preparations for the treatment of wounds in humans; or\n\n (b) all other preparations containing adrenaline except when included in or expressly excluded from Schedule 3.\n\nADRENOCORTICAL HORMONES except when separately specified in these Schedules.\n\nAFAMELANOTIDE.\n\nAFATINIB DIMALEATE.\n\nAFLIBERCEPT.\n\nAGALSIDASE.\n\nAGLEPRISTONE.\n\nAGOMELATINE.\n\nALANYLGLUTAMINE.\n\nALATROFLOXACIN MESILATE.\n\nALBENDAZOLE except:\n\n (b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.\n\nALCLOFENAC.\n\nALCLOMETASONE except when included in Schedule 3.\n\nALCURONIUM.\n\nALDESLEUKIN.\n\nALDOSTERONE.\n\nALECTINIB.\n\n# ALEFACEPT.\n\nALEMTUZUMAB.\n\nALENDRONIC ACID.\n\nALFACALCIDOL.\n\nALFUZOSIN.\n\nALGLUCERASE.\n\nALGLUCOSIDASE.\n\nALIMEMAZINE except when included in Schedule 2 or 3.\n\nALIROCUMAB.\n\nALISKIREN.\n\nALKYL NITRITES except when separately specified in these schedules.\n\nALLERGENS for therapeutic use.\n\nALLOPURINOL.\n\nALLYLESTRENOL.\n\nALOGLIPTIN.\n\nALOSETRON.\n\nALPELISIB.\n\nALPHA1‑PROTEINASE INHIBITOR (HUMAN).\n\nALPHADOLONE.\n\nALPHAXALONE.\n\nALPRENOLOL.\n\nALPROSTADIL.\n\nALSEROXYLON.\n\nALTEPLASE.\n\nALTRENOGEST.\n\nALTRETAMINE (hexamethylmelamine).\n\nAMANTADINE.\n\nAMBENONIUM CHLORIDE.\n\n# AMBRISENTAN.\n\nAMBUCETAMIDE.\n\nAMBUTONIUM BROMIDE.\n\nAMCINONIDE.\n\nAMIFAMPRIDINE.\n\nAMIFOSTINE.\n\nAMIKACIN.\n\nAMILORIDE.\n\nAMINOCAPROIC ACID.\n\nAMINOGLUTETHIMIDE.\n\n5‑AMINOLEVULINIC ACID.\n\nAMINOMETRADINE.\n\nAMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.\n\nAMINOPHYLLINE except when included in Schedule 3.\n\nAMINOPTERIN.\n\n4‑AMINOPYRIDINE for therapeutic use.\n\nAMINOREX.\n\nAMINOSALICYLIC ACID.\n\nAMIODARONE.\n\nAMIPHENAZOLE.\n\nAMISOMETRADINE.\n\nAMISULPRIDE.\n\nAMITRIPTYLINE.\n\nAMLODIPINE.\n\nAMMI VISNAGA.\n\nAMMONIUM BROMIDE for therapeutic use.\n\nAMOBARBITAL when packed and labelled for injection.\n\nAMODIAQUINE.\n\nAMOROLFINE except:\n\nAMOXAPINE.\n\nAMOXICILLIN.\n\nAMPHOMYCIN.\n\nAMPHOTERICIN B.\n\nAMPICILLIN.\n\nAMPRENAVIR.\n\nAMRINONE.\n\nAMSACRINE.\n\nAMYL NITRITE except when included in Schedule 3.\n\nAMYLOCAINE.\n\n# ANABOLIC STEROIDAL AGENTS.\n\nANAGRELIDE.\n\nANAKINRA.\n\nANASTROZOLE.\n\nANCESTIM.\n\nANCROD and its immunoglobulin antidote.\n\nANDEXANET ALFA.\n\nANECORTAVE.\n\n# ANDROGENIC STEROIDAL AGENTS.\n\n# ANDROISOXAZOLE.\n\n# ANDROSTANOLONE.\n\n# ANDROSTENEDIOL.\n\n# ANDROSTENEDIONE.\n\nANGIOTENSIN AMIDE.\n\nANIDULAFUNGIN.\n\nANIRACETAM.\n\nANISTREPLASE.\n\nANTAZOLINE except when included in Schedule 2.\n\nANTIBIOTIC SUBSTANCES except:\n\n (b) nisin.\n\nANTIGENS for human therapeutic use except when separately specified in this Schedule.\n\nANTIHISTAMINES except:\n\nANTIMONY for therapeutic use except when separately specified in these Schedules.\n\nANTISERA (immunosera) for human use by injection except when separately specified in these Schedules.\n\n# AOD‑9604 (CAS No. 221231‑10‑3).\n\nAPALUTAMIDE.\n\nAPIXABAN.\n\nAPOCYNUM spp.\n\nAPOMORPHINE.\n\nAPRACLONIDINE.\n\nAPRAMYCIN.\n\nAPREMILAST.\n\nAPREPITANT.\n\nAPROTININ.\n\nARBUTIN (BETA) in oral preparations except herbal preparations containing 500 mg or less beta‑arbutin per recommended daily dose.\n\nARECOLINE.\n\nARIPIPRAZOLE.\n\nARMODAFINIL.\n\nARSENIC for human therapeutic use except when separately specified in these Schedules.\n\nARTEMETHER.\n\nARTICAINE.\n\nASCIMINIB.\n\nASENAPINE.\n\nASFOTASE ALFA.\n\nASPARAGINASE.\n\nASPIRIN when:\n\n (a) combined with caffeine, paracetamol or salicylamide; or\n\n (b) combined with any derivative of the substances mentioned in paragraph (a); or\n\n (c) for injection.\n\nASTEMIZOLE.\n\nASUNAPREVIR.\n\n# ATAMESTANE.\n\nATAZANAVIR.\n\nATENOLOL.\n\nATEZOLIZUMAB.\n\nATIPAMEZOLE.\n\nATOMOXETINE.\n\nATORVASTATIN.\n\nATOSIBAN.\n\nATOVAQUONE.\n\nATRACURIUM BESILATE.\n\nATROPA BELLADONNA (belladonna) except when included in Schedule 2.\n\nATROPINE except when included in Schedule 2.\n\nATROPINE METHONITRATE.\n\nAURANOFIN.\n\nAUROTHIOMALATE SODIUM.\n\nAVACOPAN.\n\nAVATROMBOPAG.\n\nAVELUMAB.\n\nAVILAMYCIN except:\n\n (a) in animal feed premixes containing 15% or less of avilamycin activity; or\n\n (b) in animal feeds containing 50 mg/kg or less of avilamycin activity.\n\nAVIPTADIL.\n\nAXITINIB.\n\nAVOPARCIN.\n\nAZACITIDINE.\n\nAZACYCLONOL.\n\nAZAPERONE.\n\nAZAPROPAZONE.\n\nAZARIBINE.\n\nAZATADINE except when included in Schedule 3.\n\nAZATHIOPRINE.\n\nAZELAIC ACID except:\n\n (b) in preparations containing 1% or less of azelaic acid for non‑human use.\n\nAZELASTINE except when included in Schedule 2.\n\nAZITHROMYCIN.\n\nAZLOCILLIN.\n\nAZTREONAM.\n\nBACAMPICILLIN.\n\nBACITRACIN.\n\nBACLOFEN.\n\nBALOXAVIR MARBOXIL.\n\nBALSALAZIDE.\n\nBAMBERMYCIN (flavophospholipol) except:\n\n (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.\n\nBAMBUTEROL.\n\nBAMETHAN.\n\nBAMIPINE.\n\nBARBITURATES except when separately specified in these Schedules.\n\nBARICITINIB.\n\nBASILIXIMAB.\n\nBAZEDOXIFENE.\n\nBECAPLERMIN.\n\nBECLAMIDE.\n\nBECLOMETASONE except when included in Schedule 2.\n\nBELATACEPT.\n\nBELIMUMAB.\n\nBELUMOSUDIL.\n\nBELZUTIFAN.\n\nBEMEGRIDE.\n\nBENACTYZINE.\n\nBENAZEPRIL.\n\nBENDAMUSTINE.\n\nBENDROFLUAZIDE.\n\nBENETHAMINE PENICILLIN.\n\nBENORYLATE.\n\nBENOXAPROFEN.\n\nBENPERIDOL.\n\nBENRALIZUMAB.\n\nBENSERAZIDE.\n\nBENZATHINE PENICILLIN.\n\nBENZILONIUM.\n\nBENZOCAINE except:\n\n (b) in dermal preparations containing 2% or less of total local anaesthetic substances; or\n\n (c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.\n\n# BENZODIAZEPINE derivatives except when separately specified in these Schedules.\n\nBENZOYL PEROXIDE in preparations for human therapeutic use except:\n\n (b) in preparations for external use containing 5% or less of benzoyl peroxide.\n\nBENZPHETAMINE.\n\nBENZTHIAZIDE.\n\nBENZATROPINE.\n\nBENZYDAMINE except:\n\n (b) in preparations for dermal use; or\n\n (c) in divided topical oral preparations containing 3 mg or less of benzydamine; or\n\n (d) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.\n\nBENZYLPENICILLIN.\n\nBEPRIDIL.\n\nBERACTANT.\n\nBESIFLOXACIN.\n\nBETAHISTINE.\n\nBETAMETHASONE.\n\nBETAXOLOL.\n\nBETHANECHOL CHLORIDE.\n\nBETHANIDINE.\n\nBEVACIZUMAB.\n\nBEVANTOLOL.\n\n# BEXAROTENE.\n\nBEZAFIBRATE.\n\nBEZLOTOXUMAB.\n\nBICALUTAMIDE.\n\nBICTEGRAVIR.\n\nBIFONAZOLE except:\n\n (b) in preparations for dermal use containing 1% or less of bifonazole for the treatment of the scalp; or\n\n (c) in preparations for dermal use for the treatment of tinea pedis.\n\nBILASTINE except when included in Schedule 2 or 3.\n\nBIMATOPROST.\n\nBINIMETINIB.\n\nBIPERIDEN.\n\nBISMUTH COMPOUNDS for cosmetic use, except:\n\n (a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5% or less; or\n\n (b) bismuth oxychloride.\n\nBISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth.\n\nBISOPROLOL.\n\nBIVALIRUDIN.\n\nBLEOMYCIN.\n\nBLINATUMOMAB.\n\nBOCEPREVIR.\n\n# BOLANDIOL.\n\n# BOLASTERONE.\n\n# BOLAZINE.\n\n# BOLDENONE (dehydrotestosterone).\n\n# BOLENOL.\n\n# BOLMANTALATE.\n\nBORON, including boric acid and borax, for human therapeutic use except:\n\n (a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose; or\n\n (b) in preparations for dermal use containing 0.35% or less of boron, which are not for paediatric or antifungal use; or\n\n (c) when present as an excipient.\n\nBORTEZOMIB.\n\n# BOSENTAN.\n\nBOSUTINIB.\n\nBOTULINUM TOXINS for human use except when separately specified in these Schedules.\n\n# BPC‑157.\n\nBRENTUXIMAB VEDOTIN.\n\nBRETYLIUM TOSILATE.\n\nBREXPIPRAZOLE.\n\nBRIGATINIB.\n\nBRIMONIDINE except when included in Schedule 2.\n\nBRINZOLAMIDE.\n\nBRIVARACETAM.\n\n# BROMAZEPAM.\n\nBROMIDES, inorganic, for therapeutic use except when separately specified in these Schedules.\n\nBROMOCRIPTINE.\n\nBROMOFORM for therapeutic use.\n\nBROMPHENIRAMINE except when included in Schedule 2 or 3.\n\nBROMVALETONE.\n\nBRUGMANSIA spp.\n\nBUCLIZINE except when included in Schedule 3.\n\nBUDESONIDE except when included in Schedule 2.\n\nBUFEXAMAC.\n\nBULEVIRTIDE.\n\nBUMETANIDE.\n\nBUPHENINE.\n\nBUPIVACAINE except when included in Schedule 5.\n\nBUPROPION.\n\nBUSERELIN.\n\nBUSPIRONE.\n\nBUSULPHAN.\n\nBUTACAINE.\n\nBUTAMBEN except in dermal preparations containing 2% or less of total local anaesthetic substances.\n\nBUTOCONAZOLE except when included in Schedule 3.\n\nBUTRACONAZOLE.\n\nBUTYLCHLORAL HYDRATE.\n\nBUTYL NITRITE.\n\nCABAZITAXEL.\n\nCABERGOLINE.\n\nCABOTEGRAVIR.\n\nCABOZANTINIB.\n\nCADMIUM COMPOUNDS for human therapeutic use.\n\nCAFFEINE for internal therapeutic use except:\n\n (a) in divided preparations when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or\n\n (b) in undivided preparations with a concentration of less than 5% of caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine.\n\nCALCIFEDIOL for human internal therapeutic use except in preparations containing 10 micrograms or less of calcifediol per recommended daily dose.\n\nCALCIPOTRIOL.\n\nCALCITONIN.\n\nCALCITONIN SALMON.\n\nCALCITRIOL.\n\nCALCIUM CARBIMIDE for therapeutic use.\n\nCALCIUM HYDROXYLAPATITE in preparations for injection or implantation:\n\nCALCIUM POLYSTYRENE SULPHONATE.\n\nCALOTROPIS GIGANTEA.\n\nCALOTROPIS PROCERA.\n\n# CALUSTERONE.\n\nCAMPHORATED OIL for therapeutic use.\n\nCAMPHOTAMIDE.\n\nCANAGLIFLOZIN.\n\nCANAKINUMAB.\n\nCANDESARTAN CILEXETIL.\n\nCANDICIDIN.\n\nCANINE TICK ANTI‑SERUM.\n\nCANNABIDIOL in preparations for therapeutic use or analytical and scientific research where:\n\n (a) cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and\n\n (b) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation;\n\n (c) included in Schedule 3; or\n\n (d) in hemp seed oil at a concentration of 75 mg/kg or less.\n\nCANTHARIDIN.\n\nCAPECITABINE.\n\nCAPREOMYCIN.\n\n# CAPROMORELIN.\n\nCAPTODIAME.\n\nCAPTOPRIL.\n\nCAPURIDE.\n\nCARAMIPHEN.\n\nCARBACHOL.\n\nCARBAMAZEPINE.\n\nCARBARYL for human therapeutic use.\n\nCARBAZOCHROME.\n\nCARBENICILLIN.\n\nCARBENOXOLONE for internal use.\n\nCARBETOCIN.\n\nCARBIDOPA.\n\nCARBIMAZOLE.\n\nCARBOCROMEN.\n\nCARBOPLATIN.\n\nCARBOPROST.\n\nCARBROMAL.\n\nCARBUTAMIDE.\n\nCARBUTEROL.\n\nCARFILZOMIB.\n\nCARGLUMIC ACID (N‑carbamoyl‑L‑glutamic acid).\n\nCARINDACILLIN.\n\nCARIPRAZINE.\n\nCARISOPRODOL.\n\nCARMUSTINE.\n\nCARNIDAZOLE.\n\nCARPROFEN.\n\nCARVEDILOL.\n\nCASIRIVIMAB.\n\nCASPOFUNGIN.\n\nCATHINE.\n\nCATUMAXOMAB.\n\nCEDAZURIDINE.\n\nCEFACETRILE.\n\nCEFACLOR.\n\nCEFADROXIL.\n\nCEFALEXIN.\n\nCEFALORIDINE.\n\nCEFALOTIN.\n\nCEFAMANDOLE.\n\nCEFAPIRIN.\n\nCEFAZOLIN.\n\nCEFEPIME.\n\nCEFETAMET.\n\nCEFIXIME.\n\nCEFODIZIME.\n\nCEFONICID.\n\nCEFOPERAZONE.\n\nCEFOTAXIME.\n\nCEFOTETAN.\n\nCEFOTIAM.\n\nCEFOVECIN for veterinary use.\n\nCEFOXITIN.\n\nCEFPIROME.\n\nCEFPODOXIME.\n\nCEFQUINOME.\n\nCEFTAROLINE FOSAMIL.\n\nCEFSULODIN.\n\nCEFTAZIDIME.\n\nCEFTIBUTEN.\n\nCEFTIOFUR.\n\nCEFTRIAXONE.\n\nCEFUROXIME.\n\nCELECOXIB except when included in Schedule 3.\n\nCELIPROLOL.\n\nCENEGERMIN.\n\nCEPHAELIS ACUMINATA (ipecacuanha) except in preparations containing 0.2% or less of emetine.\n\nCEPHAELIS IPECACUANHA except in preparations containing 0.2% or less of emetine.\n\nCEPHALONIUM.\n\nCEPHRADINE.\n\nCERITINIB.\n\nCERIVASTATIN.\n\nCERLIPONASE ALFA.\n\nCERTOLIZUMAB PEGOL.\n\nCERULETIDE.\n\nCETIRIZINE except\n\n (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:\n\n (i) in a primary pack containing not more than 10 days’ supply; and\n\n (ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.\n\nCETRORELIX.\n\nCETUXIMAB.\n\nCHENODEOXYCHOLIC ACID.\n\nCHLORAL FORMAMIDE.\n\nCHLORAL HYDRATE except in preparations for topical use containing 2% or less of chloral hydrate.\n\nCHLORALOSE except when included in Schedule 6.\n\nCHLORAMBUCIL.\n\nCHLORAMPHENICOL except when included in Schedule 3.\n\n# CHLORANDROSTENOLONE.\n\nCHLORAZANIL.\n\nCHLORCYCLIZINE.\n\n# CHLORDIAZEPOXIDE.\n\nCHLORMERODRIN.\n\nCHLORMETHIAZOLE.\n\nCHLORMEZANONE.\n\nCHLOROFORM for use in anaesthesia.\n\n# 4‑CHLOROMETHANDIENONE.\n\n2‑(4‑CHLOROPHENYL)‑(1,2,4)TRIAZOLO[5,1‑A]ISOQUINOLINE.\n\nCHLOROQUINE.\n\nCHLOROTHIAZIDE.\n\nCHLOROTRIANISENE.\n\n# CHLOROXYDIENONE.\n\nCHLORPHENAMINE except when included in Schedule 2 or 3.\n\nCHLORPHENTERMINE.\n\nCHLORPROMAZINE.\n\nCHLORPROPAMIDE.\n\nCHLORPROTHIXENE.\n\nCHLORQUINALDOL for human topical use.\n\nCHLORTALIDONE.\n\nCHLORTETRACYCLINE except when included in Schedule 5.\n\nCHLORZOXAZONE.\n\nCHOLERA VACCINE.\n\nCHOLIC ACID.\n\nCHYMOPAPAIN for human therapeutic use.\n\nCICLACILLIN.\n\nCICLESONIDE.\n\nCICLOPIROX except:\n\nCICLOSPORIN.\n\nCIDOFOVIR.\n\nCILASTATIN.\n\nCILAZAPRIL.\n\nCILGAVIMAB.\n\nCILOSTAZOL.\n\nCIMETIDINE except when included in Schedule 3.\n\nCIMICOXIB.\n\nCINACALCET.\n\nCINCHOCAINE except when included in Schedule 2.\n\nCINNARIZINE.\n\nCINOXACIN.\n\nCIPROFLOXACIN.\n\nCISAPRIDE.\n\nCISATRACURIUM BESILATE.\n\nCISPLATIN.\n\nCITALOPRAM.\n\n# CJC‑1295 (CAS No. 863288‑34‑0).\n\nCLADRIBINE.\n\nCLANOBUTIN.\n\nCLARITHROMYCIN.\n\nCLASCOTERONE.\n\nCLAVULANIC ACID.\n\nCLEMASTINE except when included in Schedule 3.\n\nCLEMIZOLE.\n\nCLENBUTEROL.\n\nCLEVIDIPINE.\n\nCLIDINIUM BROMIDE.\n\nCLINDAMYCIN.\n\nCLIOQUINOL and other halogenated derivatives of oxyquinoline for human topical use except when separately specified in this Schedule.\n\nCLOBAZAM.\n\nCLOBETASOL.\n\nCLOBETASONE (clobetasone‑17‑butyrate) except when included in Schedule 3.\n\nCLOCORTOLONE.\n\nCLODRONIC ACID (includes sodium clodronate).\n\nCLOFARABINE.\n\nCLOFAZIMINE.\n\nCLOFENAMIDE.\n\nCLOFIBRATE.\n\n# CLOMIFENE.\n\nCLOMIPRAMINE.\n\nCLOMOCYCLINE.\n\n# CLONAZEPAM.\n\nCLONIDINE.\n\nCLOPAMIDE.\n\nCLOPIDOGREL.\n\nCLOPROSTENOL.\n\n# CLORAZEPATE.\n\nCLOREXOLONE.\n\nCLORPRENALINE.\n\n# CLOSTEBOL (4‑chlorotestosterone).\n\nCLOTRIMAZOLE except:\n\nCLOXACILLIN.\n\n# CLOZAPINE.\n\nCOBALT for human therapeutic use except as dicobalt edetate in preparations for the treatment of cyanide poisoning.\n\nCOBICISTAT.\n\nCOBIMETINIB.\n\nCODEINE when compounded with one or more other therapeutically active substances:\n\n (a) in divided preparations containing 30 mg or less of codeine per dosage unit; or\n\n (b) in undivided preparations containing 1% or less of codeine.\n\nCO‑DERGOCRINE.\n\nCOLCHICINE.\n\nCOLCHICUM AUTUMNALE.\n\nCOLESTIPOL.\n\nCOLESTYRAMINE for human therapeutic use.\n\nCOLFOSCERIL PALMITATE for human therapeutic use.\n\nCOLISTIN.\n\nCOLLAGEN in preparations for injection or implantation:\n\nCOLLAGENASE CLOSTRIDIUM HISTOLYTICUM.\n\nCOLURACETAM.\n\nCONCIZUMAB.\n\nCONVALLARIA KEISKI.\n\nCONVALLARIA MAJALIS.\n\nCOPPER COMPOUNDS for human use except:\n\n (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or\n\n (c) in other preparations containing 5% or less of copper compounds.\n\n# CORIFOLLITROPIN ALFA.\n\nCORONILLA spp.\n\nCORTICOSTERONE.\n\nCORTICOTROPHIN.\n\nCORTISONE.\n\nCO‑TRIMOXAZOLE.\n\nCOUMARIN for therapeutic use (excluding when present as an excipient).\n\nCRISABOROLE.\n\nCRIZOTINIB.\n\nCROFELEMER.\n\nCUPRIMYXIN.\n\nCURARE.\n\nCYCLANDELATE.\n\nCYCLIZINE except when included in Schedule 3.\n\nCYCLOBENZAPRINE.\n\n# CYCLOFENIL.\n\nCYCLOHEXIMIDE.\n\nCYCLOPENTHIAZIDE.\n\nCYCLOPENTOLATE.\n\nCYCLOPHOSPHAMIDE.\n\nCYCLOPROPANE for therapeutic use.\n\nCYCLOSERINE.\n\nCYCLOTHIAZIDE.\n\nCYCRIMINE.\n\nCYMARIN.\n\nCYPROHEPTADINE except when included in Schedule 3.\n\nCYPROTERONE.\n\nCYTARABINE.\n\nDABRAFENIB MESILATE.\n\nDABIGATRAN.\n\nDACARBAZINE.\n\nDACLATASVIR.\n\nDACLIZUMAB.\n\nDACTINOMYCIN.\n\nDALFOPRISTIN.\n\nDALTEPARIN (includes dalteparin sodium).\n\nDANAPAROID (includes danaparoid sodium).\n\n# DANAZOL.\n\nDANTHRON for human use.\n\nDANTROLENE.\n\nDAPAGLIFLOZIN.\n\nDAPOXETINE.\n\nDAPSONE.\n\nDAPTOMYCIN.\n\nDARATUMUMAB.\n\n# DARBEPOETIN.\n\nDARIFENACIN.\n\nDAROLUTAMIDE.\n\nDARUNAVIR.\n\nDATURA spp. except:\n\nDASABUVIR.\n\nDASATINIB.\n\nDATURA STRAMONIUM (stramonium) except:\n\n (b) for smoking or burning.\n\nDATURA TATULA (stramonium) except:\n\n (b) for smoking or burning.\n\nDAUNORUBICIN.\n\nDEANOL for therapeutic use.\n\nDEBRISOQUINE.\n\nDECAMETHONIUM.\n\nDECITABINE.\n\nDEFERASIROX.\n\nDEFERIPRONE.\n\nDEFIBROTIDE.\n\nDEFLAZACORT.\n\nDEGARELIX.\n\n# DEHYDROCHLOROMETHYLTESTOSTERONE.\n\nDEHYDROCORTICOSTERONE.\n\nDELAVIRDINE MESILATE.\n\nDEMBREXINE except when included in Schedule 5.\n\nDEMECARIUM.\n\nDEMECLOCYCLINE.\n\nDENGUE VACCINE.\n\nDENOSUMAB.\n\nDEOXYCHOLIC ACID.\n\nDEOXYCORTONE.\n\nDEOXYRIBONUCLEASE except:\n\n (b) for external use.\n\nDERACOXIB.\n\nDERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT.\n\nDESFERRIOXAMINE.\n\nDESFLURANE.\n\nDESIPRAMINE.\n\nDESIRUDIN.\n\nDESLANOSIDE.\n\nDESLORATADINE except when included in Schedule 2.\n\nDESLORELIN.\n\nDESMOPRESSIN (D.D.A.V.P.).\n\nDESOGESTREL.\n\nDESONIDE.\n\nDESOXYMETHASONE.\n\nDESVENLAFAXINE.\n\nDETOMIDINE.\n\nDEUCRAVACITINIB.\n\nDEUTETRABENAZINE.\n\nDEXAMETHASONE.\n\nDEXCHLORPHENAMINE except when included in Schedule 2 or 3.\n\nDEXFENFLURAMINE.\n\nDEXMEDETOMIDINE.\n\nDEXTROMETHORPHAN (excluding its stereoisomers) except when included in Schedule 2.\n\n# DEXTROPROPOXYPHENE:\n\n (a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or\n\n (b) liquid preparations containing 2.5% or less of dextropropoxyphene.\n\nDEXTRORPHAN (excluding its stereoisomers).\n\nDIAMTHAZOLE.\n\nDIAVERIDINE.\n\n# DIAZEPAM.\n\nDIAZOXIDE.\n\nDIBENZEPIN.\n\nDIBOTERMIN.\n\nDIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.\n\nDICHLORALPHENAZONE.\n\nDICHLOROPHEN for human therapeutic use.\n\nDICHLORPHENAMIDE.\n\nDICLOFENAC except:\n\n (b) in preparations for dermal use unless:\n\n (i) for the treatment of solar keratosis; or\n\n (ii) containing more than 4% of diclofenac.\n\nDICLOXACILLIN.\n\nDICYCLOMINE.\n\nDIDANOSINE.\n\nDIENESTROL.\n\nDIENOGEST.\n\nDIETHAZINE.\n\nDIETHYLCARBAMAZINE for human therapeutic use.\n\nDIETHYLPROPION.\n\nDIFELIKEFALIN.\n\nDIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5% of the dose of difenoxin.\n\nDIFLORASONE.\n\nDIFLOXACIN.\n\nDIFLUCORTOLONE.\n\nDIFLUNISAL.\n\nDIGITALIS LANATA.\n\nDIGITALIS PURPUREA.\n\nDIGITOXIN.\n\nDIGOXIN.\n\nDIGOXIN‑SPECIFIC ANTIBODY FRAGMENT F (Ab).\n\nDIHYDRALAZINE.\n\nDIHYDROCODEINE when compounded with one or more other therapeutically active substances:\n\n (a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or\n\n (b) in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine;\n\n except when included in Schedule 3.\n\nDIHYDROERGOTOXINE.\n\n# DIHYDROLONE.\n\nDIHYDROSTREPTOMYCIN.\n\nDIHYDROTACHYSTEROL.\n\nDIIODOHYDROXYQUINOLINE (iodoquinol) except:\n\n (a) when included in Schedule 3; or\n\n (b) for human internal use.\n\nDIISOPROPYLAMINE DICHLOROACETATE.\n\nDILTIAZEM.\n\nDIMENHYDRINATE except when included in Schedule 2 or 3.\n\nDIMERCAPROL.\n\n# DIMETHANDROSTANOLONE.\n\n# DIMETHAZINE.\n\nDIMETHINDENE except when included in Schedule 3.\n\nDIMETHOTHIAZINE.\n\nDIMETHOXANATE.\n\nDIMETHYL FUMARATE.\n\nDIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use except:\n\n (b) in in vitro test kits; or\n\n (c) when used as a flavour component in compliance with the current Therapeutic Goods (Permissible Ingredients) determination for listed medicines.\n\nDIMETRIDAZOLE.\n\nDIMIRACETAM.\n\n2,4‑DINITROCHLOROBENZENE for therapeutic use.\n\nDINITROCRESOLS for therapeutic use except when separately specified in these Schedules.\n\nDINITRONAPHTHOLS for therapeutic use except when separately specified in these Schedules.\n\nDINITROPHENOLS for therapeutic use.\n\nDINITROTHYMOLS for therapeutic use except when separately specified in these Schedules.\n\n# DINOPROST.\n\n# DINOPROSTONE.\n\nDIPERODON.\n\nDIPHEMANIL except in preparations for dermal use.\n\nDIPHENHYDRAMINE except when included in Schedule 2 or 3.\n\nDIPHENIDOL.\n\nDIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate except when included in Schedule 3.\n\nDIPHENYLPYRALINE.\n\nDIPHTHERIA TOXOID.\n\nDIPIVEFRIN.\n\nDIPYRIDAMOLE.\n\nDIRITHROMYCIN.\n\nDIRLOTAPIDE.\n\nDIROXIMEL FUMARATE.\n\nDISOPHENOL.\n\nDISOPYRAMIDE.\n\nDISTIGMINE.\n\nDISULFIRAM for therapeutic use.\n\nDISULPHAMIDE.\n\nDITHIAZANINE except when included in Schedule 6.\n\nDITIOCARB.\n\nDOBUTAMINE.\n\nDOCETAXEL.\n\nDOFETILIDE.\n\nDOLASETRON.\n\nDOLUTEGRAVIR.\n\nDOMPERIDONE.\n\nDONEPEZIL.\n\nDOPAMINE.\n\nDOPEXAMINE.\n\nDORAVIRINE.\n\nDORIPENEM.\n\nDORNASE.\n\nDORZOLAMIDE.\n\nDOSULEPIN.\n\nDOXANTRAZOLE.\n\nDOXAPRAM.\n\nDOXAZOSIN.\n\nDOXEPIN.\n\nDOXORUBICIN.\n\nDOXYCYCLINE.\n\nDOXYLAMINE except when included in Schedule 2 or 3.\n\nDRONEDARONE.\n\nDROPERIDOL.\n\nDROSPIRENONE.\n\n# DROSTANOLONE.\n\nDROTRECOGIN.\n\nDUBOISIA LEICHHARDTII except when included in Schedule 2.\n\nDUBOISIA MYOPOROIDES except when included in Schedule 2.\n\nDULAGLUTIDE.\n\nDULOXETINE.\n\nDUPILUMAB.\n\nDURVALUMAB.\n\nDUTASTERIDE.\n\nDYDROGESTERONE.\n\nECONAZOLE except:\n\nECOTHIOPATE (includes ecothiopate iodide).\n\nECTYLUREA.\n\nECULIZUMAB.\n\nEDARAVONE.\n\nEDETIC ACID for human therapeutic use except:\n\n (a) in preparations containing 0.25% or less of edetic acid; or\n\n (b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or\n\n (c) in contact lens preparations.\n\nEDOXUDINE.\n\nEDROPHONIUM.\n\nEFALIZUMAB.\n\nEFAVIRENZ.\n\nEFLORNITHINE.\n\nELBASVIR.\n\nELETRIPTAN except when included in Schedule 3.\n\nELEXACAFTOR.\n\nELOSULFASE ALFA.\n\nELOTUZUMAB.\n\nELRANATAMAB.\n\nELTENAC.\n\nELTROMBOPAG.\n\nELUXADOLINE.\n\nELVITEGRAVIR.\n\nEMEPRONIUM.\n\nEMETINE except in preparations containing 0.2% or less of emetine.\n\nEMPAGLIFLOZIN.\n\nEMTRICITABINE.\n\nENALAPRIL.\n\nENASIDENIB.\n\nENCORAFENIB.\n\n# ENESTEBOL.\n\nENFLURANE for therapeutic use.\n\nENFORTUMAB VEDOTIN.\n\nENFUVIRTIDE.\n\n# ENOBOSARM.\n\nENOXACIN.\n\nENOXAPARIN.\n\nENOXIMONE.\n\nENPROSTIL.\n\nENROFLOXACIN.\n\nENTACAPONE.\n\nENTECAVIR.\n\nENTRECTINIB.\n\nENZALUTAMIDE.\n\nEPHEDRA spp. except in preparations containing 0.001% or less of ephedrine.\n\n# EPHEDRINE.\n\nEPICILLIN.\n\nEPINASTINE.\n\nEPIRUBICIN.\n\n# EPITIOSTANOL.\n\nEPLERENONE.\n\n# EPOETINS.\n\nEPOPROSTENOL.\n\nEPROSARTAN.\n\nEPTIFIBATIDE.\n\nERENUMAB.\n\nERGOMETRINE.\n\nERGOT.\n\nERGOTAMINE.\n\nERGOTOXINE.\n\nERIBULIN MESILATE.\n\nERLOTINIB.\n\nERTAPENEM.\n\nERTUGLIFLOZIN.\n\nERYSIMUM spp.\n\nERYTHROMYCIN.\n\n# ERYTHROPOIETIN.\n\n# ERYTHROPOIETINS except when separately specified in these Schedules.\n\nESCITALOPRAM.\n\nESLICARBAZEPINE ACETATE.\n\nESMOLOL.\n\nESOMEPRAZOLE except when included in Schedule 2.\n\nESTETROL MONOHYDRATE.\n\nESTRADIOL except when included in Schedule 5.\n\nESTRIOL.\n\nESTRAMUSTINE.\n\nESTROGENS except when separately specified in these Schedules.\n\nESTRONE.\n\nESTROPIPATE (piperazine estrone sulfate).\n\nETACRYNIC ACID.\n\nETANERCEPT.\n\nETHAMBUTOL.\n\nETHAMIVAN.\n\nETHCHLORVYNOL.\n\nETHER for use in anaesthesia.\n\nETHINAMATE.\n\nETHINYLESTRADIOL.\n\nETHIONAMIDE.\n\n# ETHISTERONE.\n\nETHOGLUCID.\n\nETHOHEPTAZINE.\n\nETHOPROPAZINE.\n\nETHOSUXIMIDE.\n\nETHOTOIN.\n\nETHOXZOLAMIDE.\n\nETHYL CHLORIDE for human therapeutic use.\n\n# ETHYLDIENOLONE.\n\nETHYLMORPHINE when compounded with one or more other therapeutically active substances:\n\n (a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or\n\n (b) in undivided preparations with a concentration of not more than 2.5% of ethylmorphine;\n\n# ETHYLESTRENOL.\n\nETIDOCAINE.\n\nETIDRONIC ACID (includes etidronate disodium):\n\n (b) in topical preparations except in preparations containing 1% or less of etidronic acid.\n\nETILEFRIN.\n\nETIPROSTON.\n\nETODOLAC.\n\nETOFENAMATE except when included in Schedule 2.\n\nETONOGESTREL.\n\nETOPOSIDE.\n\nETORICOXIB.\n\nETRANACOGENE DEZAPARVOVEC.\n\nETRASIMOD.\n\nETRAVIRINE.\n\n# ETRETINATE.\n\nETYNODIOL.\n\nEVEROLIMUS.\n\nEXEMESTANE.\n\nEXENATIDE.\n\nEZETIMIBE.\n\nFAMCICLOVIR except when included in Schedule 3.\n\nFAMOTIDINE except when included in Schedule 2.\n\nFARICIMAB.\n\nFASORACETAM.\n\nFEBUXOSTAT.\n\nFELBINAC except when included in Schedule 2.\n\nFELODIPINE.\n\nFELYPRESSIN.\n\nFENBUFEN.\n\nFENCAMFAMIN.\n\nFENCLOFENAC.\n\nFENFLURAMINE.\n\nFENOFIBRATE.\n\nFENOLDOPAM.\n\nFENOPROFEN.\n\nFENOTEROL.\n\nFENPIPRAMIDE.\n\nFENPIPRANE.\n\nFENPROPOREX.\n\nFENPROSTALENE.\n\nFERRIC DERISOMALTOSE.\n\nFEXOFENADINE except:\n\n (b) in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n (ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or\n\n (c) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n (i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and\n\n (ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or\n\n (d) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:\n\n (ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.\n\nFEZOLINETANT.\n\nFIBRINOLYSIN except for external use.\n\n# FIBROBLAST GROWTH FACTORS.\n\nFIDAXOMICIN.\n\nFILGOTINIB.\n\nFILGRASTIM.\n\nFINASTERIDE.\n\nFINERENONE.\n\nFINGOLIMOD.\n\nFIROCOXIB.\n\nFLECAINIDE.\n\nFLEROXACIN.\n\nFLOCTAFENINE.\n\nFLORFENICOL.\n\nFLUANISONE.\n\nFLUCLOROLONE.\n\nFLUCLOXACILLIN.\n\nFLUCONAZOLE except when included in Schedule 3.\n\nFLUCYTOSINE.\n\nFLUDARABINE.\n\nFLUDROCORTISONE.\n\nFLUFENAMIC ACID.\n\nFLUMAZENIL.\n\nFLUMETASONE.\n\nFLUMETHIAZIDE.\n\nFLUNISOLIDE.\n\nFLUNIXIN MEGLUMINE.\n\nFLUOCINOLONE.\n\nFLUOCINONIDE.\n\nFLUOCORTIN.\n\nFLUOCORTOLONE.\n\nFLUORESCEIN in preparations for injection.\n\nFLUORIDES in preparations for human use except when included in or expressly excluded from Schedule 2 or 3.\n\nFLUOROMETHOLONE.\n\nFLUOROURACIL.\n\nFLUOXETINE.\n\n# FLUOXYMESTERONE.\n\nFLUPENTIXOL.\n\nFLUPHENAZINE.\n\nFLUPROSTENOL.\n\nFLURALANER in injectable preparations for use in companion animals.\n\nFLURANDRENOLONE.\n\n# FLURAZEPAM.\n\nFLURBIPROFEN except when:\n\n (a) included in Schedule 2; or\n\n (b) in divided preparations for topical oral use that contain 10 mg or less of flurbiprofen per dosage unit and that are:\n\n (i) in a primary pack containing not more than 16 dosage units; and\n\n (ii) labelled only for the treatment of adults and children over 12 years; or\n\n (c) in undivided preparations for topical oral use containing either:\n\n (i) 0.25% or less of flurbiprofen per dose; or\n\n (ii) 10 mg or less of flurbiprofen per dose; and\n\n that are:\n\n (iii) in a primary pack containing not more than 15 Ml; and\n\n (iv) labelled only for the treatment of adults 18 years and over.\n\nFLUROXENE for human therapeutic use.\n\nFLUSPIRILENE.\n\nFLUTAMIDE.\n\nFLUTICASONE except when included in Schedule 2.\n\nFLUVASTATIN.\n\nFLUVOXAMINE.\n\nFOLIC ACID in preparations for human use for injection.\n\nFOLINIC ACID in preparations for human use for injection.\n\nFOLLICLE‑STIMULATING HORMONE except when separately specified in this Schedule.\n\n# FOLLISTATIN.\n\n# FOLLITROPIN ALFA.\n\n# FOLLITROPIN BETA.\n\n# FOLLITROPIN DELTA.\n\nFOMEPIZOLE.\n\nFOMIVIRSEN.\n\nFONDAPARINUX.\n\n# FORMEBOLONE.\n\nFORMESTANE.\n\nFORMOTEROL\n\nFOSAMPRENAVIR.\n\nFOSAPREPITANT.\n\nFOSCARNET.\n\nFOSFESTROL (diethylstilbestrol diphosphate).\n\nFOSFOMYCIN.\n\nFOSINOPRIL.\n\nFOSNETUPITANT.\n\nFOSPHENYTOIN.\n\nFOSTEMSAVIR.\n\nFOTEMUSTINE.\n\nFRAMYCETIN.\n\nFULVESTRANT.\n\nFURALTADONE.\n\n# FURAZABOL.\n\nFURAZOLIDONE.\n\nFUROSEMIDE (frusemide).\n\nFUSIDIC ACID.\n\nGABAPENTIN.\n\nGALANTAMINE.\n\nGALANTHUS spp.\n\nGALCANEZUMAB.\n\nGALLAMINE.\n\nGALSULFASE.\n\nGANCICLOVIR.\n\nGANIRELIX.\n\nGATIFLOXACIN.\n\nGRAZOPREVIR.\n\nGEFITINIB.\n\nGEMCITABINE.\n\nGEMEPROST.\n\nGEMFIBROZIL.\n\nGEMIFLOXACIN.\n\nGEMTUZUMAB OZOGAMICIN.\n\nGENTAMICIN.\n\nGESTODENE.\n\nGESTONORONE.\n\n# GESTRINONE.\n\nGHRH INJECTABLE PLASMID.\n\nGILTERITINIB.\n\nGITALIN.\n\nGIVOSIRAN.\n\nGLATIRAMER ACETATE.\n\nGLECAPREVIR.\n\nGLIBENCLAMIDE.\n\nGLIBORNURIDE.\n\nGLICLAZIDE.\n\nGLIMEPIRIDE.\n\nGLIPIZIDE.\n\nGLIPTINS except when separately specified in these Schedules.\n\nGLISOXEPIDE.\n\nGLOFITAMAB.\n\nGLUTATHIONE for parenteral use.\n\n# GLUTETHIMIDE.\n\nGLYCERYL TRINITRATE except when included in Schedule 3.\n\nGLYCOPYRRONIUM.\n\nGLYMIDINE.\n\nGnRH VACCINE.\n\nGOLIMUMAB.\n\nGONADORELIN.\n\nGONADOTROPHIC HORMONES except when separately specified in this Schedule.\n\nGOSERELIN.\n\nGRAMICIDIN.\n\nGRANISETRON.\n\nGRAPIPRANT.\n\nGREPAFLOXACIN.\n\nGRISEOFULVIN.\n\n# GROWTH HORMONE RELEASING HORMONES* (GHRHs).\n\n# GROWTH HORMONE RELEASING PEPTIDES (GHRPs).\n\n# GROWTH HORMONE RELEASING PEPTIDE‑6 (GHRP‑6).\n\n# GROWTH HORMONE SECRETAGOGUES* (GHSs).\n\nGUAIFENESIN for human therapeutic use except:\n\n (b) in oral liquid preparations containing 2% or less of guaifenesin; or\n\n (c) in divided preparations containing 200 mg or less of guaifenesin per dosage unit.\n\nGUANABENZ.\n\nGUANACLINE.\n\nGUANETHIDINE.\n\nGUANFACINE.\n\nGUANIDINE for therapeutic use.\n\nGUSELKUMAB.\n\nHACHIMYCIN.\n\nHAEMATIN.\n\nHAEMOPHILUS INFLUENZAE VACCINE.\n\nHALCINONIDE.\n\nHALOFANTRINE.\n\nHALOFENATE.\n\nHALOFUGINONE in preparations containing 0.1% or less of halofuginone for the treatment of animals.\n\nHALOPERIDOL.\n\nHALOTHANE for therapeutic use.\n\nHEMEROCALLIS (Hemerocallis flava).\n\nHEPARINS for internal use except when separately specified in this Schedule.\n\nHEPATITIS A VACCINE.\n\nHEPATITIS B VACCINE.\n\nHETACILLIN.\n\nHEXACHLOROPHENE:\n\n (a) in preparations for use on infants; or\n\n (b) in other preparations except:\n\n (i) when included in Schedule 2 or 6; or\n\n (ii) in preparations containing 0.75% or less of hexachlorophene.\n\nHEXAMETHONIUM.\n\n# HEXARELIN.\n\nHEXETIDINE for human internal use.\n\nHEXOBENDINE.\n\nHEXOCYCLIUM.\n\nHEXOPRENALINE.\n\nHEXYL AMINOLEVULINATE (AS HYDROCHLORIDE).\n\nHISTAMINE for therapeutic use except in preparations containing 0.5% or less of histamine.\n\nHMG‑CoA REDUCTASE INHIBITORS (including \"statins\") except when separately specified in these Schedules.\n\nHOMATROPINE.\n\nHUMAN CHORIONIC GONADOTROPHIN except in pregnancy test kits.\n\nHUMAN PAPILLOMAVIRUS VACCINE.\n\nHYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation.\n\nHYDRALAZINE.\n\nHYDRARGAPHEN.\n\nHYDROCHLOROTHIAZIDE.\n\nHYDROCORTISONE:\n\n (a) for human use except when included in Schedule 2 or 3; or\n\n (b) for the treatment of animals.\n\nHYDROCYANIC ACID for therapeutic use.\n\nHYDROFLUMETHIAZIDE.\n\nHYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use except:\n\n (b) in hair preparations containing 0.3% or less of hydroquinone; or\n\n (c) in cosmetic nail preparations containing 0.02% or less of hydroquinone.\n\nHYDROXYCARBAMIDE.\n\n# HYDROXYCHLOROQUINE.\n\nHYDROXYEPHEDRINE.\n\nHYDROXYPHENAMATE.\n\nHYDROXYPROGESTERONE.\n\n# HYDROXYSTENOZOL.\n\nHYDROXYZINE.\n\nHYGROMYCIN.\n\nHYOSCINE except when included in Schedule 2.\n\nHYOSCYAMINE except when included in Schedule 2.\n\nHYOSCINE BUTYLBROMIDE except when included in Schedule 2 or Schedule 3.\n\nHYOSCYAMUS NIGER except:\n\n (b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.\n\nHYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule.\n\nHYPROMELLOSE in preparations for injection.\n\nIBAFLOXACIN for veterinary use.\n\nIBANDRONIC ACID.\n\nIBOGAINE.\n\nIBRITUMOMAB.\n\nIBRUTINIB.\n\nIBUFENAC.\n\nIBUPROFEN except when:\n\n (a) included in Schedule 2 or 3; or\n\n (b) in preparations for dermal use; or\n\n (c) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:\n\n (i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and\n\n (ii) packed in blister or strip packaging or in a container with a child-resistant closure; and\n\n (v) not labelled for the treatment of children 6 years and under; and\n\n (vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.\n\n# IBUTAMOREN.\n\nIBUTEROL.\n\nIBUTILIDE.\n\nICATIBANT.\n\nIDARUBICIN.\n\nIDARUCIZUMAB.\n\nIDEBENONE.\n\nIDOXURIDINE except in preparations containing 0.5% or less of idoxuridine for dermal use.\n\nIDURSULFASE.\n\nIFOSFAMIDE.\n\nILOPROST.\n\nIMATINIB.\n\nIMDEVIMAB.\n\nIMEPITOIN.\n\nIMIDAPRIL.\n\nIMIGLUCERASE.\n\nIMIPENEM.\n\nIMIPRAMINE.\n\nIMIQUIMOD.\n\nIMLIFIDASE.\n\nIMMUNOGLOBULINS for human parenteral use except when separately specified in these Schedules.\n\nINCLISIRAN.\n\nINDACATEROL.\n\nINDAPAMIDE.\n\nINDINAVIR.\n\nINDOMETACIN except when included in Schedule 2.\n\nINDOPROFEN.\n\nINDORAMIN.\n\nINFIGRATINIB.\n\nINFLIXIMAB.\n\nINFLUENZA AND CORYZA VACCINES:\n\n (a) for parenteral use; or\n\n (b) for nasal administration.\n\nINGENOL MEBUTATE.\n\nINOTUZUMAB OZOGAMICIN.\n\nINSULIN DEGLUDEC.\n\nINSULIN GLARGINE.\n\n# INSULIN‑LIKE GROWTH FACTOR I.\n\n# INSULIN‑LIKE GROWTH FACTORS except when separately specified in this Schedule.\n\nINSULINS.\n\nINTERFERONS.\n\nINTERLEUKINS except when separately specified in these Schedules.\n\nIODOTHIOURACIL.\n\n# IPAMORELIN.\n\nIPILIMUMAB.\n\nIPRATROPIUM except when included in Schedule 2.\n\nIPRIFLAVONE.\n\nIPRINDOLE.\n\nIPRONIAZID.\n\nIRBESARTAN.\n\nIRINOTECAN.\n\nIRON COMPOUNDS in injectable preparations for human use.\n\nISAVUCONAZOLE.\n\nISOAMINILE.\n\nISOAMYL NITRITE.\n\nISOBUTYL NITRITE.\n\nISOCARBOXAZID.\n\nISOCONAZOLE except when included in Schedule 2, 3 or 6.\n\nISOETARINE.\n\nISOFLURANE for therapeutic use.\n\nISOMETHEPTENE.\n\nISONIAZID.\n\nISOPRENALINE.\n\nISOPRINOSINE.\n\nISOPROPAMIDE except when included in Schedule 2.\n\nISOSORBIDE DINITRATE except when included in Schedule 3.\n\nISOSORBIDE MONONITRATE.\n\n# ISOTRETINOIN.\n\nISOXICAM.\n\nISOXSUPRINE.\n\nISRADIPINE.\n\nITRACONAZOLE.\n\nIVABRADINE.\n\nIVACAFTOR.\n\nIVERMECTIN:\n\n (a) for human use; or\n\n (b) for the treatment of mange in dogs.\n\nIVOSIDENIB.\n\nIXABEPILONE.\n\nIXAZOMIB.\n\nIXEKIZUMAB.\n\nJAPANESE ENCEPHALITIS VACCINE.\n\nKANAMYCIN.\n\nKETANSERIN except in topical veterinary preparations containing 0.5% or less of ketanserin.\n\n# KETAZOLAM.\n\nKETOCONAZOLE except:\n\n (b) in preparations for dermal use containing 1% or less of ketoconazole for the treatment of the scalp; or\n\n (c) in preparations for dermal use for the treatment of tinea pedis.\n\nKETOPROFEN except:\n\n (a) in preparations for dermal use; or\n\n (b) when included in Schedule 3.\n\nKETOROLAC (includes ketorolac trometamol).\n\nKETOTIFEN except when included in Schedule 2.\n\nKHELLIN.\n\nKITASAMYCIN except:\n\n (b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.\n\nLABETALOL.\n\nLACIDIPINE.\n\nLACOSAMIDE.\n\nLAMIVUDINE.\n\nLAMOTRIGINE.\n\nLANADELUMAB.\n\nLANATOSIDES.\n\nLANREOTIDE.\n\nLANSOPRAZOLE except when included in Schedule 2 or 3.\n\nLANTHANUM for therapeutic use.\n\nLAPATINIB.\n\nLARONIDASE.\n\nLAROPIPRANT.\n\nLAROTRECTINIB.\n\nLATAMOXEF.\n\nLATANOPROST.\n\nLAUDEXIUM.\n\nLAUROMACROGOLS in preparations for injection except:\n\n (a) when present as an excipient; or\n\nLEBRIKIZUMAB.\n\nLECANEMAB.\n\nLEDIPASVIR.\n\nLEFETAMINE.\n\nLEFLUNOMIDE.\n\nLEMBOREXANT.\n\nLENACAPAVIR.\n\n# LENALIDOMIDE.\n\nLENOGRASTIM.\n\nLENVATINIB.\n\nLEPIRUDIN.\n\nLEPTAZOL.\n\nLERCANIDIPINE.\n\nLESINURAD.\n\nLETERMOVIR.\n\nLETROZOLE.\n\nLEUPRORELIN.\n\nLEVALLORPHAN.\n\nLEVAMISOLE:\n\n (b) in preparations for the prevention or treatment of heartworm in dogs.\n\nLEVETIRACETAM.\n\nLEVOBUNOLOL.\n\nLEVOBUPIVACAINE.\n\nLEVOCABASTINE except when included in Schedule 2.\n\nLEVOCETIRIZINE except:\n\n (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n (i) in a primary pack containing not more than 5 days’ supply; and\n\n (ii) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.\n\nLEVODOPA.\n\nLEVOMEPROMAZINE.\n\nLEVOMILNACIPRAN.\n\nLEVONORGESTREL except when included in Schedule 3.\n\nLEVOSIMENDAN.\n\nLIDOCAINE except:\n\n (a) when included in Schedules 2 or 5; or\n\n (b) in dermal preparations containing 2% or less of total local anaesthetic substances per dosage unit; or\n\n (c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.\n\nLIDOFLAZINE.\n\nLIFITEGRAST.\n\nLINACLOTIDE.\n\nLINAGLIPTIN.\n\nLINCOMYCIN.\n\nLINDANE for human therapeutic use except when included in Schedule 2.\n\nLINEZOLID.\n\nLIOTHYRONINE.\n\nLIPEGFILGRASTIM.\n\nLIRAGLUTIDE.\n\nLISINOPRIL.\n\nLISURIDE.\n\nLITHIUM for therapeutic use except:\n\n (b) when present as an excipient in preparations for dermal use containing 0.25% or less of lithium; or\n\n (c) in preparations containing 0.01% or less of lithium.\n\nLIXISENATIDE.\n\nLODOXAMIDE except when included in Schedule 2.\n\nLOFEXIDINE.\n\nLOGIPARIN for internal use.\n\nLOMEFLOXACIN.\n\nLOMUSTINE.\n\nLOPERAMIDE except:\n\n (b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.\n\nLOPINAVIR.\n\n# LOPRAZOLAM.\n\nLORACARBEF.\n\nLORATADINE except:\n\n (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, when:\n\n (i) in a primary pack containing 10 dosage units or less; and\n\n (ii) labelled with a recommended daily dose not exceeding 10 mg of loratadine.\n\n# LORAZEPAM.\n\nLORLATINIB.\n\n# LORMETAZEPAM.\n\nLOSARTAN.\n\nLOTEPREDNOL.\n\nLOXAPINE.\n\nLUMACAFTOR.\n\nLUMEFANTRINE.\n\nLUMIRACOXIB.\n\nLURASIDONE.\n\nLURBINECTEDIN.\n\nLUSPATERCEPT.\n\n# LUTEINISING HORMONE except in ovulation test kits.\n\nLYMECYCLINE.\n\nMACITENTAN for human use.\n\nMAFENIDE except when included in Schedule 6.\n\nMANDRAGORA OFFICINARUM.\n\nMANNOMUSTINE.\n\nMAPROTILINE.\n\nMARAVIROC.\n\nMARBOFLOXACIN.\n\nMARIBAVIR.\n\nMAROPITANT.\n\nMAVACAMTEN.\n\nMAVACOXIB.\n\nMAZINDOL.\n\nMEASLES VACCINE.\n\nMEBANAZINE.\n\nMEBEVERINE.\n\nMEBHYDROLIN.\n\n# MEBOLAZINE.\n\nMEBUTAMATE.\n\nMECAMYLAMINE.\n\nMECASERMIN.\n\nMECILLINAM.\n\nMECLOCYCLINE.\n\nMECLOFENAMATE.\n\nMECLOFENOXATE.\n\nMECLOZINE except when included in Schedule 2.\n\n# MEDAZEPAM.\n\nMEDETOMIDINE.\n\nMEDIGOXIN (methyldigoxin).\n\nMEDROXYPROGESTERONE.\n\nMEDRYSONE.\n\nMEFENAMIC ACID except when included in Schedule 2.\n\nMEFENOREX.\n\nMEFLOQUINE.\n\nMEFRUSIDE.\n\nMEGESTROL.\n\nMELAGATRAN.\n\nMELANOTAN II.\n\nMELATONIN for human use except when included in Schedule 3.\n\nMELENGESTROL except when included in Schedule 6.\n\nMELOXICAM except when included in Schedule 6.\n\nMELPHALAN.\n\nMEMANTINE.\n\nMENINGOCOCCAL VACCINE.\n\nMENINGOCOCCAL GROUP B VACCINE.\n\nMENOTROPHIN.\n\nMEPACRINE.\n\nMEPENZOLATE.\n\nMEPHENESIN.\n\nMEPHENTERMINE.\n\nMEPINDOLOL.\n\n# MEPITIOSTANE.\n\nMEPIVACAINE.\n\nMEPROBAMATE.\n\nMEPTAZINOL.\n\nMEPYRAMINE except when included in Schedule 2 or 3.\n\nMEQUITAZINE.\n\nMERCAPTAMINE for human therapeutic use.\n\nMERCAPTOMERIN.\n\nMERCAPTOPURINE.\n\nMERCUROCHROME except when included in Schedule 2 or 6.\n\nMERCURY for cosmetic or therapeutic use except:\n\n (b) in a sealed device which prevents access to the mercury.\n\nMEROPENEM.\n\nMERSALYL.\n\n# MESABOLONE.\n\nMESALAZINE.\n\nMESNA.\n\n# MESTANOLONE (androstalone).\n\n# MESTEROLONE.\n\nMESTRANOL.\n\n# METANDIENONE.\n\nMETARAMINOL.\n\n# METENOLONE.\n\nMETERGOLINE.\n\nMETFORMIN.\n\nMETHACHOLINE.\n\nMETHACYCLINE.\n\nMETHALLENESTRIL.\n\n# METHANDRIOL.\n\nMETHANTHELINIUM.\n\nMETHAZOLAMIDE.\n\nMETHDILAZINE except when included in Schedule 3.\n\n# METHENOLONE.\n\nMETHICILLIN.\n\nMETHIMAZOLE.\n\nMETHISAZONE.\n\nMETHIXENE.\n\nMETHOCARBAMOL.\n\nMETHOHEXITONE.\n\nMETHOIN.\n\nMETHOTREXATE.\n\nMETHOXAMINE except:\n\n (b) in preparations for external use containing 1% or less of methoxamine.\n\nMETHOXSALEN.\n\nMETHOXYFLURANE.\n\nMETHSUXIMIDE.\n\nMETHYCLOTHIAZIDE.\n\nMETHYL AMINOLEVULINATE.\n\n#METHYLANDROSTANOLONE.\n\n# METHYLCLOSTEBOL.\n\nMETHYLDOPA.\n\nMETHYLENE BLUE in preparations for injection.\n\nMETHYLERGOMETRINE.\n\nMETHYLMERCURY for therapeutic use.\n\nMETHYLNALTREXONE.\n\nMETHYLPENTYNOL.\n\nMETHYLPHENOBARBITAL.\n\nMETHYLPHENYLPIRACETAM.\n\nMETHYLPREDNISOLONE.\n\nMETHYLROSANILINIUM CHLORIDE for human use except when used as a dermal marker.\n\nMETHYL SALICYLATE in preparations for internal therapeutic use.\n\n# METHYLTESTOSTERONE.\n\nMETHYLTHIOURACIL.\n\n# METHYLTRIENOLONE.\n\nMETHYPRYLONE.\n\nMETHYSERGIDE.\n\nMETOCLOPRAMIDE except when included in Schedule 3.\n\nMETOLAZONE.\n\nMETOPROLOL.\n\n# METRIBOLONE.\n\nMETRIFONATE (trichlorfon) for human therapeutic use.\n\nMETRONIDAZOLE.\n\nMETYRAPONE.\n\nMEXILETINE.\n\nMEZLOCILLIN.\n\nMIANSERIN.\n\nMIBEFRADIL.\n\n# MIBOLERONE.\n\nMICAFUNGIN.\n\nMICONAZOLE except:\n\n# MIDAZOLAM.\n\nMIDOSTAURIN.\n\nMIDODRINE.\n\nMIFEPRISTONE.\n\nMIGALASTAT.\n\nMIGLITOL.\n\nMIGLUSTAT.\n\nMILBEMYCIN OXIME except when included in Schedule 5.\n\nMILNACIPRAN.\n\nMILRINONE.\n\nMINOCYCLINE.\n\nMINOXIDIL except when included in Schedule 2.\n\nMIRABEGRON.\n\nMIRIKIZUMAB.\n\nMIRTAZAPINE.\n\nMISOPROSTOL.\n\nMITOBRONITOL.\n\nMITOMYCIN.\n\nMITOTANE.\n\nMITOXANTRONE.\n\nMITRATAPIDE.\n\nMIVACURIUM CHLORIDE.\n\nMOBOCERTINIB.\n\nMOCLOBEMIDE.\n\nMODAFINIL.\n\nMOLGRAMOSTIM.\n\nMOLINDONE.\n\nMOLNUPIRAVIR.\n\nMOMETASONE except when included in Schedule 2 or Schedule 3.\n\nMONENSIN except:\n\n (b) in animal feeds containing 360 mg/kg or less of antibiotic substances.\n\nMONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use except in cosmetic nail preparations containing 0.02% or less of monobenzone or alkyl ethers of hydroquinone.\n\nMONOCLONAL ANTIBODIES for therapeutic use except:\n\n (a) in diagnostic test kits; or\n\nMONOETHANOLAMINE in preparations for injection.\n\nMONTELUKAST.\n\nMOPERONE.\n\nMORAZONE.\n\nMORICIZINE.\n\nMOTRAZEPAM.\n\nMOTRETINIDE.\n\nMOXIDECTIN in preparations for injection containing 10% or less of moxidectin except when included in Schedule 5 or 6.\n\nMOXIFLOXACIN.\n\nMOXONIDINE.\n\nMUMPS VACCINE.\n\nMUPIROCIN.\n\nMURAGLITAZAR.\n\nMUROMONAB.\n\nMUSTINE (nitrogen mustard).\n\nMYCOPHENOLIC ACID (includes mycophenolate mofetil).\n\nNABUMETONE.\n\nNADOLOL.\n\nNADROPARIN.\n\nNAFARELIN.\n\nNAFTIDROFURYL.\n\nNALBUPHINE.\n\nNALIDIXIC ACID.\n\nNALMEFENE.\n\nNALORPHINE.\n\nNALOXEGOL.\n\nNALOXONE except when in Schedule 3.\n\nNALTREXONE.\n\n# NANDROLONE.\n\nNAPROXEN except when included in Schedule 2 or 3.\n\nNARASIN except:\n\n (b) in animal feeds containing 100 mg/kg or less of antibiotic substances.\n\nNARATRIPTAN except when included in Schedule 3.\n\nNATALIZUMAB.\n\nNATAMYCIN except for use as a food additive.\n\nNATEGLINIDE.\n\nNEBACUMAB.\n\nNEBIVOLOL.\n\nNEBRACETAM.\n\nNEDOCROMIL.\n\nNEFAZODONE.\n\nNEFIRACETAM.\n\nNEFOPAM.\n\nNELARABINE.\n\nNELFINAVIR (includes nelfinavir mesilate).\n\nNEOMYCIN.\n\nNEOSTIGMINE.\n\nNEPAFENAC.\n\nNERATINIB.\n\nNERIUM OLEANDER.\n\nNESIRITIDE.\n\nNETILMICIN.\n\nNETUPITANT.\n\nNEVIRAPINE.\n\nNIALAMIDE.\n\nNICARDIPINE.\n\nNICERGOLINE.\n\nNICOFURANOSE.\n\nNICORANDIL.\n\n# NICOTINE in preparations for human use except:\n\n (a) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tobacco smoking or nicotine vaping; or\n\n (b) in tobacco prepared and packed for smoking.\n\nNICOTINIC ACID for human therapeutic use except:\n\n (b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or\n\n (c) nicotinamide.\n\nNICOUMALONE.\n\nNIFEDIPINE.\n\nNIFENAZONE.\n\nNIKETHAMIDE.\n\nNILOTINIB.\n\nNILUTAMIDE.\n\nNIMESULIDE.\n\nNIMODIPINE.\n\nNIMORAZOLE.\n\nNINTEDANIB.\n\nNIRAPARIB.\n\nNIRIDAZOLE.\n\nNIRMATRELVIR.\n\nNIRSEVIMAB.\n\nNISOLDIPINE.\n\nNITISINONE.\n\n# NITRAZEPAM.\n\nNITRENDIPINE.\n\nNITRIC OXIDE for human therapeutic use.\n\nNITROFURANTOIN.\n\nNITROFURAZONE.\n\nNITROUS OXIDE for therapeutic use.\n\nNITROXOLINE.\n\nNIVOLUMAB.\n\nNIZATIDINE except when included in Schedule 2.\n\nNOMEGESTROL.\n\nNOMIFENSINE.\n\nNORADRENALINE.\n\n# 19‑NORANDROSTENEDIOL.\n\n# 19‑NORANDROSTENEDIONE.\n\n# NORANDROSTENOLONE.\n\n# NORBOLETHONE.\n\n# NORCLOSTEBOL.\n\nNORELGESTROMIN.\n\n# NORETHANDROLONE.\n\nNORETHISTERONE.\n\nNORFLOXACIN.\n\nNORGESTREL.\n\nNORIBOGAINE.\n\nNORMAL HUMAN IMMUNOGLOBULIN.\n\n# NORMETHANDRONE.\n\nNORTRIPTYLINE.\n\nNOVOBIOCIN.\n\nNOXIPTYLINE.\n\nNUSINERSEN.\n\nNYSTATIN except when included in Schedule 2 or 3.\n\nOBETICHOLIC ACID.\n\nOCLACITINIB.\n\nOCRELIZUMAB.\n\nOCRIPLASMIN.\n\nOCTAMYLAMINE.\n\nOCTATROPINE.\n\nOCTREOTIDE.\n\nOCTYL NITRITE.\n\nOFATUMUMAB.\n\nOFLOXACIN.\n\nOLANZAPINE.\n\nOLAPARIB.\n\nOLARATUMAB.\n\nOLEANDOMYCIN except:\n\n (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.\n\nOLEANDRIN.\n\nOLIPUDASE ALFA.\n\nOLMESARTAN.\n\nOLODATEROL.\n\nOLOPATADINE except when included in Schedule 2.\n\nOLSALAZINE.\n\nOMALIZUMAB.\n\nOMBERACETAM.\n\nOMBITASVIR.\n\nOMEGA‑3‑ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post‑myocardial infarction and/or hypertriglyceridaemia.\n\nOMEPRAZOLE except when included in Schedule 2 or 3.\n\nONASEMNOGENE ABEPARVOVEC.\n\nONDANSETRON.\n\nOPICAPONE.\n\nOPIPRAMOL.\n\nORBIFLOXACIN.\n\nORCIPRENALINE.\n\nORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:\n\n (b) in preparations containing 2% or less of malathion for external use.\n\nORLISTAT except when included in Schedule 3.\n\nORNIDAZOLE.\n\nORNIPRESSIN.\n\nORPHENADRINE.\n\nORTHOPTERIN.\n\nOSELTAMIVIR.\n\nOSILODROSTAT.\n\nOSIMERTINIB.\n\nOUABAIN.\n\n# OVANDROTONE.\n\n# OXABOLONE.\n\nOXACILLIN.\n\nOXALIPLATIN.\n\n# OXANDROLONE.\n\nOXAPROZIN.\n\n# OXAZEPAM.\n\nOXCARBAZEPINE.\n\nOXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.\n\nOXETACAINE (oxethazaine) except when included in Schedule 2.\n\nOXICONAZOLE except:\n\nOXIRACETAM.\n\nOXITROPIUM.\n\nOXOLAMINE.\n\nOXOLINIC ACID.\n\nOXPRENOLOL.\n\nOXYBUPROCAINE.\n\nOXYBUTYNIN.\n\n# OXYMESTERONE.\n\n# OXYMETHOLONE.\n\nOXYPHENBUTAZONE.\n\nOXYPHENCYCLIMINE.\n\nOXYPHENONIUM.\n\nOXYTETRACYCLINE except when included in Schedule 5.\n\nOXYTOCIN.\n\nOZANIMOD.\n\nPACLITAXEL.\n\nPALBOCICLIB.\n\nPALIFERMIN.\n\nPALIPERIDONE.\n\nPALIVIZUMAB.\n\nPALONOSETRON.\n\nPALOVAROTENE.\n\nPAMAQUIN.\n\nPAMIDRONIC ACID (includes pamidronate disodium).\n\nPANCREATIC ENZYMES except:\n\n (a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or\n\nPANCURONIUM.\n\nPANITUMUMAB.\n\nPANOBINOSTAT.\n\nPANTOPRAZOLE except when included in Schedule 2 or 3.\n\nPAPAVERINE in preparations for injection.\n\nPARACETAMOL:\n\n (a) when combined with aspirin or salicylamide or any derivative of these substances except when separately specified in these Schedules; or\n\n (b) when combined with ibuprofen in a primary pack containing more than 30 dosage units; or\n\n (c) in modified release tablets or capsules containing more than 665 mg paracetamol; or\n\n (d) in non‑modified release tablets or capsules containing more than 500 mg paracetamol; or\n\n (e) in individually wrapped powders or sachets of granules each containing more than 1000 mg paracetamol; or\n\n (f) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules except in Schedule 2 or Schedule 3; or\n\n (g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules except when included in Schedule 2; or\n\n (h) for injection; or\n\n (i) for the treatment of animals.\n\nPARALDEHYDE.\n\nPARAMETHADIONE.\n\nPARAMETHASONE.\n\nPARECOXIB.\n\nPARICALCITOL.\n\nPARITAPREVIR.\n\nPAROMOMYCIN.\n\nPAROXETINE.\n\nPASIREOTIDE.\n\nPATIROMER SORBITEX CALCIUM.\n\nPATISIRAN.\n\nPAZOPANIB.\n\nPECAZINE.\n\nPEFLOXACIN.\n\nPEGAPTANIB.\n\nPEGASPARGASE.\n\nPEGCETACOPLAN.\n\nPEGFILGRASTIM.\n\nPEGINTERFERON.\n\nPEGVALIASE.\n\nPEGVISOMANT.\n\nPEMBROLIZUMAB.\n\nPEMETREXED.\n\nPEMIGATINIB.\n\nPEMOLINE.\n\nPEMPIDINE.\n\nPENBUTOLOL.\n\nPENCICLOVIR except in preparations containing 1% or less of penciclovir for the treatment of herpes labialis in packs containing 10 g or less.\n\nPENETHAMATE.\n\nPENICILLAMINE.\n\nPENTAERYTHRITYL TETRANITRATE.\n\nPENTAGASTRIN.\n\nPENTAMETHONIUM.\n\nPENTAMIDINE (includes pentamidine isetionate).\n\nPENTHIENATE.\n\n# PENTOBARBITAL when packed and labelled for injection.\n\nPENTOLINIUM.\n\nPENTOSAN POLYSULFATE SODIUM.\n\nPENTOXIFYLLINE.\n\nPERAMIVIR.\n\n# PERAMPANEL.\n\nPERGOLIDE.\n\nPERHEXILINE.\n\nPERICIAZINE.\n\nPERINDOPRIL.\n\nPERMETHRIN for human therapeutic use except in preparations containing 5% or less of permethrin.\n\nPERPHENAZINE.\n\nPERTUSSIS ANTIGEN.\n\nPERTUZUMAB.\n\nPHENACEMIDE.\n\nPHENACETIN for therapeutic use (excluding when present as an excipient).\n\nPHENAGLYCODOL.\n\nPHENAZONE except when included in Schedule 2 or 5.\n\nPHENAZOPYRIDINE.\n\nPHENELZINE.\n\nPHENETICILLIN.\n\nPHENFORMIN.\n\nPHENGLUTARIMIDE.\n\nPHENINDIONE.\n\nPHENIRAMINE except when included in Schedule 2 or 3.\n\nPHENISATIN.\n\nPHENOBARBITAL.\n\nPHENOL in preparations for injection.\n\nPHENOLPHTHALEIN for human therapeutic use.\n\nPHENOXYBENZAMINE.\n\nPHENOXYMETHYLPENICILLIN.\n\nPHENSUXIMIDE.\n\n# PHENTERMINE.\n\nPHENTHIMENTONIUM.\n\nPHENTOLAMINE.\n\nPHENYLBUTAZONE.\n\nPHENYLEPHRINE:\n\n (a) in preparations for injection; or\n\n (b) in preparations for human ophthalmic use containing 5% or more of phenylephrine.\n\nPHENYLPIRACETAM.\n\nPHENYLPROPANOLAMINE.\n\nPHENYLTOLOXAMINE.\n\nPHENYTOIN.\n\nPHLEUM PRATENSE POLLEN EXTRACT (Timothy‑grass pollen extract).\n\nPHOLCODINE:\n\n (a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or\n\n (b) in undivided preparations containing 2.5% or less of pholcodine;\n\nPHOSPHODIESTERASE TYPE 5 INHIBITORS except:\n\n (b) when present as an unmodified, naturally occurring substance.\n\nPHTHALYLSULFATHIAZOLE.\n\nPHYSOSTIGMINE.\n\nPIBRENTASVIR.\n\nPICROTOXIN.\n\nPILOCARPINE except in preparations containing 0.025% or less of pilocarpine.\n\nPIMECROLIMUS.\n\nPIMOBENDAN.\n\nPIMOZIDE.\n\nPINACIDIL.\n\nPINDOLOL.\n\nPIOGLITAZONE.\n\nPIPECURONIUM.\n\nPIPEMIDIC ACID.\n\nPIPENZOLATE.\n\nPIPER METHYSTICUM (kava) in preparations for human use except when included on the Register in preparations:\n\n (a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:\n\n (i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or\n\n (ii) the amount of dried whole or peeled rhizome and/or root in the teabag does not exceed 3 g;\n\n  and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome and/or root or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome and/or root; or\n\n (c) in dermal preparations.\n\nPIPERACILLIN.\n\nPIPERIDINE.\n\nPIPERIDOLATE.\n\nPIPOBROMAN.\n\nPIPOTHIAZINE.\n\nPIPRADROL.\n\nPIRACETAM.\n\nPIRBUTEROL.\n\nPIRENOXINE (catalin).\n\nPIRENZEPINE.\n\nPIRETANIDE.\n\nPIRFENIDONE.\n\nPIROXICAM except in preparations for dermal use.\n\nPIRPROFEN.\n\nPITAVASTATIN.\n\nPITUITARY HORMONES except when separately specified in these Schedules.\n\nPIVAMPICILLIN.\n\nPIZOTIFEN.\n\nPLICAMYCIN.\n\nPLITIDEPSIN.\n\nPLERIXAFOR.\n\nPNEUMOCOCCAL VACCINE.\n\nPODOPHYLLOTOXIN for human use:\n\nPODOPHYLLUM EMODI (podophyllin) for human use:\n\nPODOPHYLLUM PELTATUM (podophyllin) for human use:\n\nPOLIDEXIDE.\n\nPOLIOMYELITIS VACCINE.\n\nPOLYACRYLAMIDE in preparations for injection or implantation:\n\n (b) for cosmetic use; or\n\n (c) for veterinary use.\n\nPOLYCAPROLACTONE in preparations for injection or implantation:\n\nPOLYESTRADIOL.\n\nPOLYLACTIC ACID in preparations for injection or implantation:\n\nPOLYMYXIN.\n\nPOLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, except when separately specified in these Schedules.\n\nPOLYTHIAZIDE.\n\nPOMALIDOMIDE.\n\nPONATINIB.\n\nPONESIMOD.\n\nPORACTANT.\n\nPOSACONAZOLE.\n\nPOTASSIUM BROMIDE for therapeutic use.\n\nPOTASSIUM CHLORIDE in oral preparations for human therapeutic use except:\n\n (a) when containing less than 550 mg of potassium chloride per dosage unit; or\n\n (b) in preparations for oral rehydration therapy; or\n\n (c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or\n\n (d) in preparations for enteral feeding.\n\nPOTASSIUM PERCHLORATE for therapeutic use.\n\nPRACTOLOL.\n\nPRADOFLOXACIN.\n\nPRALATREXATE.\n\nPRALIDOXIME.\n\nPRAMIPEXOLE.\n\nPRAMIRACETAM.\n\nPRAMOCAINE.\n\n# PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE‑2 (GHRP‑2)).\n\nPRALSETINIB.\n\nPRAMPINE.\n\n# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).\n\nPRASUGREL.\n\nPRAVASTATIN.\n\n# PRAZEPAM.\n\nPRAZIQUANTEL for human therapeutic use.\n\nPRAZOSIN.\n\nPREDNISOLONE.\n\nPREDNISONE.\n\nPREGABALIN.\n\nPREGNENOLONE.\n\nPRENALTEROL.\n\nPRENYLAMINE.\n\nPRILOCAINE except when included in Schedule 2.\n\nPRIMAQUINE.\n\nPRIMIDONE.\n\nPROBENECID.\n\nPROBUCOL.\n\nPROCAINAMIDE.\n\nPROCAINE.\n\nPROCAINE BENZYLPENICILLIN.\n\nPROCARBAZINE.\n\nPROCHLORPERAZINE except when included in Schedule 3.\n\nPROCYCLIDINE except when included in Schedule 2.\n\nPROGESTERONE except when included in Schedule 5.\n\nPROGESTOGENS except when separately specified in these Schedules.\n\nPROGLUMIDE.\n\nPROGUANIL.\n\nPROLINTANE.\n\nPROMAZINE.\n\nPROMETHAZINE except when included in Schedule 2 or 3.\n\nPROMOXOLANE.\n\nPROPAFENONE.\n\nPROPAMIDINE for therapeutic use except when included in Schedule 2.\n\nPROPANIDID.\n\nPROPANTHELINE.\n\nPROPENTOFYLLINE.\n\n# PROPETANDROL.\n\nPROPIONIBACTERIUM ACNES for therapeutic use.\n\nPROPOFOL.\n\nPROPRANOLOL.\n\nPROPYLHEXEDRINE.\n\nPROPYLTHIOURACIL.\n\nPROPYPHENAZONE.\n\nPROQUAZONE.\n\nPROSCILLARIDIN.\n\nPROSTAGLANDINS except when separately specified in this Schedule.\n\nPROSTIANOL.\n\nPROTAMINE.\n\nPROTHIONAMIDE.\n\nPROTHIPENDYL.\n\nPROTIRELIN.\n\nPROTOVERATRINES.\n\nPROTRIPTYLINE.\n\nPROXYMETACAINE.\n\nPRUCALOPRIDE.\n\nPSEUDOEPHEDRINE except when included in Schedule 3.\n\nPYRAZINAMIDE.\n\nPYRIDINOLCARBAMATE.\n\nPYRIDOSTIGMINE.\n\nPYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use except:\n\n (a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.\n\nPYRIMETHAMINE.\n\nPYROVALERONE.\n\nPYRVINIUM.\n\n# QUAZEPAM.\n\nQUETIAPINE.\n\nQUINAGOLIDE.\n\nQUINAPRIL.\n\n# QUINBOLONE.\n\nQUINETHAZONE.\n\nQUINIDINE.\n\nQUININE for human therapeutic use except when the maximum recommended daily dose is 50 mg or less of quinine.\n\nQUINISOCAINE (dimethisoquin).\n\nQUINUPRISTIN.\n\nRABEPRAZOLE except when included in Schedule 2 or 3.\n\nRABIES VACCINE.\n\nRACETAMS except when separately specified in these Schedules.\n\nRACTOPAMINE except when included in Schedule 5.\n\nRALOXIFENE.\n\nRALTEGRAVIR.\n\nRALTITREXED.\n\nRAMIPRIL.\n\nRAMUCIRUMAB.\n\nRANIBIZUMAB.\n\nRANITIDINE except:\n\n (b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not more than 14 dosage units; or\n\n (c) in divided preparations for oral use containing 300mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units.\n\nRANOLAZINE.\n\nRAPACURONIUM.\n\nRASAGILINE.\n\nRASBURICASE.\n\nRAUWOLFIA SERPENTINA.\n\nRAUWOLFIA VOMITORIA.\n\nRAZOXANE.\n\nREBOXETINE.\n\nRED YEAST RICE for human therapeutic use.\n\nREMDESIVIR.\n\nREGDANVIMAB.\n\nREGORAFENIB.\n\nRELUGOLIX.\n\nREMOXIPRIDE.\n\nREPAGLINIDE.\n\nRESERPINE.\n\nRESLIZUMAB.\n\nRETAPAMULIN.\n\nRETEPLASE.\n\nRETIGABINE.\n\nRIBAVIRIN.\n\nRIBOCICLIB.\n\nRIDAFOROLIMUS.\n\nRIFABUTIN.\n\nRIFAMPICIN.\n\nRIFAMYCIN.\n\nRIFAPENTINE.\n\nRIFAXIMIN.\n\nRILPIVIRINE.\n\nRILUZOLE.\n\nRIMEGEPANT.\n\nRIMEXOLONE.\n\nRIMITEROL.\n\nRIMONABANT.\n\n# RIOCIGUAT.\n\nRIPRETINIB.\n\nRISANKIZUMAB.\n\nRISDIPLAM.\n\nRISEDRONIC ACID.\n\nRISPERIDONE.\n\nRITODRINE.\n\nRITONAVIR.\n\nRITUXIMAB.\n\nRIVAROXABAN.\n\nRIVASTIGMINE.\n\nRIZATRIPTAN except when included in Schedule 3.\n\nROBENACOXIB.\n\nROCURONIUM.\n\nROFECOXIB.\n\nROFLUMILAST.\n\nROLITETRACYCLINE.\n\nROLZIRACETAM.\n\nROMIDEPSIN.\n\nROMIFIDINE.\n\nROMIPLOSTIM.\n\nROMOSOZUMAB.\n\nRONIDAZOLE.\n\nROPINIROLE.\n\nROPIVACAINE.\n\nROSIGLITAZONE.\n\nROSOXACIN.\n\nROSUVASTATIN.\n\nROTIGOTINE.\n\n# ROXIBOLONE.\n\nROXITHROMYCIN.\n\nRUBELLA VACCINE.\n\nRUBOXISTAURIN.\n\nRUFINAMIDE.\n\nRUPATADINE.\n\nRUXOLITINIB.\n\nSACITUZUMAB GOVITECAN.\n\nSACUBITRIL.\n\nSAFINAMIDE.\n\nSALBUTAMOL except when included in Schedule 3.\n\nSALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.\n\nSALINOMYCIN except:\n\n (b) in animal feeds containing 60 mg/kg or less of antibiotic substances.\n\nSALMETEROL.\n\nSAPROPTERIN.\n\nSAQUINAVIR.\n\nSARILUMAB.\n\nSARS‑COV‑2 (COVID‑19) VACCINE.\n\nSAXAGLIPTIN.\n\nSCHOENOCAULON OFFICINALE (sabadilla) except in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of Schoenocaulon officinale.\n\nSCOPOLIA CARNIOLICA for therapeutic use.\n\nSEBELIPASE ALFA.\n\nSECUKINUMAB.\n\n# SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).\n\nSELEGILINE.\n\nSELENIUM:\n\n (a) for human oral use with a recommended daily dose of more than 300 micrograms; or\n\n (b) for the treatment of animals except:\n\n (i) when included in Schedule 6 or 7; or\n\n (ii) in solid, slow release bolus preparations containing 300 mg or less of selenium per dosage unit; or\n\n (iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit; or\n\n (iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or\n\n (v) in feeds containing 1 g/tonne or less of selenium.\n\nSELETRACETAM.\n\nSELEXIPAG.\n\nSELINEXOR.\n\nSELPERCATINIB.\n\nSELUMETINIB.\n\nSEMAGLUTIDE.\n\nSERELAXIN.\n\nSERMORELIN.\n\nSERTINDOLE.\n\nSERTRALINE.\n\nSEVELAMER.\n\nSEVOFLURANE.\n\nSEX HORMONES and all substances having sex hormonal activity except when separately specified in these Schedules.\n\nSIBUTRAMINE.\n\n# SILANDRONE.\n\nSILDENAFIL.\n\nSILICONES for intra‑ocular use.\n\nSILODOSIN.\n\nSILTUXIMAB.\n\nSILVER SULFADIAZINE.\n\nSIMEPREVIR.\n\nSIMVASTATIN.\n\nSIPONIMOD.\n\nSIROLIMUS.\n\nSISOMICIN (sisomycin).\n\nSITAGLIPTIN.\n\n# SITAXENTAN.\n\nSODIUM BROMIDE for therapeutic use.\n\nSODIUM CELLULOSE PHOSPHATE for human internal use.\n\nSODIUM CROMOGLYCATE except when included in Schedule 2.\n\nSODIUM GLYCEROPHOSPHATE HYDRATE.\n\nSODIUM MORRHUATE in preparations for injection.\n\nSODIUM NITROPRUSSIDE for human therapeutic use.\n\nSODIUM PHENYLBUTYRATE.\n\nSODIUM PHOSPHATE in preparations for oral laxative use.\n\nSODIUM POLYSTYRENE SULPHONATE for human therapeutic use.\n\nSODIUM SALICYLATE in preparations for internal use for the treatment of animals.\n\nSODIUM TETRADECYLSULFATE in preparations for injection.\n\nSODIUM ZIRCONIUM CYCLOSILICATE.\n\nSOFOSBUVIR.\n\nSOLASODINE.\n\nSOLIFENACIN.\n\nSOMAPACITAN.\n\nSOMATOSTATIN.\n\nSOMATOTROPIN EQUINE.\n\n# SOMATROPIN (human growth hormone).\n\nSONIDEGIB.\n\nSONTOQUINE.\n\nSORAFENIB.\n\nSOTALOL.\n\nSOTORASIB.\n\nSOTROVIMAB.\n\nSPARFLOXACIN.\n\nSPARTEINE.\n\nSPECTINOMYCIN.\n\nSPESOLIMAB.\n\nSPIRAMYCIN.\n\nSPIRAPRIL.\n\nSPIRONOLACTONE.\n\n# STANOLONE.\n\n# STANOZOLOL.\n\nSTAVUDINE.\n\n# STENABOLIC (SR9009) and other synthetic REV‑ERB agonists.\n\n# STENBOLONE.\n\nSTEROID HORMONES except when separately specified in these Schedules.\n\nSTILBESTROL (diethylstilbestrol).\n\nSTIRIPENTOL.\n\nSTREPTODORNASE.\n\nSTREPTOKINASE.\n\nSTREPTOMYCIN.\n\nSTRONTIUM RANELATE.\n\nSTROPHANTHINS.\n\nSTROPHANTHUS spp.\n\nSTRYCHNINE in preparations containing 1.5% or less of strychnine for the treatment of animals.\n\nSTRYCHNOS spp. except in preparations containing 1 mg or less per litre or per kilogram of strychnine.\n\nSTYRAMATE.\n\nSUCCIMER.\n\nSUCROFERRIC OXYHYDROXIDE.\n\nSUGAMMADEX.\n\nSULBACTAM.\n\nSULCONAZOLE except when included in Schedule 2.\n\nSULFACETAMIDE except when included in Schedule 3 or 5.\n\nSULFADIAZINE except when included in Schedule 5.\n\nSULFADIMETHOXINE.\n\nSULFADIMIDINE except when included in Schedule 5.\n\nSULFADOXINE.\n\nSULFAFURAZOLE.\n\nSULFAGUANIDINE.\n\nSULFAMERAZINE except when included in Schedule 5.\n\nSULFAMETHIZOLE.\n\nSULFAMETHOXAZOLE.\n\nSULFAMETHOXYDIAZINE.\n\nSULFAMETHOXYPYRIDAZINE.\n\nSULFAMETROLE.\n\nSULFAMONOMETHOXINE.\n\nSULFAMOXOLE.\n\nSULFAPHENAZOLE.\n\nSULFAPYRIDINE.\n\nSULFAQUINOXALINE.\n\nSULFASALAZINE.\n\nSULFATHIAZOLE except when included in Schedule 5.\n\nSULFATROXAZOLE.\n\nSULFINPYRAZONE.\n\nSULFOMYXIN.\n\nSULFONAMIDES except:\n\n (b) when included in Schedule 3, 5 or 6; or\n\n (c) when packed and labelled solely for use as a herbicide.\n\nSULFONMETHANE (sulfonal) and alkyl sulfonals.\n\nSULINDAC.\n\nSULTAMICILLIN.\n\nSULTHIAME.\n\nSUMATRIPTAN except when included in Schedule 3.\n\nSUNIFIRAM.\n\nSUNITINIB.\n\nSUPROFEN.\n\nSUTILAINS.\n\nSUXAMETHONIUM.\n\nSUXETHONIUM.\n\nSUVOREXANT.\n\nTACRINE.\n\nTACROLIMUS.\n\nTADALAFIL.\n\nTAFAMIDIS.\n\nTAFASITAMAB.\n\nTAFENOQUINE SUCCINATE.\n\nTAFLUPROST.\n\nTAGRAXOFUSP.\n\nTALAZOPARIB.\n\nTALIGLUCERASE ALFA.\n\nTALIMOGENE LAHERPAREPVEC.\n\nTAMOXIFEN.\n\nTAMSULOSIN.\n\nTANACETUM VULGARE except in preparations containing 0.8% or less of oil of tansy.\n\nTASONERMIN.\n\nTAZAROTENE.\n\nTAZOBACTAM.\n\n# TB‑500.\n\nT‑CELL RECEPTOR ANTIBODY.\n\nTEBENTAFUSP.\n\nTECLISTAMAB.\n\nTEDUGLUTIDE.\n\nTEGAFUR.\n\nTEGASEROD.\n\nTELAPREVIR.\n\nTELITHROMYCIN.\n\nTEICOPLANIN.\n\nTELBIVUDINE.\n\nTELMISARTAN.\n\nTELOTRISTAT ETHYL.\n\n# TEMAZEPAM.\n\nTEMOZOLOMIDE.\n\nTEMSIROLIMUS.\n\nTENECTEPLASE.\n\nTENIPOSIDE.\n\nTENOFOVIR.\n\nTENOXICAM.\n\nTEPOTINIB.\n\nTEPOXALIN.\n\nTERAZOSIN.\n\nTERBINAFINE except:\n\nTERBUTALINE except when included in Schedule 3.\n\nTERFENADINE.\n\nTERIFLUNOMIDE.\n\n# TERIPARATIDE.\n\nTERLIPRESSIN.\n\nTERODILINE.\n\nTEROPTERIN.\n\n# TESTOLACTONE.\n\n# TESTOSTERONE except when included in Schedule 6.\n\nTETANUS ANTITOXIN except when used for short‑term protection or treatment of tetanus in animals.\n\nTETANUS TOXOID for human use.\n\nTETRABENAZINE.\n\nTETRACAINE except:\n\n (b) in dermal preparations containing 2% or less of total local anaesthetic substances.\n\nTETRACOSACTIDE.\n\nTETRACYCLINE except when included in Schedule 5.\n\nTETRAETHYLAMMONIUM.\n\nTETROXOPRIM.\n\nTEZACAFTOR.\n\n# THALIDOMIDE.\n\nTHENYLDIAMINE.\n\nTHEOPHYLLINE except when included in Schedule 3.\n\nTHEVETIA PERUVIANA.\n\nTHEVETIN.\n\nTHIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.\n\nTHIAMBUTOSINE.\n\nTHIAZOSULFONE.\n\nTHIETHYLPERAZINE.\n\nTHIOACETAZONE.\n\nTHIOCARLIDE.\n\n# THIOMESTERONE (tiomesterone).\n\nTHIOPENTAL.\n\nTHIOPROPAZATE.\n\nTHIOPROPERAZINE.\n\nTHIORIDAZINE.\n\nTHIOSTREPTON.\n\nTHIOTEPA.\n\nTHIOTHIXENE.\n\nTHIOURACIL.\n\nTHIOUREA for therapeutic use except in preparations containing 0.1% or less of thiourea.\n\n# THYMOSIN BETA 4 (THYMOSIN β4).\n\nTHYMOXAMINE (includes thymoxamine hydrochloride).\n\nTHYROID except when separately specified in this Schedule.\n\nTHYROTROPHIN.\n\nTHYROXINE (includes thyroxine sodium).\n\nTIAGABINE.\n\nTIAMULIN.\n\n# TIANEPTINE.\n\nTIAPROFENIC ACID.\n\nTIARAMIDE.\n\nTIBOLONE.\n\nTICAGRELOR.\n\nTICARCILLIN.\n\nTICLOPIDINE.\n\nTIEMONIUM.\n\nTIENILIC ACID.\n\nTIGECYCLINE.\n\nTIGILANOL TIGLATE.\n\nTIGLOIDINE.\n\nTILDIPIROSIN.\n\nTILETAMINE.\n\nTILMANOCEPT.\n\nTILMICOSIN.\n\nTILUDRONIC ACID (includes disodium tiludronate).\n\nTIMOLOL.\n\nTINIDAZOLE.\n\nTINZAPARIN (includes tinzaparin sodium).\n\nTIOCONAZOLE except:\n\nTIOGUANINE.\n\nTIOTROPIUM.\n\nTIPEPIDINE.\n\nTIPIRACIL.\n\nTIPRANAVIR.\n\nTIRBANIBULIN.\n\nTIRILAZAD.\n\nTIROFIBAN.\n\nTIRZEPATIDE.\n\nTISLELIZUMAB.\n\nTIXAGEVIMAB.\n\nTOBRAMYCIN.\n\nTOCAINIDE.\n\nTOCERANIB.\n\nTOCILIZUMAB.\n\nTOFACITINIB.\n\nTOLAZAMIDE.\n\nTOLAZOLINE.\n\nTOLBUTAMIDE.\n\nTOLCAPONE.\n\nTOLFENAMIC ACID.\n\nTOLMETIN.\n\nTOLONIUM.\n\nTOLPROPAMINE.\n\nTOLRESTAT.\n\nTOLTERODINE.\n\nTOLVAPTAN.\n\nTOPIRAMATE.\n\nTOPOTECAN.\n\nTORASEMIDE.\n\nTOREMIFENE.\n\nTOXOIDS for human parenteral use except when separately specified in these Schedules.\n\nTRABECTEDIN.\n\nTRAMADOL.\n\nTRANDOLAPRIL.\n\nTRAMETINIB DIMETHYL SULFOXIDE.\n\nTRANEXAMIC ACID except in preparations containing 3% or less of cetyl tranexamate hydrochloride for dermal cosmetic use.\n\nTRANYLCYPROMINE.\n\nTRASTUZUMAB.\n\nTRASTUZUMAB DERUXTECAN.\n\nTRASTUZUMAB EMTANSINE.\n\nTRAVOPROST.\n\nTRAZODONE.\n\n# TRENBOLONE (trienbolone, trienolone) except when included in Schedule 5.\n\nTREOSULPHAN.\n\nTREPROSTINIL.\n\n# TRESTOLONE.\n\nTRETAMINE.\n\n# TRETINOIN except the ester hydroxypinacolone retinoate in preparations for dermal use containing 0.5% or less of hydroxypinacolone retinoate.\n\nTRIACETYLOLEANDOMYCIN.\n\nTRIAMCINOLONE except when included in Schedule 2 or 3.\n\nTRIAMTERENE.\n\nTRIAZIQUONE.\n\n# TRIAZOLAM.\n\nTRICHLORMETHIAZIDE.\n\nTRICHLOROACETIC ACID for human dermal use except when in preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts.\n\nTRICHLOROETHYLENE for therapeutic use.\n\nTRICLOFOS.\n\nTRICYCLAMOL.\n\nTRIDIHEXETHYL.\n\nTRIENTINE.\n\nTRIFAROTENE.\n\nTRIFLUOPERAZINE.\n\nTRIFLUPERIDOL.\n\nTRIFLUPROMAZINE.\n\nTRIFLURIDINE.\n\nTRIHEXYPHENIDYL.\n\nTRILOSTANE.\n\nTRIMETAPHAN.\n\nTRIMETHOPRIM.\n\nTRIMIPRAMINE.\n\nTRIMUSTINE.\n\nTRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.\n\nTRIOXYSALEN.\n\nTRIPELENNAMINE.\n\nTRIPROLIDINE except when included in Schedule 2 or 3.\n\nTRIPTORELIN.\n\nTROGLITAZONE.\n\nTROLAMINE when in preparations for tattoo removal.\n\nTROMETAMOL in preparations for injection except in preparations containing 3% or less of trometamol.\n\nTROPICAMIDE.\n\nTROPISETRON.\n\nTROVAFLOXACIN.\n\nTROXIDONE.\n\nTRYPTOPHAN for human therapeutic use except in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.\n\nTUBERCULIN.\n\nTUBOCURARINE.\n\nTUCATINIB.\n\nTULATHROMYCIN.\n\nTULOBUTEROL.\n\nTYLOSIN.\n\nTYPHOID VACCINE.\n\nULIPRISTAL except when included in Schedule 3.\n\nUMECLIDINIUM.\n\nUNIFIRAM.\n\nUNOPROSTONE.\n\nUPADACITINIB.\n\nURACIL.\n\nURAPIDIL.\n\nURETHANE (excluding its derivatives) for therapeutic use.\n\n# UROFOLLITROPIN.\n\nUROKINASE.\n\nURSODEOXYCHOLIC ACID.\n\nUSTEKINUMAB.\n\nVACCINES for human therapeutic use except when separately specified in this Schedule.\n\nVACCINES for veterinary live virus except:\n\n (a) poultry vaccines; or\n\n (b) pigeon pox vaccine; or\n\n (c) scabby mouth vaccine; or\n\n (d) bovine ephemeral fever vaccine; or\n\n (e) bovine herpesvirus‑1 vaccine.\n\nVACCINES – PLASMID DNA for animal use except when separately specified in these Schedules.\n\nVACCINIA VIRUS VACCINE.\n\n# VADADUSTAT.\n\nVALACICLOVIR.\n\nVALDECOXIB.\n\nVALGANCICLOVIR.\n\nVALNOCTAMIDE.\n\nVALPROIC ACID.\n\nVALSARTAN.\n\nVANCOMYCIN.\n\nVANDETANIB.\n\nVARDENAFIL.\n\nVARENICLINE.\n\nVARICELLA VACCINE.\n\nRECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN.\n\nVASOPRESSIN.\n\nVECURONIUM.\n\nVEDAPROFEN.\n\nVEDOLIZUMAB.\n\nVELAGLIFLOZIN.\n\nVELAGLUCERASE ALFA.\n\nVELPATASVIR.\n\nVEMURAFENIB.\n\nVENETOCLAX.\n\nVENLAFAXINE.\n\nVERAPAMIL.\n\nVERATRUM spp. except when separately specified in this Schedule.\n\nVERICIGUAT.\n\nVERNAKALANT.\n\nVERTEPORFIN.\n\nVIDARABINE.\n\nVIGABATRIN.\n\nVILANTEROL.\n\nVILDAGLIPTIN.\n\nVILOXAZINE.\n\nVINBLASTINE.\n\nVINCAMINE.\n\nVINCRISTINE.\n\nVINDESINE.\n\nVINFLUNINE.\n\nVINORELBINE.\n\nVINYL ETHER for therapeutic use.\n\nVIRGINIAMYCIN except when included in Schedule 5.\n\nVISMODEGIB.\n\nVISNADINE.\n\nVITAMIN A for human therapeutic or cosmetic use except:\n\n (a) in preparations for topical use containing 1% or less of Vitamin A; or\n\n (b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or\n\n (c) in preparations for parenteral nutrition replacement.\n\nVITAMIN D for human internal therapeutic use except:\n\n (a) in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or\n\n (b) when included in Schedule 3.\n\nVORAPAXAR.\n\nVORETIGENE NEPARVOVEC.\n\nVORICONAZOLE.\n\nVORINOSTAT.\n\nVORTIOXETINE.\n\nVOSORITIDE.\n\nVOXILAPREVIR.\n\nWARFARIN for therapeutic use.\n\nXAMOTEROL.\n\nXANTHINOL NICOTINATE.\n\nXIMELAGATRAN.\n\nXIPAMIDE.\n\nXYLAZINE.\n\nYOHIMBINE.\n\nZAFIRLUKAST.\n\nZALCITABINE.\n\nZALEPLON.\n\nZANAMIVIR.\n\nZANUBRUTINIB.\n\nZERANOL except when included in Schedule 6.\n\nZIDOVUDINE.\n\nZILPATEROL.\n\nZILUCOPLAN.\n\nZIMELDINE.\n\nZINC COMPOUNDS for human internal use except:\n\n (a) in preparations with a recommended daily dose of 25 mg or less of zinc; or\n\n (b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the required advisory statements for medicine labels.\n\nZIPRASIDONE.\n\nZOLAZEPAM.\n\nZOLEDRONIC ACID.\n\nZOLMITRIPTAN except when included in Schedule 3.\n\nZOLPIDEM.\n\nZONISAMIDE.\n\nZOPICLONE.\n\nZOXAZOLAMINE.\n\nZUCLOPENTHIXOL.\n\n","sortOrder":81},{"sectionNumber":"Sch 5","sectionType":"schedule","heading":"Caution","content":"Schedule 5—Caution\n\n \n\n \n\nNote: See paragraph (e) of the definition of designated solvent in section 6, paragraph 7(j), sections 16 and 25, subsection 26(2) and sections 42, 46, 47, 49, 55 and 61.\n\nABAMECTIN\n\n (a) in preparations, for internal use for the treatment of animals, containing 1% or less of abamectin; or\n\n (b) in gel formulations containing 0.05% or less of abamectin in applicators containing 50 mg or less of abamectin.\n\nABSCISIC ACID.\n\nACEQUINOCYL.\n\nACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30% of acetic acid (CH3COOH) except:\n\n (a) when included in Schedule 2 or 6; or\n\nACETONE except in preparations containing 25% or less of designated solvents.\n\nACRIFLAVINIUM CHLORIDE in preparations for veterinary use containing 2.5% or less of acriflavinium chloride.\n\nAFOXOLANER in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit\n\n (a) for the treatment and prevention of flea infestations and control of ticks in dogs; or\n\n (b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with milbemycin oxime.\n\nAKLOMIDE.\n\nALBENDAZOLE for the treatment of animals, in preparations containing 12.5% or less of albendazole except in intraruminal implants each containing 3.85 g or less of albendazole.\n\nALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:\n\n (a) in solid orthodontic device cleaning preparations, tHE pH of which as an “in‑use” aqueous solution is more than 11.5; or\n\n (b) in solid automatic dishwashing preparations, tHE pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5; or\n\n (c) in other solid preparations, tHE pH of which in a 10 g/L aqueous solution is more than 11.5; or\n\n (d) in liquid or semi‑solid preparations, tHE pH of which is more than 11.5, unless:\n\n (i) in food additive preparations for domestic use; or\n\n (ii) in automatic dish washing preparations for domestic use with A pH of more than 12.5;\n\nexcept when separately specified in these Schedules.\n\nALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50% or less of alkoxylated fatty alkylamine polymer except in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.\n\nALLETHRIN in preparations containing 10% or less of allethrin except:\n\n (a) in insecticidal mats; or\n\n (b) in other preparations containing 1% or less of allethrin.\n\nALLOXYDIM.\n\nALPHA‑CYPERMETHRIN:\n\n (a) in aqueous preparations containing 3% or less of alpha‑cypermethrin; or\n\n (b) in other preparations containing 1.5% or less of alpha‑cypermethrin.\n\nAMETRYN.\n\nAMINES for use as curing agents for epoxy resins except when separately specified in these Schedules.\n\nAMINOACRIDINE in preparations for veterinary use containing 2.5% or less of aminoacridine.\n\nAMINOCYCLOPYRACHLOR except in preparations containing 25% or less of aminocyclopyrachlor.\n\nAMINOPYRALID in preparations containing 22% or less of aminopyralid.\n\nAMISULBROM.\n\nAMITROLE.\n\nAMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5% or less of ammonia except:\n\n (a) in preparations for human internal therapeutic use; or\n\n (b) in preparations for inhalation when absorbed in an inert solid material; or\n\n (c) in preparations containing 0.5% or less of free ammonia.\n\nAMMONIUM THIOCYANATE except in preparations containing 10% or less of ammonium thiocyanate.\n\nANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins except when separately specified in these Schedules.\n\nANISE OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n (c) in preparations containing 50% or less of anise oil.\n\nASPIRIN for the treatment of animals, that is in divided preparations, when:\n\n (a) packed in blister or strip packaging; or\n\n (b) in a container with a child-resistant closure.\n\nATRAZINE.\n\nAZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5% or less of total limonoids, for agricultural use.\n\nAZOXYSTROBIN.\n\nBACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas fluorescens.\n\nBARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.\n\nBASIL OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n (c) in preparations containing 5% or less of methyl chavicol.\n\nBEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFu)/mL or less of Beauveria bassiana.\n\nBENALAXYL.\n\nBENDIOCARB in preparations containing 2% or less of bendiocarb.\n\nBENTAZONE.\n\nBENZALKONIUM CHLORIDE in preparations containing 10% or less of benzalkonium chloride except in preparations containing 5% or less of benzalkonium chloride.\n\nBENZOFENAP.\n\nBENZOIC ACID (excluding its salts and derivatives) in preparations for agricultural use except preparations containing 1% or less of benzoic acid.\n\nBENZOYL PEROXIDE except:\n\n (b) in preparations containing 5% or less of benzoyl peroxide.\n\nBERGAMOT OIL except:\n\n (c) in preparations containing 0.4% or less of bergamot oil; or\n\n (e) in medicines for human therapeutic use when compliant with the requirements of the required advisory statements for medicine labels; or\n\nBETACYFLUTHRIN:\n\n (a) in aqueous preparations containing 2.5% or less of betacyfluthrin; or\n\n (b) in solid preparations containing 8% or less of betacyfluthrin in a plastic matrix.\n\nBICYCLOPYRONE in preparations containing 20% or less of bicyclopyrone.\n\nBIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3% or less of total bifluorides.\n\nBIOALLETHRIN in preparations containing 10% or less of bioallethrin except in preparations containing 1% or less of bioallethrin.\n\nBIORESMETHRIN except in preparations containing 10% or less of bioresmethrin.\n\nBISPYRIBAC except in preparations containing 10% or less of bispyribac.\n\nBIXAFEN.\n\nBORIC ACID except:\n\n (b) in cosmetic hand cleaning preparations when labelled with a warning to the following effect:\n\n (c) in cosmetic talc preparations containing 5% or less calculated as boric acid when labelled with a warning to the following effect:\n\n (d) in cosmetic oral hygiene preparations containing 0.1% or less calculated as boric acid when labelled with a warning to the following effect:\n\n  NOT TO BE SWALLOWED. NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; or\n\n (e) in other cosmetic preparations containing 3% or less calculated as boric acid when labelled with a warning to the following effect:\n\n (f) in preparations, other than insect baits, containing 6% or less calculated as boric acid.\n\nBORON TRIFLUORIDE in preparations containing 0.1% or less of boron trifluoride (BF3).\n\nBROFLANILIDE in preparations containing 0.3% or less of broflanilide.\n\nBROMUCONAZOLE in preparations containing 20% or less of bromuconazole.\n\nBUPIVACAINE in aqueous gel preparations containing 0.5% or less of bupivacaine, for the dermal spray‑on administration to the wounds of animals.\n\nBUPROFEZIN except in preparations containing 40% or less of buprofezin.\n\nBUTHIDAZOLE.\n\nBUTOXYCARBOXIM in solid preparations containing 10% or less of butoxycarboxim.\n\nBUTRALIN.\n\nBUTROXYDIM.\n\nn‑BUTYL ALCOHOL in preparations containing 10% or less of n‑butyl alcohol except:\n\n (a) in preparations containing 5% or less of n‑butyl alcohol; or\n\n (b) in preparations for cosmetic or therapeutic use other than spray form.\n\nCAMPHOR as a natural component in essential oils containing 10% or less of camphor except:\n\n (a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:\n\n (c) in rosemary oil, sage oil (Spanish), or lavandin oils; or\n\n (d) in preparations containing 2.5% or less of camphor.\n\nCARBAMIDE PEROXIDE in preparations containing 18% or less of carbamide peroxide except in preparations containing 9% or less of carbamide peroxide.\n\nCARBARYL:\n\n (a) in preparations containing 10% or less of carbaryl except when included in Schedule 4; or\n\n (b) when impregnated into plastic resin material containing 20% or less of carbaryl.\n\nCASSIA OIL except:\n\n (a) in food additives; or\n\n (b) in preparations for dermal use as a rubefacient containing 5% or less of cassia oil; or\n\n (c) in other preparations containing 2% or less of cassia oil.\n\nCHLORFENAC.\n\nCHLORFENAPYR. in preparations containing 0.5% or less of chlorfenapyr.\n\nCHLORFENSON.\n\nCHLORHEXIDINE in preparations containing 3% or less of chlorhexidine except:\n\n (a) in preparations containing 1% or less of chlorhexidine; or\n\n (b) when in solid preparations.\n\nCHLORINATING COMPOUNDS containing 20% or less of available chlorine, except:\n\n (b) sodium hypochlorite preparations with A pH of less than 11.5; or\n\n (c) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:\n\n  WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or\n\n (d) liquid preparations containing less than 2% of available chlorine; or\n\n (e) other preparations containing 4% or less of available chlorine.\n\nCHLORNIDINE.\n\nCHLOROCRESOL except in preparations containing 3% or less of chlorocresol.\n\nCHLORPROPHAM.\n\nCHLORPYRIFOS:\n\n (a) in aqueous preparations containing 20% or less of microencapsulated chlorpyrifos; or\n\n (b) in controlled release granular preparations containing 10% or less of chlorpyrifos; or\n\n (c) in other preparations containing 5% or less of chlorpyrifos;\n\n except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.\n\nCHLORSULFURON.\n\nCHLORTETRACYCLINE in preparations:\n\n (b) containing 40% or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\nCHLORTHAL‑DIMETHYL.\n\nCINMETHYLIN.\n\nCINNAMON BARK OIL except:\n\n (a) in food additives; or\n\n (b) in preparations containing 2% or less of cinnamon bark oil.\n\nCIS‑JASMONE when prepared and packaged as an agricultural chemical except when present as a fragrance.\n\nCLETHODIM.\n\nCLIMBAZOLE in preparations containing 40% or less of climbazole except:\n\n (a) in leave‑on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or\n\n (b) in other preparations (that are not leave‑on cosmetic preparations) containing 2% or less of climbazole.\n\nCLOFENTEZINE.\n\nCLOPYRALID.\n\nCLOQUINTOCET.\n\nCLORSULON.\n\nCLOTHIANIDIN in preparations containing 20% or less of clothianidin except in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin.\n\nCLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil except in preparations containing 25% or less of clove oil.\n\nCOPPER ACETATE in preparations containing 20% or less of copper acetate except in preparations containing 5% or less of copper acetate.\n\nCOPPER COMPOUNDS in animal feed additives containing 5% or less of copper except in preparations containing 1% or less of copper.\n\nCOPPER HYDROXIDE in preparations containing 50% or less of copper hydroxide except in preparations containing 12.5% or less of copper hydroxide.\n\nCOPPER OXIDES in preparations containing 25% or less of copper oxides except:\n\n (a) in preparations for internal use; or\n\n (b) in marine paints; or\n\n (c) in other preparations containing 5% or less of copper oxides.\n\nCOPPER OXYCHLORIDE in preparations containing 50% or less of copper oxychloride except in preparations containing 12.5% or less of copper oxychloride.\n\nCOPPER SULFATE in preparations containing 15% or less of copper sulfate except:\n\n (a) in preparations for internal use; or\n\n (b) in other preparations containing 5% or less of copper sulfate.\n\nCOUMATETRALYL in rodenticides containing 0.05% or less of coumatetralyl.\n\n4‑CPA.\n\nCYANATRYN.\n\nCYANOACRYLATE ESTERS in contact adhesives except:\n\n (a) when labelled with the warning:\n\n  KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or\n\n (b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:\n\n (i) labelled with the approved name or trade name of the poison, the quantity and the warning:\n\n  Can cause eye injury. Instantly bonds skin; and\n\n  enclosed in a primary pack labelled with the warning:\n\n  KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.\n\nCYANTRANILIPROLE.\n\nCYANURIC ACID (excluding its salts and derivatives).\n\nCYAZOFAMID.\n\nCYCLOHEXANONE PEROXIDE.\n\nCYCLOPROTHRIN except in preparations containing 10% or less of cycloprothrin.\n\nCYCLOXYDIM.\n\nCYFLUFENAMID.\n\nCYFLUMETOFEN.\n\nCYFLUTHRIN:\n\n (a) in wettable powders containing 10% or less of cyfluthrin; or\n\n (b) in emulsifiable concentrates containing 2% or less of cyfluthrin; or\n\n (c) in emulsions containing 5% or less of cyfluthrin.\n\nCYHALOFOP‑BUTYL.\n\nCYMIAZOLE.\n\nCYPERMETHRIN in preparations containing 10% or less of cypermethrin.\n\nCYPHENOTHRIN in preparations containing 10% or less of cyphenothrin.\n\nCYPROCONAZOLE except in preparations containing 10% or less of cyproconazole.\n\nCYPRODINIL.\n\nCYTHIOATE for the treatment of animals:\n\n (a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child‑resistant closure; or\n\n (b) in undivided preparations containing 5% or less of cythioate.\n\n2,4‑D in preparations containing 20% or less of 2,4‑D.\n\nDAMINOZIDE.\n\n2,4‑DB.\n\nDECOQUINATE:\n\nDELTAMETHRIN:\n\n (a) when impregnated in plastic resin strip material containing 4% or less of deltamethrin; or\n\n (b) in aqueous preparations containing 5% or less of deltamethrin when no organic solvent other than a glycol is present; or\n\n (c) in wettable granular preparations containing 25% or less of deltamethrin when packed in child‑resistant packaging each containing 3 g or less of the formulation; or\n\n (d) in water‑dispersible tablets each containing 500 mg or less of deltamethrin in child‑resistant packaging; or\n\n (e) in other preparations containing 0.5% or less of deltamethrin;\n\n (f) in factory prepared mosquito nets containing 1% or less deltamethrin; or\n\n (g) in preparations containing 0.1% or less of deltamethrin.\n\nDEMBREXINE in oral preparations for the treatment of animals.\n\n2,4‑DES.\n\nDIAFENTHIURON.\n\nN,N‑DIALLYLDICHLOROACETAMIDE except in preparations containing 10% or less of N,N‑diallyldichloroacetamide.\n\nDIAZINON in dust preparations containing 2% or less of diazinon.\n\nDICAMBA (including its salts and derivatives) in preparations containing 20% or less of dicamba.\n\nDICHLONE.\n\np‑DICHLOROBENZENE.\n\nDICHLOROISOCYANURIC ACID containing 40% or less of available chlorine, except in:\n\n (a) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:\n\n  WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or\n\n (b) liquid preparations containing less than 2% of available chlorine; or\n\n (c) other preparations containing 4% or less of available chlorine.\n\nDICHLOROMETHANE (methylene chloride) except:\n\n (a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10% or less of dichloromethane; or\n\n (b) in other preparations in pressurised spray packs; or\n\n (c) in paints and tinters containing 5% or less of dichloromethane; or\n\n (d) in preparations for human therapeutic use.\n\nDICHLOROPHEN for the treatment of animals.\n\nDICHLORVOS:\n\n (a) when impregnated in plastic resin strip material containing 20% or less of dichlorvos; or\n\n (b) in sustained release resin pellets containing 20% or less of dichlorvos for the treatment of animals; or\n\n (c) in pressurised spray packs containing 10 g or less of dichlorvos.\n\nDICLOBUTRAZOL.\n\nDICLORAN.\n\nDICOFOL.\n\nDIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of diethanolamine except in preparations containing 5% or less of diethanolamine.\n\nDIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:\n\n (a) in paints or paint tinters; or\n\n (b) in toothpastes or mouthwashes containing more than 0.25% of diethylene glycol; or\n\n (c) in other preparations containing 2.5% or less of diethylene glycol.\n\nDIETHYLENE GLYCOL MONOBUTYL ETHER except in preparations containing 10% or less of diethylene glycol monobutyl ether.\n\nDIETHYLTOLUAMIDE (DEET) except:\n\n (a) in medicines for human therapeutic use containing 20% or less of diethyltoluamide, when compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in preparations for human use, other than medicines, containing 20% or less of diethyltoluamide, when labelled with the warning statement:\n\n  WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or\n\n (c) in preparations other than for human use containing 20% or less of diethyltoluamide.\n\nDIFENOCONAZOLE.\n\nDIFLUBENZURON.\n\nDIMETHICODIETHYLBENZALMALONATE except when included in preparations containing 10% or less of dimethicodiethylbenzalmalonate.\n\nDIMETHIRIMOL.\n\nDIMETHOMORPH except in preparations containing 10% or less of dimethomorph.\n\nDIMETHYLACETAMIDE in preparations containing 20% or less of dimethylacetamide.\n\nDIMETHYLFORMAMIDE in preparations containing 10% or less of dimethylformamide except in silicone rubber mastic containing 2% or less of dimethylformamide.\n\n3,7‑DIMETHYL‑2,6‑OCTADIENAL and its isomers in cosmetic and household cleaning preparations except in preparations containing 5% or less of 3,7‑dimethyl‑2,6,‑octadienal isomers.\n\nDIMPROPYRIDAZ in preparations containing 13% or less of dimpropyridaz.\n\nDINICONAZOLE.\n\nDINOTEFURAN except in preparations containing 1% or less of dinotefuran.\n\nDI‑n‑PROPYL ISOCINCHOMERONATE except in preparations containing 25% or less of di‑n‑propyl isocinchomeronate.\n\nDIPHENAMID.\n\nDIRECT RED 254 in preparations containing 30% or less of Direct Red 254 calculated as free acid.\n\nDITHIOPYR.\n\nN‑(N‑DODECYL)‑2‑PYRROLIDONE in preparations containing 50% or less of N‑(N‑dodecyl)‑2‑pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N‑(N‑dodecyl)‑2‑pyrrolidone, N‑methyl‑2‑pyrrolidone or N‑(N‑octyl)‑2‑pyrrolidone except in preparations containing 25% or less of designated solvents.\n\nDORAMECTIN for internal use for the treatment of animals, in preparations containing 2% or less of doramectin.\n\nEMAMECTIN in preparations containing 2% or less of emamectin.\n\nEMODEPSIDE in preparations:\n\n (a) containing 2.5% or less of emodepside for the external treatment of animals; or\n\n (b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.\n\nEPOXICONAZOLE.\n\nEPOXY RESINS, LIQUID.\n\nEPRINOMECTIN in preparations containing 0.5% or less of eprinomectin.\n\nESBIOTHRIN in preparations containing 10% or less of esbiothrin except in pressurised spray packs containing 1% or less of esbiothrin.\n\nESFENVALERATE in preparations containing 0.1% or less of esfenvalerate.\n\nESTRADIOL in implant preparations for growth promotion in animals.\n\n1,2‑ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL) OXIRANE AND N‑METHYLMETHANAMINE.\n\nETHER in preparations containing more than 10% of ether for use in internal combustion engines.\n\nETHOFUMESATE.\n\nETHOXYQUIN except in preparations containing 10% or less of ethoxyquin.\n\nETHOXYSULFURON.\n\nETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:\n\n (a) in paints or paint tinters; or\n\n (b) in toothpastes or mouthwashes containing more than 0.25% of ethylene glycol; or\n\n (c) in other preparations containing 2.5% or less of ethylene glycol.\n\nETHYL METHACRYLATE (excluding its derivatives) for cosmetic use except in preparations containing 1% or less of ethyl methacrylate as residual monomer in a polymer.\n\nETRIDIAZOLE.\n\nEUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol except in preparations containing 25% or less of eugenol.\n\nEXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (Corymbia citriodora), except in preparations containing 40% or less of extract of lemon eucalyptus.\n\nFENARIMOL.\n\nFENBENDAZOLE for the treatment of animals.\n\nFENBUCONAZOLE.\n\nFENCHLORAZOLE‑ETHYL.\n\nFENNEL OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of an instrument made under subsection 3(5A) of the Act relating to medicine advisory statements; or\n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n (c) in preparations containing 5% or less of methyl chavicol.\n\nFENOPROP.\n\nFENOXAPROP‑ETHYL.\n\nFENOXAPROP‑p‑ETHYL.\n\nFENPYRAZAMINE except in preparations containing 40% or less of fenpyrazamine.\n\nFENSON.\n\nFENTHION:\n\n (a) in preparations containing 25% or less of fenthion when packed in single‑use containers having a capacity of 2 mL or less; or\n\n (b) in preparations containing 10% or less of fenthion.\n\nFIPRONIL in preparations containing 10% or less of fipronil except in preparations containing 0.05% or less of fipronil.\n\nFLAMPROP‑METHYL.\n\nFLAMPROP‑M‑METHYL.\n\nFLAZASULFURON.\n\nFLORASULAM.\n\nFLUAZAINDOLIZINE in preparations containing 50% or less fluazaindolizine.\n\nFLUAZURON.\n\nFLUBENDAZOLE for the treatment of animals.\n\nFLUBENDIAMIDE.\n\nFLUCHLORALIN.\n\nFLUDIOXONIL except in preparations containing 10% or less of fludioxonil.\n\nFLUMETHRIN:\n\n (a) when impregnated in plastic resin strip material containing 3% or less of flumethrin; or\n\n (b) in oil based preparations containing 1% or less of flumethrin.\n\nFLUMICLORAC PENTYL.\n\nFLUOPYRAM except in preparations containing 50% or less of fluopyram.\n\nFLUORIDES in preparations containing 3% or less of fluoride ion except:\n\n (a) in preparations for human use; or\n\nFLURALANER except when included in Schedule 4.\n\nFLUVALINATE in aqueous preparations containing 25% or less of fluvalinate.\n\nFLUXAPYROXAD.\n\nFORAMSULFURON.\n\nFORMIC ACID (excluding its salts and derivatives) except in preparations containing 0.5% or less of formic acid.\n\nFOSPIRATE when impregnated in plastic resin strip material containing 20% or less of fospirate.\n\nFURALAXYL.\n\nFURATHIOCARB in microencapsulated suspensions containing 50% or less of furathiocarb.\n\nGAMMA‑CYHALOTHRIN in aqueous preparations containing 15% or less of microencapsulated gamma‑cyhalothrin.\n\nGLUFOSINATE‑AMMONIUM.\n\nGLUTARAL in preparations containing 5% or less of glutaral except:\n\n (b) in preparations containing 0.5% or less of glutaral when labelled with the statements:\n\n (A) IRRITANT; and\n\n (B) Avoid contact with eyes.\n\nGLYPHOSATE.\n\nHALOSULFURON‑METHYL.\n\nHEXACONAZOLE except in preparations containing 5% or less of hexaconazole.\n\nHEXAZINONE in preparations containing 25% or less of hexazinone.\n\nHYDRAMETHYLNON in solid baits containing 2% or less of hydramethylnon in welded plastic labyrinths.\n\nHYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), except:\n\n (a) toluene and xylene when included in Schedule 6; or\n\n (b) benzene and liquid aromatic hydrocarbons when included in Schedule 7; or\n\n (c) food grade and pharmaceutical grade white mineral oils; or\n\n (d) in solid or semi‑solid preparations; or\n\n (e) in preparations containing 25% or less of designated solvents; or\n\n (f) in preparations packed in pressurised spray packs; or\n\n (g) in adhesives packed in containers each containing 50 g or less of adhesive; or\n\n (h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or\n\n (i) in other preparations when packed in containers with a capacity of 2 mL or less.\n\nHYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of hydrochloric acid (HCl) except:\n\n (a) in preparations containing 0.5% or less of hydrochloric acid (HCl); or\n\nHYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1% or less of hydrogen fluoride.\n\nHYDROGEN PEROXIDE (excluding its salts and derivatives):\n\n (a) in hair dye preparations containing 12% or less of hydrogen peroxide except in hair dyes containing 6% or less of hydrogen peroxide; or\n\n (b) in other preparations containing 6% (20 volume) or less of hydrogen peroxide except in preparations containing 3% (10 volume) or less of hydrogen peroxide.\n\nHYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1% or less of hydrosilicofluoric acid (H2SiF6).\n\n2‑HYDROXYETHYL METHACRYLATE except:\n\n (a) when included in dental restorative preparations for therapeutic use; or\n\n (b) in nail preparations when labelled “Avoid contact with skin”; or\n\n (c) in other preparations containing 0.1% or less of 2‑hydroxyethyl methacrylate when labelled “Avoid contact with skin”.\n\n2‑HYDROXYPROPYL METHACRYLATE in nail preparations except when labelled “Avoid contact with skin”.\n\nIMAZALIL.\n\nIMAZAMOX except in preparations containing 25% or less of imazamox.\n\nIMAZAPIC except in preparations containing 25% or less of imazapic.\n\nIMAZAPYR except in preparations containing 25% or less of imazapyr.\n\nIMAZETHAPYR except in preparations containing 25% or less of imazethapyr.\n\nIMIDACLOPRID in preparations containing 20% or less of imidacloprid except in preparations containing 5% or less of imidacloprid.\n\nIMIPROTHRIN in preparations containing 50% or less of imiprothrin except in preparations containing 10% or less of imiprothrin.\n\nINDOXACARB (includes the R and S enantiomers) in preparations containing 1% or less of indoxacarb.\n\n3‑IODO‑2‑PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10% or less of 3‑iodo‑2‑propynyl butyl carbamate except:\n\n (a) in aqueous preparations not for cosmetic use containing 10% or less 3‑iodo‑2‑propynyl butyl carbamate; or\n\n (b) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3‑iodo‑2‑propynyl butyl carbamate.\n\nIODOSULFURON‑METHYL‑SODIUM.\n\nIPCONAZOLE in preparations containing 2% or less of ipconazole.\n\nIRON COMPOUNDS:\n\n (a) for the treatment of animals (excluding up to 1% of iron oxides when present as an excipient):\n\n (i) in preparations for injection containing 20% or less of iron except in preparations containing 0.1% or less of iron; or\n\n (ii) in other preparations containing 4% or less of iron except:\n\n (A) in liquid or gel preparations containing 0.1% or less of iron; or\n\n (B) in animal feeds or feed premixes; or\n\n (b) for use as agricultural chemicals except in preparations containing 4% or less of iron.\n\nISOEUGENOL in preparations not intended for skin contact containing 25% or less of isoeugenol except in preparations containing 10% or less of isoeugenol.\n\nISOPHORONE.\n\nISOXABEN.\n\nISOXAFLUTOLE.\n\nIVERMECTIN for use in animals:\n\n (a) in preparations for the prophylaxis of heartworm in cats and dogs; or\n\n (b) in intraruminal implants containing 160 mg or less of ivermectin; or\n\n (c) in preparations containing 3.5% or less of ivermectin when packed in child‑resistant packaging or in packaging approved by the relevant registration authority; or\n\n (d) in other preparations containing 2% or less of ivermectin.\n\nKITASAMYCIN in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.\n\nLAMBDA‑CYHALOTHRIN:\n\n (a) in aqueous preparations containing 1% or less of lambda‑ cyhalothrin; or\n\n (b) in aqueous preparations containing 10% or less of microencapsulated lambda‑cyhalothrin.\n\nLASIODIPLODIA PSEUDOTHEOBROMAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.\n\nLEMON OIL except:\n\n (c) in preparations containing 0.05% or less of lemon oil; or\n\n (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or\n\nLEMONGRASS OIL in cosmetic and household cleaning preparations except in preparations containing 5% or less of 3,7‑dimethyl‑2,6‑octadienal.\n\nLEVAMISOLE in preparations containing 15% or less of levamisole for the treatment of animals except:\n\n (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.\n\nLIDOCAINE:\n\n (a) in aqueous gel preparations containing 4.5% or less of lidocaine, for the dermal spray‑on administration to the wounds of animals; or\n\n (b) in injectable preparations containing 2% or less of lidocaine when packaged in a container with a tamper resistant cartridge which can only be dispensed through a rubber ring applicator for tail docking and castration of lambs; or castration of calves.\n\nLIME OIL except:\n\n (c) in preparations containing 0.5% or less of lime oil; or\n\n (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or\n\nLINDANE in preparations containing 10% or less of lindane except when included in Schedule 2 or 4.\n\nLOTILANER.\n\nLUFENURON except:\n\n (a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or\n\n (b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.\n\nMACROPHOMINA PHASEOLINA except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.\n\nMADURAMICIN in animal feed premixes containing 1% or less of antibiotic substances.\n\nMAGNESIUM CHLORATE except in preparations containing 10% or less of magnesium chlorate.\n\nMALACHITE GREEN in preparations for veterinary use containing 10% or less of malachite green.\n\nMALATHION in preparations containing 10% or less of malathion except:\n\n (b) in dust preparations containing 2% or less of malathion.\n\nMANCOZEB.\n\nMANDESTROBIN except in preparations containing 25% or less of mandestrobin.\n\nMANDIPROPAMID.\n\nMARJORAM OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n (c) in preparations containing 50% or less of marjoram oil.\n\nMCPA:\n\n (a) in preparations containing 25% or less of MCPA (acid); or\n\n (b) in preparations containing 50% or less of the salts and esters of MCPA.\n\nMEBENDAZOLE for the treatment of animals:\n\n (a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or\n\n (b) in undivided preparations containing 25% or less of mebendazole.\n\nMECLOFENAMIC ACID for the treatment of animals.\n\nMECOPROP in preparations containing 2% or less of mecoprop.\n\nMEFENPYR‑DIETHYL.\n\nMEFENTRIFLUCONAZOLE except in preparations containing 7.5% or less of mefentrifluconazole.\n\nMEPIQUAT.\n\nMERCAPTAMINE in cosmetic preparations containing 6% or less of mercaptamine except in preparations containing 1% or less of mercaptamine.\n\nMERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations containing 20% or less of mercaptoacetic acid or its salts (as mercapturic acid), except in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid)\n\nMESOTRIONE.\n\nMETAFLUMIZONE.\n\nMETALAXYL in preparations containing 35% or less of metalaxyl.\n\nMETALDEHYDE in preparations containing 2% or less of metaldehyde.\n\nMETAZACHLOR.\n\nMETHABENZTHIAZURON.\n\nMETHANOL (excluding its derivatives) in preparations containing 10 % or less of methanol except:\n\n (a) when included in Schedule 10; or\n\n (b) in preparations containing 2% or less of methanol; or\n\n (c) when methanol is present only as a denaturant of ethanol.\n\nMETHENAMINE in cosmetic preparations, except in preparations containing 0.15% or less of methenamine.\n\nMETHIOCARB in pelleted preparations containing 2% or less of methiocarb.\n\nMETHIOZOLIN.\n\nMETHOXYCHLOR.\n\nMETHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) except:\n\n (a) when included in preparations or admixtures; or\n\n (b) when packed in containers having a capacity of more than 5 L.\n\nMETHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners”.\n\nMETHYLENE BLUE in preparations for veterinary use containing 50% or less of methylene blue.\n\nMETHYL ETHYL KETONE except in preparations containing 25% or less of designated solvents.\n\nMETHYL ETHYL KETONE PEROXIDE.\n\nMETHYL ISOAMYL KETONE except in preparations containing 25% or less of designated solvents.\n\nMETHYL ISOBUTYL KETONE except in preparations containing 25% or less of designated solvents.\n\nN‑METHYL‑2‑PYRROLIDONE:\n\n (a) when packed in single use containers having a capacity of 2 mL or less; or\n\n (b) in preparations containing 50% or less of N‑methyl‑2‑pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N‑methyl‑2‑pyrrolidone, N‑(N‑octyl)‑2‑pyrrolidone or N‑(N‑dodecyl)‑2‑pyrrolidone except in preparations containing 25% or less of designated solvents.\n\nMETHYL SALICYLATE in preparations containing 25% or less of methyl salicylate except:\n\n (a) in preparations for therapeutic use; or\n\n (b) in preparations containing 5% or less of methyl salicylate.\n\n2‑METHYLTHIO‑4‑(2‑METHYLPROP‑2‑YL) AMINO‑6‑CYCLOPROPYLAMINO‑5‑ TRIAZINE.\n\nMETIRAM.\n\nMETOBROMURON except in preparations containing 50% or less of metobromuron.\n\nMETOFLUTHRIN:\n\n (a) in impregnated fabric mosquito repellent preparations for use in a vaporiser containing 15 mg or less of metofluthrin per disk; or\n\n (b) when impregnated into a polyethylene slow release matrix containing 250 mg or less of metofluthrin.\n\nMETOLACHLOR.\n\nMETRAFENONE in preparations containing 50% or less of metrafenone.\n\nMILBEMECTIN in preparations containing 1% or less of milbemectin.\n\nMILBEMYCIN OXIME\n\n (a) for the prophylaxis of heartworm in dogs and cats; or\n\n (b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with afoxolaner, in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit.\n\nMONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.\n\nMONEPANTEL.\n\nMONOETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of monoethanolamine except:\n\n (b) in preparations containing 5% or less of monoethanolamine.\n\nMORANTEL in preparations containing 25% or less of morantel except in preparations containing 10% or less of morantel.\n\nMOXIDECTIN:\n\n (a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5% or less of moxidectin; or\n\n (b) in preparations for external use for the treatment of cats and dogs, containing 2.5% or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or\n\n (c) for internal use for the treatment of animals:\n\n (i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or\n\n (ii) in other preparations containing 2% or less of moxidectin.\n\nMYCLOBUTANIL.\n\nNAA except in preparations containing 25% or less of NAA.\n\nNALED when impregnated in plastic resin strip material containing 20% or less of naled.\n\nNAPTALAM.\n\nNEOSCYTALIDIUM NOVAEHOLLANDIAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.\n\nNETOBIMIN for the treatment of animals, in preparations containing 12.5% or less of netobimin.\n\nNITRIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of nitric acid (HNO3) except in preparations containing 0.5% or less of nitric acid.\n\nNITROSCANATE for the treatment of animals.\n\nNONANOIC ACID:\n\n (a) when used in a pesticide; or\n\n (b) in other preparations except in preparations containing 10% or less of nonanoic acid.\n\nNONOXINOL 9 in preparations containing 25% or less of nonoxinol 9 except:\n\n (a) when labelled with the statements:\n\n (i) IRRITANT; and\n\n (ii) Avoid contact with eyes; or\n\n (b) in preparations containing 12.5% or less of nonoxinol 9; or\n\n (c) in preparations for human use.\n\nNORBORMIDE.\n\nNUTMEG OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n (c) in preparations containing 50% or less of nutmeg oil.\n\nN‑OCTYL BICYCLOHEPTENE DICARBOXIMIDE except in preparations containing 10% or less of N‑octyl bicycloheptene dicarboximide.\n\nN‑(N‑OCTYL)‑2‑PYRROLIDONE in preparations containing 50% or less of:\n\n (a) N‑(N‑octyl)‑2‑pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N‑(N‑octyl)‑2‑pyrrolidone, N‑methyl‑2‑pyrrolidone; or\n\n (b) N‑(N‑dodecyl)‑2‑pyrrolidone except in preparations containing 25% or less of designated solvents.\n\nOLEANDOMYCIN in animal feed premixes for growth promotion.\n\nOMETHOATE in pressurised spray packs containing 0.2% or less of omethoate.\n\nORANGE OIL (BITTER) except:\n\n (c) in preparations containing 1.4% or less of orange oil (bitter); or\n\n (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or\n\nOXADIARGYL.\n\nOXADIXYL.\n\nOXANTEL EMBONATE for the treatment of animals.\n\nOXFENDAZOLE for the treatment of animals.\n\nOXIBENDAZOLE for the treatment of animals.\n\nOXYCARBOXIN.\n\nOXYTETRACYCLINE in preparations:\n\n (b) containing 40% or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\nOXYTHIOQUINOX.\n\nPACLOBUTRAZOL.\n\nPENCONAZOLE.\n\nPENDIMETHALIN.\n\nPENFLUFEN.\n\nPENTHIOPYRAD except in preparations containing 20% or less of penthiopyrad.\n\nPERACETIC ACID in concentrations of 10% or less of peracetic acid.\n\nPERMETHRIN (excluding preparations for human therapeutic use):\n\n (a) in preparations containing 25% or less of permethrin; or\n\n (b) in preparations for external use, for the treatment of dogs, containing 50% or less of permethrin when packed in single use containers having a capacity of 4 mL or less;\n\n except in preparations containing 2% or less of permethrin.\n\nPETROL except preparations containing 25% or less of petrol.\n\nPHENAZONE for the external treatment of animals.\n\nPHENISOPHAM.\n\nPHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15% or less of such substances, except in preparations containing 1% or less of phenol and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol.\n\nPHENYL METHYL KETONE except in preparations containing 25% or less of designated solvents.\n\no‑PHENYLPHENOL except in preparations containing 5% or less of o‑phenylphenol.\n\nPHOSPHONIC ACID (excluding its salts and derivatives) except in preparations containing 10% or less of phosphonic acid (H3PO3).\n\nPHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35% or less of phosphoric acid (H3PO4) except:\n\n (a) in preparations containing 15% or less of phosphoric acid (H3PO4); or\n\n (b) in solid or semi‑solid preparations; or\n\n (c) in professional dental kits.\n\no‑PHTHALALDEHYDE in preparations containing 1% or less of o‑phthalaldehyde.\n\nPICARIDIN except in preparations containing 20% or less of picaridin.\n\nPINE OILS in preparations containing 25% or less of pine oils when packed and labelled as a herbicide.\n\nPINOXADEN in preparations containing 10% or less of pinoxaden.\n\nPIPERAZINE for animal use.\n\nPIRIMICARB in preparations containing 0.5% or less of pirimicarb.\n\nPOLIXETONIUM SALTS in preparations containing 60% or less of polixetonium salts except in preparations containing 1% or less of polixetonium salts.\n\nPOLYETHANOXY (15) TALLOW AMINE.\n\nPOLYOXIN D ZINC SALT.\n\nPOLY(OXY‑1,2‑ETHANEDIYL), α ‑[2‑[(2‑HYDROXYETHYL)AMINO]‑2‑OXOETHYL]‑ α ‑HYDROXY‑,MONO‑C13‑15‑ALKYL ETHERS.\n\nPOTASSIUM CHLORATE except:\n\n (b) in preparations containing 10% or less of potassium chlorate.\n\nPOTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of potassium hydroxide being:\n\n (a) solid preparations, tHE pH of which in a 10 g/L aqueous solution is more than 11.5; or\n\n (b) liquid or semi‑solid preparations, tHE pH of which is more than 11.5 except in food additive preparations for domestic use.\n\nPOTASSIUM METABISULPHITE when packed for domestic use except in preparations containing 10% or less of potassium metabisulphite.\n\nPOTASSIUM NITRITE in preparations containing 1% or less of potassium nitrite except:\n\n (a) in preparations containing 0.5% or less of potassium nitrite;\n\n (b) when present as an excipient in preparations for therapeutic use; or\n\n (c) in aerosols.\n\nPOTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:\n\n (a) solid preparations, tHE pH of which in a 10 g/L aqueous solution is less than 2.5; or\n\n (b) liquid or semi‑solid preparations, tHE pH of which is less than 2.5.\n\nPOTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.\n\nPRALLETHRIN (cis:trans=20:80) in preparations containing 10% or less of prallethrin except in insecticidal mats containing 1% or less of prallethrin.\n\nPROFOXYDIM except in preparations containing 20% or less of profoxydim.\n\nPROGESTERONE:\n\n (a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or\n\n (b) in implant preparations for growth promotion in cattle.\n\nPROHEXADIONE CALCIUM.\n\nPROMETRYN.\n\nPROPAMOCARB.\n\nPROPANIL.\n\nPROPAQUIZAFOP.\n\nPROPICONAZOLE in preparations containing 20% or less of propiconazole.\n\nPROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80% or less of propionic acid, except:\n\n (a) in preparations containing 30% or less of propionic acid; or\n\nPROPOXUR:\n\n (a) when impregnated in plastic resin strip material containing 10% or less of propoxur; or\n\n (b) in dust preparations containing 3% or less of propoxur; or\n\n (c) in granular sugar‑based fly baits containing 1% or less of propoxur, a dark colouring agent and a separate bittering agent; or\n\n (d) in pressurised spray packs containing 2% or less of propoxur; or\n\n (e) in printed paper sheets for pest control containing 0.5% or less of propoxur and in any case not more than 100 mg of propoxur per sheet.\n\nn‑PROPYL ALCOHOL in preparations containing 10% or less of n‑propyl alcohol except:\n\n (a) in preparations containing 5% or less of n‑propyl alcohol; or\n\n (b) in preparations for cosmetic or therapeutic use other than in spray form.\n\nPROPYZAMIDE.\n\nPROTHIOCONAZOLE‑DESCHLORO except in preparations containing 0.5% or less of prothioconazole‑deschloro.\n\nPROTHIOCONAZOLE‑TRIAZOLIDINETHIONE except in preparations containing 0.5% or less of prothioconazole‑triazolidinethione.\n\nPYMETROZINE.\n\nPYRACLOSTROBIN.\n\nPYRAFLUFEN‑ETHYL.\n\nPYRASULFOTOLE.\n\nPYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except:\n\n (b) in preparations containing 10% or less of such substances.\n\nPYRIDABEN in preparations containing 25% or less of pyridaben.\n\nPYRIFENOX.\n\nPYRITHIOBAC SODIUM.\n\nPYRITHIONE ZINC in paints containing 0.5% or less of pyrithione zinc calculated on the non‑volatile content of the paint except in paints containing 0.1% or less of pyrithione zinc calculated on the non‑volatile content of the paint.\n\nPYRIOFENONE in preparations containing 30% or less of pyriofenone.\n\nQUATERNARY AMMONIUM COMPOUNDS in preparations containing 20% or less of quaternary ammonium compounds except:\n\n (b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or\n\n (c) in preparations containing 5% or less of such quaternary ammonium compounds.\n\nQUINCLORAC.\n\nQUININE in preparations for veterinary use containing 1% or less of quinine.\n\nQUINTOZENE.\n\nQUIZALOFOP‑p‑ETHYL in aqueous preparations containing 40% or less of   quizalofop‑p‑ethyl.\n\nRACTOPAMINE in animal feed premixes containing 10% or less of ractopamine.\n\nRESMETHRIN in preparations containing 10% or less of resmethrin.\n\nRIMSULFURON.\n\nROBENIDINE except in preparations containing 20% or less of robenidine.\n\nROSIN when packaged for use as a soldering flux or in flux‑cored solder.\n\nSAFLUFENACIL in water dispersible granules or a water‑based suspension concentrate.\n\nSALICYLANILIDE.\n\nSAROLANER for veterinary use in divided preparations each containing 120 mg or less of sarolaner per dosage unit.\n\nSEDAXANE.\n\nSELAMECTIN except in preparations containing 12% or less of selamectin.\n\nSETHOXYDIM.\n\nSIDURON.\n\nSILICOFLUORIDES in preparations containing 3% or less of fluoride ion except:\n\n (a) barium silicofluoride when separately specified in this Schedule; or\n\nSINBIOALLETHRIN in preparations containing 10% or less of sinbioallethrin except in preparations containing 1% or less of sinbioallethrin.\n\nSODIUM BROMIDE except when included in Schedule 4.\n\nSODIUM CHLORATE except in preparations containing 10% or less of sodium chlorate.\n\nSODIUM DIACETATE except in preparations containing 60% or less of sodium diacetate.\n\nSODIUM DODECYLBENZENE SULFONATE except in preparations containing 30% or less of sodium dodecylbenzene sulfonate.\n\nSODIUM HYDROGEN SULFATE except in preparations containing 10% or less of sodium hydrogen sulfate.\n\nSODIUM HYDROSULFITE when packed for domestic use except in preparations containing 10% or less of sodium hydrosulfite.\n\nSODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of sodium hydroxide being:\n\n (a) solid preparations, tHE pH of which in a 10 g/L aqueous solution is more than 11.5; or\n\n (b) liquid or semi‑solid preparations, tHE pH of which is more than 11.5 except in food additive preparations for domestic use.\n\nSODIUM LAURETH‑6 CARBOXYLATE except in preparations containing 1% or less of sodium laureth‑6 carboxylate.\n\nSODIUM METABISULPHITE when packed for domestic use except in preparations containing 10% or less of sodium metabisulphite.\n\nSODIUM NITRITE in preparations containing 1% or less of sodium nitrite except:\n\n (a) in preparations containing 0.5% or less of sodium nitrite; or\n\n (b) when present as an excipient in preparations for therapeutic use; or\n\n (c) in aerosols.\n\nSODIUM PERCARBONATE (CAS No. 15630‑89‑4) in preparations containing 35% or less of sodium percarbonate except in preparations containing 15% or less of sodium percarbonate.\n\nSODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use except in preparations containing 10% or less of sodium polystyrene sulphonate.\n\nSODIUM STANNATE except in preparations for cosmetic use containing 1% or less of sodium stannate.\n\nSODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.\n\nSPINETORAM.\n\nSPINOSAD except in aqueous suspensions containing 25% or less of spinosad.\n\nSPIROMESIFEN for agricultural use.\n\nSTAR ANISE OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n (c) in preparations containing 50% or less of star anise oil.\n\nSTYRENE (excluding its derivatives).\n\nSULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\nSULFADIAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\nSULFADIMIDINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\nSULFAMERAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\nSULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of sulfamic acid (H3NO3S).\n\nSULFATHIAZOLE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\nSULFOMETURON‑METHYL.\n\nSULFOXAFLOR in preparations containing 25% or less of sulfoxaflor.\n\nSYMPHYTUM spp. (Comfrey) for dermal therapeutic or dermal cosmetic use.\n\n2,3,6‑TBA.\n\nTDE (1,1‑dichloro‑2,2‑bis[4‑chlorophenyl]ethane) in preparations containing 10% or less of TDE.\n\nTEBUCONAZOLE.\n\nTEBUFENOZIDE.\n\nTEFLUTHRIN in preparations containing 2% or less of tefluthrin.\n\nTEMEPHOS:\n\n (a) in liquid preparations containing 10% or less of temephos; or\n\n (b) in powders containing 2% or less of temephos; or\n\n (c) in preparations containing 40% or less of temephos when packed in single use containers having a capacity of 2 mL or less.\n\nTEPRALOXYDIM.\n\nTERBUTRYN.\n\nTETRACHLOROETHYLENE in preparations containing 5% or less of tetrachloroethylene except:\n\n (b) in preparations for the treatment of animals; or\n\n (c) when absorbed into an inert solid.\n\nTETRACHLORVINPHOS except in animal feeds containing 0.2% or less of tetrachlorvinphos.\n\nTETRACONAZOLE in preparations containing 20% or less of tetraconazole.\n\nTETRACYCLINE in preparations:\n\n (b) containing 40% or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\nTETRAMETHRIN [(R, cis): (R, trans) = 20:80] except in pressurised spray packs.\n\nTETRANILIPROLE except in preparations containing 20% or less tetraniliprole.\n\nTHIABENDAZOLE:\n\n (a) for the treatment of animals; or\n\n (b) when packed and labelled for use as a fungicide except in preparations containing 50% or less of thiabendazole.\n\nTHIAMETHOXAM in preparations containing 60% or less of thiamethoxam.\n\nTHIAZOPYR.\n\nTHIFENSULFURON.\n\nTHIOBENCARB.\n\nTHIODICARB in pelleted preparations containing 1.5% or less of thiodicarb.\n\nTHIOPHANATE‑METHYL in preparations containing 25% or less of thiophanate‑methyl.\n\nTHYME OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n (c) in preparations containing 50% or less of thyme oil.\n\nTIGOLANER in preparations containing 10% or less of tigolaner.\n\nTIOCARBAZIL.\n\nTOLCLOFOS‑METHYL.\n\nTOLTRAZURIL.\n\nTOPRAMEZONE\n\nTRALKOXYDIM.\n\nTRENBOLONE in implant preparations for growth promotion in animals.\n\nTRIADIMEFON in wettable powders containing 25% or less of triadimefon.\n\nTRIADIMENOL.\n\nTRI‑ALLATE.\n\nTRIBENURON‑METHYL.\n\nTRICHLOROACETIC ACID, alkali salts of.\n\n1,1,1‑TRICHLOROETHANE except:\n\n (a) in preparations packed in pressurised spray packs; or\n\n (b) in preparations containing 25% or less of designated solvents; or\n\n (c) in preparations, other than writing correction fluids or thinners for writing correction fluids in containers having a capacity of 50 mL or less; or\n\n (d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:\n\n (i) the word “Trichloroethane” written in letters not less than 1 mm in height and in distinct contrast to the background; and\n\n (ii) the expression:\n\n  WARNING – DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;\n\n  written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.\n\nTRIDIPHANE.\n\nTRIETAZINE.\n\nTRIFLOXYSTROBIN.\n\nTRIFLUDIMOXAZIN except in preparations containing 12.5% or less.\n\nTRIFLUMIZOLE.\n\nTRIFLUMURON.\n\nTRIISOPROPANOLAMINE LAURYL ETHER SULFATE except in preparations containing 30% or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:\n\n (a) Avoid contact with eyes and skin; and\n\n (b) Wash hands after handling.\n\nTRINEXAPAC‑ETHYL except:\n\n (a) when packed in a sealed water‑soluble measure pack; or\n\n (b) in solid preparations containing 25% or less of trinexapac‑ethyl in packs of 50 g or less.\n\n3,6,9‑TRIOXAUNDECANEDIOIC ACID except in preparations containing 5% or less of 3,6,9‑trioxaundecanedioic acid, tHE pH of which is 3.5 or greater.\n\nTRITICONAZOLE.\n\nTROLAMINE (excluding its salts and derivatives) except:\n\n (a) when in Schedule 4; or\n\n (b) in preparations containing 5% or less of trolamine.\n\nTURPENTINE OIL except in preparations containing 25% or less of turpentine oil.\n\nVIRGINIAMYCIN in animal feed additives containing 1% or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.\n\nVERNOLATE.\n\nWARFARIN in rodent baits containing 0.1% or less of warfarin.\n\nZINEB.\n\n","sortOrder":82},{"sectionNumber":"Sch 6","sectionType":"schedule","heading":"Poisons","content":"Schedule 6—Poisons\n\n \n\n \n\nNote: See section 16, subsection 46(2), section 49, subsection 54(3) and sections 55 and 61.\n\nABAMECTIN:\n\n (a) in preparations for pesticidal use containing 4% or less of abamectin except when included in Schedule 5; or\n\n (b) in slow‑release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.\n\nACEPHATE.\n\nACETAMIPRID except in preparations containing 1% or less of acetamiprid.\n\nACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) except when included in Schedule 2.\n\nACETIC ANHYDRIDE excluding its derivatives.\n\nACIFLUORFEN.\n\nACINITRAZOLE except in preparations containing 20% or less of acinitrazole.\n\nACLONIFEN.\n\nALBENDAZOLE for the treatment of animals except:\n\n (b) in intraruminal implants each containing 3.85 g or less of albendazole.\n\nALDRIN.\n\nALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non‑domestic use:\n\n (a) in solid automatic dishwashing preparations, tHE pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or\n\n (b) in liquid or semi‑solid automatic dishwashing preparations, tHE pH of which is more than 12.5.\n\nALKOXYLATED FATTY ALKYLAMINE POLYMER except:\n\n (b) in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.\n\nALLETHRIN except:\n\n (b) in insecticidal mats containing 20% or less of allethrin; or\n\n (c) in other preparations containing 1% or less of allethrin.\n\nALLYL ESTERS (excluding derivatives) being:\n\n (a) ALLYL CYCLOHEXANEACETATE (CAS No. 4728‑82‑9); or\n\n (b) ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705‑87‑5); or\n\n (c) ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142‑19‑8); or\n\n (d) ALLYL HEXANOATE (CAS No. 123‑68‑2); or\n\n (e) ALLYL ISOVALERATE (CAS No. 2835‑39‑4); or\n\n (f) ALLYL NONANOATE (CAS No. 7493‑72‑3); or\n\n (g) ALLYL OCTANOATE (CAS No. 4230‑97‑1); or\n\n (h) ALLYL PHENYLACETATE (CAS No. 1797‑74‑6); or\n\n (i) ALLYL TRIMETHYLHEXANOATE (CAS No. 68132‑80‑9);\n\n in preparations containing 0.1% or less of free allyl alcohol by weight of allyl ester except in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl esters.\n\nALPHA‑CYPERMETHRIN:\n\n (a) in aqueous preparations containing 30% or less of alpha‑cypermethrin; or\n\n (b) in other preparations containing 10% or less of alpha‑cypermethrin;\n\nAMICARBAZONE.\n\nAMIDITHION.\n\nAMIDOPROPYL BETAINES except:\n\n (a) in cosmetic wash‑off preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines when labelled with a warning to the following effect:\n\n (b) in cosmetic leave‑on preparations containing 1.5% or less of amidopropyl betaines; or\n\n (c) in other preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines, when labelled with warnings to the following effect:\n\n2‑AMINO‑6‑CHLORO‑4‑NITROPHENOL in hair dye and eyebrow/eyelash colouring preparations, except:\n\n (a) in preparations containing 2% or less of 2‑amino‑6‑chloro‑4‑nitrophenol when applied directly to the hair, or containing 2% or less of 2‑amino‑6‑chloro‑4‑nitrophenol after mixing and when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n (b) in eyelash and eyebrow tinting products containing 1.5% or less of 2‑amino‑6‑chloro‑4‑nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statement:\n\n  WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;\n\n4‑AMINO‑m‑CRESOL in hair dyes and eyebrow/eyelash colouring preparations except:\n\n (a) in hair dye preparations containing 1.5% or less of 4‑amino‑m‑cresol after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n  written in letters not less than 1.5mm in height; or\n\n (b) in eyelash and eyebrow tinting products containing 1.5% or less of 4‑amino‑m‑cresol after mixing for use when the immediate container and primary pack are labelled with the following statement:\n\n  WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;\n\n2‑AMINO‑5‑ETHYLPHENOL in hair dye preparations except in preparations containing 1% or less of 2‑amino‑5‑ethylphenol when the immediate container and primary pack are labelled with the following statements:\n\n (b) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes and eyebrows; to do so may be injurious to the eye;\n\n4‑AMINO‑2‑HYDROXYTOLUENE in hair dyes and eyebrow/eyelash colouring products except:\n\n (a) in hair dye preparations containing 1.5% or less of 4‑amino‑2‑hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n  written in letters not less than 1.5mm in height; or\n\n (b) in eyelash and eyebrow tinting products containing 1.5% or less of 4‑amino‑2‑hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statement:\n\n  WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;\n\nAMINOCARB in preparations containing 25% or less of aminocarb.\n\nAMINOETHOXYVINYLGLYCINE except in preparations containing 15% or less of aminoethoxyvinylglycine.\n\n1‑AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.\n\n4‑AMINO‑3‑NITROPHENOL except:\n\n (a) in non‑oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4‑amino‑3‑nitrophenol when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\n (b) in oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4‑amino‑3‑nitrophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\n2,2'‑[(4‑AMINO‑3‑NITROPHENYL)IMINO]BISETHANOL (including its salts) except:\n\n (a) in non‑oxidative hair dye preparations containing 2.5% or less of 2,2'‑[(4‑amino‑3‑nitrophenyl)imino]bisethanol after mixing when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\n (b) in oxidative hair dye preparations containing 1.25% or less of 2,2'‑[(4‑amino‑3‑nitrophenyl)imino]bisethanol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\nm‑AMINOPHENOL except when used in hair dye and eyebrow/eyelash preparations at a concentration of 1.2% or less of m‑aminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\np‑ AMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of p‑aminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\nAMINOPYRALID except when included in Schedule 5.\n\nAMITRAZ.\n\nAMMONIA (excluding its salts and derivatives other than ammonium hydroxide) except:\n\n (b) in preparations for human internal therapeutic use; or\n\n (c) in preparations for inhalation when absorbed in an inert solid material; or\n\n (d) in preparations containing 0.5% or less of ammonia.\n\nAMMONIUM COCOYL ISETHIONATE, except in cosmetic rinse‑off preparations containing 30% or less of ammonium cocoyl isethionate and, if containing more than 5% of ammonium cocoyl isethionate, when labelled with a warning to the following effect:\n\nAMMONIUM PERSULFATE in hair preparations.\n\nANILINE (excluding its salts and derivatives) except in preparations containing 1% or less of aniline.\n\nANTIMONY COMPOUNDS except:\n\n (b) antimony chloride in polishes; or\n\n (c) antimony titanate pigments in paint; or\n\n (d) in paints or tinters containing 5% or less of antimony calculated on the non‑volatile content of the paint or tinter.\n\nARBUTIN (ALPHA) except:\n\n (a) in preparations for application to the face containing 2% or less alpha‑arbutin with hydroquinone levels of 10mg/kg or less; or\n\n (b) in preparations for application to the body containing 0.5% or less alpha‑arbutin with hydroquinone levels of 10mg/kg or less.\n\nARBUTIN (BETA) except:\n\n (b) oral herbal preparations containing 500 mg or less beta‑arbutin per recommended daily dose; or\n\n (c) in preparations for application to the face containing 7% or less beta‑arbutin with hydroquinone levels of 10mg/kg or less.\n\nARBUTIN (DEOXY OR OTHER DERIVATIVES).\n\nARSENIC:\n\n (a) in ant poisons containing 0.4% or less of arsenic; or\n\n (b) in animal feed premixes containing 4% or less of arsenic; or\n\n (c) in preparations for the treatment of animals except thiacetarsamide when included in Schedule 4,\n\n except when separately specified in this Schedule.\n\nASPIRIN for the treatment of animals except when included in Schedule 4 or 5.\n\nAZACONAZOLE except in preparations containing 1% or less of azaconazole.\n\nAZADIRACHTA INDICA (Neem) including its extracts and derivatives except:\n\n (b) in preparations for human internal use; or\n\n (c) debitterised neem seed oil; or\n\n (d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (e) in preparations for dermal use containing 1% or less of cold pressed neem seed oil.\n\nAZAMETHIPHOS.\n\nAZOBENZENE.\n\nBAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.\n\nBARIUM SALTS except:\n\n (b) barium sulfate; or\n\n (c) in paints or tinters containing 5% or less of barium calculated on the non‑volatile content of the paint or tinter.\n\nBASIC BLUE 26 (CAS No. 2580‑56‑5) except when used as a colourant in cosmetics not intended to be in contact with mucous membranes.\n\nBASIC ORANGE 31 (2‑[(4‑aminophenyl)azo]‑1,3‑dimethyl‑1H‑imidazolium chloride) except:\n\n (a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or\n\n (b) in hair dye preparations containing 1% or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:\n\n (i) KEEP OUT OF REACH OF CHILDREN;\n\n (ii) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and\n\n (iii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\nBASIC RED 76 (CAS No. 68391‑30‑0) in non‑oxidative hair dye preparations and eyebrow/eyelash colouring products containing 2% or less of Basic Red 76 and 0.001% or less of free o‑anisidine.\n\nBAY OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (e) in preparations containing 25% or less of bay oil.\n\nBEAUVERIA BASSIANA except when included in Schedule 5.\n\nBENDIOCARB:\n\n (a) in wettable powders containing 80% or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb; or\n\n (b) in wettable powders containing 20% or less of bendiocarb and not less than 0.002% of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation; or\n\n (c) in insoluble granular preparations containing 5% or less of bendiocarb; or\n\n (d) when impregnated in plastic resin strip material containing 10% or less of bendiocarb;\n\nBENQUINOX.\n\nBENSULIDE.\n\nBENZALKONIUM CHLORIDE except:\n\n (b) in preparations containing 5% or less of benzalkonium chloride.\n\n1,2‑BENZENEDIOL.\n\nBENZOVINDIFLUPYR.\n\n6‑BENZYLADENINE except in preparations containing 10% or less of 6‑benzyladenine.\n\nBERYLLIUM.\n\nBETACYFLUTHRIN in preparations containing 12.5% or less of betacyfluthrin except when included in Schedule 5.\n\nBETA‑CYPERMETHRIN.\n\nBHC (excluding lindane).\n\nBICYCLOPYRONE except when included in Schedule 5.\n\nBIFENTHRIN in preparations containing 25% or less of bifenthrin except in preparations containing 0.5% or less of bifenthrin.\n\nBIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3% or less of total bifluorides except when included in Schedule 5.\n\nBIOALLETHRIN except:\n\n (b) in preparations containing 1% or less of bioallethrin.\n\n1,3‑BIS(2,4‑DIAMINOPHENOXY)PROPANE (including its salts) except when in hair dye preparations containing 1.2% or less of 1,3‑bis(2,4‑diaminophenoxy)propane after mixing when the immediate container and primary pack are labelled with the following statements:\n\n (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\nBIS‑ISOBUTYL PEG/PPG‑20/35/AMODIMETICONE COPOLYMER except in rinse‑off cosmetic products containing 1% or less of bis‑isobutyl PEG/PPG‑20/35/amodimeticone copolymer when labelled with a warning to the following effect:\n\n  IF IN EYES, WASH OUT IMMEDIATELY WITH WATER.\n\nN,N‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,5‑DIMETHANAMINE except in preparations containing 1% or less of N,N‑bis(phenylmethylene)‑bicyclo‑ (2.2.1)heptane‑2,5‑dimethanamine, or a combination of N,N‑bis(phenylmethylene)‑bicyclo‑(2.2.1)heptane‑2,5‑dimethanamine and N,N‑bis(phenylmethylene)‑bicyclo‑(2.2.1)heptane‑2,6‑dimethanamine, when labelled with statements to the effect of:\n\n (a) IRRITANT; and\n\n (b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and\n\n (c) Avoid contact with eyes; and\n\n (d) Avoid contact with skin; and\n\n (e) Wear protective gloves when mixing or using; and\n\n (f) Ensure adequate ventilation when using.\n\nN,N‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,6‑DIMETHANAMINE except in preparations containing 1% or less of N,N‑bis(phenylmethylene)‑bicyclo‑(2.2.1)heptane‑2,6‑dimethanamine, or a combination of N,N‑bis(phenylmethylene)‑bicyclo‑(2.2.1)heptane‑2,5‑dimethanamine and N,N‑bis(phenylmethylene)‑bicyclo‑(2.2.1)heptane‑2,6‑dimethanamine, when labelled with statements to the effect of:\n\n (a) IRRITANT; and\n\n (b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and\n\n (c) Avoid contact with eyes; and\n\n (d) Avoid contact with skin; and\n\n (e) Wear protective gloves when mixing or using; and\n\n (f) Ensure adequate ventilation when using.\n\nBITHIONOL for the treatment of animals.\n\nBORON TRIFLUORIDE in preparations containing 1% or less of boron trifluoride (BF3) except when included in Schedule 5.\n\nBRODIFACOUM in preparations containing 0.25% or less of brodifacoum.\n\nBROFLANILIDE except when included in Schedule 5.\n\nBROMADIOLONE in preparations containing 0.25% or less of bromadiolone.\n\nBROMETHALIN in rodent baits containing 0.01% or less of bromethalin.\n\nBROMOFORM except when included in Schedule 4.\n\nBROMOPHOS.\n\nBROMOPHOS‑ETHYL.\n\nBROMOXYNIL.\n\nBROMUCONAZOLE except when included in Schedule 5.\n\nBROTIANIDE.\n\nBUNAMIDINE.\n\nBUTACARB.\n\nBUTOXYCARBOXIM except when included in Schedule 5.\n\n2‑BUTOXYETHANOL and its acetates except:\n\n (a) in plant growth regulator preparations containing 20% or less of such substances; or\n\n (b) in other preparations containing 10% or less of such substances.\n\n2‑BUTOXY‑2'‑THIOCYANODIETHYL ETHER.\n\nn‑BUTYL ALCOHOL except:\n\n (b) in preparations containing 5% or less of n‑butyl alcohol; or\n\n (c) in preparations for cosmetic or therapeutic use other than in spray form.\n\nBUTYRIC ACID in preparations for use as insect lures.\n\nCACODYLIC ACID:\n\n (a) in animal feed premixes containing 4% or less of arsenic; or\n\n (b) in herbicide or defoliant preparations containing 10% or less of cacodylic acid.\n\nCADMIUM COMPOUNDS except:\n\n (b) in paints or tinters containing 0.1% or less of cadmium calculated on the non‑volatile content of the paint or tinter.\n\nCADUSAFOS in aqueous preparations containing 20% or less of microencapsulated cadusafos.\n\nCAFFEINE except:\n\n (b) in divided preparations for internal human therapeutic use when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or\n\n (c) in undivided preparations for internal human therapeutic use with a concentration of less than 5% of total caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or\n\n (d) in preparations for external use; or\n\n (e) in other preparations with a concentration of less than 5% of caffeine.\n\nCAJUPUT OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (e) in preparations containing 25% or less of cajuput oil; or\n\n (f) in oils containing 25% or less of cajuput oil.\n\nCALCIFEROL in rodent baits containing 0.1% or less of calciferol.\n\nCAMBENDAZOLE.\n\nCAMPHOR except:\n\n (b) when enclosed in an inhaler device which prevents ingestion of its contents; or\n\n (c) in solid or semi‑solid preparations containing 12.5% or less of camphor; or\n\n (d) in liquid preparations containing 2.5% or less of camphor; or\n\n (e) in essential oils when the camphor is present as a natural component of the oil:\n\n (i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n (A) KEEP OUT OF REACH OF CHILDREN; and\n\n (B) NOT TO BE TAKEN; or\n\n (iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (A) KEEP OUT OF REACH OF CHILDREN; and\n\n (B) NOT TO BE TAKEN; or\n\n (f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.\n\nCAPTAN.\n\nCARBARYL except when included in Schedule 4 or 5.\n\nCARBON DISULFIDE.\n\nCARBAMIDE PEROXIDE except:\n\n (b) in other preparations containing 9% or less of carbamide peroxide.\n\nCARBETAMIDE.\n\nCASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use except in wash‑off preparations containing 1% or less of castor oil, monomaleate.\n\nCHLORALOSE (alpha‑CHLORALOSE) when packed and labelled for use as a pesticide.\n\nCHLORDANE.\n\nCHLORFENAPYR in preparations containing 36% or less of chlorfenapyr except when included in Schedule 5.\n\nCHLORFENETHOL.\n\nCHLORHEXIDINE in preparations containing 7% or less of chlorhexidine except:\n\n (b) in preparations containing 1% or less of chlorhexidine; or\n\n (c) when in solid preparations.\n\nCHLORINATING COMPOUNDS except:\n\n (b) when separately specified in these Schedules; or\n\n (c) sodium hypochlorite preparations with A pH of less than 11.5; or\n\n (d) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:\n\n  WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or\n\n (e) in liquid preparations containing less than 2% of available chlorine; or\n\n (f) in other preparations containing 4% or less of available chlorine.\n\nCHLORMEQUAT.\n\nCHLOROACETAMIDE\n\n (a) in preparations for cosmetic use; or\n\n (b) in preparations for topical therapeutic use; or\n\n (c) in other preparations containing more than 0.3% of chloroacetamide.\n\n2‑CHLORO‑6‑(ETHYLAMINO)‑4‑NITROPHENOL except:\n\n (a) in non‑oxidative hair dye preparations containing 3% or less of 2‑chloro‑6‑(ethylamino)‑4‑nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\n (b) in oxidative hair dye preparations containing 1.5% or less of 2‑chloro‑6‑(ethylamino)‑4‑nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\nCHLOROFORM except:\n\n (b) in preparations containing 10% or less of chloroform.\n\nALPHA‑CHLOROHYDRIN.\n\nCHLOROPHACINONE.\n\n(E)‑(S)‑1‑(4‑CHLOROPHENYL)‑4,4‑DIMETHYL‑2‑(1H‑1,2,4‑TRIAZOL‑1‑YL)PENT‑1‑EN‑3‑OL (uniconazole‑p) except in preparations containing 5% or less of (E)‑(S)‑1‑(4‑chlorophenyl)‑4,4‑dimethyl‑2‑(1H‑1,2,4‑triazol‑1‑yl)pent‑1‑en‑3‑ol.\n\nCHLOROPICRIN in preparations containing 5% or less of chloropicrin.\n\nCHLOROTHALONIL except in water‑based paint containing 0.5% or less of chlorothalonil.\n\n2‑CHLORO‑6‑(TRICHLOROMETHYL)‑PYRIDINE.\n\nCHLORPYRIFOS except:\n\n (b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.\n\nCHLORPYRIFOS‑METHYL.\n\nCHLORTHIAMID.\n\nCHROMATES (including dichromates) except in paints or tinters containing 5% or less of chromium as the ammonium, barium, calcium, iron, potassium, sodium, strontium or zinc chromate calculated on the non‑volatile content of the paint or tinter.\n\nCHROMIUM TRICHLORIDE HEXAHYDRATE except in preparations containing 0.5% or less chromium.\n\nCHROMIUM TRIOXIDE (excluding its salts and derivatives).\n\nCHRYSOIDINE BASE except when in Schedule 10.\n\nCINEOLE except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (e) in preparations containing 25% or less of cineole; or\n\n (f) in oils containing 25% or less of cineole; or\n\n (g) in rosemary oil or camphor oil (white).\n\nCINNAMON LEAF OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (e) in preparations containing 25% or less of cinnamon leaf oil.\n\nCLIMBAZOLE except:\n\n (b) in leave‑on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or\n\n (c) in other preparations (that are not leave‑on cosmetic preparations) containing 2% or less of climbazole.\n\nCLODINAFOP‑PROPARGYL.\n\nCLOMAZONE.\n\nCLOSANTEL.\n\nCLOTHIANIDIN except\n\n (b) when in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin.\n\nCLOTRIMAZOLE for the external treatment of animals.\n\nCLOVE OIL except:\n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n (ii) NOT TO BE TAKEN;\n\n (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (f) in preparations containing 25% or less of clove oil.\n\nN‑COCO‑1,3‑DIAMINOPROPANE.\n\nCOCOYL GLYCINATE in cosmetic preparations except:\n\n (a) in leave‑on preparations containing 5% or less of cocoyl glycinate; or\n\n (b) in wash‑off preparations containing 30% or less of cocoyl glycinate and, when containing more than 5% of cocoyl glycinate labelled with a warning to the following effect:\n\nCOPPER ACETATE except:\n\n (b) in preparations containing 5% or less of copper acetate.\n\nCOPPER COMPOUNDS except:\n\n (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or\n\n (c) pigments where the solubility of the copper compound(s) in water is 1 g per litre or less; or\n\n (d) in feed additives containing 1% or less of copper; or\n\n (e) in other preparations containing 5% or less of copper compounds.\n\nCOPPER HYDROXIDE except:\n\n (b) in preparations containing 12.5% or less of copper hydroxide.\n\nCOPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.\n\nCOPPER OXIDES except:\n\n (c) in marine paints; or\n\n (d) in other preparations containing 5% or less of copper oxides.\n\nCOPPER OXYCHLORIDE except:\n\n (b) in preparations containing 12.5% of less of copper oxychloride.\n\nCOPPER SULFATE except:\n\n (c) in other preparations containing 5% or less of copper sulfate.\n\nCOUMAPHOS:\n\n (a) in slow‑release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or\n\n (b) in other preparations containing 5% or less of coumaphos.\n\nCOUMATETRALYL in rodenticides containing 1% or less of coumatetralyl except when included in Schedule 5.\n\nCREOSOTE derived from wood other than beechwood except:\n\n (b) in preparations for human therapeutic use containing 10% or less of creosote derived from wood other than beechwood; or\n\n (c) in other preparations containing 3% or less of phenols and homologues of phenol boiling below 220°C.\n\nCROTOXYPHOS.\n\nCRUFOMATE.\n\nCYANAMIDE.\n\nCYANAZINE.\n\nCYCLANILIDE.\n\nN‑CYCLOHEXYLDIAZENIUMDIOXY‑POTASSIUM.\n\nCYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) when presented in a wipe and when packaged in a container with a child‑resistant closure, with chemical resistant gloves and labelled with the following effect:\n\n (a) DO NOT USE WITHOUT PROTECTIVE GLOVES; and\n\n (b) KEEP OUT OF EYES.\n\nCYFLUTHRIN except:\n\n (b) in pressurised spray packs containing 1% or less of cyfluthrin.\n\nCYOMETRINIL.\n\nCYPERMETHRIN except when included in Schedule 5.\n\nCYPHENOTHRIN except when included in Schedule 5.\n\nCYTHIOATE except when included in Schedule 5.\n\n2,4‑D except when included in Schedule 5.\n\nDAZOMET.\n\nDELTAMETHRIN:\n\n (a) in aqueous preparations containing 25% or less of deltamethrin, when no organic solvent, other than 10% or less of a glycol, is present; or\n\n (b) in wettable granular preparations containing 25% or less of deltamethrin; or\n\n (c) in water‑dispersible tablets each containing 500 mg or less of deltamethrin; or\n\n (d) in emulsifiable concentrates containing 11% or less of deltamethrin in a solvent containing 40% or less of acetophenone and 45% or less of liquid hydrocarbons; or\n\n (e) in other preparations containing 3% or less of deltamethrin;\n\n (f) when included in Schedule 5; or\n\n (g) in factory prepared mosquito nets containing 1% or less of deltamethrin; or\n\n (h) in preparations containing 0.1% or less of deltamethrin.\n\nDERQUANTEL.\n\n1‑DEOXY‑1‑(METHYLAMINO)‑d‑GLUCITOL N‑COCO ACYL DERIVATIVES except:\n\n (a) in cosmetic rinse‑off preparations containing 8% or less of 1‑deoxy‑1‑(methylamino)‑d‑glucitol N‑coco acyl derivatives when labelled with the following statement:\n\n  IF IN EYES WASH OUT IMMEDIATELY WITH WATER, or\n\n (b) in household cleaning preparations, other than those intended to be sprayed, containing 10% or less of 1‑deoxy‑1‑(methylamino)‑d‑glucitol N‑coco acyl derivatives when labelled with the following statement:\n\n2,4‑DIAMINOPHENOXYETHANOL except when used in hair dye and eyebrow/eyelash preparations at concentrations of 2% or less of 2,4‑diaminophenoxyethanol after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\nDIAZINON except when included in Schedule 5.\n\nDICAMBA (including its salts and derivatives) except when included in Schedule 5.\n\nDICHLOBENIL.\n\nDICHLOFENTHION.\n\nDICHLOFLUANID.\n\no‑DICHLOROBENZENE.\n\nDICHLOROETHYL ETHER.\n\nDICHLOROISOCYANURIC ACID except:\n\n (b) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:\n\n  WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or\n\n (c) in liquid preparations containing less than 2% of available chlorine; or\n\n (d) in other preparations containing 4% or less of available chlorine.\n\n4,5‑DICHLORO‑2‑N‑OCTYL‑3(2H)‑ISOTHIAZOLONE.\n\nDICHLOROPHEN except:\n\n (b) in fabrics other than when:\n\n (i) for human therapeutic use; or\n\n (ii) as part of a registered pesticidal product.\n\n1,2‑DICHLOROPROPANE.\n\n2,4‑DICHLORPROP (including the R and S enantiomers).\n\nDICHLORVOS in preparations containing 50% or less of dichlorvos except when included in Schedule 5.\n\nDICLOFOP‑METHYL.\n\nDICYCLANIL except in preparations containing 6.5% or less of dicyclanil.\n\nDIDECYLDIMETHYLAMMONIUM SALTS except in preparations containing 1% or less of didecyldimethylammonium salts labelled with the statement:\n\n  Avoid contact with eyes.\n\nDIELDRIN.\n\nDIETHANOLAMINE (excluding its salts and derivatives) except:\n\n (b) in preparations containing 5% or less of diethanolamine.\n\nDIETHYLENE GLYCOL (excluding its salts and derivatives) except:\n\n (b) in paints or paint tinters; or\n\n (c) in toothpastes or mouthwashes containing more than 0.25% of diethylene glycol; or\n\n (d) in other preparations containing 2.5% or less of diethylene glycol.\n\nDIETHYLENE GLYCOL MONOMETHYL ETHER.\n\nDIFENACOUM in preparations containing 0.25% or less of difenacoum.\n\nDIFENZOQUAT.\n\nDIFETHIALONE in rodent baits containing 0.0025% or less of difethialone.\n\n5,6‑DIHYDROXYINDOLINE.\n\nDIMETHENAMID‑P.\n\nDIMETHIPIN.\n\nDIMETHOATE.\n\n2,6‑DIMETHOXY‑3,5‑PYRIDINEDIAMINE except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 0.25% or less of 2,6‑dimethoxy‑3,5‑pyridinediamine after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\nDIMETHYLACETAMIDE except when included in Schedule 5.\n\nN,N‑DIMETHYLDECANAMIDE.\n\nDIMETHYLFORMAMIDE except:\n\n (b) in silicone rubber mastic containing 2% or less of dimethylformamide.\n\n4,4‑DIMETHYL‑1‑CYCLOHEXENE‑1‑PROPANAL except:\n\n (a) in leave‑on cosmetic preparations containing 0.1% or less of 4,4‑dimethyl‑1‑cyclohexene‑1‑propanal; or\n\n (b) in rinse‑off cosmetic preparations containing 0.5% or less of 4,4‑dimethyl‑1‑cyclohexene‑1‑propanal; or\n\n (c) in other preparations containing 1% or less of 4,4‑dimethyl‑1‑cyclohexene‑1‑propanal.\n\n3,7‑DIMETHYL‑2,6‑OCTADIEN‑1‑OL and its isomers except in products containing 5% or less 3,7‑dimethyl‑2,6‑octadien‑1‑ol and its isomers.\n\nN,N‑DIMETHYLOCTANAMIDE.\n\nDIMETHYL SULFOXIDE (excluding dimethyl sulfone):\n\n (a) when not for therapeutic use; or\n\n (b) in cosmetic preparations; or\n\n (c) for the treatment of animals:\n\n (i) when combined with no other therapeutic substance(s); or\n\n (ii) in liquid preparations containing copper salicylate and 1% or less of methyl salicylate as the only other therapeutic substances; or\n\n (iii) in clay poultices containing 2% or less of dimethyl sulfoxide; or\n\n (d) in other preparations except when containing 10% or less of dimethyl sulfoxide.\n\nDIMPROPYRIDAZ except when included in Schedule 5.\n\nDINITROCRESOLS and their homologues in preparations containing 5% or less of such compounds except:\n\nDINITROPHENOLS and their homologues in preparations containing 5% or less of such compounds except:\n\nDIOXACARB.\n\nDIOXANE except:\n\n (a) in preparations for cosmetic or human internal therapeutic use containing 0.001% or less of dioxane; or\n\n (b) in other preparations containing 0.01% or less of dioxane.\n\nDIPHACINONE.\n\nDIQUAT in preparations containing 20% or less of diquat.\n\nDIRECT RED 254 except when included in Schedule 5.\n\nDISPERSE YELLOW 3 except when in Schedule 10.\n\nDISULFIRAM except when included in Schedule 4.\n\nDISULFOTON in granular preparations containing 5% or less of disulfoton.\n\nDITHIANON.\n\nDITHIAZANINE in preparations containing 2% or less of dithiazanine for the treatment of animals.\n\nDIUREDOSAN.\n\nN‑(N‑DODECYL)‑2‑PYRROLIDONE except:\n\nDODINE.\n\nDORAMECTIN for external use for the treatment of animals, in preparations containing 2% or less of doramectin.\n\nDSMA in herbicide or defoliant preparations containing 10% or less of DSMA.\n\nECONAZOLE for the external treatment of animals.\n\nEMAMECTIN in preparations containing 5% or less of emamectin except when included in Schedule 5.\n\n \n\nEMODEPSIDE for the treatment of animals except when included in Schedule 5.\n\nENDOSULFAN in aqueous preparations containing 33% or less of microencapsulated endosulfan.\n\nENDOTHAL in preparations containing 20% or less of endothal.\n\nEPRINOMECTIN for internal use in preparations containing 5% or less of eprinomectin except when included in Schedule 5.\n\nEPTC.\n\nESBIOTHRIN except:\n\n (b) in pressurised spray packs containing 1% or less of esbiothrin.\n\nESFENVALERATE except when included in Schedule 5.\n\nETHEPHON (excluding its salts and derivatives).\n\nETHER except:\n\n (a) when included in Schedule 2, 4 or 5; or\n\n (b) in preparations containing 10% or less of ether.\n\nETHIOFENCARB.\n\nETHOATE‑METHYL.\n\nETHOPROPHOS in granular formulations containing 10% or less of ethoprophos and 2% of linseed oil.\n\nETHYL BROMIDE.\n\nETHYLENE CHLOROHYDRIN.\n\nETHYLENE DICHLORIDE.\n\nETHYLENE GLYCOL (excluding its salts and derivatives) except:\n\n (b) in paints or paint tinters; or\n\n (c) in toothpastes or mouthwashes containing more than 0.25% of ethylene glycol; or\n\n (d) in other preparations containing 2.5% or less of ethylene glycol.\n\nETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, except:\n\n (b) in preparations containing 10% or less of such substances.\n\nETHYL FORMATE when packed and labelled for use as a fumigant.\n\nETHYLHEXANEDIOL except in preparations containing 5% or less of ethylhexanediol.\n\n2‑ETHYLHEXANOIC ACID and its alkyl esters except in preparations containing 5% or less calculated as 2‑ethylhexanoic acid.\n\nETRIMFOS.\n\nEUCALYPTUS OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (e) in preparations containing 25% or less of eucalyptus oil.\n\nEUGENOL except:\n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (f) in preparations containing 25% or less of eugenol.\n\nFAMOXADONE.\n\nFAMPHUR in preparations containing 20% or less of famphur.\n\nFEBANTEL except:\n\n (a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or\n\n (b) in undivided preparations containing 10% or less of febantel.\n\nFENAMIPHOS in granular preparations containing 5% or less of fenamiphos.\n\nFENAZAFLOR.\n\nFENBUTATIN OXIDE.\n\nFENCHLORPHOS.\n\nFENITROTHION.\n\nFENOXACRIM in preparations for the treatment of carpets during manufacture.\n\nFENPROPIDIN.\n\nFENPYROXIMATE.\n\nFENTHION in preparations containing 60% or less of fenthion except when included in Schedule 5.\n\nFENVALERATE.\n\nFIPRONIL except:\n\n (b) in preparations containing 0.05% or less of fipronil.\n\nFLOCOUMAFEN in preparations containing 0.005% or less of flocoumafen.\n\nFLONICAMID.\n\nFLUAZAINDOLIZINE except when included in Schedule 5.\n\nFLUAZIFOP‑BUTYL.\n\nFLUAZIFOP‑p‑BUTYL.\n\nFLUAZINAM.\n\nFLUCOFURON in preparations for the treatment of carpets during manufacture.\n\nFLUENSULFONE.\n\nFLUMETHRIN except when included in Schedule 5.\n\nFLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.\n\nFLUORIDES except:\n\n (b) in preparations for human use; or\n\n (c) in preparations containing 15 mg/kg or less of fluoride ion.\n\nFLUPROPANATE.\n\nFLUPYRADIFURONE.\n\nFLUQUINCONAZOLE.\n\nFLUSILAZOL.\n\nFLUTRIAFOL except in fertilisers containing 0.5% or less of flutriafol.\n\nFLUVALINATE except when included in Schedule 5.\n\nFOMESAFEN SODIUM.\n\nFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde except:\n\n (b) in oral hygiene preparations; or\n\n (d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement:\n\n  PROTECT CUTICLES WITH GREASE OR OIL;\n\n (e) in all other cosmetic preparations; or\n\n (f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:\n\nFORMOTHION.\n\nFOSPIRATE except when included in Schedule 5.\n\nFUMAGILLIN.\n\nFURFURAL except in preparations containing 0.1% or less of furfural.\n\nGLUTARAL except:\n\n (b) in preparations containing 0.5% or less of glutaral when labelled with the statements:\n\n  IRRITANT; and\n\n  Avoid contact with eyes.\n\nGLYCERYL THIOGLYCOLLATE in hair waving preparations except when labelled with directions for use that include the statement:\n\n  Wear protective gloves when using. Keep out of eyes.\n\nGLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical except:\n\n (a) in cosmetic preparations for salon use only, when labelled in accordance with requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time; or\n\n (b) in preparations containing 5% or less of glycolic acid; or\n\n (c) in preparations containing 20% or less of glycolic acid with A pH of 3.5 or greater.\n\nGUANIDINE except:\n\n (b) in preparations containing 1% or less of guanidine.\n\nGUAZATINE.\n\nHALOXON.\n\nHALOXYFOP.\n\nHC VIOLET 1 except:\n\n (a) in non‑oxidative hair dye preparations containing 0.28% or less of HC Violet 1 after mixing when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\n (b) in oxidative hair dye preparations containing 0.25% or less of HC Violet 1 after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\nHEPTACHLOR.\n\nHEXACHLOROPHENE:\n\n (a) in preparations for the treatment of animals; or\n\nHEXAZINONE except when included in Schedule 5.\n\nHEXYLOXYETHANOL except in preparations containing 10% or less of hexyloxyethanol.\n\nHYDRAMETHYLNON except when included in Schedule 5.\n\nHYDRAZINE.\n\nHYDROCHLORIC ACID (excluding its salts and derivatives) except:\n\n (b) in preparations for therapeutic use; or\n\n (c) in preparations containing 0.5% or less of hydrochloric acid (HCl).\n\nHYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1% or less of hydrogen fluoride except when included in Schedule 5.\n\nHYDROGEN PEROXIDE (excluding its salts and derivatives) except:\n\n (b) in hair dye preparations containing 6% (20 volume) or less of hydrogen peroxide; or\n\n (c) in other preparations containing 3% (10 volume) or less of hydrogen peroxide.\n\nHYDROQUINONE except:\n\n (b) in preparations containing 10% or less of hydroquinone.\n\nHYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1% or less of hydrosilicofluoric acid (H2SiF6) except when included in Schedule 5.\n\nHYDROXYETHYL‑3,4‑METHYLENEDIOXYANILINE (including its salts) except in oxidative hair dye preparations containing 1.5% or less of hydroxyethyl‑3,4‑methylenedioxyaniline after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:\n\n (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\nIMIDACLOPRID except:\n\n (b) in preparations containing 5% or less of imidacloprid.\n\nIMIDOCARB.\n\nIMINOCTADINE TRIALBESILATE.\n\nIMIPROTHRIN except:\n\n (b) in preparations containing 10% or less of imiprothrin.\n\nINDAZIFLAM.\n\nINDOXACARB (includes the R and S enantiomers) except when included in Schedule 5.\n\nINPYRFLUXAM.\n\nIODINE (excluding its salts, derivatives and iodophors) except:\n\n (b) in solid or semi‑solid preparations containing 2.5% or less of available iodine.\n\nIODOPHORS except in preparations containing 1.5% or less of available iodine.\n\n3‑IODO‑2‑PROPYNYL BUTYL CARBAMATE (Iodocarb) except:\n\n (b) in aqueous preparations not for cosmetic use containing 10% or less of 3‑iodo‑2‑propynyl butyl carbamate (Iodocarb); or\n\n (c) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3‑iodo‑2‑propynyl butyl carbamate.\n\nIOXYNIL.\n\nIPCONAZOLE except when included in Schedule 5.\n\nIRON COMPOUNDS (excluding up to 1% of iron oxides when present as an excipient) for the treatment of animals except:\n\n (b) in liquid or gel preparations containing 0.1% or less of iron; or\n\n (c) in animal feeds or feed premixes.\n\nISOCONAZOLE for the external treatment of animals.\n\nISOCYANATES, free organic, boiling below 300° C, except in:\n\n (a) viscous polyurethane adhesives; or\n\n (b) viscous polyurethane sealants;\n\n containing not more than 0.7% of free organic isocyanates boiling below 300°C.\n\nISOCYCLOSERAM.\n\nISOEUGENOL except:\n\n (b) in preparations not intended for skin contact containing 10% or less of isoeugenol; or\n\n (c) in preparations intended for skin contact containing 0.02% or less of isoeugenol.\n\nISOPYRAZAM.\n\nISOTIANIL.\n\nLAMBDA‑CYHALOTHRIN:\n\n (a) in aqueous preparations containing 25% or less of microencapsulated lambda‑cyhalothrin; or\n\n (b) in emulsifiable granule formulations containing 25% or less lambda‑cyhalothrin; or\n\n (c) in other preparations containing 1.6% or less of lambda‑cyhalothrin;\n\nLASALOCID except in animal feeds containing 100 mg/kg or less of antibiotic substances.\n\nLAURETH CARBOXYLIC ACIDS (excluding their salts and derivatives) except:\n\n (a) in leave‑on preparations containing 1.5% or less of laureth carboxylic acids; or\n\n (b) in wash‑off preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with a warning to the following effect:\n\n (c) in other preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with warnings to the following effect:\n\nLAURYL ISOQUINOLINIUM BROMIDE.\n\nLAURYL SULFATE SALTS (excluding their derivatives) except:\n\n (a) in wash‑off preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with a warning to the following effect:\n\n (b) in leave‑on preparations containing 1.5% or less of lauryl sulfates; or\n\n (c) in toothpaste and oral hygiene preparations containing 5% or less of lauryl sulfates; or\n\n (d) in other preparations for animal use containing 2% or less of lauryl sulfates; or\n\n (e) in other preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with warnings to the following effect:\n\nLEAD COMPOUNDS except:\n\n (a) when included in, or expressly excluded from, Schedule 10; or\n\n (b) in preparations for cosmetic use containing 10 mg/kg or less of lead; or\n\n (c) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 25 mg/kg or less of lead; or\n\n (d) in ceramic glazes when labelled with the warning statement:\n\n  CAUTION – Harmful if swallowed. Do not use on surfaces which contact food or drink;\n\nLEPTOSPERMUM SCOPARIUM OIL (manuka oil) except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings;\n\n (e) in preparations containing 25% or less of Leptospermum scoparium oil.\n\nLEVAMISOLE for the treatment of animals except:\n\n (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.\n\nLINDANE except when included in Schedule 2, 4 or 5.\n\nMAFENIDE when packed and labelled for the treatment of ornamental fish only.\n\nMALATHION except:\n\n (b) for human therapeutic use; or\n\n (c) in dust preparations containing 2% or less of malathion.\n\nMCPA except when included in Schedule 5.\n\nMCPB.\n\nMEBENDAZOLE for the treatment of animals except when included in Schedule 5.\n\nMECOPROP except when included in Schedule 5.\n\nMECOPROP‑P.\n\nMEFLUIDIDE.\n\nMELALEUCA OIL (tea tree oil) except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (e) in preparations containing 25% or less of melaleuca oil.\n\nMELENGESTROL ACETATE when used as an animal feed additive.\n\nMELOXICAM in:\n\n (a) oral transmucosal preparations containing 1% or less of meloxicam for pre‑surgical treatment and pain management in livestock during routine husbandry procedures; or\n\n (b) injectable vaccines containing bacterial antigens and 1% or less of meloxicam for single use in lambs undergoing husbandry procedures at marking.\n\nMENAZON.\n\nMERCAPTAMINE for cosmetic use except:\n\n (b) in preparations containing 1% or less of mercaptamine.\n\nMERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations except:\n\n (b) in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid).\n\n2‑MERCAPTOETHANOL in preparations for use as insect lures.\n\nMERCURIC OXIDE for the treatment of animals, in preparations for ocular use.\n\nMERCUROCHROME for the treatment of animals, in preparations for topical use.\n\nMETACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.\n\nMETALAXYL except when included in Schedule 5.\n\nMETALDEHYDE except when included in Schedule 5.\n\nMETHACRIFOS in preparations containing 60% or less of methacrifos.\n\nMETHAM.\n\nMETAMITRON.\n\nMETHANOL (excluding its derivatives) except:\n\n (b) when included in Schedule 10; or\n\n (c) in preparations containing 2% or less of methanol.\n\nMETHIOCARB in preparations containing 20% or less of methiocarb except when included in Schedule 5.\n\nMETHOMYL in fly‑baits containing 1% or less of methomyl and not less than 0.002% of denatonium benzoate as a bittering agent.\n\n6‑METHOXY‑N2‑METHYL‑2,3‑PYRIDINEDIAMINE except when used in oxidative or non‑ oxidative hair dyes at a concentration of 1% or less when the immediate container and primary pack are labelled with the following statements:\n\n (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.\n\n2‑METHOXY‑5‑NITROPHENOL.\n\nMETHYLCHLOROISOTHIAZOLINONE except:\n\n (a) in rinse‑off cosmetic preparations or therapeutic goods intended for topical rinse‑off application containing 0.0015% or less of methylchloroisothiazolinone and methylisothiazolinone in total; or\n\n (b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylchloroisothiazolinone and methylisothiazolinone in total.\n\nMETHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10% or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child‑resistant closure.\n\nMETHYLDIBROMO GLUTARONITRILE except when in Schedule 10.\n\nMETHYLENE BISTHIOCYANATE except in preparations containing 1% or less of methylene bisthiocyanate.\n\nMETHYLEUGENOL except in preparations containing 1% or less of methyleugenol.\n\nMETHYL ETHYL KETONE OXIME except:\n\n (a) in viscous silicone adhesives or viscous silicone sealants containing 2.5% or less of methyl ethyl ketone oxime; or\n\n (b) in other preparations containing 1% or less of methyl ethyl ketone oxime.\n\np‑METHYLAMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of p‑methylaminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\nMETHYL ISOTHIOCYANATE.\n\nMETHYL METHACRYLATE (excluding its derivatives) except:\n\n (a) for cosmetic use; or\n\n (b) in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.\n\nMETHYL NEODECANAMIDE except in liquid preparations containing 2% or less of methyl neodecanamide.\n\nMETHYLISOTHIAZOLINONE except:\n\n (a) in rinse‑off cosmetic preparations or therapeutic goods intended for topical rinse‑off application containing 0.0015% or less of methylisothiazolinone; or\n\n (b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylisothiazolinone\n\nMETHYLNORBORNYLPYRIDINE.\n\nN‑METHYL‑2‑PYRROLIDONE except:\n\n2‑METHYLRESORCINOL except:\n\n (a) in non‑oxidative hair dye preparations containing 1.8% or less of 2‑methylresorcinol when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n (b) in oxidative hair dye preparations containing 1.8% or less of 2‑methylresorcinol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n  written in letter not less than 1.5 mm in height.\n\nMETHYLROSANILINIUM CHLORIDE (formerly known as crystal violet CAS No. 548‑62‑9) and the following TRIARYLMETHANE DYES:\n\n (a) Acid Violet 49 (CAS No. 1694‑09‑3);\n\n (b) Ethyl Violet (CAS No. 2390‑59‑2);\n\n (c) Basic Blue 7 (CAS No. 2390‑60‑5);\n\n (d) Methylium, 4‑(dimethylamino)phenylbis4‑(ethylamino)‑3‑methylphenyl‑, acetate (CAS No. 72102‑55‑7);\n\n except when included in Schedule 4 or Schedule 10.\n\nMETHYL SALICYLATE except:\n\n (b) in preparations for therapeutic use; or\n\n (c) in preparations containing 5% or less of methyl salicylate.\n\nMETOFLUTHRIN except when included in Schedule 5.\n\nMETOSULAM.\n\nMETRAFENONE except when included in Schedule 5.\n\nMETRIBUZIN.\n\nMICONAZOLE for the external treatment of animals.\n\nMILBEMECTIN except when included in Schedule 5.\n\nMOMFLUOROTHRIN except in preparations containing 0.2% or less of momfluorothrin.\n\nMONENSIN:\n\n (a) in animal feed premixes containing 12.5% or less of antibiotic substances; or\n\n (b) in stockfeed supplements, blocks or licks containing 0.75% or less of antibiotic substances.\n\nMONOETHANOLAMINE (excluding its salts and derivatives) except:\n\n (b) in preparations containing 5% or less of monoethanolamine.\n\nMORANTEL except:\n\n (b) in preparations containing 10% or less of morantel.\n\nMOXIDECTIN:\n\n (a) in preparations for external use containing 2.5% or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or\n\n (b) in preparations for external use containing 2% or less of moxidectin for the treatment of animals; or\n\n (c) in preparations for internal use containing 10% or less of moxidectin for the treatment of sheep or cattle;\n\nMSMA in herbicide or defoliant preparations containing 10% or less of MSMA.\n\nNALED except when included in Schedule 5.\n\nNAPHTHALENE (excluding its derivatives) except in liquid hydrocarbons.\n\n1,5‑NAPHTHALENEDIOL except:\n\n (a) in non‑oxidative hair dye preparations containing 1% or less of 1,5‑naphthalenediol when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n (b) in oxidative hair dye preparations containing 1% or less of 1,5‑naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n2,7‑NAPHTHALENEDIOL except:\n\n (a) in non‑oxidative hair dye preparations containing 1% or less of 2,7‑naphthalenediol when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n (b) in oxidative hair dye preparations containing 1% or less of 2,7‑naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n1‑NAPHTHOL except in hair dye preparations containing 1% or less of 1‑naphthol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\nNAPHTHALOPHOS in preparations containing 80% or less of naphthalophos.\n\nNARASIN in animal feed premixes containing 12% or less of narasin.\n\nNETOBIMIN for the treatment of animals except when included in Schedule 5.\n\nNICKEL SULFATE.\n\nNIMIDANE in preparations containing 25% or less of nimidane.\n\nNITENPYRAM except in divided preparations containing 100 mg or less of nitenpyram.\n\nNITRIC ACID (excluding its salts and derivatives) except:\n\n (b) in preparations containing 0.5% or less of nitric acid (HNO3).\n\nNITROBENZENE except:\n\n (a) in solid or semi‑solid polishes; or\n\n (b) in soaps containing 1% or less of nitrobenzene; or\n\n (c) in other preparations containing 0.1% or less of nitrobenzene.\n\n3‑NITRO‑p‑HYDROXYETHYLAMINOPHENOL except\n\n (a) in non‑oxidative hair dye preparations containing 1.85% or less of 3‑nitro‑p‑hydroxyethylaminophenol after mixing when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n (b) in oxidative hair dye preparations containing 3% or less of 3‑nitro‑p‑hydroxyethylaminophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\nNITROPHENOLS, ortho, meta and para, except when separately specified in these Schedules.\n\nNITROPRUSSIDES in preparations containing 2.5% or less of nitroprussides except when included in Schedule 4.\n\nNITROUS OXIDE except when included in Schedule 4.\n\nNITROXYNIL.\n\nNONOXINOL 9 except:\n\n (b) in preparations containing 25% or less of nonoxinol 9 when labelled with the statements:\n\n (i) IRRITANT; and\n\n (ii) Avoid contact with eyes; or\n\n (c) in preparations containing 12.5% or less of nonoxinol 9; or\n\n (d) in preparations for human use.\n\n1‑OCTEN‑3‑OL except in preparations containing 5% or less of 1‑octen‑3‑ol.\n\nOCTHILINONE except in paints, jointing compounds and sealants containing 1% or less of octhilinone calculated on the non‑volatile content.\n\nN‑(N‑OCTYL)‑2‑PYRROLIDONE except:\n\nOLAQUINDOX except in preparations containing 10% or less of olaquindox.\n\nN‑OLEYL‑1,3‑DIAMINOPROPANE.\n\nOMETHOATE in preparations containing 30% or less of omethoate except when included in Schedule 5.\n\nOXADIAZON.\n\nOXALIC ACID except\n\n (a) in dental care preparations, including mouthwashes, containing 3% or less of soluble salts of oxalic acid; or\n\n (b) its insoluble salts.\n\nOXYCLOZANIDE.\n\nPAECILOMYCES LILACINUS STRAIN 251.\n\nPARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde except:\n\n (b) in oral hygiene preparations; or\n\n (d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement:\n\n  PROTECT CUTICLES WITH GREASE OR OIL; or\n\n (e) in all other cosmetic preparations; or\n\n (f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:\n\nPARATHION‑METHYL in aqueous preparations containing 45% or less of microencapsulated parathion‑methyl.\n\nPARBENDAZOLE.\n\nPEBULATE.\n\nPENNYROYAL OIL except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (c) in preparations containing 4% or less of d‑pulegone.\n\nPENTACHLOROPHENOL in preparations containing 1.5% or less of pentachlorophenol.\n\nPERACETIC ACID except when included in Schedule 5.\n\nPERFLUIDONE.\n\nPERMANGANATES except potassium permanganate in aqueous solutions containing 1% or less of potassium permanganate.\n\nPERMETHRIN except:\n\n (b) in preparations for human therapeutic use containing 5% or less of permethrin; or\n\n (c) in preparations containing 2% or less of permethrin.\n\n2‑PHENOXYETHANOL except:\n\n (a) in cosmetic preparations containing 1% or less of 2‑phenoxyethanol; or\n\n (b) in other preparations containing 15% or less of 2‑phenoxyethanol.\n\nPHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, except:\n\n (b) in preparations containing 1% or less of phenols, and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol.\n\nPHENOTHIAZINE (excluding its derivatives) except in preparations containing 10% or less of phenothiazine.\n\nPHENOXYMETHYL OXIRANE.\n\nPHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives not elsewhere specified in these Schedules:\n\n (a) in preparations packed and labelled for photographic purposes; or\n\n (b) in preparations packed and labelled for testing water except tablets containing 10 mg or less of diethyl‑para‑phenylenediamine or dimethyl‑para‑phenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”; or\n\n (c) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n (d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:\n\n  WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;\n\nPHENYL METHYL PYRAZOLONE except when used in hair dye and eyebrow/eyelash preparations at a concentration of 0.25% or less after mixing for use when the immediate container and primary pack are labelled with warning statements to the following effect:\n\n (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.\n\nPHOSALONE.\n\nPHOSMET.\n\nPHOSPHORIC ACID (excluding its salts and derivatives) except:\n\n (b) in preparations containing 15% or less of phosphoric acid (H3PO4); or\n\n (c) in solid or semi‑solid preparations; or\n\n (d) in professional dental kits.\n\nPHOXIM.\n\no‑PHTHALALDEHYDE except when included in Schedule 5.\n\nPICRAMIC ACID including its salts (excluding other derivatives) except when used in hair dye products at a concentration of 0.6% or less of picramic acid after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (b) WARNING ‒ This product contains ingredients which may cause skin allergy to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\nPINDONE.\n\nPINE OILs when packed and labelled as a herbicide except when included in Schedule 5.\n\nPINOXADEN except when included in Schedule 5.\n\nPIPEROPHOS.\n\nPIRIMICARB except when included in Schedule 5.\n\nPIRIMIPHOS‑ETHYL.\n\nPIRIMIPHOS‑METHYL.\n\nPOLIHEXANIDE except:\n\n (a) in cosmetic preparations containing 0.3% or less of polihexanide; or\n\n (b) when packed and labelled for therapeutic use; or\n\n (c) in other preparations containing 5% or less of polihexanide.\n\nPOLIXETONIUM SALTS except:\n\n (b) in preparations containing 1% or less of polixetonium salts.\n\nPOTASSIUM AZELOYL DIGLYCINATE except in preparations for cosmetic use containing 1% or less of potassium azeloyl diglycinate.\n\nPOTASSIUM BROMATE except in preparations containing 0.5% or less of potassium bromate.\n\nPOTASSIUM CYANATE.\n\nPOTASSIUM HYDROXIDE (excluding its salts and derivatives) except:\n\n (a) when included in Schedule 5 or Schedule 10; or\n\n (b) in preparations containing 5% or less of potassium hydroxide being:\n\n (i) solid preparations, tHE pH of which in a 10 g/L aqueous solution is 11.5 or less; or\n\n (ii) liquid or semi‑solid preparations, tHE pH of which is 11.5 or less.\n\nPOTASSIUM NITRITE in preparations containing 40% or less of potassium nitrite except:\n\n (b) in preparations containing 0.5% or less of potassium nitrite; or\n\n (d) in aerosols containing 2% or less of potassium nitrite.\n\nPOTASSIUM PEROXOMONOSULFATE TRIPLE SALT except:\n\n (b) in solid orthodontic device cleaning preparations, tHE pH of which as an “in‑use” aqueous solution is 2.5 or more, but not more than 11.5; or\n\n (c) in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:\n\n (i) solid preparations, tHE pH of which in a 10 g/L aqueous solution is 2.5 or more; or\n\n (ii) liquid or semi‑solid preparations, tHE pH of which is 2.5 or more.\n\nPOTASSIUM PERSULFATE in hair preparations.\n\nPRALLETHRIN (cis:trans=20:80) except:\n\n (b) in insecticidal mats containing 1% or less of prallethrin.\n\nPROCHLORAZ.\n\nPROFENOFOS.\n\nPROMACYL.\n\nPROPACHLOR.\n\nPROPARGITE.\n\nPROPETAMPHOS.\n\nPROPICONAZOLE except when included in Schedule 5.\n\nPROPINEB.\n\nPROPIONIC ACID (excluding its salts and derivatives) except:\n\n (b) in preparations containing 30% or less of propionic acid; or\n\n (c) for therapeutic use.\n\nPROPOXUR except when included in Schedule 5.\n\nn‑PROPYL ALCOHOL except:\n\n (b) in preparations containing 5% or less of n‑propyl alcohol; or\n\n (c) in preparations for cosmetic or therapeutic use other than in spray form.\n\nPROQUINAZID.\n\nPROSULFOCARB.\n\nPROSULFURON.\n\nPROTHIOFOS.\n\nd‑PULEGONE except in preparations containing 4% or less of d‑pulegone.\n\nPYRACLOFOS.\n\nPYRAZOPHOS.\n\nPYRIDABEN except when included in Schedule 5.\n\nPYRIDALYL.\n\nPYRIDATE.\n\nPYRIPROLE.\n\nPYRITHIONE COPPER.\n\nPYRITHIONE ZINC except:\n\n (b) for human use in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels; or\n\n (c) in semi‑solid hair preparations for animal use; or\n\n (d) in shampoos for animal use containing 2% or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with water”; or\n\n (e) when immobilised in solid preparations containing 0.5% or less of pyrithione zinc; or\n\n (f) in paints, jointing materials or sealants containing 0.1% or less of pyrithione zinc calculated on the non‑volatile content.\n\nPYRIOFENONE except when included in Schedule 5.\n\nPYROXASULFONE.\n\nPYROXSULAM.\n\nQUATERNARY AMMONIUM COMPOUNDS except:\n\n (b) when included in Schedule 5; or\n\n (c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or\n\n (d) in preparations containing 5% or less of such quaternary ammonium compounds.\n\nQUININE in cosmetic preparations except:\n\n (a) in rinse‑off hair preparations containing 0.5% or less of quinine calculated as free base; or\n\n (b) in leave‑on hair preparations containing 0.2% or less of quinine calculated as free base.\n\nQUINOLINE and its salts (excluding other derivatives).\n\nQUIZALOFOP ETHYL.\n\nQUIZALOFOP‑p‑ETHYL except when included in Schedule 5.\n\nQUIZALOFOP‑p‑TEFURYL.\n\nRESCALURE for agricultural use except when enclosed in a vapour releasing device which in normal use prevents access to its contents.\n\nRESMETHRIN except when included in Schedule 5.\n\nRESORCINOL except:\n\n (b) in oxidative hair dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n (c) in oxidative eyelash and eyebrow dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;\n\n (d) in hair lotions/shampoo products containing 0.5% or less of resorcinol when the immediate container and primary pack are labelled with the following statement:\n\n  WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals;\n\nROTENONE except in solid or semi‑solid preparations containing 2% or less of rotenone.\n\nSAFROLE except:\n\n (b) in other preparations containing 1% or less of safrole.\n\nSAGE OIL (Dalmatian) except:\n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or\n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:\n\n (c) in preparations containing 4% or less of thujone.\n\nSALINOMYCIN in animal feed premixes containing 12% or less of antibiotic substances.\n\nSAROLANER except when included in Schedule 5.\n\nSASSAFRAS OIL except:\n\n (b) in other preparations containing 1% or less of safrole.\n\nSELENIUM:\n\n (a) in preparations containing 2.5% or less of selenium when packed and labelled:\n\n (i) for the blueing of gun barrels; or\n\n (ii) for photographic purposes; or\n\n (iii) for the colouring of lead or lead alloys; or\n\n b) in coated granules containing 1% or less of selenium for application to pasture except in fertilisers containing 200 g/tonne or less of selenium; or\n\n (c) for the treatment of animals:\n\n (i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5% or less of selenium; or\n\n (ii) in animal feed premixes containing 2% or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium; or\n\n (iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or\n\n (iv) as barium selenate in preparations for injection containing 5% or less of selenium.\n\nSEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5% or less of antibiotic substances.\n\nSILICOFLUORIDES except:\n\nSILVER NITRATE except:\n\n (a) when included in or expressly excluded from Schedule 2; or\n\n (b) in preparations containing 1% or less of silver.\n\nSINBIOALLETHRIN except:\n\n (b) in preparations containing 1% or less of sinbioallethrin.\n\nSODIUM ALUMINATE (excluding its salts and derivatives) except:\n\n (a) in solid preparations, tHE pH of which in a 10 g/L aqueous solution is 11.5 or less; or\n\n (b) in liquid preparations, tHE pH of which is 11.5 or less.\n\nSODIUM BROMATE except in preparations containing 0.5% or less of sodium bromate.\n\nSODIUM HYDROXIDE (excluding its salts and derivatives) except:\n\n (a) when included in Schedule 5 or Schedule 10; or\n\n (b) in preparations containing 5% or less of sodium hydroxide being:\n\n (i) solid preparations, tHE pH of which in a 10 g/L aqueous solution is 11.5 or less; or\n\n (ii) liquid or semi‑solid preparations, tHE pH of which is 11.5 or less.\n\nSODIUM NITRITE:\n\n (a) in preparations containing 15% or less of sodium nitrite except:\n\n (i) when included in Schedule 2 or 5; or\n\n (ii) in preparations containing 0.5% or less of sodium nitrite; or\n\n (iii) when present as an excipient in preparations for therapeutic use; or\n\n (iv) in aerosols containing 2% or less of sodium nitrite; or\n\n (b) for use in closed‑loop water treatment systems (products).\n\nSODIUM PERCARBONATE (CAS No. 15630‑89‑4) except:\n\n (b) in preparations containing 15% or less of sodium percarbonate.\n\nSODIUM PERSULFATE:\n\n (a) in hair preparations; or\n\n (b) in products for the treatment of water for swimming pools and spas.\n\nSODIUM SULFIDE in preparations for use as insect lures.\n\nSPIROPIDION.\n\nSPIROTETRAMAT.\n\nSPIROXAMINE.\n\nSULCOFURON in preparations for the treatment of carpets during manufacture.\n\nSULFAMIC ACID (excluding its salts and derivatives) except when included in Schedule 5.\n\nSULFLURAMID.\n\nSULFOXAFLOR except when included in Schedule 5.\n\nSULFURIC ACID (excluding its salts and derivatives) except:\n\n (a) in fire extinguishers; or\n\n (b) in preparations containing 0.5% or less of sulfuric acid (H2SO4).\n\nSULFURYL FLUORIDE.\n\nSULPROFOS.\n\n2,4,5‑T.\n\nN‑TALLOW ALKYL‑1,3‑PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.\n\nTAR ACIDS distilling within the range 230‑290°C inclusive.\n\nTCMTB (2‑[thiocyanomethylthio]benzothiazole).\n\nTDE (1,1‑dichloro‑2,2‑bis[4‑chlorophenyl]ethane) except when included in Schedule 5.\n\nTEBUFENPYRAD.\n\nTEBUTHIURON.\n\nTEMEPHOS except when in Schedule 5.\n\nTERBUTHYLAZINE except in preparations containing 5% or less of terbuthylazine.\n\nTERPENES, CHLORINATED.\n\nTESTOSTERONE in implant preparations for use in animals.\n\nTETRACHLOROETHYLENE except:\n\n (b) in preparations containing 6% or less of tetrachloroethylene when absorbed into an inert solid; or\n\n (c) in preparations for the treatment of animals.\n\nTETRACONAZOLE except when included in Schedule 5.\n\nTETRADIFON.\n\nTETRAHYDROFURFURYL ALCOHOL (excluding its derivatives).\n\n2,2',6,6'‑TETRAISOPROPYL‑DIPHENYL‑CARBODIIMIDE in amitraz formulations containing 2% or less of 2,2',6,6'‑tetraisopropyl‑diphenyl‑carbodiimide.\n\nTETRAMISOLE in preparations for the treatment of animals.\n\nTHIACLOPRID.\n\nTHIAMETHOXAM except when included in Schedule 5.\n\nTHIAZAFLURON.\n\nTHIODICARB except when included in Schedule 5.\n\nTHIOMETON.\n\nTHIOPHANATE‑METHYL except when included in Schedule 5.\n\nTHIOUREA AND ALKYL THIOUREAS except:\n\nTHIRAM except in paint containing 0.5% or less of thiram.\n\nTHUJONE except in preparations containing 4% or less of thujone.\n\nTHYMOL when packed and labelled for use as a pesticide.\n\nTIGOLANER except when in Schedule 5.\n\nTOLUENE (excluding its derivatives) except in preparations containing 50% or less of toluene or toluene and xylene.\n\nTOLUENEDIAMINES not elsewhere specified in these Schedules:\n\n (a) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:\n\n (ii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;\n\n (b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:\n\n  WARNING – This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;\n\n (c) in nail polish preparations containing 2,5‑toluenediamine except when labelled “avoid contact with skin”.\n\nTOLYLFLUANID.\n\nTRANSFLUTHRIN except:\n\n (a) in preparations containing 1% or less of transfluthrin; or\n\n (b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.\n\nTRIADIMEFON except:\n\n (b) in fertilisers containing 5 g/kg or less of triadimefon.\n\nTRICHLORFON except metrifonate included in Schedule 4.\n\nTRICHLOROACETIC ACID except:\n\n (b) in human dermal preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts.\n\nTRICHLOROETHYLENE except when included in Schedule 4.\n\nTRICHLOROPHENOL.\n\nTRICLABENDAZOLE except in preparations containing 20% or less of triclabendazole.\n\nTRICLOPYR.\n\nTRICLOSAN in cosmetic preparations for human use containing more than 0.3% of triclosan.\n\nTRIDEMORPH.\n\nTRIETHYL PHOSPHATE.\n\nTRIFLUOROMETHANESULFONIC ACID.\n\nTRINITROPHENOL (excluding its derivatives) except:\n\n (b) in preparations containing 5% or less of trinitrophenol.\n\nTRISODIUM NITRILOTRIACETATE except in preparations containing 20% or less of trisodium nitrilotriacetate.\n\nVAMIDOTHION.\n\nVINYL ACETATE MONOMER (excluding its derivatives) except:\n\n (a) in preparations for therapeutic use; or\n\n (b) in cosmetic preparations containing 0.01% or less of vinyl acetate as residual monomer in a polymer; or\n\n (c) in other preparations containing 1% or less of vinyl acetate.\n\nWARFARIN except when included in Schedule 4 or 5.\n\nXYLENE (excluding its derivatives) except in preparations containing 50% or less of xylene or xylene and toluene.\n\nZERANOL in ear implants for use as a growth promotant in steer cattle.\n\nZETA‑CYPERMETHRIN in preparations containing 10% or less of zeta‑cypermethrin.\n\nZINC BORATE (excluding its derivatives) for use as an agricultural chemical.\n\nZINC CHLORIDE except:\n\n (b) in preparations containing 5% or less of zinc chloride.\n\nZINC para‑PHENOLSULFONATE except in preparations containing 5% or less of zinc para‑phenolsulfonate.\n\nZINC LACTATE in toothpaste except in toothpaste preparations containing 2.5% or less of zinc lactate and labelled with the statement:\n\n  Not recommended for children under twelve years of age.\n\nZINC SULFATE except:\n\n (a) when included in or expressly excluded from Schedule 4; or\n\n (b) in other preparations containing 5% or less of zinc sulfate.\n\nZIRAM in granular preparations.\n\n","sortOrder":83},{"sectionNumber":"Sch 7","sectionType":"schedule","heading":"Dangerous poisons","content":"Schedule 7—Dangerous poisons\n\n \n\n \n\nNote: See section 16, subsection 54(4) and sections 55, 56, 62 and 65.\n\nABAMECTIN except when included in Schedule 5 or 6.\n\nACIBENZOLAR‑S‑METHYL.\n\nACRIFLAVINIUM CHLORIDE for veterinary use except when in Schedule 5.\n\nACROLEIN.\n\nACRYLONITRILE.\n\nALACHLOR.\n\nALDICARB.\n\nALDOXYCARB.\n\nALLYL ALCOHOL except:\n\n (a) in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl ester; or\n\nALPHA‑CYPERMETHRIN except when included in Schedule 5 or 6.\n\nAMINOACRIDINE for veterinary use except when included in Schedule 5.\n\nAMINOCARB except when included in Schedule 6.\n\n2‑AMINO‑5‑METHYLPHENOL except when included in Schedule 10.\n\n4‑AMINOPROPIOPHENONE.\n\n4‑AMINOPYRIDINE except when included in Schedule 4.\n\nAMITON.\n\nARPRINOCID.\n\nARSENIC except:\n\n (b) when included in Schedule 4 or 6; or\n\n (c) as selenium arsenide in photocopier drums; or\n\n (d) as 10,10'‑oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic; or\n\n (e) as 10,10'‑oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles:\n\n (i) in contact with foodstuffs, animal feeds or potable water; or\n\n (ii) of clothing and footwear in contact with the skin; or\n\n (iii) used as infant wear; or\n\n (iv) intended for use as packaging materials; or\n\n (f) in animal feeds containing 75 g/tonne or less of arsenic; or\n\n (g) in paints containing 0.1% or less of arsenic calculated on the non‑volatile content of the paint.\n\nAZAFENIDIN.\n\nAZINPHOS‑ETHYL.\n\nAZINPHOS‑METHYL.\n\nAZOCYCLOTIN.\n\nAZO DYES that are derivatives by diazotisation of any of the following substances:\n\n (a) p‑aminoazobenzene (CAS No. 60‑09‑3);\n\n (b) o‑aminoazotoluene (CAS No. 97‑56‑3);\n\n (c) o‑anisidine (CAS No. 90‑04‑0);\n\n (d) p‑chloroaniline (CAS No. 106‑47‑8);\n\n (e) 4‑chloro‑o‑toluidine (CAS No. 95‑69‑2);\n\n (f) 2,4‑diaminoanisole (CAS No. 615‑05‑4);\n\n (g) 6‑methoxy‑m‑toluidine (p‑cresidine) (CAS No. 120‑71‑8);\n\n (h) 4,4‑methylenedianiline (CAS No. 101‑77‑9);\n\n (i) 2‑naphthylamine (CAS No. 91‑59‑8);\n\n (j) 5‑nitro‑o‑toluidine (CAS No. 99‑55‑8);\n\n (k) 2,4‑toluenediamine (CAS No. 95‑80‑7);\n\n (l) o‑toluidine (CAS No. 95‑53‑4);\n\n (m) 2,4,5‑trimethylaniline (CAS No. 137‑17‑7);\n\n except for BASIC RED 76 (CAS No. 68391‑30‑0) when included in Schedule 6.\n\nBENDIOCARB except when included in Schedule 5 or 6.\n\nBENOMYL except in paints containing 0.5% or less of benomyl.\n\nBENZENE (excluding its derivatives) except:\n\n (a) preparations containing 15 mL/L or less of benzene; or\n\n (b) petrol containing 50 mL/L or less of benzene.\n\nBENZIDINE‑BASED AZO DYES being:\n\n (a) 2,2'‑[[1,1'‑biphenyl]‑4,4'‑diylbis(azo)]bis[N‑(4‑chlorophenyl)‑3‑oxobutanamide] (CAS No. 94249‑03‑3); or\n\n (b) Acid Red 85 (Acid Fast Red A): 1,3‑Naphthalenedisulfonic acid, 7‑hydroxy‑8‑[[4'‑[[4‑[[(4‑methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'‑biphenyl]‑4‑yl]azo]‑, disodium salt (CAS No. 3567‑65‑5); or\n\n (c) C.I Acid Black 29: (CAS No. 12217‑14‑0); or\n\n (d) C.I. Direct Orange 1: (CAS No. 54579‑28‑1); or\n\n (e) Direct Black 38: 2,7‑Naphthalenedisulfonic acid, 4‑amino‑3‑[[4'‑[(2,4‑diaminophenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑5‑hydroxy‑6‑(phenylazo)‑, disodium salt (CAS No. 1937‑37‑7); or\n\n (f) Direct Blue 2: 2,7‑Naphthalenedisulfonic acid, 5‑amino‑3‑[[4'‑[(7‑amino‑1‑hydroxy‑3‑sulfo‑2‑naphthalenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑4‑hydroxy‑, trisodium salt (CAS No. 2429‑73‑4); or\n\n (g) Direct Blue 6: 2,7‑Naphthalenedisulfonic acid, 3,3'‑[[1,1'‑biphenyl]‑4,4'‑diylbis(azo)]bis[5‑amino‑4‑hydroxy‑, tetrasodium salt (CAS No. 2602‑46‑2); or\n\n (h) Direct Brown 2: 5‑[[4'‑[(7‑amino‑1‑hydroxy‑3‑sulfo‑2‑naphthalenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑2‑hydroxy‑ benzoic acid disodium salt (CAS No. 2429‑82‑5); or\n\n (i) Direct Brown 95: Cuprate(2‑), [5‑[[4'‑[[2,6‑dihydroxy‑3‑[(2‑hydroxy‑5‑sulfophenyl)azo]phenyl]azo][1,1'‑biphenyl]‑4‑yl]azo]‑2‑hydroxybenzoato(4‑)]‑, disodium salt (CAS No. 16071‑86‑6); or\n\n (j) Direct Green 1: 2,7‑Naphthalenedisulfonic acid, 4‑amino‑5‑hydroxy‑3‑[[4'‑[(4‑hydroxyphenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑6‑(phenylazo)‑, disodium salt (CAS No. 3626‑28‑6); or\n\n (k) Direct Green 6: 2,7‑Naphthalenedisulfonic acid, 4‑amino‑5‑hydroxy‑6‑[[4'‑[(4‑hydroxyphenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑3‑[(4‑nitrophenyl)azo]‑, disodium salt (CAS No. 4335‑09‑5); or\n\n (l) Direct Red 28 (Congo Red): 1‑Naphthalenesulfonic acid, 3,3'‑[[1,1'‑biphenyl]‑4,4'‑diylbis(azo)]bis[4‑amino‑, disodium salt (CAS No. 573‑58‑0); or\n\n (m) Direct Red 37: 1,3‑Naphthalenedisulfonic acid, 8‑[[4'‑[(4‑ethoxyphenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑7‑hydroxy‑, disodium salt (CAS No. 3530‑19‑6).\n\nBENZIDINE‑CONGENER (3,3'‑disubstituted) AZO DYES.\n\nBETACYFLUTHRIN except when included in Schedule 5 or 6.\n\nBIFENTHRIN except:\n\n (b) in preparations containing 0.5% or less of bifenthrin.\n\nBIFLUORIDES (including ammonium, potassium and sodium salts) except when included in Schedule 5 or 6.\n\nBORON TRIFLUORIDE except when included in Schedule 5 or 6.\n\nBRODIFACOUM except when included in Schedule 6.\n\nBROMADIOLONE except when included in Schedule 6.\n\nBROMETHALIN except when included in Schedule 6.\n\nBROMINE (excluding its salts and derivatives).\n\nBRUCINE except in alcohol containing 0.02% or less of brucine as a denaturant.\n\nCACODYLIC ACID except:\n\n (b) in animal feeds containing 75 g/tonne or less of arsenic.\n\nCADUSAFOS except when included in Schedule 6.\n\nCALCIFEROL for use as a rodenticide except when included in Schedule 6.\n\nCAPTAFOL.\n\nCARBADOX.\n\nCARBENDAZIM except in paints, jointing compounds and sealants containing 0.1% or less of carbendazim.\n\nCARBOFURAN.\n\nCARBON TETRACHLORIDE except in chlorinated rubber based paint containing 1% or less of carbon tetrachloride.\n\nCARBONYL SULFIDE when packed and labelled for use as a fumigant.\n\nCARBOPHENOTHION.\n\nCARBOSULFAN.\n\nCHLORDECONE.\n\nCHLORDIMEFORM.\n\nCHLORFENAPYR except when included in Schedule 5 or 6.\n\nCHLORFENVINPHOS.\n\nCHLORINE (excluding its salts and derivatives).\n\nCHLORHEXIDINE except:\n\n (b) in preparations containing 1% or less of chlorhexidine; or\n\n (c) in solid preparations.\n\nCHLOROMETHIURON.\n\n5‑CHLORO‑3‑METHYL‑4‑NITROPYRAZOLE.\n\n4‑CHLORO‑o‑TOLUIDINE.\n\nCHLOROPICRIN except when included in Schedule 6.\n\nCHLORTHIOPHOS.\n\nCOLECALCIFEROL for use as a rodenticide.\n\nCOUMAPHOS except when included in Schedule 6.\n\nCOUMATETRALYL except when included in Schedule 5 or 6.\n\nCREOSOTE derived from coal.\n\nCREOSOTE derived from beechwood.\n\nCYANIDES, metallic except:\n\n (a) ferricyanides; or\n\n (b) ferrocyanides; or\n\n (c) when separately specified in these Schedules.\n\nCYANOGEN.\n\nCYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) except when included in Schedule 6.\n\nCYHALOTHRIn (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.\n\nCYHEXATIN.\n\nDELTAMETHRIN except:\n\n (b) in factory prepared mosquito nets containing 1% or less of deltamethrin; or\n\n (c) in preparations containing 0.1% or less of deltamethrin.\n\nDEMETON.\n\nDEMETON‑O‑METHYL.\n\nDEMETON‑S‑METHYL.\n\nDIALIFOS.\n\n4,4‑DIAMINODIPHENYLMETHANE (Methylene dianiline).\n\n1,2‑DIBROMO‑3‑CHLOROPROPANE.\n\n1,3‑DICHLOROPROPENE except in biocidal preparations containing 0.3% or less of 1,3‑dichloropropene.\n\nDICHLORVOS except when included in Schedule 5 or 6.\n\nDICROTOPHOS.\n\nDIFENACOUM except when included in Schedule 6.\n\nDIFETHIALONE except when included in Schedule 6.\n\nDIMEFOX.\n\n4‑DIMETHYLAMINOAZOBENZENE (N,N‑dimethyl‑4‑[phenylazo]‑benzenamine).\n\nDIMETHYL SULFATE.\n\nDIMETILAN.\n\nDINITROCRESOLS except when included in Schedule 4 or 6.\n\nDINITROPHENOLS except when included in Schedule 4, 6 or 10.\n\nDINOCAP.\n\nDINOSEB.\n\nDIQUAT except when included in Schedule 6.\n\nDISULFOTON except when included in Schedule 6.\n\nDORAMECTIN except when included in Schedule 5 or 6.\n\nDSMA except when included in Schedule 6.\n\nEMAMECTIN except when included in Schedule 5 or 6.\n\nENDOSULFAN except when included in Schedule 6.\n\nENDOTHAL except when included in Schedule 6.\n\nENDRIN.\n\nEPICHLOROHYDRIN.\n\nEPIDERMAL GROWTH FACTOR except in preparations for human therapeutic use.\n\nEPRINOMECTIN except when included in Schedule 5 or 6.\n\nETACONAZOLE.\n\nETHALFLURALIN.\n\nETHION.\n\nETHOPROPHOS except when included in Schedule 6.\n\n2‑ETHOXYETHANOL and its acetates except in preparations containing 0.5% or less of 2‑ethoxyethanol.\n\nETHYLENE DIBROMIDE.\n\nETHYLENE OXIDE.\n\nFAMPHUR except when included in Schedule 6.\n\nFENAMIPHOS except when included in Schedule 6.\n\nFENOXACRIM except:\n\nFENSULFOTHION.\n\nFENTHION except when included in Schedule 5 or 6.\n\nFENTHION‑ETHYL.\n\nFLOCOUMAFEN except when included in Schedule 6.\n\nFLUCOFURON except:\n\nFLUCYTHRINATE.\n\nFLUMIOXAZIN except when included in Schedule 6.\n\nFLUOROACETAMIDE.\n\nFLUOROACETIC ACID.\n\nFOLPET.\n\nFORMETANATE.\n\nFOSTHIAZATE.\n\nFURATHIOCARB except when included in Schedule 5.\n\nGAMMA‑CYHALOTHRIN except when included in Schedule 5.\n\nHALOFUGINONE except when included in Schedule 4.\n\nHALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.\n\nHCB.\n\nHYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C except:\n\n (a) when in solid polymers; or\n\n (b) when containing 1% or less of total polycyclic aromatic compounds as measured by IP 346; or\n\n (c) when having a Mutagenicity Index of zero as measured by ASTM E1687‑95.\n\nHYDROCYANIC ACID except:\n\n (b) its salts and derivatives other than cyanides separately specified in this Schedule.\n\nHYDROFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.\n\nHYDROGEN SULFIDE.\n\nHYDROSILICOFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.\n\nIODOMETHANE.\n\nISOCARBOPHOS.\n\nISOFENPHOS.\n\nISOPROTURON.\n\nIVERMECTIN except when included in Schedule 4 or 5.\n\nLAMBDA‑CYHALOTHRIN except when included in Schedule 5 or 6.\n\nLEPTOPHOS.\n\nLITHIUM PERFLUOROOCTANE SULFONATE except in sealed bait stations containing 1% or less of lithium perfluorooctane sulfonate.\n\nMADURAMICIN except:\n\n (b) in animal feeds containing 5 mg/kg or less of antibiotic substances.\n\nMALACHITE GREEN for veterinary use except when included in Schedule 5.\n\nMAZIDOX.\n\nMECARBAM.\n\n2‑METHOXYETHANOL and its acetates except in preparations containing 0.5% or less of 2‑methoxyethanol.\n\nMERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.\n\nMERCURY except:\n\n (b) when included in Schedule 2, 4 or 6; or\n\n (c) in preparations containing 0.01% or less of mercury in organic form as a preservative; or\n\n (d) mercury (metallic) in scientific instruments; or\n\n (e) dental amalgams; or\n\n (f) in a sealed device, for therapeutic use, which prevents access to the mercury.\n\nMETHACRIFOS except when included in Schedule 6.\n\nMETHAMIDOPHOS.\n\nMETHAPYRILENE.\n\nMETHAZOLE.\n\nMETHIDATHION.\n\nMETHIOCARB except when included in Schedule 5 or 6.\n\nMETHOMYL except when included in Schedule 6.\n\nMETHOXYETHYLMERCURIC ACETATE.\n\nMETHOXYETHYLMERCURIC CHLORIDE.\n\nMETHYL BROMIDE.\n\nMETHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL except:\n\n (b) when used in laboratory analysis; or\n\n (c) when packed for industrial use in containers with a nominal capacity of 100 L or more.\n\n4,4'‑METHYLENEBIS[2‑CHLOROANILINE] (MOCA).\n\nMETHYLENE BLUE for veterinary use except when included in Schedules 4 or 5.\n\nMEVINPHOS.\n\nMIPAFOX.\n\nMIREX.\n\nMOLINATE.\n\nMONOCROTOPHOS.\n\nMOXIDECTIN except when included in Schedule 4, 5 or 6.\n\nMSMA except when included in Schedule 6.\n\nNAPHTHALOPHOS except when included in Schedule 6.\n\nNICOTINE except:\n\n (b) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tobacco smoking or nicotine vaping; or\n\n (c) in tobacco prepared and packed for smoking.\n\nNIMIDANE except when included in Schedule 6.\n\nNITROFEN.\n\nNITROPRUSSIDES except when included in Schedule 4 or 6.\n\n2‑NITROTOLUENE.\n\nOMETHOATE except when included in Schedule 5 or 6.\n\nOXAMYL.\n\nOXYDEMETON METHYL.\n\nPARAQUAT.\n\nPARATHION.\n\nPARATHION‑METHYL except when included in Schedule 6.\n\nPENTACHLOROPHENOL except when included in Schedule 6.\n\nPHENYLMERCURIC ACETATE except in preparations containing 0.01% or less of mercury as a preservative.\n\nPHORATE.\n\nPHOSFOLAN.\n\nPHOSPHIDES, METALLIC.\n\nPHOSPHINE.\n\nPHOSPHORUS, YELLOW (excluding its salts and derivatives).\n\nPOTASSIUM NITRITE except:\n\n (b) in preparations containing 0.5% or less of potassium nitrite; or\n\n (d) in aerosols containing 2% or less of potassium nitrite.\n\nPROCYMIDONE.\n\nPROPYLENE OXIDE.\n\nPYRINURON.\n\nQUININE for veterinary use except when included in Schedule 5.\n\nSAFLUFENACIL except when included in Schedule 5.\n\nSCHRADAN.\n\nSELENIUM except:\n\n (b) as selenium arsenide in photocopier drums; or\n\n (c) in preparations for therapeutic use other than:\n\n (i) drench concentrates containing 2.5% or less of selenium; or\n\n (ii) pour‑on preparations containing 0.5% or less of selenium; or\n\n (d) in paints or tinters containing 0.1% or less of selenium calculated on the non‑volatile content of the paint or tinter; or\n\n (e) in fertilisers containing 200 g/tonne or less of selenium.\n\nSEMDURAMICIN except:\n\n (b) in animal feeds containing 25 mg/kg or less of antibiotic substances.\n\nSODIUM NITRITE except:\n\n (a) when included in Schedule 2, 5 or 6; or\n\n (b) in preparations containing 0.5% or less of sodium nitrite; or\n\n (d) in aerosols containing 2% or less of sodium nitrite.\n\nSTRYCHNINE except when included in Schedule 4.\n\nSULCOFURON except:\n\nSULFENTRAZONE.\n\nSULFOTEP.\n\nTEFLUTHRIN except when included in Schedule 5.\n\nTEPP.\n\nTERBUFOS.\n\nTETRACHLOROETHANE.\n\n2,2',6,6'‑TETRAISOPROPYL‑DIPHENYL‑CARBODIIMIDE except when included in Schedule 6.\n\nTHALLIUM.\n\nTHIOFANOX.\n\nTIN ORGANIC COMPOUNDS, being dialkyl, trialkyl and triphenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl except:\n\n (b) in plastics; or\n\n (c) in semi‑solid sealants, adhesives or elastomers containing 1% or less of the dialkyl, trialkyl or triphenyl tin component; or\n\n (d) in paint containing 1% or less of such compounds calculated as tin in the non‑volatile content of the paint.\n\no‑TOLIDINE except in solid‑state diagnostic therapeutic reagents.\n\nTRIAMIPHOS.\n\nTRIAZBUTIL.\n\nTRIBUFOS (S,S,S‑tributylphosphorotrithioate).\n\nVINCLOZOLIN.\n\nVINYL CHLORIDE.\n\nZETA‑CYPERMETHRIN except when included in Schedule 6.\n\nZIRAM except when included in Schedule 6.\n\n","sortOrder":84},{"sectionNumber":"Sch 8","sectionType":"schedule","heading":"Controlled drugs","content":"Schedule 8—Controlled drugs\n\n \n\n \n\nNote 1: See paragraph 7(b), sections 16, 17, 28, 31, 50 and subsection 57(1).\n\nNote 2: Substances marked # are listed in Appendix D.\n\nACETYLDIHYDROCODEINE.\n\nACETYLMETHADOL.\n\nACETYLMORPHINES.\n\nALFENTANIL.\n\nALPHACETYLMETHADOL.\n\nALPHAPRODINE.\n\n# ALPRAZOLAM.\n\nAMFETAMINE.\n\nAMOBARBITAL except when included in Schedule 4.\n\nANILERIDINE.\n\nBENZYLMORPHINE.\n\nBEZITRAMIDE.\n\nBUPRENORPHINE.\n\nBUTOBARBITAL.\n\nBUTORPHANOL.\n\n# CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:\n\n (a) cultivated or produced, or in products manufactured[[1]](#_ftn1), in accordance with the Narcotic Drugs Act 1967; and/or\n\n (b) for use in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or\n\n (c) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or\n\n (d) in therapeutic goods supplied in accordance with the Act;\n\n (e) when it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or\n\n (f) when separately specified in the NABIXIMOLS entry in this Schedule; or\n\n (g) when captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or\n\n (h) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.\n\nCARFENTANYL.\n\nCOCAINE.\n\nCODEINE except when included in Schedule 4.\n\nCODEINE‑N‑OXIDE.\n\nCONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).\n\n4‑CYANO‑1‑METHYL‑4‑PHENYLPIPERIDINE (Pethidine intermediate A).\n\nCYCLOBARBITAL.\n\nDEXAMFETAMINE.\n\nDEXTROMORAMIDE.\n\n# DEXTROPROPOXYPHENE except when included in Schedule 4.\n\nDIFENOXIN except when included in Schedule 4.\n\nDIHYDROCODEINE except when included in Schedule 3 or 4.\n\nDIHYDROMORPHINE.\n\n# N, α ‑DIMETHYL‑3,4‑(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human therapeutic use for the treatment of post-traumatic stress disorder.\n\nDIPHENOXYLATE except when included in Schedule 3 or 4.\n\nDIPIPANONE.\n\n# DRONABINOL (delta‑9‑tetrahydrocannabinol) when prepared and packed for therapeutic use.\n\nDROTEBANOL.\n\nESKETAMINE.\n\nETHYLAMFETAMINE.\n\nETHYLMORPHINE except when included in Schedule 2 or 4.\n\nFENTANYL.\n\n# FLUNITRAZEPAM.\n\nHYDROCODONE.\n\nHYDROMORPHINOL.\n\nHYDROMORPHONE.\n\nKETAMINE.\n\nLEVAMFETAMINE.\n\nLEVOMETHAMFETAMINE.\n\nLEVOMORAMIDE.\n\nLEVORPHANOL (excluding its stereoisomers).\n\nLISDEXAMFETAMINE.\n\nMETHADONE.\n\nMETAMFETAMINE.\n\nMETHYLDIHYDROMORPHINE.\n\nMETHYLPHENIDATE.\n\n1‑METHYL‑4‑PHENYLPIPERIDINE‑4‑CARBOXYLIC ACID (Pethidine intermediate C).\n\nMORPHINE.\n\nMORPHINE METHOBROMIDE.\n\nMORPHINE‑N‑OXIDE.\n\nNABILONE.\n\n# NABIXIMOLS (botanical extract of Cannabis sativa which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90% of the total cannabinoid content) in a buccal spray for human therapeutic use.\n\nNORCODEINE.\n\nNORMETHADONE.\n\nOPIUM except the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.\n\nOXYCODONE.\n\nOXYMORPHONE.\n\nPENTAZOCINE.\n\n# PENTOBARBITAL except when included in Schedule 4.\n\nPETHIDINE.\n\nPHENDIMETRAZINE.\n\nPHENMETRAZINE.\n\nPHENOPERIDINE.\n\n4‑PHENYLPIPERIDINE‑4‑CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).\n\nPHOLCODINE except when included in Schedule 2 or 4.\n\nPIRITRAMIDE.\n\nPROPIRAM.\n\n# PSILOCYBINE in preparations for human therapeutic use for the treatment of treatment‑resistant depression.\n\nRACEMORAMIDE.\n\nREMIFENTANIL.\n\nSECBUTOBARBITAL.\n\nSECOBARBITAL.\n\n# SODIUM OXYBATE for human therapeutic use.\n\nSUFENTANIL.\n\nTAPENTADOL.\n\n# TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use, when:\n\n (a) included in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or\n\n (b) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or\n\n (c) in therapeutic goods supplied in accordance with the Act;\n\n (d) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or\n\n (e) separately specified in the NABIXIMOLS entry in this Schedule; or\n\n (f) captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or\n\n (g) in hemp seed oil at a concentration of 10 mg/kg or less.\n\nTHEBACON.\n\nTHEBAINE.\n\nTILIDINE.\n\nSchedule 9—Prohibited substances\n\n \n\n \n\nNote 1: See paragraph 7(b) and subsection 57(2).\n\nNote 2: Trivial or unofficial names are marked *.\n\nACETORPHINE.\n\nACETYL‑ALPHA‑METHYLFENTANYL.\n\nALKOXYAMFETAMINES and substituted alkoxyamfetamines except when separately specified in these Schedules.\n\nALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines except when separately specified in these Schedules.\n\nALKYLTHIOAMFETAMINES and substituted alkylthioamfetamines except when separately specified in these Schedules.\n\nALLYLPRODINE.\n\nALPHAMEPRODINE.\n\nALPHA‑METHYLFENTANYL.\n\nALPHA‑METHYLTHIOFENTANYL.\n\nALPHAMETHADOL.\n\nALPHA‑PYRROLIDINOVALEROPHENONE *(ALPHA‑PVP).\n\n2‑AMINO‑1‑(2,5‑DIMETHOXY‑4‑METHYL)PHENYLPROPANE *(STP or DOM).\n\n5‑(2‑AMINOPROPYL)INDAN and substituted 5‑(2‑aminopropyl)indans except when separately specified in these Schedules.\n\nBENZETHIDINE.\n\nBENZOYLINDOLES except when separately specified in these Schedules.\n\nBENZYLPIPERAZINE *(BZP).\n\nBETACETYLMETHADOL.\n\nBETA‑HYDROXYFENTANYL.\n\nBETA‑HYDROXY‑3‑METHYLFENTANYL.\n\nBETAMEPRODINE.\n\nBETAMETHADOL.\n\nBETAPRODINE.\n\n1‑(8‑BROMOBENZO[1,2‑B;4,5‑B]DIFURAN‑4‑YL)‑2‑AMINOPROPANE *(Bromo‑Dragonfly).\n\n4‑BROMO‑2,5‑DIMETHOXYPHENETHYLAMINE *(BDMPEA).\n\nBUFOTENINE.\n\nBUTONITAZENE.\n\nCANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when packed or prepared), except:\n\n (b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols and hemp fibre products manufactured from such fibre; or\n\n (c) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.\n\nCATHINONES except when separately specified in these Schedules.\n\nCLONAZOLAM.\n\nCLONITAZENE.\n\nCOCA LEAF.\n\nCODOXIME.\n\n4‑CYANO‑2‑DIMETHYLAMINO‑4,4'‑DIPHENYLBUTANE.\n\nCYCLOHEXYLPHENOLS except:\n\n (b) in preparations containing 0.5% or less of cyclohexylphenols.\n\nDESCHLOROETIZOLAM.\n\nDESOMORPHINE.\n\nN,N‑DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES except when separately specified in these Schedules.\n\nN,N‑DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES except when separately specified in these Schedules.\n\nDIAMPROMIDE.\n\nDIBENZOPYRANS except when separately specified in these Schedules.\n\n3,4‑DICHLORO‑N‑[(1R,2R)‑2‑(DIMETHYLAMINO)CYCLOHEXYL]‑N‑METHYLBENZAMIDE (U‑47700).\n\n3,4‑DICHLORO‑N‑{[1‑ (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH‑7921).\n\nDICLAZEPAM.\n\nDIETHYLTHIAMBUTENE.\n\nN,N‑DIETHYLTRYPTAMINE *(DET).\n\n2,5‑DIHYDRO‑2‑(1‑METHYL‑1‑PHENYLETHYL)‑5‑PENTYL‑1H‑PYRIDO[4,3‑B]INDOL‑1‑ONE (SGT‑151).\n\nDIMENOXADOL.\n\nDIMEPHEPTANOL.\n\n2,5‑DIMETHOXYAMFETAMINE *(DMA).\n\n2,5‑DIMETHOXY‑4‑BROMOAMFETAMINE *(DOB).\n\n2,5‑DIMETHOXY‑4‑ETHYL‑a‑AMFETAMINE *(DOET).\n\n2,5‑DIMETHOXY‑4‑ETHYLTHIOPHENETHYLAMINE *(2C‑T‑2).\n\n2,5‑DIMETHOXY‑4‑IODOPHENETHYLAMINE *(2C‑I).\n\n2,5‑DIMETHOXY‑4‑(N)‑PROPYLTHIOPHENETHYLAMINE *(2C‑T‑7).\n\n3‑(2‑DIMETHYLAMINOETHYL)‑4‑HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).\n\n3‑(1,2‑DIMETHYLHEPTYL)‑1‑HYDROXY‑7,8,9,10‑TETRAHYDRO‑6,6,9‑ TRIMETHYL‑6H‑DIBENZO (b,d) PYRAN *(DMHP).\n\nN, α ‑DIMETHYL‑3,4‑(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) except when included in Schedule 8.\n\nN,N‑DIMETHYLAMFETAMINE (Dimetamfetamine).\n\nDIMETHYLTHIAMBUTENE.\n\nN,N‑DIMETHYLTRYPTAMINE *(DMT).\n\nDIOXAPHETYL BUTYRATE.\n\nECGONINE.\n\nN‑ETHYL‑α‑METHYL‑3,4‑(METHYLENEDIOXY)PHENETHYLAMINE *(N‑ETHYL MDA).\n\nETHYLMETHYLTHIAMBUTENE.\n\nETICYCLIDINE *(PCE).\n\nETODESNITAZENE.\n\nETONITAZENE.\n\nETONITAZEPIPNE.\n\nETONITAZEPYNE.\n\nETORPHINE.\n\nETOXERIDINE.\n\nFENETYLLINE.\n\n4‑FLUORO‑N‑METHYLAMFETAMINE.\n\nFLUBROMAZEPAM.\n\nFLUBROMAZOLAM.\n\nFLUNITAZENE.\n\n1‑(5‑FLUOROPENTYL)‑3‑(2‑IODOBENZOYL)INDOLE *(AM‑694).\n\nFURETHIDINE.\n\nHARMALA ALKALOIDS except in herbs, or preparations, for therapeutic use:\n\n (a) containing 0.1% or less of harmala alkaloids; or\n\n (b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.\n\nHEROIN.\n\n3‑HEXYL‑1‑HYDROXY‑7,8,9,10‑TETRAHYDRO‑6,6,9‑TRIMETHYL‑6H‑DIBENZO (b,d) PYRAN *(PARAHEXYL).\n\n4‑HYDROXYBUTANOIC ACID and its salts except for sodium oxybate when in Schedule 8. *(GAMMA HYDROXYBUTYRATE (GHB)).\n\n2‑[(1R,3S)‑3‑HYDROXYCYCLOHEXYL]‑5‑(2‑METHYLNONAN‑2‑YL)PHENOL *(Cannabicyclohexanol or CP 47,497 C8 homologue).\n\n2‑[(1R,3S)‑3‑HYDROXYCYCLOHEXYL]‑5‑(2‑METHYLOCTAN‑2‑YL)PHENOL *(CP 47,497).\n\nHYDROXYPETHIDINE.\n\nIBOTENIC ACID.\n\nISOMETHADONE.\n\nISOTONITAZENE.\n\nKETOBEMIDONE.\n\nLEVOMETHORPHAN (excluding its stereoisomers).\n\nLEVOPHENACYLMORPHAN.\n\nLYSERGIC ACID.\n\nLYSERGIDE.\n\nMECLONAZEPAM.\n\nMECLOQUALONE.\n\nMETAZOCINE.\n\nMETHAQUALONE.\n\nMETHCATHINONE.\n\n5‑METHOXY‑ α –METHYLTRYPTAMINE *(5‑MeO‑AMT).\n\n5‑METHOXY‑3,4‑METHYLENEDIOXYAMFETAMINE *(MMDA).\n\n4‑METHOXY‑ α –METHYLPHENYLETHYLAMINE *(PMA).\n\n2‑(2‑METHOXYPHENYL)‑1‑(1‑PENTYLINDOL‑3‑YL)ETHANONE *(JWH‑250).\n\nMETHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)‑9‑ACETOXY‑6a,10b‑DIMETHYL‑4,10‑DIOXO‑DODECAHYDRO‑2‑(3‑FURYL)‑2H‑NAPHTHO[2,1‑c]PYRAN‑7‑CARBOXYLATE *(SALVINORIN A).\n\n4‑METHYLAMINOREX.\n\nMETHYLDESORPHINE.\n\n3,4‑METHYLENEDIOXYAMFETAMINE *(MDA).\n\n3,4‑METHYLENEDIOXYPYROVALERONE *(MDPV).\n\n3‑METHYLFENTANYL.\n\n4‑METHYLMETHCATHINONE *(MEPHEDRONE).\n\nN‑ α ‑[METHYL‑3,4‑(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE *(N‑HYDROXY MDA).\n\nN‑METHYL‑1‑(3,4‑METHYLENEDIOXYPHENYL)‑2‑BUTANAMINE *(MBDB).\n\n2‑METHYL‑3‑MORPHOLINO‑1, 1‑DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).\n\nMETHYLONE *(MDMC).\n\n1‑METHYL‑4‑PHENYL‑4‑PIPERIDINOL PROPIONATE *(MPPP).\n\n4‑METHYLTHIOAMFETAMINE.\n\n3‑METHYLTHIOFENTANYL.\n\nMETODESNITAZENE.\n\nMETONITAZENE.\n\nMETOPON.\n\nMITRAGYNA SPECIOSA.\n\nMITRAGYNINE.\n\nMORPHERIDINE.\n\n(1‑(2‑MORPHOLIN‑4‑YLETHYL)INDOL‑3‑YL)‑NAPTHALEN‑1‑YLMETHANONE *(JWH‑200).\n\nMUSCIMOL.\n\nMYROPHINE.\n\nNAPHTHOYLINDOLES except when separately specified in these Schedules.\n\nNAPHTHYLMETHYLINDOLES except when separately specified in these Schedules.\n\nNAPHTHOYLPYRROLES except when separately specified in these Schedules.\n\nNAPHTHYLMETHYLINDENES except when separately specified in these Schedules.\n\nNAPHTHALEN‑1‑YL‑(1‑BUTYLINDOL‑3‑YL)METHANONE *(JWH‑073).\n\nNICOCODINE.\n\nNICODICODINE.\n\nNICOMORPHINE.\n\nNIFOXIPAM.\n\nNORACYMETHADOL.\n\nNORLEVORPHANOL.\n\nNORMORPHINE.\n\nNORPIPANONE.\n\nPARA‑FLUOROFENTANYL.\n\n1‑PENTYL‑3‑(4‑METHYL‑1‑NAPTHOYL)INDOLE. *(JWH‑122).\n\n1‑PENTYL‑3‑(1‑NAPHTHOYL)INDOLE *(JWH‑018).\n\nPHENADOXONE.\n\nPHENAMPROMIDE.\n\nPHENAZOCINE.\n\nPHENCYCLIDINE *(PCP).\n\nPHENIBUT.\n\nN‑PHENETHYL‑4‑PIPERIDONE.\n\nPHENOMORPHAN.\n\nPHENYLACETYLINDOLES except when separately specified in these Schedules.\n\n1‑PHENYLETHYL‑4‑PHENYL‑4‑PIPERIDINOL ACETATE *(PEPAP).\n\nPIMINODINE.\n\nPROHEPTAZINE.\n\nPROPERIDINE.\n\nPROTONITAZENE.\n\nPSILOCYBINE except when included in Schedule 8.\n\nPYRAZOLAM.\n\nRACEMETHORPHAN.\n\nRACEMORPHAN.\n\nROLICYCLIDINE *(PHP or PCPY).\n\nSALVIA DIVINORUM.\n\nSYNTHETIC CANNABINOMIMETICS except when separately specified in these Schedules.\n\nTENOCYCLIDINE *(TCP).\n\nTETRAHYDROCANNABINOLS and their alkyl homologues, except:\n\n (a) when included in Schedule 4 or Schedule 8; or\n\n (b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or\n\n (c) in hemp seed oil at a concentration of 10 mg/kg or less.\n\nTHIOFENTANYL.\n\n1‑(3‑TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).\n\nTRIMEPERIDINE.\n\n3,4,5‑TRIMETHOXY‑ α –METHYLPHENYLETHYLAMINE *(TMA).\n\n3,4,5‑TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy‑phenylethylamine except:\n\n (a) methoxyphenamine; or\n\n1‑(3,4,5‑TRIMETHOXYPHENYL)‑2‑AMINOBUTANE.\n\nSchedule 10—Substances of such danger to health as to warrant prohibition of supply and use\n\n \n\n \n\nNote 1: See subsection 57(2) and section 63.\n\nNote 2: Schedule 10 contains substances previously included in Appendix C.\n\nABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.\n\nACORUS CALAMUS (calamus) for human therapeutic use.\n\nALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:\n\n (a) in liquid or semi‑solid food additive preparations, tHE pH of which is more than 11.5; or\n\n (b) in solid automatic dishwashing preparations, tHE pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or\n\n (c) in liquid or semi‑solid automatic dishwashing preparations, tHE pH of which is more than 12.5.\n\nALKYLAMINES WITH STIMULANT PROPERTIES except when separately specified in these schedules.\n\n2‑AMINO‑5‑METHYLPHENOL in preparations for cosmetic use.\n\nAMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.\n\nAMYGDALIN for therapeutic use.\n\nANCHUSA OFFICINALIS for therapeutic use.\n\no‑ANISIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001% or less of o‑anisidine.\n\nAPRONAL for therapeutic use.\n\nARISTOLOCHIA spp. for therapeutic use.\n\nARISTOLOCHIC ACID(S) for human therapeutic use.\n\nASARUM spp. containing aristolochic acid(s) for human therapeutic use.\n\nAZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use except “debitterised neem seed oil”.\n\nBASIC ORANGE 31 (2‑[(4‑aminophenyl)azo]‑1,3‑dimethyl‑1H‑imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.\n\n1,2‑BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).\n\n1,3‑BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).\n\nBITHIONOL for human therapeutic use.\n\nBORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis.\n\nBRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.\n\nBUCLOSAMIDE for therapeutic use.\n\nBUNIODYL SODIUM for therapeutic use.\n\n1,4‑BUTANEDIOL (excluding its derivatives) in non‑polymerised form in preparations for domestic use.\n\nBUTYL BENZYL PHTHALATE for cosmetic use.\n\nCACALIA spp. for therapeutic use.\n\nCARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18% of carbamide peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.\n\nCARDARINE.\n\nCHRYSOIDINE BASE in preparations for use in hair dyes.\n\nCINCHOPHEN and its derivatives for therapeutic use.\n\nCLIOQUINOL and other halogenated derivatives of oxyquinoline for human internal use except or when being used solely for experimental purposes in humans and where such use:\n\n (a) is in accordance with:\n\n (i) an approval granted under paragraph 19(1)(b) of the Act, including any conditions specified in the notice of approval; and\n\n (ii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(1A) of the Act; and\n\n (iii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(4A) of the Act; or\n\n (b) is in accordance with the requirements of item 3 of Schedule 5A to the Therapeutic Goods Regulations 1990.\n\nCOAL TAR for cosmetic use other than in therapeutic goods.\n\nCONIUM MACULATUM (coniine) for therapeutic use.\n\nCOTARNINE for therapeutic use.\n\nCROTALARIA spp. for therapeutic use.\n\nCROTON TIGLIUM for therapeutic use.\n\nCYNOGLOSSUM spp. for therapeutic use.\n\nDIBUTYL PHTHALATE for cosmetic use.\n\nDICOPHANE (DDT) for therapeutic use.\n\nDIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25% or less of diethylene glycol.\n\nDIETHYLENE GLYCOL MONOMETHYL ETHER for cosmetic use.\n\nDIETHYLHEXYL PHTHALATE for cosmetic use.\n\nDIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5% or less of diethylphthalate.\n\n5,6‑DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2% of 5,6‑dihydroxyindoline.\n\nDIIODOHYDROXYQUINOLINE (iodoquinol) for human internal use.\n\nDIISOBUTYL PHTHALATE for cosmetic use.\n\n1,3‑DIMETHYLAMYLAMINE (DMAA).\n\n1,3‑DIMETHYLBUTYLAMINE (DMBA) except when separately specified in these schedules.\n\n1‑(1,1‑DIMETHYLETHYL)‑2‑METHOXY‑4‑METHYL‑3,5‑DINITROBENZENE (musk ambrette).\n\n1,5‑DIMETHYLHEXYLAMINE (DMHA) except when separately specified in these schedules.\n\nDI(METHYLOXYETHYL) PHTHALATE for cosmetic use.\n\n1,4‑DIMETHYLPENTYLAMINE (DMPA).\n\nDIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5% or less of dimethylphthalate.\n\n2,4‑DINITROPHENOL for human use.\n\nDISPERSE YELLOW 3 for use in hair dyes.\n\nDULCIN for therapeutic use.\n\nETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25% or less of ethylene glycol.\n\nEUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.\n\nFARFUGIUM JAPONICUM for therapeutic use.\n\nFORMALDEHYDE (excluding its derivatives):\n\n (a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or\n\n (b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or\n\n (d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde except in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:\n\nGAMMA BUTYROLACTONE (excluding its derivatives) in non‑polymerised form in preparations for domestic and cosmetic use.\n\nHELIOTROPIUM spp. for therapeutic use.\n\nHYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6% (20 volume) of hydrogen peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.\n\nISOPROPYL NITRITE.\n\nJUNIPERUS SABINE [savin(e)] for therapeutic use.\n\nKAMBO.\n\nLEAD COMPOUNDS:\n\n (a) in anti‑fouling paints except in preparations containing 0.1% or less of lead calculated on the non‑volatile content of the paint; or\n\n (b) in paints (other than anti‑fouling paints), tinters, inks or ink additives except in preparations containing 0.009% or less of lead calculated on the non‑volatile content of the paint, tinter, ink or ink additive; or\n\n (c) for human therapeutic use except in preparations containing 10 mg/kg or less of lead.\n\nLIGULARIA DENTATA for therapeutic use.\n\nMELIA AZEDARACH including its extracts and derivatives.\n\nMETHANOL in hand sanitiser preparations containing more than 5% methanol.\n\nMETHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.\n\nMETHYL METHACRYLATE for cosmetic use except in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.\n\nMETHYLROSANILINIUM CHLORIDE (formerly known as crystal violet) and the following TRIARYLMETHANE DYES – for use in hair dyes:\n\n (a) Acid Violet 49; or\n\n (b) Ethyl Violet; or\n\n (c) Basic Blue 7; or\n\n (d) Basic Blue 26 (CI 44045).\n\nNAPHTHALENE (excluding derivatives) in preparations in block, ball, disc, pellet or flake form for domestic use except when enclosed in a device which, in normal use, prevents removal or ingestion of its contents.\n\nOXYPHENISATIN for therapeutic use.\n\nPARAFORMALDEHYDE (excluding its derivatives):\n\n (a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or\n\n (b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or\n\n (d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde except in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:\n\nPETASITES spp. for therapeutic use.\n\nPHENPROMETHAMINE.\n\nPHENYLENEDIAMINES, including alkylated, arylated, halogenated and nitro derivatives, in preparations for skin colouration, tattooing and dyeing of eyelashes or eyebrows except when included in Schedule 6.\n\nPOTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi‑solid food additive preparations, for domestic use, tHE pH of which is more than 11.5.\n\nn‑PROPYL NITRITE.\n\nPTERIDIUM spp. for therapeutic use.\n\nPULMONARIA spp. for therapeutic use.\n\nSAFROLE for internal therapeutic use except in preparations containing 0.1% or less of safrole.\n\nSANGUINARIA CANADENSIS (bloodroot) in preparations for human use except in preparations containing 0.01% or less of SANGUINARINE.\n\nSENECIO spp. for therapeutic use.\n\nSILICONES for injection or implantation except when included in Schedule 4.\n\nSODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi‑solid food additive preparations, for domestic use, tHE pH of which is more than 11.5.\n\nSYMPHYTUM spp. (Comfrey) in preparations for human or animal use except when in Schedule 5.\n\n2,4‑TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows.\n\nTOLUENEDIAMINES in preparations for skin colouration (including tattooing) and dyeing of eyelashes or eyebrows except when included in Schedule 6.\n\no‑TOLUIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001% or less of o‑toluidine.\n\n1,1,1‑TRICHLOROETHANE in pressurised spray packs for therapeutic use.\n\nTRICHODESMA AFRICANA for therapeutic use.\n\nTRIPARANOL for therapeutic use.\n\nTUSSILAGO FARFARA for therapeutic use.\n\nAppendix A—General exemptions\n\n \n\n \n\nNote: See paragraph 11(a).\n\n1  Exempt preparations and products\n\n  The following table specifies preparations and products for the purposes of paragraph 11(a).\n\n \n\n- Exempt preparations and products\n- Item Column 1 Preparation or product\n- 1 ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that are not agricultural chemical products or veterinary chemical products\n- 2 BACTERIAL CULTURE MEDIA containing antibiotics\n- 3 CERAMICS\n- 4 CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4‑2003, Safety of toys, Part 4: Experimental sets for chemistry and related activities\n- 5 COPPER COMPOUNDS in paints\n- 6 DEXTRANS, GELATIN ‑ SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/blood volume expanders\n- 7 ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS\n- 8 ELECTRONIC COMPONENTS\n- 9 ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging\n- 10 EXPLOSIVES\n- 11 FOOD except:(a) food additives before incorporation into food; or(b) when used as a means of administering a poison for therapeutic use\n- 12 FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non‑migratory component of glassy solid flakes or granules\n- 13 GLASS (including CRYSTAL WARE)\n- 14 GLAZED POTTERY\n- 15 HUMAN BLOOD PRODUCTS including:(a) whole blood;(b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and(c) the following plasma‑derived therapeutic proteins; and their equivalent recombinant alternatives:(i) albumin;(ii) anticoagulation complex;(iii) C1 esterase inhibitors;(iv) clotting factors;(v) fibrinogen;(vi) protein C;(vii) prothrombin complex concentrate (PCC);(viii) thrombin\n- 16 IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001% or less of a poison included in Schedules 1 to 8\n- 17 INTRAOCULAR VISCOELASTIC PRODUCTS\n- 18 LUBRICANTS in preparations that provide a lubricating action between machinery parts, except soluble oils and solvent‑deposited lubricating agents\n- 19 MATCHES\n- 20 MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS\n- 21 MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the Therapeutic Goods (Medical Devices) Regulation 2002, except the following:(a) injectable tissue reconstructive, augmentation and restoration materials, including collagen;(b) medical devices which include anticoagulants;(c) artificial tears;(d) urinary catheters;(e) intra‑articular fluids\n- 22 MOTOR, HEATING or FURNACE FUELS except the following:(a) when the contrary intention appears in any Schedule;(b) when containing methanol;(c) toy or hobby fuels; or(d) petrol or kerosene when packed in containers having a capacity of 20 L or less\n- 23 NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION\n- 24 PAPER except:(a) when prepared for pesticidal use; or(b) when containing a poison included in Schedule 8 or 9\n- 25 PHOTOGRAPHIC PAPER or FILM\n- 26 PIGMENTS when immobilised in a polymer\n- 27 PORCELAIN\n- 28 PRINTING INKS or INK ADDITIVES except:(a) when containing a pesticide; or(b) preparations containing more than 0.009% of lead calculated on the non‑volatile content of the ink or ink additive\n- 29 RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use\n- 30 RADIOISOTOPES for therapeutic use\n- 31 SEEDS treated with seed protectants\n- 32 SINGLE‑USE TUBES for the estimation of alcohol content of breath\n- 33 TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting\n- 34 TIMBER or WALLBOARD\n- 35 TREATMENT LAYERS OF COATED METAL ARTICLES except articles intended for use in the collection of drinking water when not compliant with the health and safety requirements of the Australian Standard AS 4020:2018, Testing of products for use in contact with drinking water\n- 36 VITREOUS ENAMELS\n- 37 WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5\n\nAppendix B—Substances considered not to require control by scheduling\n\n \n\n \n\nNote: See paragraph 11(b).\n\n1  Reasons for including substances in the table in clause 3\n\n  For the purposes of the table in clause 3, the letter specified in column 1 of an item of the following table represents the reason specified in column 2 of the item.\n\n \n\n- Reasons for including substances in the table in clause 3\n- Item Column 1 Letter Column 2 Reason\n- 1 a Low Toxicity\n- 2 b Use pattern restricts hazard\n- 3 c Presentation/packaging restricts hazard\n- 4 d Industrial use only\n\n2  Areas of use in relation to substances included in the table in clause 3\n\n  For the purposes of the table in clause 3, the number specified in column 1 of an item of the following table represents the area, sub‑area or sub‑sub‑area of use specified in column 2, 3 or 4 (as applicable) of the item.\n\n \n\n- Areas of use in relation to substances included in the table in clause 3\n- Item Column 1 Number Column 2 Area Column 3 Sub‑area Column 4 Sub‑sub‑area\n- 1 1 Agriculture\n- 2 1.1 Herbicide\n- 3 1.2 Insecticide\n- 4 1.2.1 Insecticide for codling moth\n- 5 1.2.2 Termiticide\n- 6 1.3 Fungicide\n- 7 1.3.1 On seed fungicide\n- 8 1.4 Bird Repellent\n- 9 1.5 Fertiliser\n- 10 1.6 Plant Growth Regulator\n- 11 1.7 Insect Pheromone\n- 12 1.8 Mushroom Bactericide\n- 13 1.9 Acaricide\n- 14 1.10 Biological control agent\n- 15 1.11 Adjuvant in agricultural products\n- 16 2 Veterinary\n- 17 2.1 For animal use\n- 18 2.2 Treatment of mastitis in cows\n- 19 2.3 Coccidiostat\n- 20 2.4 Feed additive\n- 21 2.5 Antiseptic\n- 22 2.6 Scabicide\n- 23 2.7 Anthelmintic\n- 24 2.8 Vitamin/Mineral\n- 25 2.9 Growth Promotant\n- 26 2.10 Ectoparasiticide\n- 27 3 Domestic\n- 28 3.1 Aromatherapy\n- 29 3.2 Food additive\n- 30 3.3 Cosmetic\n- 31 3.4 Human use\n- 32 3.5 Miticide\n- 33 4 Industrial\n- 34 4.1 Water treatment\n- 35 4.2 Biological control agent\n- 36 5 Environmental\n- 37 5.1 Mosquito control\n- 38 6 Human therapeutic use\n- 39 6.1 Diagnostic agent\n- 40 6.2 Medical device\n- 41 6.3 Antiseptic\n- 42 6.4 Sunscreen\n- 43 6.5 External use\n- 44 6.6 Laxative\n- 45 6.7 Antiseborrheic\n- 46 6.8 Cytoprotective\n- 47 6.9 Vitamin/Mineral\n- 48 6.10 Eye Drops\n- 49 7 General\n- 50 7.1 Any use\n- 51 7.2 Excipient\n- 52 7.3 Synergist\n- 53 7.4 Flux\n- 54 7.5 Pesticide\n- 55 7.6 Insect repellent\n- 56 7.7 Solvent\n- 57 7.8 Disinfectant\n- 58 7.9 Preservative\n- 59 7.10 Antioxidant\n- 60 7.11 Resin activator/accelerant\n- 61 7.12 Sweetener artificial\n- 62 7.13 Food additive\n\n3  Substances exempt in certain uses\n\n  For the purposes of paragraph 11(b), the following table specifies:\n\n (a) substances; and\n\n (b) areas, sub‑areas and sub‑sub‑areas of use in relation to those substances.\n\nNote: Columns 3 and 4 of the table are included for information only.\n\n \n\n- Substances exempt in certain uses\n- Item Column 1 Substance Column 2 Area, sub‑area or sub‑sub‑area of use Column 3 Reason for inclusion Column 4 Date of inclusion\n- 1 4‑[4‑(ACETYLOXY)PHENYL]‑2‑BUTANONE 1.7 b Feb 2005\n- 2 AFIDOPYROPEN 1.2 b Jun 2018\n- 3 ALCOHOL, DEHYDRATED 6 b Aug 2000\n- 4 ALUM 7.1 a May 1997\n- 5 ALUMINIUM AMMONIUM SULFATE 7.1 a May 1997\n- 6 ALUMINIUM POTASSIUM SULFATE 7.1 a May 1997\n- 7 ALUMINIUM SILICATE 7.1 a Nov 1974\n- 8 ALUMINIUM tris (ETHYLPHOSPHONATE) 1 a Aug 1986\n- 9 AMETOCTRADIN 1.3 a May 2012\n- 10 AMMONIUM PHOSPHATE 7.1 a Nov 1974\n- 11 AMMONIUM THIOSULPHATE 7.1 a Nov 1974\n- 12 AMPROLIUM 2.3 a Jun 1969\n- 13 AMYL ACETATE 7.1 a Nov 1974\n- 14 α ‑AMYLASE derived from Aspergillus niger 2.4 a Feb 2005\n- 15 AMYL CINNAMALDEHYDE 3.3 a, b Feb 2017\n- 16 ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT 2.1 a Jun 2004\n- 17 ASPARTIC ACID 6 a ‑\n- 18 ASULAM 1 a May 1986\n- 19 AUREOBASIDIUM PULLULANS (strains DSM14940 and DSM14941) 1.3 a Oct 2017\n- 20 AZIMSULFURON 1.1 a Jun 2003\n- 21 BACILLUS AMYLOLIQUEFACIENS 1.3 a Jun 2018\n- 22 BACILLUS SPHAERICUS, STRAIN 2362 5.1 a Feb 2003\n- 23 BACILLUS THURINGIENSIS 5.1 a May 1992\n- 24 BACILLUS THURINGIENSIS (excluding endotoxin) 2.10 a Jun 2003\n- 25 BACILLUS TOYOI 2.9 a Aug 1980\n- 26 BACULOVIRUS CYDIA POMONELLA 1.2 a Jun 2006\n- 27 BENFLURALIN 1.1 a ‑\n- 28 BENSULFURON‑METHYL 1 a Aug 1987\n- 29 BENTONITE 7.1 a Jun 2002\n- 30 BENZYL BENZOATE 1.2 a Aug 1989\n- 31 BETAINE HYDROCHLORIDE 7.1 a Nov 1974\n- 32 BIFENAZATE 1.9 a Oct 2002\n- 33 BISMUTH SUBNITRATE 2.1 b, c Nov 1999\n- 34 BISTRIFLURON 1.2.2 a Feb 2014\n- 35 BIURET 2.4 a Nov 1974\n- 36 BIXLOZONE 1.1 a Feb 2020\n- 37 BLAD (banda de Lupinus albus doce) 1.3 a Feb 2016\n- 38 BOSCALID 1.3 a June 2003\n- 39 BOVINE SOMATOTROPHIN 2 a May 1992\n- 40 BROMACIL 1 a Aug 1987\n- 41 BROMOPROPYLATE 1 a Nov 1994\n- 42 BUPIRIMATE 1 a Nov 1990\n- 43 BUTAFENACIL 1 a May 2000\n- 44 BUTOXYPOLYPROPYLENE GLYCOL 7.7 a Nov 1974\n- 45 n‑BUTYL BUTYRATE 7.1 a ‑\n- 46 n‑BUTYL LACTATE 7.1 a ‑\n- 47 CARBOXIN 1 a Aug 1987\n- 48 CARFENTRAZONE‑ETHYL 1 a Aug 1998\n- 49 CELLULASE derived from Aspergillus niger 2.4 a Feb 2005\n- 50 CETYL ALCOHOL 7.1 a Nov 1974\n- 51 CHAMOMILE OIL 3.1 a Feb 2000\n- 52 CHINA CLAY 1.2 a Sep 2008\n- 53 CHLORANTRANILIPROLE 1.2 a Sep 2008\n- 54 CHLORFLUAZURON 1.2.2 a Oct 2005\n- 55 CHLORFLURENOL 1.6 a Feb 1974\n- 56 CHLORIDAZON 1 a May 1988\n- 57 CHLOROXYLENOLS 7.8 a Feb 1975\n- 58 CITRONELLA OIL 7.1 a Feb 2000\n- 59 CLARY SAGE OIL 7.1 a Feb 2000\n- 60 CLITORIA TERNATEA EXTRACT 1.2 a Feb 2016\n- 61 CLOPIDOL 2.3 d Nov 1974\n- 62 COBALT NAPHTHENATE 7.1 d ‑\n- 63 CROSPOVIDONE 2 a Aug 1996\n- 64 CULICINOMYCES CLAVOSPORUS 5.1 a Nov 1982\n- 65 CYCLAMIC ACID 7.1 a Nov 1971\n- 66 CYCLANILIPROLE 1.2 a Oct 2016\n- 67 CYCLOBUTRIFLURAM 1.3, 1.3.1 a Oct 2022\n- 68 CYCLOHEXANE 7.7 a Nov 1974\n- 69 CYCLOHEXANOL ACETATE 7.7 a ‑\n- 70 CYPRINID HERPESVIRUS‑3 1.10 a Oct 2018\n- 71 CYROMAZINE 2 a Nov 1980\n- 72 DICLAZURIL 2.3 a Nov 2001\n- 73 DIETHYL CARBONATE 7.1 a ‑\n- 74 DIFLUFENICAN 1 a Feb 1987\n- 75 DIKEGULAC‑SODIUM 1.6 a Mar 1980\n- 76 DIMETHYL ETHER 4 d Nov 1988\n- 77 DIMETICONE 7.1 a ‑\n- 78 DIPHENYLAMINE 1 a Feb 1988\n- 79 DIPROPYLENE GLYCOL MONOMETHYL ETHER 4 a Nov 1987\n- 80 DISODIUM MANGANESE EDTA 2.1 a Feb 2022\n- 81 DIURON 1 a Nov 1987\n- 82 DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE) 7.1 a Feb 1970\n- 83 2,2‑DPA 1 a Nov 1989\n- 84 DROMETRIZOLE TRISILOXANE 6.4 a Oct 2003\n- 85 DUDDINGTONIA FLAGRANS, STRAIN IAH 1297 2.7 a Feb 2018\n- 86 EPSIPRANTEL 2 a Nov 1991\n- 87 ETHAMETSULFURON‑METHYL 1.1 a Nov 2000\n- 88 ETHOPABATE 2.3 d Jun 1969\n- 89 ETHYL ACETATE 7.1 a Nov 1974\n- 90 ETHYL ALCOHOL 7.1 a Nov 1974\n- 91 ETHYLBUTYLACETYL AMINOPROPRIONATE 3.4 a Aug 2000\n- 92 ETHYL BUTYRATE 7.1 a ‑\n- 93 ETHYL LACTATE 7.1 a ‑\n- 94 ETOFENPROX 1.2 a Jun 2018\n- 95 ETOXAZOLE 1.2 a Oct 2003\n- 96 EUBACTERIUM sp. strain DSM11798 2.4 a Sep 2013\n- 97 FENFURAM 1.3.1 a May 1977\n- 98 FENHEXAMID 1 a Feb 1999\n- 99 FENOXYCARB 1 a Feb 1988\n- 100 FLORPYRAUXIFEN‑BENZYL 1, 1.1 a Feb 2018\n- 101 FLORYLPICOXAMID 1.3 a Feb 2021\n- 102 FLUFENOXURON 1 a Feb 1997\n- 103 FLUMETSULAM 1 a Feb 1992\n- 104 FLUOMETURON 1 a Aug 1989\n- 105 FLUOPICOLIDE 1.3 a Oct 2016\n- 106 FLUOXAPIPROLIN 1.3 a Feb 2022\n- 107 FLUTOLANIL 1.3 a Nov 2001\n- 108 FLUROXYPYR 1 a, c May 1986\n- 109 FORCHLORFENURON 1.6 a Feb 2005\n- 110 FULLERS EARTH 7.1 a Nov 1974\n- 111 FUNGAL PROTEASE derived from Aspergillus niger 2.4 a Feb 2005\n- 112 GERANIUM OIL 7.1 a Feb 2000\n- 113 GIBBERELLIC ACID 1.6 a Nov 1974\n- 114 α‑GLUCANASE derived from Aspergillus niger 2.4 a Feb 2005\n- 115 HALAUXIFEN METHYL 1, 1.1 a Oct 2014\n- 116 HELIONAL 7 a Feb 2023\n- 117 HEXAFLURON 1 a Nov 1988\n- 118 HEXYL ACETATE 7.7 a ‑\n- 119 HEXYL CINNAMALDEHYDE 3.3 a, b Feb 2017\n- 120 HEXYTHIAZOX 1 a Feb 1988\n- 121 HUMAN OSTEOGENIC PROTEIN‑1 (OP‑1) 6.2 b Aug 2001\n- 122 HYDROPRENE 1 a Feb 1988\n- 123 HYDROXYPROPYL CELLULOSE 7.1 a Nov 1982\n- 124 ICODEXTRIN 6 b Nov 2000\n- 125 INDOLE‑3‑ACETIC ACID 1.6 b Feb 1985\n- 126 IPFLUFENOQUIN 1.3, 1.3.1 a Sep 2022\n- 127 ISOPRENE ALCOHOL 7.1 a ‑\n- 128 IPRODIONE 1 a Feb 1997\n- 129 ISETHIONATE, as mixed ammonium and ethanolamine salts of 2‑hydroxyethanesulfonic acid 1.11 a, b Jun 2016\n- 130 ISOFETAMID 1.3 a Feb 2018\n- 131 ISOSTEARYL ALCOHOL ETHOXYLATE 5.1 a Nov 1999\n- 132 KAOLIN 7.1 a Nov 1974\n- 133 KINETIN 1.6 a Feb 2022\n- 134 KRESOXIM‑METHYL 1 a Aug 1999\n- 135 KUNZEA OIL 7.1 a Feb 2000\n- 136 LAURIC ACID 7.1 a Oct 2005\n- 137 LAURYL ALCOHOL (1‑DODECANOL) 7.1 a Nov 1974\n- 138 LAVANDIN OIL 7.1 a Feb 2000\n- 139 LAVENDER OIL 7.1 a Feb 2000\n- 140 LEAD METALLIC 7.1 a ‑\n- 141 LEPIDOPTEROUS SEX PHEROMONES 1 a Nov 1990\n- 142 LIMONENE (DIPENTENE) 7.1 a Jun 2002\n- 143 LINOLEIC ACID 7.1 a Oct 2005\n- 144 LINSEED FATTY ACIDS 2.1 a Aug 1990\n- 145 LINURON 1 a Feb 1990\n- 146 LIQUORICE, DEGLYCYRRHISINISED 7.1 a May 1999\n- 147 MAGNESIUM HYDROXIDE 7.1 a Jun 2021\n- 148 MALEIC HYDRAZIDE 1 a Nov 1992\n- 149 MANGANESE DIOXIDE 1 b May 1999\n- 150 MEGASPHAERA ELSDENII strain 41125 2.4 a Sep 2013\n- 151 MESOSULFURON‑METHYL 1.1 a Feb 2002\n- 152 METARHIZIUM ANISOPLIAE 4.2 b Feb 2000\n- 153 METARHIZIUM ANISOPLIAE 1.10 a Jun 2003\n- 154 METCAMIFEN 1.1 a Feb 2020\n- 155 METHOPRENE 1 a Aug 1987\n- 156 METHOXYFENOZIDE 1 a Nov 2000\n- 157 METHYL ACETATE 7.7 a ‑\n- 158 METHYL BENZOQUATE 2.3 d Nov 1974\n- 159 1‑METHYLCYCLOPROPENE 1.6 a Jun 2003\n- 160 METHYL p‑HYDROXYBENZOATE 7.9 a Nov 1974\n- 161 METSULFURONMETHYL 1.1 a Nov 1985\n- 162 MYRISTIC ACID 7.1 a Oct 2005\n- 163 NAPROPAMIDE 1 a Aug 1987\n- 164 NAPTHYL ACETAMIDE 1.6 a Nov 1974\n- 165 NEROLI OIL 7.1 a Feb 2000\n- 166 NICARBAZIN 2.3 d Jun 1969\n- 167 NISIN 3.2 a Jun 2003\n- 168 NORFLURAZON 1.1 a Nov 1983\n- 169 NOVALURON 1 a Nov 2000\n- 170 NUCLEAR POLYHEDROSIS VIRUS of Helicoverpa armigera occlusion bodies 1.2 a Feb 2004\n- 171 OCTYL ALCOHOLS 7.1 a Nov 1974\n- 172 OLEIC ACID 7.1 a Oct 2005\n- 173 ORANGE OIL, SWEET 7.1 a Aug 2000\n- 174 OXABETRINIL 1 a Feb 1987\n- 175 OXATHIAPIPROLIN 1.3 a Jun 2016\n- 176 OXYFLUORFEN 1 a May 2001\n- 177 PALMAROSA OIL 7.1 a Feb 2000\n- 178 PALMITIC ACID 7.1 a Oct 2005\n- 179 PATCHOULI OIL 7.1 a Feb 2000\n- 180 PECTINASE derived from Aspergillus niger 2.4 a Feb 2005\n- 181 PEGBOVIGRASTIM 2.1 a Jun 2017\n- 182 PENCYCURON 1 a Aug 1994\n- 183 PENTADECANOIC ACID 7.1 a Oct 2005\n- 184 PEPPERMINT OIL 7.1 a Feb 2000\n- 185 PHENMEDIPHAM 1.1 a May 1989\n- 186 D‑PHENOTHRIN 7.5, 1.2 a Feb 1982\n- 187 PHYTASE 2.4 a Feb 1996\n- 188 PICLORAM 1 a Aug 1987\n- 189 PICOLINAFEN 1 a May 2000\n- 190 PIMELIC ACID 7.1 a Oct 2005\n- 191 PIPERONYL BUTOXIDE 7.5 a Aug 1991\n- 192 POLOXALENE 7.1 a Nov 1974\n- 193 POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC) 4.1 a Nov 1997\n- 194 POLYHEDROSIS VIRUS of Helico zea occlusion bodies 1 a Nov 1996\n- 195 POLY (GNRF) OVALBUMIN 2 a Feb 1990\n- 196 POLYSORBATE 20 1 a May 2001\n- 197 PORCINE SOMATOTROPHIN 2 c Nov 1991\n- 198 POTASSIUM SORBATE 1.3 a Oct 2004\n- 199 POTASSIUM BICARBONATE 1 a Jun 2004\n- 200 PROPYL ACETATES 7.1 a ‑\n- 201 PROPYLENE GLYCOL 7.1 a Nov 1974\n- 202 2‑PROPYLENE GLYCOL 1‑MONOMETHYL ETHER 4 a Nov 1987\n- 203 PROTHIOCONAZOLE 1.3.1 a Jun 2005\n- 204 PSEUDOMONAS FLUORESCENS 1.8 a May 1985\n- 205 PYDIFLUMETOFEN 1.3 a Feb 2018\n- 206 PYRIMETHANIL 1 a Feb 1996\n- 207 PYRIPROXYFEN 1 a Aug 1994\n- 208 QUASSIA 6, 2.1 d Nov 1974\n- 209 QUINOXYFEN 1.3 a Nov 2001\n- 210 RHIZOBIUM RHIZOGENES 1 b Nov 1989\n- 211 ROSEMARY OIL 7.1 a Feb 2000\n- 212 SAGE OIL (Spanish) 7.1 a Feb 2000\n- 213 SANDALWOOD OIL 7.1 a Feb 2000\n- 214 SEAWEED & UNFRACTIONED SEAWEED EXTRACTS 1.5 d Feb 1985\n- 215 SILVER OXIDE 7.14 b Jun 2018\n- 216 SIMAZINE 1.1 a Nov 1987\n- 217 SODIUM BICARBONATE 1 a Jun 2004\n- 218 SODIUM PROPIONATE 1.3 a Oct 2004\n- 219 STERIC ACID 7.1 a Oct 2005\n- 220 STREPTOMYCES LYDICUS WYEC 108 1.3 a Oct 2016\n- 221 SUCRALFATE 6.8 a Aug 1982\n- 222 SULESOMAB 6.1 b Jun 2002\n- 223 SULFOSULFURON 1 a Feb 1998\n- 224 SULPHATED POLYSACCHARIDES 7.1 a ‑\n- 225 TANNIC ACID 7.1 a Dec 1965\n- 226 TANNIC ACID/BENZYL ALCOHOL PRODUCT 7.1 a Nov 1993\n- 227 TERBACIL 1 a Aug 1987\n- 228 THAUMATIN 3.2 a Nov 1990\n- 229 THIDIAZURON 1 a Nov 1989\n- 230 TIAFENACIL 1 a June 2019\n- 231 TRIASULFURON 1 a Feb 1988\n- 232 TRICHODERMA HARZIANUM 1 a May 1996\n- 233 (Z)‑9‑TRICOSENE 1 a Aug 1991\n- 234 TRIETHYLENE GLYCOL 7.1 a Nov 1974\n- 235 TRIFLOXYSULFURON 1.1 a Feb 2002\n- 236 TRIFLURALIN 1 a Aug 1990\n- 237 TRIFORINE 1 a Aug 1987\n- 238 ULOCLADIUM OUDEMANSII 1.10 a Oct 2003\n- 239 UREA 7.1 a Nov 1974\n- 240 13C‑UREA 6.1 a May 2001\n- 241 VETIVER OIL 7.1 a Feb 2000\n- 242 VINYL ETHER 6 b Nov 1987\n- 243 VITAMIN K 6.9, 2.8 a Jul 1963\n- 244 XANTHOPHYLL (lutein) 7.1 a Nov 1974\n- 245 XYLANASE derived from Aspergillus niger 2.4 a Feb 2005\n- 246 YLANG YLANG OIL 7.1 a Feb 2000\n- 247 ZINC NAPHTHENATE 1.3 a ‑\n\n \n\nAppendix C—Blank\n\n \n\n   \n\nNote 1: Appendix C is intentionally blank.\n\nNote 2: Appendix C previously included poisons now included in Schedule 10.\n\nAppendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8\n\n \n\n \n\nNote: See section 64.\n\n1  Poisons available for human use only from or on the prescription or order of an authorised medical practitioner\n\n  A poison specified in the following table may be supplied for human use only by, on the prescription or order of, an authorised medical practitioner.\n\n \n\n| 1 | CANNABIS for human use |\n| 2 | CLOMIFENE for human use |\n| 3 | CLOZAPINE for human use |\n| 4 | CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use |\n| 5 | CYCLOFENIL for human use |\n| 6 | DINOPROST for human use |\n| 7 | DINOPROSTONE for human use |\n| 8 | FOLLITROPIN ALFA (recombinant human follicle‑stimulating hormone) for human use |\n| 9 | FOLLITROPIN BETA (recombinant human follicle‑stimulating hormone) for human use |\n| 10 | FOLLITROPIN DELTA (recombinant human follicle‑stimulating hormone) for human use |\n| 11 | LUTEINISING HORMONE for human use |\n| 12 | NABIXIMOLS for human use |\n| 13 | SODIUM OXYBATE for human use |\n| 14 | TETRAHYDROCANNABINOLS for human use |\n| 15 | TERIPARATIDE for human use |\n| 16 | UROFOLLITROPIN (human follicle‑stimulating hormone) for human use |\n\n2  Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist\n\n  A poison specified in the following table may be supplied for human use:\n\n (a) only by, or on the prescription or order of, a specialist physician or a dermatologist; and\n\n (b) if the person to whom the poison is to be supplied is a woman of child‑bearing age—only if the specialist physician or dermatologist has:\n\n (ii) if the poison is acitretin or etretinate—advised the patient to avoid becoming pregnant during or for a period of 36 months after completion of treatment; and\n\n (iii) if the poison is bexarotene, isotretinoin or thalidomide—advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.\n\n \n\n| 1 | ACITRETIN for human use |\n| 2 | BEXAROTENE for human use |\n| 3 | ETRETINATE for human use |\n| 4 | ISOTRETINOIN for human oral use |\n| 5 | THALIDOMIDE for human use |\n\n3  Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act\n\n  A poison specified in the following table may be supplied only by, or on the prescription or order of, a medical practitioner for whom an approval or authority under section 19 of the Act that covers the poison is in force.\n\n \n\n| 1 | DRONABINOL (delta‑9‑tetrahydrocannabinol) |\n\n4  Poisons available only from or on the order of a specialist physician\n\n  A poison specified in the following table may be supplied:\n\n (a) only by, or on the prescription or order of, a specialist physician; and\n\n (b) if the person to whom the poison is to be supplied is a woman of child‑bearing age—only if the specialist physician has:\n\n (ii) advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.\n\n \n\n| 1 | LENALIDOMIDE |\n| 2 | POMALIDOMIDE |\n| 3 | RIOCIGUAT for human use |\n| 4 | TRETINOIN for human oral use |\n\n5  Poisons for which possession without authority is illegal\n\n  The following table specifies poisons that must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription).\n\n \n\n| 1 | ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4 |\n| 2 | ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4 |\n| 3 | AOD‑9604 (CAS No. 221231‑10‑3) |\n| 4 | BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8 |\n| 5 | BPC‑157 |\n| 6 | CAPROMORELIN |\n| 7 | CJC‑1295 (CAS No. 863288‑34‑0) |\n| 8 | DARBEPOETIN |\n| 9 | DEXTROPROPOXYPHENE |\n| 10 | N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) |\n| 11 | EPHEDRINE |\n| 12 | EPOETINS |\n| 13 | ERYTHROPOIETIN |\n| 14 | ERYTHROPOIETINS except when separately specified in this Appendix |\n| 15 | FIBROBLAST GROWTH FACTORS |\n| 16 | FOLLISTATIN |\n| 17 | GLUTETHIMIDE |\n| 18 | GROWTH HORMONE RELEASING HORMONES (GHRHs) including those separately specified in Schedule 4 |\n| 19 | GROWTH HORMONE RELEASING PEPTIDES (GHRPs) including those separately specified in Schedule 4 |\n| 20 | GROWTH HORMONE RELEASING PEPTIDE‑6 (GHRP‑6) |\n| 21 | GROWTH HORMONE SECRETAGOGUES including those separately specified in Schedule 4 |\n| 22 | HEXARELIN |\n| 23 | IBUTAMOREN |\n| 24 | INSULIN‑LIKE GROWTH FACTORS |\n| 25 | IPAMORELIN |\n| 26 | NICOTINE |\n| 27 | PERAMPANEL for human use |\n| 28 | PHENTERMINE |\n| 29 | PRALMORELIN ((GROWTH HORMONE RELEASING PEPTIDE‑2) (GHRP‑2)) |\n| 30 | PSILOCYBINE |\n| 31 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4 |\n| 32 | SOMATROPIN (human growth hormone) |\n| 33 | STENABOLIC (SR9009) and other synthetic REV‑ERB agonists |\n| 34 | TB‑500 |\n| 35 | THYMOSIN BETA 4 (THYMOSIN β4) |\n| 36 | TIANEPTINE |\n| 37 | VADADUSTAT |\n\n6  Poisons available for human use only from or on the prescription or order of a specialist physician\n\n  A poison specified in the following table may be supplied for human use:\n\n (a) only by, or on the prescription or order of, a specialist physician; and\n\n (b) if the person to whom the poison is to be supplied is a woman of child‑bearing age—only if the specialist physician has:\n\n (ii) advised the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.\n\n \n\n| 1 | AMBRISENTAN for human use |\n| 2 | BOSENTAN for human use |\n| 3 | ENZALUTAMIDE for human use |\n| 4 | MACITENTAN for human use |\n| 5 | SITAXENTAN for human use |\n\n7  Poisons available for human use only from or on the prescription or order of a dermatologist\n\n  A poison specified in the following table may be supplied for human use only by, or on the prescription or order of, a dermatologist.\n\n \n\n| 1 | ALEFACEPT for human use |\n\n8  Poisons available for initial treatment of a patient only if authorised by certain health practitioners\n\n  HYDROXYCHLOROQUINE may be supplied, for human use, for the initial treatment of a patient only if that treatment is authorised by:\n\n (a) a medical practitioner registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist in any of the following specialties or fields of specialty practice:\n\n (i) dermatology;\n\n (ii) emergency medicine;\n\n (iii) intensive care medicine;\n\n (iv) paediatrics and child health;\n\n (v) physician; or\n\n (b) a dental practitioner registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist in the specialty of oral medicine.\n\n9  Poisons which must be stored in a locked container to prevent unauthorised access\n\n  The following table specifies poisons that must be stored in a locked container to prevent unauthorised access.\n\n \n\n| 1 | PENTOBARBITAL in injectable preparations |\n\n10  Poisons available only when prescribed or authorised in certain circumstances\n\n  N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human use may be supplied only for the treatment of post-traumatic stress disorder:\n\n (a) if MDMA is prescribed, or its supply is authorised, by a medical practitioner:\n\n (i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and\n\n (ii) for whom an authority under subsection 19(5) of the Act that covers MDMA is in force; or\n\n (b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act.\n\n \n\n  PSILOCYBINE in preparations for human use may be supplied only for the treatment of treatment-resistant depression:\n\n (a) if psilocybine is prescribed, or its supply is authorised, by a medical practitioner:\n\n (i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and\n\n (ii) for whom an authority under subsection 19(5) of the Act that covers psilocybine is in force; or\n\n (b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act.\n\nAppendix E—First aid instructions for poisons\n\n \n\n \n\nNote: See section 31.\n\n1  Standard statements for first aid instructions\n\n  For the purposes of the table in clause 3, the statement code specified in column 2 of an item of the following table represents:\n\n (a) the statement specified in column 3 of the item; or\n\n (b) a different statement that has the same intent as the statement specified in column 3 of the item.\n\n \n\n- Standard statements for first aid instructions\n- Item Column 1 Category Column 2 Statement code Column 3 Statement\n- 1 Basic A For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once).\n- 2 Basic Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.\n- 3 General G1 Urgent hospital treatment is likely to be needed.(Note ‑ the words “at once” to be added to instruction A).\n- 4 General G2 If swallowed, give activated charcoal if instructed.(Note ‑ the words “at once” to be added to instruction A).\n- 5 General G3 If swallowed, do NOT induce vomiting.\n- 6 General G4 Immediately give a glass of water.\n- 7 General G5 Avoid giving milk or oils.\n- 8 General G6 If sprayed in mouth, rinse mouth with water.\n- 9 Eyes E1 If in eyes wash out immediately with water.\n- 10 Eyes E2 If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.\n- 11 Respiratory system R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.\n- 12 Respiratory system R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth‑to‑mouth resuscitation. To protect rescuer, use air‑viva, oxy‑viva or one‑way mask. Resuscitate in a well‑ventilated area.\n- 13 Skin S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.\n- 14 Skin S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.\n- 15 Skin S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.\n- 16 Skin S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.\n- 17 Skin S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766).\n- 18 Special Purpose SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.\n\n2  Poisons information centre contact information in statements\n\n  A statement required for a poison that includes a reference to a Poisons Information Centre must include:\n\n (a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and\n\n (b) immediately following the reference to a Poisons Information Centre:\n\n (i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or\n\n (ii) the telephone number for another poisons information centre:\n\n (A) that is attended by adequately trained staff for 24 hour emergency poisons information; and\n\n (B) calls to which are logged and submitted for incorporation into the official collection of poisoning data.\n\nNote: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766.\n\n3  First aid instructions for poisons\n\n (1) For the purposes of subsection 31(1), and subject to subclause (2), the statement represented by each statement code specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item.\n\n (2) A statement required for a poison must:\n\n (a) be modified for its use in relation to that poison as appropriate for the poison (for example if the poison is combined with other substances (whether toxic or non‑toxic) or is in a particular physical form or presentation); and\n\n (b) if the statement refers to a Poisons Information Centre—comply with clause 2.\n\n \n\n- Poisons that must be labelled with first aid instructions\n- Item Column 1 Poison Column 2 Statement code\n- 1 ACETIC ACID A, G3, E2, S1\n- 2 ACETIC ANHYDRIDE A, G3, E2, S1\n- 3 ACETONE A, G3\n- 4 ACROLEIN A, G1, G2, G3, E2, R2, S2\n- 5 ALKALINE SALTS A, G3, E2, S1\n- 6 ALKYL NITRITES A\n- 7 AMIDOPROPYL BETAINES—in cosmetic wash‑off preparations when included in Schedule 6 E1\n- 8 AMIDOPROPYL BETAINES—in other preparations when included in Schedule 6 E1, S1\n- 9 AMINES for use as curing agents A, G3, E1, S1\n- 10 2‑AMINO‑6‑CHLORO‑4‑NITROPHENOL A, E1\n- 11 4‑AMINO‑m‑CRESOL A, E1\n- 12 2‑AMINO‑5‑ETHYLPHENOL A\n- 13 4‑AMINO‑2‑HYDROXYTOLUENE A, E1\n- 14 4‑AMINO‑3‑NITROPHENOL A\n- 15 2,2'‑[(4‑AMINO‑3‑NITROPHENYL)IMINO]BISETHANOL E1\n- 16 m‑AMINOPHENOL A, S1\n- 17 p‑AMINOPHENOL A, S1\n- 18 4‑AMINOPYRIDINE A, G1, G2, E1, S1\n- 19 AMMONIA—5% or less A\n- 20 AMMONIA—above 5% A, G3, E1, R1, S1\n- 21 AMMONIUM COCOYL ISETHIONATE E1\n- 22 AMMONIUM PERSULFATE A, G3, E2\n- 23 AMMONIUM THIOCYANATE A\n- 24 AMYL NITRITE A\n- 25 ANHYDRIDES, organic acid, for use as curing agents for epoxy resins A, G3, E1, S1\n- 26 ANILINE A, E2, R1, S1\n- 27 ANISE OIL A, G3\n- 28 ANITMONY CHLORIDE A, E2, S2\n- 29 ANTIMONY COMPOUNDS, except antimony chloride A\n- 30 ARBUTIN when included in Schedule 6 A, G2, G3, E2, R2, S1\n- 31 AZADIRACHTA INDICA (neem) including its extracts and derivatives when included in Schedule 6 A, E1\n- 32 AZO DYES (derivatives by diazotisation) A\n- 33 BARIUM SALTS, except barium sulfate A\n- 34 BASIC RED 76 A\n- 35 BASIL OIL A, G3\n- 36 BAY OIL A, G3\n- 37 BENZALKONIUM CHLORIDE—when included in Schedule 5 A, G3, E2\n- 38 BENZALKONIUM CHLORIDE—when included in Schedule 6 A, G3, E2, S1\n- 39 BENZENE A, G3, E1, R1, S1\n- 40 1,2‑BENZENEDIOL (Catechol) A, E1, S1\n- 41 BENZOYL PEROXIDE—above 20% A, E2, S1\n- 42 BENZOYL PEROXIDE—above 10% up to 20% A, E1\n- 43 BENZOYL PEROXIDE—10% or less A\n- 44 BERGAMOT OIL A, G3\n- 45 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5 A\n- 46 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7 A, G3, E2, S5\n- 47 1,3‑BIS(2,4‑DIAMINOPHENOXY)PROPANE E1, S1\n- 48 BIS‑ISOBUTYL PEG/PPG‑20/35/AMODIMETICONE COPOLYMER A, E1\n- 49 BORAX A\n- 50 BORIC ACID A\n- 51 BORON TRIFLUORIDE—when included in Schedule 5 A\n- 52 BORON TRIFLUORIDE—when included in Schedule 6 or 7 A, G3, E2, S5\n- 53 BROMOFORM A, G3, E2, R1, S2\n- 54 BRUCINE A, G1, G2, G3, R2\n- 55 2‑BUTOXYETHANOL and its acetates A, E2, S1\n- 56 n‑BUTYL ALCOHOL A, E1, S1\n- 57 BUTYL NITRITE A\n- 58 CADMIUM COMPOUNDS A\n- 59 CAJUPUT OIL A, G3\n- 60 CAMPHOR A, G1, G3, G5\n- 61 CARBAMIDE PEROXIDE—more than 9% up to 60% A, G3, E2, S1\n- 62 CARBAMIDE PEROXIDE—more than 60% A, G1, G3, G4, E2, S1\n- 63 CARBON DISULFIDE A, G3, E2, R1, S2\n- 64 CARBON TETRACHLORIDE A, G3, E1, R1, S1\n- 65 CASSIA OIL A, G3\n- 66 CHLORINATING COMPOUNDS, except when separately specified—containing above 4% and below 10% of available chlorine A, G3, E1, S1\n- 67 CHLORINATING COMPOUNDS, except when separately specified—containing 10% or more of available chlorine A, G3, E2, S1\n- 68 CHLORIDE (gas) A, E1, R1\n- 69 CHLOROACETAMIDE A\n- 70 CHLOROCRESOL A, G3, E2, S2\n- 71 2‑CHLORO‑6‑(ETHYLAMINO)‑4‑NITROPHENOL A, S1\n- 72 CHLOROFORM A, G3, E1, R1, S1\n- 73 CHROMATES A, G3, E2, S1\n- 74 CHROMIUM TRIOXIDE A, G3, E2, S1\n- 75 CHRYSOIDINE BASE A, S1, E1\n- 76 CINEOLE A, G1, G3\n- 77 CINNAMON BARK OIL A, G3\n- 78 CINNAMON LEAF OIL A, G3\n- 79 CLIMBAZOLE A\n- 80 CLOVE OIL A, G1, G3, E2\n- 81 COCOYL GLYCINATE E1\n- 82 COPPER SULFATE A, G3, E2, S1\n- 83 CREOSOTE A, G3, E2, S1\n- 84 CRESOLS A, G3, E2, S3\n- 85 CRESOLS in pressurised spray packs A, G6, E1, S1\n- 86 CYANIDES A, G1, E1, R2\n- 87 CYANOACRYLIC ACID ESTERS A\n- 88 CYANURIC ACID A\n- 89 CYCLOHEXANONE PEROXIDE A, G3, E2, S1\n- 90 CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) A, E2, S1\n- 91 CYCTEAMINE E1\n- 92 1‑DEOXY‑1‑(METHYLAMINO)‑d‑GLUCITOL N‑COCO ACYL DERIVATIVES E1\n- 93 2,4‑DIAMINOPHENOXYETHANOL A, E2, S1\n- 94 o‑DICHLOROBENZENE A, G3, E1, S1\n- 95 para‑DICHLOROBENZENE (PDB) A\n- 96 DICHLOROETHYL ETHER A, G3, E1, R1, S1\n- 97 DICHLOROISOCYANURATES A, G3, E1, S1\n- 98 DICHLOROMETHANE (methylene chloride) A, G3, G5, E1, R1, S1\n- 99 DICHLOROMETHANE (methylene chloride)—in pressurised spray packs A, G6, S1\n- 100 DICHROMATES A, G1, G3, E2, S1\n- 101 DIDECYLDIMETHYLAMMONIUM SALTS A, G3\n- 102 DIESEL (distillate) A, G3\n- 103 DIETHANOLAMINE—when included in Schedule 5 A, G3\n- 104 DIETHANOLAMINE—when included in Schedule 6 A, G3, E2, S1\n- 105 DIETHYLENE GLYCOL MONOBUTYL ETHER A, E1, S1\n- 106 5,6‑DIHYDROXYINDOLINE E1\n- 107 DIMETHYLFORMAMIDE—less than 75% A\n- 108 DIMETHYLFORMAMIDE—75% or more A, E1, R1, S1\n- 109 4,4‑DIMETHYL‑1‑CYCLOHEXENE‑1‑PROPANAL A, E2\n- 110 3,7‑DIMETHYL‑2,6‑OCTADIEN‑1‑OL A, E1, S1\n- 111 DIMETHYL SULFOXIDE A, G3, E1, S1\n- 112 DINITROCRESOLS A, G1, E1, S1\n- 113 DINITROPHENOLS A, G1, E1, S1\n- 114 DIOXANE A, G3, E1, R1, S1\n- 115 DISPERSE YELLOW 3 A, S1\n- 116 DISTILLATE A, G3\n- 117 N‑(N‑DODECYL)‑2‑PYRROLIDONE—when included in Schedule 5 A, G3, E1\n- 118 N‑(N‑DODECYL)‑2‑PYRROLIDONE—when included in Schedule 6 A, G3, E2, S1\n- 119 EPOXY RESINS liquid A, G3, E2, S1\n- 120 Essential oils containing CAMPHOR as natural component unless otherwise specified A, G3\n- 121 ETHER A, G3, E1, R1\n- 122 ETHYL BROMIDE A, E2, S1, R1\n- 123 ETHYLENE GLYCOL A\n- 124 ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, except when separately specified A, G3, E2, S1\n- 125 ETHYLENE OXIDE A, E2, R1\n- 126 ETHYLHEXANEDIOL A, E2\n- 127 2‑ETHYLHEXANOIC ACID A\n- 128 EUCALYPTUS OIL A, G1, G3\n- 129 EUGENOL A, G1, G3, E2\n- 130 FENNEL OIL A, G3\n- 131 FLUORIDES except when separately specified—when included in Schedule 5 A\n- 132 FLUORIDES except when separately specified—when included in Schedule 6 A, G1, G3, E2, S1\n- 133 FORMALDEHYDE (see also paraformaldehyde) A, G3, E2, R1, S1\n- 134 FORMIC ACID A, G3, E2, S1\n- 135 FURFURAL A, E1, S1\n- 136 GLUTARAL—below 5% A, G3, E1\n- 137 GLUTARAL—5% or more A, G3, E2, S1\n- 138 GLYCOLIC ACID A, G3, E2\n- 139 GUANIDINE when included in Schedule 6 A, G3, E2, S1\n- 140 HC VIOLET 1 E1\n- 141 HEXACHLOROPHENE when included in Schedule 6 A\n- 142 HEXYLOXYETHANOL A, G3, E2, S1\n- 143 HYDRAZINE A, G1, G3, E2, R1, S1\n- 144 HYDROCARBONS, liquid A, G3\n- 145 HYDROCHLORIC ACID A, G3, E2, S1\n- 146 HYDROCHLORIC ACID—when included in Schedule 5 A, G3\n- 147 HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid—when included in Schedule 5 A\n- 148 HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid—when included in Schedule 6 or 7 A, G3, E2, S5\n- 149 HYDROGEN PEROXIDE—more than 3% up to 20% A, G3, E2, S1\n- 150 HYDROGEN PEROXIDE—more than 20% A, G1, G3, G4, E2, S1\n- 151 HYDROQUINONE—when included in Schedule 2 A\n- 152 HYDROQUINONE—when included in Schedule 4 or 6 A, G2, G3, E2, R2, S1\n- 153 HYDROSILICOFLUORIC ACID—when included in Schedule 5 A\n- 154 HYDROSILICOFLUORIC ACID—when included in Schedule 6 or 7 A, G3, E2, S5\n- 155 2‑HYDROXYETHYL METHACRYLATE A, E1, S1\n- 156 HYDROXYETHYL‑3,4‑METHYLENEDIOXYANILINE E1, S1\n- 157 IODINE (excluding salts, derivatives and iodophors)—2.5% or more for human external use A, E2\n- 158 IODINE (excluding salts, derivatives and iodophors)—2.5% or more for other uses A, E2, S1\n- 159 IODINE (excluding salts, derivatives and iodophors)—below 2.5% A\n- 160 IODOPHORS A\n- 161 ISOAMYL NITRITE A\n- 162 ISOBUTYL NITRITE A\n- 163 ISOCYANATES, free organic A, E2, S1\n- 164 ISOEUGENOL A, E1, S1\n- 165 ISOPHORONE A, G3, E2, S1\n- 166 KEROSENE A, G3\n- 167 LAURETH CARBOXYLIC ACIDS—leave‑on or wash‑off preparations above 5% E1\n- 168 LAURETH CARBOXYLIC ACIDS—other preparations above 5% E1, S1\n- 169 LAURYL ISOQUINOLINIUM BROMIDE A, E1\n- 170 LEAD COMPOUNDS—in hair cosmetics A\n- 171 LEAD COMPOUNDS—in other preparations A, S1\n- 172 LEMON OIL A, G3\n- 173 LEPTOSPERMUM SCOPARIUM OIL (manuka oil) A, G1, G3\n- 174 LIME OIL A, G3\n- 175 MAGNESIUM CHLORATE A\n- 176 MALATHION at 20% or less A\n- 177 MARJORAM OIL A, G3\n- 178 MELALEUCA OIL A, G1, G3\n- 179 MERCAPTOACETIC ACID A, E1\n- 180 MERCURIC CHLORIDE—for external therapeutic use A\n- 181 MERCURIC CHLORIDE—for other uses A, G1, G3, E2, R2, S1\n- 182 MERCURIC IODIDE A, G1, G3, E2, R2, S1\n- 183 MERCURIC NITRATE A, G1, G3, E2, R2, S1\n- 184 MERCURIC OXIDE A, G1, G3\n- 185 MERCURIC POTASSIUM IODIDE A, G1, G3, E2, R2, S1\n- 186 MERCURIC THIOCYANATE A, G1, G3, E2, R2, S1\n- 187 MERCUROCHROME A\n- 188 MERCUROUS CHLORIDE A\n- 189 MERCURY—metallic A\n- 190 MERCURY—organic compounds A, S1\n- 191 MERCURY—organic compounds in preparations for human external use A\n- 192 METALDEHYDE A, E1, S1\n- 193 METHANOL—above 10% A, G3\n- 194 METHANOL—10% or less A\n- 195 METHYLATED SPIRIT(S) A, G3\n- 196 METHYLATED SPIRIT(S)—when packed and labelled as a “biofuel” suitable for use in “spirit burners” A, G3\n- 197 METHYL ETHYL KETONE A, G3\n- 198 METHYL ETHYL KETONE OXIME A, E1, S1\n- 199 METHYL ETHYL KETONE PEROXIDE A, G3, E2, S1\n- 200 METHYLEUGENOL A\n- 201 METHYL ISOAMYL KETONE A, G3\n- 202 METHYL ISOBUTYL KETONE A, G3\n- 203 N‑METHYL‑2‑PYRROLIDONE—when included in Schedule 5 A, G3, E1\n- 204 N‑METHYL‑2‑PYRROLIDONE—when included in Schedule 6 A, G3, E2\n- 205 2‑METHYLRESORCINOL A, E1\n- 206 METHYL SALICYLATE LIQUID when included in Schedule 5 or 6 A, G3, E1\n- 207 MONOETHANOLAMINE—when included in Schedule 5 A, G3, E1\n- 208 MONOETHANOLAMINE—when included in Schedule 6 A, G3, E2, S1\n- 209 1,5‑NAPHTHALENEDIOL A, E1, S1\n- 210 2,7‑NAPHTHALENEDIOL A, E1, S1\n- 211 NAPHTHALENE A, G1, G3\n- 212 1‑NAPHTHOL A, E1, S1\n- 213 NITRIC ACID A, G3, E2, S1\n- 214 NITROBENZENE A, G3, E1, S1\n- 215 3‑NITRO‑p‑HYDROXYETHYLAMINOPHENOL E1\n- 216 NITROPHENOL A, G3, E2, S1\n- 217 NITROPRUSSIDES—in aerosols A, G6, R1\n- 218 NITROPRUSSIDES—in other preparations A, G3\n- 219 NITROUS OXIDE A\n- 220 NONOXINOL 9 A, E2\n- 221 NUTMEG OIL A, G3\n- 222 OCTHILINONE A, G3, E2, S1\n- 223 OCTYL NITRITE A\n- 224 N‑(N‑OCTYL)‑2‑PYRROLIDONE—when included in Schedule 5 A, G3, E1\n- 225 N‑(N‑OCTYL)‑2‑PYRROLIDONE—when included in Schedule 6 A, G3, E2\n- 226 ORANGE OIL (bitter) A, G3\n- 227 OXALIC ACID A, G3, E2, S1\n- 228 PARAFORMALDEHYDE A, G3, E2, R1, S1\n- 229 PENNYROYAL OIL A, G3\n- 230 PERACETIC ACID—when included in Schedule 5 A, G3, E1, S1\n- 231 PERACETIC ACID—when included in Schedule 6 A, G3, E2, S1\n- 232 PETROL A, G3, R1\n- 233 2‑PHENOXYETHANOL A, E1\n- 234 PHENOL when included in Schedule 6 A, E1\n- 235 PHENOLS—25% and less A, G3, E2, S3\n- 236 PHENOLS—above 25% A, G3, E2, S4\n- 237 PHENOLS—in pressurised spray packs A, E1\n- 238 PHENOXYMETHYL OXIRANE A, E1\n- 239 PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in hair dyes A, E1\n- 240 PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in preparations other than hair dyes A, G1, G3, E1, S1\n- 241 PHENYL METHYL KETONE as such, or in preparations of similar viscosity A, G3, E1\n- 242 PHENYL METHYL PYRAZOLONE A, S1\n- 243 N,N‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,5‑DIMETHANAMINE A, E2, S1\n- 244 N,N‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,6‑DIMETHANAMINE A, E2, S1\n- 245 o‑PHENYLPHENOL A, G3, E2, S1\n- 246 o‑PHENYLPHENOL—in pressurised spray packs A, G6, E2, S1\n- 247 PHOSPHONIC ACID A, G3, E2, S1\n- 248 PHOSPHONIC ACID—neutralised to pH 6 (approx) A\n- 249 PHOSPHONIC ACID—in spray packs A, E2, S1\n- 250 PHOSPHORIC ACID A, G3, E2, S1\n- 251 PHOSPHORUS, YELLOW A, G1, G3, E2, R2, S2\n- 252 o‑PHTHALALDEHYDE—when included in Schedule 5 A, E1\n- 253 o‑PHTHALALDEHYDE—when included in Schedule 6 A, G3, E2, S1\n- 254 PICRAMIC ACID including its salts (excluding other derivatives) A, E1\n- 255 PICRIC ACID A, G1, G3, E2, R1, S1\n- 256 POLIHEXANIDE E1\n- 257 POLYETHANOXY (15) TALLOW AMINE A, E2, S1\n- 258 POLY(OXY‑1,2‑ETHANEDIYL), Α ‑[2‑[(2‑HYDROXYETHYL)AMINO]‑2‑OXOETHYL]‑ Α ‑HYDROXY‑,MONO‑C13‑15‑ALKYL ETHERS A, E1\n- 259 POTASSIUM BROMATE A\n- 260 POTASSIUM CHLORATE A\n- 261 POTASSIUM CYANATE A, E1, S1\n- 262 POTASSIUM HYDROXIDE A, G3, E2, S1\n- 263 POTASSIUM METABISULPHITE A\n- 264 POTASSIUM NITRITE—when included in Schedule 7 A, G1, G3\n- 265 POTASSIUM NITRITE—when included in Schedule 5 or 6 A, G3\n- 266 POTASSIUM PEROXOMONOSULFATE TRIPLE SALT—when included in Schedule 5 A, G3, E1\n- 267 POTASSIUM PEROXOMONOSULFATE TRIPLE SALT—when included in Schedule 6 A, G3, E2, S1\n- 268 POTASSIUM PERSULFATE A, G3, E2\n- 269 POTASSIUM SULFIDE A, G3, E2, S1\n- 270 PROPIONIC ACID A, G3, E1, S1\n- 271 n‑PROPYL ALCOHOL A, E1\n- 272 D‑PULEGONE A, G3\n- 273 PYRITHIONE ZINC A, E1\n- 274 QUATERNARY AMMONIUM COMPOUNDS except when separately specified—above 20% A, G3, E2\n- 275 QUATERNARY AMMONIUM COMPOUNDS except when separately specified—20% and below A, E2\n- 276 QUATERNARY AMMONIUM COMPOUNDS except when separately specified—in pressurised spray packs A, E2, G6\n- 277 QUINOLINE A, E1, S1\n- 278 RESORCINOL A, E2, S1\n- 279 SAFROLE A, G1, G3\n- 280 SAGE OIL (Dalmatian) A, G3\n- 281 SASSAFRAS OIL A, G1, G3\n- 282 SELENIUM COMPOUNDS A, G1, E1, S1\n- 283 SILICOFLUORIDES—when included in Schedule 5 A\n- 284 SILICOFLUORIDES—when included in Schedule 6 A, G1, G3, E2, S1\n- 285 SILVER SALTS A, E2\n- 286 SODIUM ALUMINATE A, G3, E2, S1\n- 287 SODIUM BROMATE A, G1\n- 288 SODIUM CHLORATE A\n- 289 SODIUM DIACETATE A, G3, E2, S1\n- 290 SODIUM DICHLOROISOCYANURATE A, G3, E1, S1\n- 291 SODIUM DODECYLBENZENE SULFONATE A, G3, E2, S1\n- 292 SODIUM HYDROGEN SULFATE A, G3, E1, S1\n- 293 SODIUMHYDROSULFITE A, G3, E2, S1\n- 294 SODIUM HYDROXIDE A, G3, E2, S1\n- 295 SODIUM LAURETH‑6 CARBOXYLATE A\n- 296 LAURYL SULFATE SALTS—leave‑on or wash‑off preparations above 5% E1\n- 297 LAURYL SULFATE SALTS—other preparations above 5% E1, S1\n- 298 SODIUM METABISULPHITE A, G3\n- 299 SODIUM NITRITE—when included in Schedule 7 A, G1, G3\n- 300 SODIUM NITRITE—when included in Schedule 5 or 6 A, G3\n- 301 SODIUM PERCARBONATE—when included in Schedule 5 A, G3, S1\n- 302 SODIUM PERCARBONATE—when included in Schedule 6 A, G3, E2, S1\n- 303 SODIUM PERSULFATE A, G3, E2\n- 304 SODIUM STANNATE A, E1\n- 305 SODIUM SULFIDE A, G3, E2, S1\n- 306 SODIUM TRICHLOROACETATE A\n- 307 STRYCHNINE A, G1, G2, G3, R2\n- 308 STYRENE A, G3, S1, E1\n- 309 SULCOFURON A\n- 310 SULFAMIC ACID A, G3, E2, S1\n- 311 SULFURIC ACID A, G3, E2, S1\n- 312 TERPENES, chlorinated A, G3\n- 313 TETRACHLOROETHANE A, G3, E1, R1, S1\n- 314 TETRACHLOROETHYLENE A, G3, E2, R1, S1\n- 315 THIOUREA A\n- 316 THUJONE A, G3\n- 317 THYME OIL A, G3\n- 318 o‑TOLIDINE A\n- 319 TOLUENE—above 75% A, G3, E1, R1, S1\n- 320 TOLUENE—75% and below A, G3\n- 321 TOLUENE—in pressurised spray packs A\n- 322 TOLUENEDIAMINES—in hair dyes A, E1\n- 323 TOLUENEDIAMINES—in other preparations A, G1, G3, E1, S1\n- 324 TRICHLOROACETIC ACID A, G3, E2, S1\n- 325 TRICHLOROACETIC ACID ALKALI SALTS A\n- 326 1,1,1‑TRICHLOROETHANE A, G3, E1, R1, S1\n- 327 TRICHLOROETHYLENE A, G3, E1, R1, S1\n- 328 TRICHLOROISOCYANURIC ACID A, G3, E1, S1\n- 329 TRIETHYL PHOSPHATE A, E1\n- 330 TRIFLUOROMETHANESULFONIC ACID A, G3, E2\n- 331 TRIISOPROPANOLAMINE LAURYL ETHER SULFATE A, E1, S1\n- 332 TROLAMINE A, G3, E1, S1\n- 333 TURPENTINE (mineral) A, G3\n- 334 TURPENTINE OIL (vegetable) A, G3, E2\n- 335 VINYL ACETATE MONOMER A, R1\n- 336 WHITE SPIRIT A, G3\n- 337 XYLENE—above 75% A, G3, E1, R1, S1\n- 338 XYLENE—75% and below A, G3\n- 339 XYLENE—in pressurised spray packs A, G6, E1, S1\n- 340 XYLENOLS in pressurised spray packs A, E1\n- 341 ZINC CHLORIDE A, G3, E2, S1\n- 342 ZINC SULFATE A, G3, E2, S1\n\nAppendix F—Warning statements and general safety directions for poisons\n\n \n\n \n\nNote: See sections 29 and 30, subsection 33(2) and section 42.\n\n1  Warning statements\n\n  For the purposes of the table in clause 4 of this Appendix and the table in clause 2 of Appendix L, the item number of an item of the following table represents the warning statement specified in column 1 of the item.\n\nNote: See section 30.\n\n \n\n- Warning statements\n- Item Column 1 Warning statement\n- 1 Highly corrosive.\n- 2 Corrosive.\n- 3 Corrosive liquid.\n- 4 Strongly alkaline.\n- 5 Irritant.\n- 6 May cause cancer.\n- 7 WARNING – Causes birth defects.\n- 8 WARNING – May be fatal to children.\n- 9 Can be fatal to children if sucked or swallowed.\n- 10 May produce severe burns.\n- 11 WARNING – Vapour may be harmful.\n- 12 Vapour is harmful to health on prolonged exposure.\n- 13 May be fatal if inhaled, swallowed or absorbed through skin.\n- 14 Dust will irritate and burn eyes, nose and skin.\n- 15 Liquid will cause burns.\n- 16 Forms dangerous gas near radiators or naked flames.\n- 17 Contact with eyes even for short periods can cause blindness.\n- 18 Product will irritate the eyes, nose, throat and skin.\n- 19 WARNING – Skin contact may be dangerous. Take every precaution to avoid contact – wash off after spillage and after use.\n- 20 May give off dangerous gas if mixed with other products.\n- 21 WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.\n- 22 Highly reactive oxidising chlorine compound.\n- 23 May cause fire or explosion.\n- 24 For external washing only. Rinse skin thoroughly after use.\n- 25 Do not use on broken skin. Wash hands thoroughly after use.\n- 26 (Powder) (and) (concentrated solutions) are dangerous if swallowed.\n- 27 Not for therapeutic use.\n- 28 (Over) (Repeated) exposure may cause sensitisation.\n- 29 If congestion persists, consult your doctor or pharmacist.\n- 30 WARNING – Do not use on face or on anal or genital areas.\n- 31 WARNING – Do not use on face or on anal or genital areas except on doctor’s advice.\n- 32 This preparation should be part of an overall treatment plan regularly assessed with your doctor.\n- 33 Do not take for periods longer than four weeks except on medical advice.\n- 34 WARNING – This medication may be dangerous when used in large amounts or for a long time (period).\n- 35 CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.orCAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.\n- 36 For use under medical supervision only.\n- 37 Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.\n- 38 CAUTION – Do not use for children under 2 years unless a doctor has told you to.\n- 39 This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.\n- 40 This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.\n- 41 Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice.\n- 42 WARNING – Overuse may stain the skin or mouth.\n- 43 Use of this product is not necessary in areas supplied with fluoridated water.\n- 44 WARNING – May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.\n- 45 WARNING – If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice.\n- 46 WARNING – Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).\n- 47 WARNING – This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.\n- 48 WARNING – This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.\n- 49 WARNING – Do not mix with other medication except on veterinarian’s advice.\n- 50 Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.\n- 51 Irritant to skin, eyes, mucous membranes and upper respiratory tract.\n- 52 Breathing vapour or spray mist is harmful and may cause an asthma‑like reaction.\n- 53 CAUTION – (Name of substance) should not be used by pregnant women.\n- 54 Seek medical advice before first course of treatment.\n- 55 Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.\n- 56 WARNING – Can cause elevated blood pressure and interact adversely with other medication.\n- 57 Not to be applied to infants under 12 months of age unless on doctor’s advice.\n- 58 Highly reactive oxidising bromine and chlorine compound.\n- 59 May cause allergy.\n- 60 Do not mix with detergents or other chemicals.\n- 61 WARNING ‑ Can react with other medicines. Ask your doctor or pharmacist before taking.\n- 62 Do not use if pregnant.\n- 63 See a doctor if you are pregnant or diabetic.\n- 64 See a doctor (or) (dentist) if no better after (Insert number of days as per approved Product Information) days.\n- 65 If getting better, keep using for (Insert number of days as per approved Product Information) days.\n- 66 See a doctor if problem returns.\n- 67 Do not use if pregnant or likely to become pregnant.\n- 68 If symptoms persist beyond 5 days consult a doctor (or) (dentist).\n- 69 If symptoms recur within two weeks of completing the course, consult a doctor.\n- 70 Use only under medical supervision if you are taking other medicines.\n- 71 Do not use during the last three months of pregnancy.\n- 72 Do not use in the eyes.\n- 73 Do not use for acne.\n- 74 Do not use under waterproof bandages unless a doctor has told you to.\n- 75 Do not use for more than 7 days unless a doctor has told you to.\n- 76 Do not become pregnant during use or within (Insert number of months as per approved Product Information) month(s) of stopping treatment.\n- 77 WARNING ‑ May cause birth defects.\n- 78 Attacks skin and eyes.\n- 79 Will irritate eyes.\n- 80 WARNING: Do not attempt to refill burner while it is in use or still warm; it could lead to serious burn injury.\n- 81 (Intentionally blank)\n- 82 (Intentionally blank)\n- 83 This paint is dangerous to health, even when dry.For industrial use only.Do not use on toys or furniture.Do not use on, in or around the home.\n- 84 Breathing the vapour is dangerous.Provide adequate ventilation during application.Do not use in the presence of a naked flame.Do not smoke.\n- 85 This paint contains lead and is dangerous to health, even when dry.For industrial use only.Do not use on toys or furniture.Do not use for painting any building or fixed structure.Do not use where contact with food or drinking water is possible.\n- 86 This tinter contains lead.Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.\n- 87 (Insert brand name) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.\n- 88 This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.\n- 89 Application to skin may increase sensitivity to sunlight.\n- 90 This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.\n- 91 CAUTION – Total iodine intake may exceed recommended level when taking this preparation.\n- 92 WARNING – Contains iodine ‑ do not take when pregnant except on physician’s advice.\n- 93 Causes severe burns, which are not likely to be immediately painful or visible.\n- 94 WARNING – Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.\n- 95 CAUTION – Do not use for children under 12 years unless a doctor has told you to.\n- 96 CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.\n- 97 Adults: Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor.\n- 98 Children and adolescents: Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.\n- 99 If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.\n- 100 Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.\n- 101 Don’t use [this product/name of the product]:If you have a stomach ulcer.In the last 3 months of pregnancy. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]If you are allergic to (name of substance) or anti‑inflammatory medicines.\n- 102 Unless a doctor has told you to, don’t use [this product/name of the product]:For more than a few days at a time.With other medicines containing aspirin or other anti‑inflammatory medicines.If you have asthma.In children under 12 years of age.In children 12‑16 years of age with or recovering from chicken pox, influenza or fever.If you are pregnant.\n- 103 See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.]\n- 104 Unless a doctor has told you to, don’t use [this product/name of the product]:For more than a few days at a time.With other medicines containing (name of substance) or other anti‑inflammatory medicines.If you have asthma.If you are pregnant. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]\n- 105 Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.\n- 106 Contains formaldehyde.\n- 107 Not recommended for children under twelve years of age.\n- 108 Breathing of solder fumes is harmful and may cause asthma or sensitisation.\n- 109 See your healthcare provider if you consider that you may be at risk of a Sexually Transmitted Infection (STI).\n- 110 See a doctor if you plan to become pregnant, or are breastfeeding or plan to breastfeed.\n- 111 Do not use if breastfeeding or planning to breastfeed.\n- 112 WARNING – May cause irreversible nerve damage if inhaled.\n\n2  Safety directions—general\n\n  For the purposes of the table in clause 4, the item number of an item of the following table represents the safety direction specified in column 1 of the item.\n\nNote: See section 29.\n\n \n\n- Safety directions\n- Item Column 1 Safety direction\n- 1 Avoid contact with eyes.\n- 2 Attacks eyes ‑ protect eyes when using.\n- 3 Wear eye protection when mixing or using.\n- 4 Avoid contact with skin.\n- 5 Wear protective gloves when mixing or using.\n- 6 Wash hands after use.\n- 7 Wash hands thoroughly after use.\n- 8 Avoid breathing dust (or) vapour (or) spray mist.\n- 9 Use only in well ventilated area.\n- 10 Ensure adequate ventilation when using.\n- 11 No smoking.\n- 12 Do not allow product to come into contact with other chemicals, especially acids.\n- 13 Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.\n- 14 Do not allow to get damp.\n- 15 Store under cover in a dry, clean, cool, well ventilated place away from sunlight.\n- 16 Store and transport in an upright container.\n- 17 Do not mix with other chemicals.\n- 18 Do not mix with different types of chlorinating chemicals.\n- 19 Use clean containers for dispensing.\n- 20 Mix with water only.\n- 21 Do not add water to product ‑ add product to water, but in case of fire drench with water.\n- 22 In case of spillage flush with large quantities of water.\n- 23 Keep away from heat, sparks and naked flames.\n- 24 Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.\n- 25 Avoid contact with food.\n- 26 Avoid contact with clothing.\n- 27 Wear a positive‑pressure air‑supplied full‑face respirator whilst spraying and until spray mist has been effectively dispersed.\n- 28 Do not mix with hot water.\n- 29 Obtain a supply of calcium gluconate gel.\n- 30 (Intentionally blank)\n- 31 Do not use on broken skin.\n- 32 Do not use under occlusive dressing.\n- 33 Mix strictly according to instructions.\n- 34 May cause fire if it comes into contact with other chemicals, paper or other flammable materials.\n- 35 Wash gloves thoroughly, immediately after use.\n- 36 Protect cuticles with grease or oil.\n- 37 Avoid breathing solder fumes.\n- 38 Do not intentionally inhale contents.\n\n3  Poisons information centre contact information in statements\n\n  A statement required for a poison that includes a reference to a Poisons Information Centre must include:\n\n (a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and\n\n (b) immediately following the reference to a Poisons Information Centre:\n\n (i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or\n\n (ii) the telephone number for another poisons information centre:\n\n (A) that is attended by adequately trained staff for 24 hour emergency poisons information; and\n\n (B) calls to which are logged and submitted for incorporation into the official collection of poisoning data.\n\nNote: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766.\n\n4  Poisons that must be labelled with warning statements and safety directions\n\n (1) For the purposes of subsections 29(1) and 30(1), and subject to subclauses (2) and (3), the following are required for a poison specified in column 1 of an item of the following table:\n\n (a) the warning statement represented by each item number specified in column 2 of the item;\n\n (b) the safety direction represented by each item number specified in column 3 of the item.\n\n (2) A warning statement or safety direction required for a poison must:\n\n (a) be completed or modified for its use in relation to that poison if the statement or direction indicates that such completion is required or such modification is appropriate; and\n\n (b) if the statement includes a reference to a Poisons Information Centre—comply with clause 3.\n\nNote: For paragraph (a), for example:\n\n(a) a statement or direction may require completion by including the name of the poison; and\n\n(b) a statement or direction may indicate that modification is appropriate by including different options for the text, or by stating that certain text is not needed in certain circumstances.\n\n (3) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate).\n\n- Poisons that must be labelled with warning statements and safety directions\n- Item Column 1 Poison Column 2 Warning statement item number Column 3 Safety direction item number\n- 1 ACETIC ACID in concentrations of 80% or more except when included in Schedule 2 2 1, 4, 8\n- 2 ACETIC ANHYDRIDE 2 1, 4, 8\n- 3 ACETONE in concentrations greater than 75% 1, 4, 8\n- 4 ACITRETIN—for oral use 7, 62, 76\n- 5 ACITRETIN—for topical use 62, 77\n- 6 ADAPALENE for topical use 62, 77\n- 7 ALCLOMETASONE when included in Schedule 3 38, 72, 73, 74, 75\n- 8 ALKALINE SALTS 4 1, 4\n- 9 AMBRISENTAN 7, 62, 76\n- 10 AMINES used as curing agents for epoxy resins 1, 3, 4, 5, 8\n- 11 2‑AMINO‑6‑CHLORO‑4‑NITROPHENOL 28\n- 12 4‑AMINO‑m‑CRESOL 28\n- 13 2‑AMINO‑5‑ETHYLPHENOL 21\n- 14 4‑AMINO‑2‑HYDROXYTOLUENE 28\n- 15 4‑AMINO‑3‑NITROPHENOL 28\n- 16 2,2'‑[(4‑AMINO‑3‑NITROPHENYL)IMINO] BISETHANOL 28\n- 17 m‑AMINOPHENOL 28 4, 8\n- 18 p‑AMINOPHENOL 28\n- 19 AMMONIA/AMMONIUM HYDROXIDE in concentrations greater than 20% ammonia except in smelling salts 4 1, 4, 8\n- 20 AMMONIUM PERSULFATE 5, 21, 25 1, 5, 23, 33, 34\n- 21 ANHYDRIDES, organic acid, for use as curing agents for epoxy resins 1, 3, 4, 5, 8\n- 22 ANILINE 13 1, 4, 8\n- 23 ANTIHISTAMINES not separately specified in this Appendix except the following:(a) dermal, ocular, parenteral and paediatric preparations;(b) oral preparations of astemizole, azelastine, bilastine, cetirizine, desloratadine, fexofenadine, loratadine, or terfenadine;(c) nasal preparations of azelastine or olopatadine;(d) preparations for the treatment of animals 39 or 40\n- 24 ARBUTIN when included in Schedule 6 45 1, 4\n- 25 AROMATIC EXTRACT OILS 1, 3, 4, 5, 6\n- 26 ASPIRIN—for inhibition of platelet aggregation 36\n- 27 ASPIRIN—in sustained release preparations containing 650 mg or more of aspirin 36\n- 28 ASPIRIN—in other preparations 101, 102, 103\n- 29 ASTEMIZOLE 61\n- 30 ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis 63, 64, 69, 75, 109, 110\n- 31 ASTODRIMER SODIUM—for the prevention of recurrent bacterial vaginosis 63, 75, 109, 110\n- 32 AZADIRACHTA INDICA including its extracts and derivatives when included in Schedule 6 67\n- 33 AZOCYCLOTIN 48\n- 34 AZO DYES (derivatives by diazotisation) 6 5\n- 35 BASIC RED 76 5\n- 36 BENOMYL 46\n- 37 BENZENE 12 1, 4, 9\n- 38 1,2‑BENZENEDIOL (Catechol) 51, 59 1, 4, 8\n- 39 BENZOYL PEROXIDE—when included in Schedule 2 55\n- 40 BENZOYL PEROXIDE—when included in Schedule 5 1, 4, 8\n- 41 BERGAMOT OIL 89\n- 42 BERYLLIUM 1, 4, 8\n- 43 BEXAROTENE—for human use 7, 62, 76\n- 44 BEXAROTENE—for topical use 62, 77\n- 45 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5 1, 4\n- 46 BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7 1, 17, 93 1, 3, 4, 5, 8, 29, 35\n- 47 1,3‑BIS(2,4‑DIAMINOPHENOXY)PROPANE 28, 79 1\n- 48 BIS‑ISOBUTYL PEG/PPG‑20/35/AMODIMETICONE COPOLYMER 1\n- 49 BITHIONOL for the treatment of animals 1, 4, 8\n- 50 BORIC ACID when used in Schedule 5 25, 26\n- 51 BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 5 2 1, 4\n- 52 BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 6 or 7 1, 17, 93 1, 3, 4, 5, 8, 29, 35\n- 53 BOSENTAN 7, 62, 76\n- 54 BROMOFORM 1, 4, 8\n- 55 2‑BUTOXY‑2'‑THIOCYANODIETHYL ETHER 1, 4, 8\n- 56 2‑BUTOXYETHANOL and its acetates 1, 4, 8\n- 57 n‑BUTYL ALCOHOL 5 2, 4, 8\n- 58 CAMPHOR—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents 9\n- 59 CAMPHOR—in other forms 9 1\n- 60 CANNABIDIOL when included in Schedule 3 67, 111\n- 61 CARBAMIDE PEROXIDE—more than 9% up to 30% 5 1\n- 62 CARBAMIDE PEROXIDE—more than 30% up to 60% 5 2\n- 63 CARBAMIDE PEROXIDE—more than 60% 2 2, 4\n- 64 CARBON DISULFIDE 12 1, 4, 8, 9, 23\n- 65 CARBON TETRACHLORIDE 12 1, 4, 8, 9\n- 66 CASSIA OIL 4\n- 67 CHLORINATING COMPOUNDS—in household cleaning or bleaching preparations 20\n- 68 CHLORINATING COMPOUNDS—in preparations containing less than 10% of available chlorine 11 1, 4, 10\n- 69 CHLORINATING COMPOUNDS—in liquid preparations containing 10% or more of available chlorine 3, 18 1, 4, 6, 8, 10, 15, 16, 17, 18, 19, 20, 22, 26\n- 70 CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine 10, 18, 22, 23 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26\n- 71 CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code 10, 18, 22 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 26\n- 72 CHLORINATING COMPOUNDS—in compressed block or tablets containing 10% or more of available chlorine except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid 10, 22, 23 12, 13, 14, 15, 17, 18, 19, 21\n- 73 CHLORINATING COMPOUNDS—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid 10, 22 12, 13, 14, 15, 17, 18, 19, 21\n- 74 CHLOROACETAMIDE 28 4\n- 75 2‑CHLORO‑6‑(ETHYLAMINO)‑4‑NITROPHENOL 28 4\n- 76 CHLOROFORM when included in Schedule 6 1, 4, 8\n- 77 alpha‑CHLOROHYDRIN 13, 51 1, 4, 8, 9\n- 78 CHROMATES (including dichromates) of alkali metals or ammonia 1, 4, 8\n- 79 CHROMIUM TRIOXIDE 2, 14, 15, 23 1, 4, 8, 13\n- 80 CIMETIDINE when included in Schedule 3 70, 96\n- 81 CINNAMON BARK OIL 4\n- 82 CLOBETASONE when included in Schedule 3 72, 73, 74, 75, 95\n- 83 CLOTRIMAZOLE in vaginal preparations when included in Schedule 3 54, 63, 64, 66\n- 84 CLOVE OIL 1\n- 85 CYANIDES when included in Schedule 7 13 4, 8\n- 86 CYANURIC ACID 1, 4, 8\n- 87 CYCLOHEXANONE PEROXIDE 1, 4, 8\n- 88 CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) 2, 10, 78 1, 4, 5, 35\n- 89 CYCTEAMINE 1\n- 90 1‑DEOXY‑1‑(METHYLAMINO)‑d‑GLUCITOL N‑COCO ACYL DERIVATIVES 79 1\n- 91 4,4‑DIAMINODIPHENYLMETHANE (methylene dianiline) 1, 4, 8\n- 92 2,4‑DIAMINOPHENOXYETHANOL 28, 79 1, 4\n- 93 o‑DICHLOROBENZENE 1, 4, 8\n- 94 para‑DICHLOROBENZENE 1, 4\n- 95 DICHLOROETHYLENE 1, 4, 8\n- 96 DICHLOEOETHYL ETHER 1, 4, 8\n- 97 DICHLOROISOCYANURATES—in household cleaning or bleaching preparations 20\n- 98 DICHLOROISOCYANURATES—in preparations containing less than 10% of available chlorine 11 1, 4, 10\n- 99 DICHLOROISOCYANURATES—in liquid preparations containing 10% or more of available chlorine 3, 18 1, 4, 6, 8, 10,15, 16, 17, 18, 19, 20, 22, 26\n- 100 DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine 10, 18, 22, 23 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26\n- 101 DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code 10, 18, 22 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26\n- 102 DICHLOROISOCYANURATES—in anti‑bacterial tablets containing 2.5 g or less of sodium dichloroisocyanurate 60\n- 103 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine except in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only 10, 22, 23 12, 13, 14, 15, 17, 18, 19, 21\n- 104 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code except in preparations containing 21 g less of sodium dichloroisocyanurate for use in toilet cisterns only 10, 22 12, 13, 14, 15, 17, 18, 19, 21\n- 105 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage 10, 22, 23 12, 13, 14, 15, 17, 18, 21\n- 106 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use 5 1, 4, 7, 12\n- 107 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage 10, 22 12, 13, 14, 15, 17, 18, 21\n- 108 DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use 5 1, 4, 7, 12\n- 109 DICHLOROMETHANE (methylene chloride)—in paint or lacquer removers 12, 16 1, 4, 8, 11\n- 110 DICHLOROMETHANE (methylene chloride)—other than in paint or lacquer removers 1, 4, 8, 25\n- 111 DICLOFENAC 101, 104\n- 112 DIENESTROL 67\n- 113 DIETHANOLAMINE—when included in Schedule 5 5 1, 4\n- 114 DIETHANOLAMINE—when included in Schedule 6 2, 11, 18 1, 4, 8\n- 115 DIETHYLTOLUAMIDE for human use 44\n- 116 DIETHYLENE GLYCOL MONOBUTYL ETHER 5 1, 4, 8, 9\n- 117 5,6‑DIHYDROXYINDOLINE 21, 28\n- 118 2,6‑DIMETHOXY‑3,5‑PYRIDINEDIAMINE 28\n- 119 DIMETHYLFORMAMIDE 1, 4, 8\n- 120 4,4‑DIMETHYL‑1‑CYCLOHEXENE‑1‑PROPANAL 5, 28 1, 2\n- 121 3,7‑DIMETHYL‑2,6‑OCTADIEN‑1‑OL 5 1, 4\n- 122 DIMETHYL SULFATE 2 1, 4, 8\n- 123 DIMETHYL SULFOXIDE—when not packed and labelled for therapeutic use 27 1, 4, 5, 8\n- 124 DIMETHYL SULFOXIDE—when packed and labelled for the treatment of animals 49 1, 4, 5, 8\n- 125 DINITROCRESOLS (and their homologues) except when for therapeutic use 1, 4, 8\n- 126 DINITROPHENOLS (and their homologues) except when for therapeutic use 1, 4, 8\n- 127 DINOCAP 47\n- 128 DIOXANE 1, 4, 8\n- 129 DIPHENOXYLATE when included in Schedule 3 39 or 40, 41\n- 130 DISPERSE YELLOW 3 28 4\n- 131 ECONAZOLE in vaginal preparations when included in Schedule 3 54, 63, 64, 66\n- 132 ENZALUTAMIDE 7, 67, 87\n- 133 EPHEDRINE in nasal preparations for topical use 29\n- 134 EPICHLOROHYDRIN 2 1, 4, 8\n- 135 EPOXY RESINS, liquid 1, 3, 4, 5, 8\n- 136 ETHER when included in Schedule 5 or 6 1, 4, 8\n- 137 2‑ETHOXYETHANOL 77 1, 4, 8\n- 138 ETHOXYETHYLMERCURIC CHLORIDE 1, 4\n- 139 ETHYL BROMIDE 1, 4, 8\n- 140 ETHYLENE CHLOROHYDRIN 1, 4, 8\n- 141 ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates except when separately specified 1, 4, 8\n- 142 ETHYLENE OXIDE 1, 4, 8\n- 143 ETHYLHEXANEDIOL 79 1\n- 144 2‑ETHYLHEXANOIC ACID 53\n- 145 ETHYLMERCURIC CHLORIDE 1, 4\n- 146 ETHYL METHACRYLATE 28 4, 9, 23\n- 147 ETRETINATE 7, 62, 76\n- 148 EUGENOL 1\n- 149 FAMOTIDINE when included in Schedule 2 96\n- 150 FENTEROL in metered aerosols 32\n- 151 FLUCONAZOLE in oral preparations when included in Schedule 3 64\n- 152 FLUORIDES (including silicofluorides) when included in Schedule 5 or 6 except when separately specified 1, 4\n- 153 FORMALDEHYDE—in nail hardener cosmetics 106 1, 4, 8, 36\n- 154 FORMALDEHYDE—in other preparations 106 1, 4, 8\n- 155 FORMIC ACID 1, 4, 8\n- 156 FURFURAL 5 1, 4\n- 157 Glazing preparations containing LEAD COMPOUNDS 50\n- 158 GLUTARAL except when included in Schedule 2—25% or less 5, 59 1, 4, 5\n- 159 GLUTARAL except when included in Schedule 2—more than 25% 3, 59 1, 4, 5, 8\n- 160 GLYCOLIC ACID 79 1, 5, 6, 31\n- 161 HC VIOLET 1 28\n- 162 HEXACHLOROPHENE in preparations for skin cleansing purposes containing 3% or less of hexachlorophene 24\n- 163 HEXYLOXYETHANOL 2 1, 4, 8\n- 164 HYDRAZINE 1, 4, 8\n- 165 HYDROCHLORIC ACID—30% or less of HCl 1, 4\n- 166 HYDROCHLORIC ACID—more than 30% of HCl 1, 4, 8\n- 167 HYDROCORTISONE—for dermal use when included in Schedule 2 or 3 38, 72, 73, 74, 75\n- 168 HYDROCORTISONE—for topical rectal use when included in Schedule 2 or 3 38, 75\n- 169 HYDROCYANIC ACID when included in Schedule 7 13 4, 8\n- 170 HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid)—when included in Schedule 5 2 1, 4\n- 171 HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid)—when included in Schedule 6 or 7 1, 17, 93 1, 3, 4, 5, 8, 29, 35\n- 172 HYDROGEN PEROXIDE—more than 3% up to 10% 5 1\n- 173 HYDROGEN PEROXIDE—more than 10% up to 20% 5 2\n- 174 HYDROGEN PEROXIDE—more than 20% 2 2, 4\n- 175 HYDROQUINONE—when included in Schedule 2 45\n- 176 HYDROQUINONE—except when included in Schedule 2 or 4 1, 4\n- 177 HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid)—when included in Schedule 5 2 1, 4\n- 178 HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid)—when included in Schedule 6 or 7 1, 17, 93 1, 3, 4, 5, 8, 29, 35\n- 179 2‑HYDROXYETHYL METHACRYLATE 28 4\n- 180 HYDROXYETHYL‑3,4‑METHYLENEDIOXYANILINE 28\n- 181 IBUPROFEN 101, 104\n- 182 IODINE—more than 20% 1, 4, 8\n- 183 IODINE—in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose 91, 92\n- 184 IPRATROPIUM BROMIDE in metered aerosols 32\n- 185 ISOCYANATES (free organic)—when in paint 28, 52 1, 5, 8, 10, 27\n- 186 ISOCYANATES (free organic)—other than in paint 28, 52 1, 4, 8\n- 187 ISOEUGENOL 19, 28, 79 1, 4\n- 188 ISOPRENALINE in metered aerosols 32\n- 189 ISOTRETINOIN—for human oral use 7, 62, 76\n- 190 ISOTRETINOIN—for topical use 62, 77\n- 191 LEAD COMPOUNDS—in hair cosmetics 25\n- 192 LEAD COMPOUNDS—when included in Schedule 6 preparations that are not hair cosmetics 1, 4, 8\n- 193 LEFLUNOMIDE 7, 62, 87\n- 194 LEMON OIL 89\n- 195 LENALIDOMIDE 7, 62, 76\n- 196 LEVOCABASTINE—in eye or nasal preparations containing 0.5 mg/mL or less of levocabastine 62\n- 197 LEVOCABASTINE—in other preparations 62 and either 39 or 40\n- 198 LIME OIL 89\n- 199 LOPERAMIDE when included in Schedule 2 41\n- 200 MAGNESIUM CHLORATE 1, 4\n- 201 MEFENAMIC ACID 101, 104\n- 202 MERCAPTOACETIC ACID 5, 28 1, 31\n- 203 MERCURIC THIOCYANATE 1, 4\n- 204 METACRESOLSULPHONIC ACID and formaldehyde condensation product for the treatment of animals 1, 4\n- 205 METHANOL except in methylated spirit 1, 4, 8\n- 206 METHOXAMINE in nasal preparations for topical use 29\n- 207 2‑METHOXYETHANOL 77 1, 4, 8\n- 208 METHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners” 80\n- 209 p‑METHYLAMINOPHENOL 28\n- 210 METHYL CHLORIDE 1, 4, 8\n- 211 METHYL ETHYL KETONE 5 1, 4, 8\n- 212 METHYL ETHYL KETONE OXIME 5, 28 1, 4\n- 213 METHYL ETHYL KETONE PEROXIDE 2 2, 3, 4, 6\n- 214 METHYL ISOAMYL KETONE 1, 4, 8\n- 215 METHYL ISOBUTYL KETONE 1, 4, 8\n- 216 METHYL ISOTHIOCYANATE 5, 12 1, 4, 8\n- 217 METHYL METHACRYLATE 28 4, 9, 23\n- 218 METHYLCHLOROISOTHIAZOLINONE 28\n- 219 METHYLDIBROMO GLUTARONITRILE 28 1, 4, 7\n- 220 METHYLENE BISTHIOCYANATE 1, 4\n- 221 METHYLEUGENOL 1, 6\n- 222 METHYLISOTHIAZOLINONE 28\n- 223 METHYLNORBORNYLPYRIDINE 59\n- 224 2‑METHYLRESORCINOL 1\n- 225 1‑(BETA‑METHYL SULPHONAMIDOETHYL)‑ 2‑AMINO‑3‑N,N‑DIETHYLAMINOBENZENE 1, 4, 8\n- 226 MICONAZOLE in vaginal preparations when included in Schedule 3 54, 63, 64, 66\n- 227 MISOPROSTOL 53\n- 228 MONOETHANOLAMINE when included in Schedule 5 5 1, 4\n- 229 MONOETHANOLAMINE when included in Schedule 6 2, 11, 18 1, 4, 8\n- 230 NAPHAZOLINE in nasal preparations for topical use 29\n- 231 NAPHTHALENE—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents 9, 105\n- 232 NAPHTHALENE—in other forms 9, 105 1\n- 233 1,5‑NAPHTHALENEDIOL 28 1\n- 234 2,7‑NAPHTHALENEDIOL 28 1, 3\n- 235 1‑NAPHTHOL 28 1\n- 236 NAPROXEN 101, 104\n- 237 NICOTINE except when in tobacco 1, 4\n- 238 NITRIC ACID—75% or less HNO3 2 1, 4\n- 239 NITRIC ACID—more than 75% HNO3 2 1, 4, 8\n- 240 NITROBENZENE 1, 4, 8\n- 241 3‑NITRO‑p‑HYDROXYETHYLAMINOPHENOL 28\n- 242 NITROPHENOLS 1, 4\n- 243 NITROPRUSSIDES in aerosols 84 8\n- 244 NITROUS OXIDE 112 38\n- 245 NIZATIDINE when included in Schedule 2 96\n- 246 NORADRENALINE in metered aerosols 32\n- 247 NYSTATIN in vaginal preparations when included in Schedule 3 54, 63, 64, 65, 66\n- 248 ORANGE OIL (bitter) 89\n- 249 ORCIPRENALINE in metered aerosols 32\n- 250 OXALATES, metallic 4, 8\n- 251 OXALIC ACID 2 4, 8\n- 252 OXYMETAZOLINE in nasal preparations for topical use 29\n- 253 OXYQUINOLINE (including salts and derivatives) when prepared for internal use 33\n- 254 PAINT—first group paints 83\n- 255 PAINT—second group paints 84\n- 256 PALOVAROTENE 7, 62, 76, 111\n- 257 PARACETAMOL 97 and/or 98, 99, 100\n- 258 PENTACHLOROPHENOL 1, 4, 8\n- 259 PERACETIC ACID 2 1, 4, 8\n- 260 PERMANGANATES 2 24\n- 261 2‑PHENOXYETHANOL 5 1\n- 262 PHENOL and any other homologue of phenol 1, 4\n- 263 PHENOL when included in Schedule 6 3, 51 2, 4, 8\n- 264 PHENOLS 5\n- 265 PHENOXYMETHYL OXIRANE 12, 28, 51 1, 3, 4, 5, 7, 8, 9\n- 266 PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in hair dyes 21\n- 267 PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in preparations other than hair dyes 28 1, 4, 8\n- 268 PHENYL METHYL PYRAZOLONE 28 4\n- 269 PHENYLEPHRINE in nasal preparations for topical use 29\n- 270 POMALIDOMIDE 7, 62, 76\n- 271 N,N‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,5‑DIMETHANAMINE 5, 28 1, 4, 5, 10\n- 272 o‑PHENYLPHENOL except when in antiseptics 1, 4\n- 273 PHENYLPROPANOLAMINE 56\n- 274 PHENYTOIN in pastes for the treatment of horses 9\n- 275 PHOSPHONIC ACID 1, 4\n- 276 PHOSPHORIC ACID 1, 4\n- 277 PHOSPHORUS (yellow) 2 1, 4\n- 278 o‑PHTHALALDEHYDE—when included in Schedule 5 51, 52, 59 1, 4, 5, 8, 10\n- 279 o‑PHTHALALDEHYDE—when included in Schedule 6 51, 52, 59 2, 4, 5, 8, 10\n- 280 PICRAMIC ACID including its salts (excluding other derivatives) 28 5\n- 281 PICRIC ACID (more than 20%) 1, 4\n- 282 PODOPHYLLIN—in preparations specifically for use on anal or genital area 36\n- 283 PODOPHYLLIN—in other liquid preparations when included in Schedule 2 or 3 31\n- 284 PODOPHYLLIN—in other solid or semi‑solid preparations when included in Schedule 2 30\n- 285 PODOPHYLLOTOXIN—in preparations specifically for use on anal or genital area 36\n- 286 PODOPHYLLOTOXIN—in other liquid preparations when included in Schedule 2 or 3 31\n- 287 PODOPHYLLOTOXIN—in other solid or semi‑solid preparations when included in Schedule 2 30\n- 288 POLIHEXANIDE 28 1, 4, 8\n- 289 POLYETHANOXY (15) TALLOW AMINE 1, 4\n- 290 POLY(OXY‑1,2‑ETHANEDIYL), Α ‑[2‑[(2‑HYDROXYETHYL)AMINO] ‑2‑OXOETHYL]‑ Α ‑HYDROXY‑,MONO‑C13‑15 ‑ALKYL ETHERS 5, 88 1, 5\n- 291 POTASSIUM HYDROXIDE—in preparations containing 0.5% or less of potassium hydroxide 5 1, 4, 6\n- 292 POTASSIUM HYDROXIDE—in solid preparations containing more than 0.5% of potassium hydroxide 2, 10, 78 3, 5, 28\n- 293 POTASSIUM HYDROXIDE—in liquid preparations containing more than 0.5% of potassium hydroxide 2, 10, 78 3, 5\n- 294 POTASSIUM PERSULFATE 5, 21, 25 1, 5, 23, 33, 34\n- 295 POTASSIUM SULFIDE 2 1, 4\n- 296 PROPIONIC ACID when included in Schedule 6 2 1, 4\n- 297 n‑PROPYL ALCOHOL 5 1, 9\n- 298 QUININE 28\n- 299 QUINOLINE 79 1, 4\n- 300 RANITIDINE when included in Schedule 2 96\n- 301 RESORCINOL 19, 28, 79 1, 3, 4\n- 302 ROSIN 108 37\n- 303 SAFROLE—in preparations for therapeutic use 1\n- 304 SAFROLE—other than for therapeutic use 1, 4\n- 305 SALBUTAMOL in metered aerosols or in dry powder formulations 32\n- 306 SALICYLAMIDE 34 or 35\n- 307 SASSAFRAS OIL—in preparations for therapeutic use 1\n- 308 SASSAFRAS OIL—other than for therapeutic use 1, 4\n- 309 SELENIUM COMPOUNDS except when for therapeutic use (human or animal) 1, 4, 8\n- 310 SILVER in smoking deterrents 42\n- 311 SITAXENTAN 7, 62, 76\n- 312 SODIUM ALUMINATE 2 1, 4\n- 313 SODIUM CHLORATE 1, 4\n- 314 SODIUM DODECYLBENZENE SULFONATE 79 1\n- 315 SODIUM FLUORIDE in preparations for human ingestion when included in Schedule 2 43\n- 316 SODIUM HYDROGEN SULFATE 1, 4, 8\n- 317 SODIUM HYDROSULFITE (more than 50%) 5, 26 1, 4, 8\n- 318 SODIUM HYDROXIDE—in preparations containing 0.5% or less of sodium hydroxide 5 1, 4, 6\n- 319 SODIUM HYDROXIDE—in solid preparations containing more than 0.5% of sodium hydroxide 2, 10, 78 3, 5, 28\n- 320 SODIUM HYDROXIDE—in liquid preparations containing more than 0.5% of sodium hydroxide 2, 10, 78 3, 5\n- 321 SODIUM LAURETH‑6 CARBOXYLATE 79 1\n- 322 SODIUM METABISULPHITE (more than 50%) 5, 26 1, 4\n- 323 SODIUM NITRITE in pickling or curing salts 94\n- 324 SODIUM PERSULFATE 5, 21, 25 1, 5, 23, 33, 34\n- 325 SODIUM SULFIDE 2 1, 4\n- 326 STYRENE 1, 4, 8\n- 327 SULFAMIC ACID 2 1, 4\n- 328 SULFURIC ACID 2 1, 4\n- 329 SYMPHYTUM SPP. (Comfrey) when included in Schedule 5 31, 32\n- 330 TAZAROTENE for topical use 77, 62\n- 331 TERBUTALINE in metered aerosols or in dry powder formulations 32\n- 332 TERFENADINE 61\n- 333 TERIFLUNOMIDE 7, 62, 87\n- 334 TERPENES, chlorinated 1, 4, 8\n- 335 TETRACHLOROETHANE 12 8\n- 336 TETRACHLOROETHYLENE when included in Schedule 5 or 6 12, 16 1, 4, 8, 11\n- 337 TETRYZOLINE in nasal preparations for topical use 29\n- 338 THALIDOMIDE 7, 62, 76\n- 339 THIOUREA 1, 4\n- 340 TOLUENE 1, 4, 8\n- 341 TOLUENEDIAMINES—in hair dyes 21\n- 342 TOLUENEDIAMINES—in preparations other than hair dyes 1, 4, 8\n- 343 TRAMAZOLINE in nasal preparations for topical use 29\n- 344 TRETINOIN—for human oral use 7, 62, 76\n- 345 TRETINOIN—for topical use 62, 77\n- 346 TRIAMCINOLONE when in topical preparations for the treatment of mouth ulcers 64 or 68\n- 347 TRICHLOROACETIC ACID except when for therapeutic use 2 1, 4\n- 348 1,1,1‑TRICHLOROETHANE 8, 9\n- 349 TRICHLOROETHYLENE except when for therapeutic use 12 1, 4, 5, 8, 9\n- 350 TRICHLOROPHENOL 1, 4, 8\n- 351 TRIETHYL PHOSPHATE 1, 4, 8\n- 352 TRIFLUOROMETHANESULFONIC ACID—more than 10% 1, 17 1, 4, 8\n- 353 TRIFLUOROMETHANESULFONIC ACID—10% or less 1, 4, 8\n- 354 TRIISOPROPANOLAMINE LAURYL ETHER SULFATE 1, 4, 6\n- 355 3,6,9‑TRIOXAUNDECANEDIOIC ACID 5 1\n- 356 TROLAMINE 5 1, 4\n- 357 TYMAZOLINE in nasal preparations for topical use 29\n- 358 VINCLOZOLIN 46\n- 359 VINYL ACETATE MONOMER 11 8, 9\n- 360 XYLENE 1, 4, 8\n- 361 XYLOMETAZOLINE in nasal preparations for topical use 29\n- 362 ZINC CHLORIDE 1, 4\n- 363 ZINC LACTATE 107\n- 364 ZINC SULFATE when included in Schedule 6 1, 4\n\n \n\nAppendix G—Dilute preparations\n\n \n\n \n\nNote: See paragraph 11(c).\n\n1  Substances exempt at or below certain concentrations\n\n  For the purposes of paragraph 11(c), the following table specifies:\n\n (a) substances; and\n\n (b) concentrations in relation to those substances.\n\n \n\n- Substances and concentrations\n- Item Column 1 Substance Column 2 Concentration (quantity per litre or kilogram)\n- 1 ACETYLCHOLINE 1 mg\n- 2 ALDOSTERONE 10 micrograms\n- 3 ANTIMONY COMPOUNDS 1 mg\n- 4 APOMORPHINE 1 mg\n- 5 ARSENIC 1 mg\n- 6 ATROPA BELLADONNA (belladonna) 300 micrograms\n- 7 ATROPINE 300 micrograms\n- 8 CANTHARIDIN 10 micrograms\n- 9 CHLORINE 5 mg\n- 10 CROTON TIGLIUM (croton oil) 1 mg\n- 11 EPIDERMAL GROWTH FACTOR 2 mg\n- 12 ERYSIMUM spp. 1 mg\n- 13 ESTRADIOL 10 micrograms\n- 14 ESTRONE 100 micrograms\n- 15 FOLLICLE‑STIMULATING HORMONE 100 micrograms\n- 16 GELSEMIUM SEMPERVIRENS 1 mg\n- 17 GLUCAGON 100 micrograms\n- 18 GLYCERYL TRINITRATE 100 micrograms\n- 19 GROWTH HORMONE 10 micrograms\n- 20 HALOPERIDOL 1 mg\n- 21 HYDROCYANIC ACID 1 microgram\n- 22 HYOSCINE 300 micrograms\n- 23 HYOSCYAMINE 300 micrograms\n- 24 HYOSCYAMUS NIGER 300 micrograms\n- 25 HYPOTHALAMIC RELEASING FACTORS 10 micrograms\n- 26 INDOMETACIN 1 mg\n- 27 MERCURY 1 mg\n- 28 METHYLMERCURY 300 micrograms\n- 29 NAPHTHALENE 1 mg\n- 30 NERIUM OLEANDER 1 mg\n- 31 OXYTOCIN 1 microgram\n- 32 PHOSPHORUS 1 mg\n- 33 PODOPHYLLUM RESIN (podophyllin) 1 mg\n- 34 PROGESTERONE 1 mg\n- 35 PROPRANOLOL 1 mg\n- 36 SELENIUM 100 micrograms\n- 37 STROPHANTHUS spp. 1 mg\n- 38 STRYCHNINE 1 mg\n- 39 TESTOSTERONE 1 mg\n- 40 THYROXINE 10 micrograms\n\n \n\nAppendix H—Schedule 3 medicines permitted to be advertised\n\n \n\n \n\nNote: See paragraph 57(1)(a).\n\n1  Schedule 3 medicines permitted to be advertised\n\n  The following table specifies poisons for the purposes of paragraph 57(1)(a).\n\n \n\n- Schedule 3 medicines permitted to be advertised\n- Item Column 1 Poison\n- 1 ADAPALENE\n- 2 ADRENALINE\n- 3 ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis and for the prevention of recurrent bacterial vaginosis\n- 4 BILASTINE\n- 5 BUTOCONAZOLE\n- 6 CELECOXIB\n- 7 CICLOPIROX\n- 8 CLOBETASONE\n- 9 CLOTRIMAZOLE\n- 10 DICLOFENAC\n- 11 DIMENHYDRINATE—for the prevention and relief of motion sickness\n- 12 DIPHENOXYLATE\n- 13 ECONAZOLE\n- 14 ELETRIPTAN\n- 15 ESOMEPRAZOLE\n- 16 FAMCICLOVIR\n- 17 FLUCONAZOLE\n- 18 FLUORIDES\n- 19 GLUCAGON\n- 20 GLYCERYL TRINITRATE\n- 21 HYDROCORTISONE\n- 22 HYOSCINE BUTYLBROMIDE\n- 23 IBUPROFEN\n- 24 ISOCONAZOLE\n- 25 KETOPROFEN\n- 26 LANSOPRAZOLE\n- 27 LEVONORGESTREL\n- 28 MELATONIN\n- 29 MICONAZOLE\n- 30 NALOXONE\n- 31 NAPROXEN\n- 32 NARATRIPTAN\n- 33 NYSTATIN\n- 34 OMEPRAZOLE\n- 35 OXICONAZOLE\n- 36 PANTOPRAZOLE\n- 37 PARACETAMOL\n- 38 PODOPHYLLOTOXIN\n- 39 PODOPHYLLUM EMODI (podophyllin)\n- 40 PODOPHYLLUM PELTATUM (podophyllin)\n- 41 RABEPRAZOLE\n- 42 RIZATRIPTAN\n- 43 SALICYLIC ACID\n- 44 SUMATRIPTAN\n- 45 TIOCONAZOLE\n- 46 TRIAMCINOLONE\n- 47 ULIPRISTAL—for emergency post‑coital contraception\n- 48 VITAMIN D\n- 49 ZOLMITRIPTAN\n\nAppendix I—Blank\n\n \n\n   \n\nNote 1: Appendix I is intentionally blank.\n\nNote 2: Appendix I previously included poisons now dealt with in Division 9 of Part 2.\n\nAppendix J—Conditions for availability and use of certain poisons included in Schedule 7\n\n \n\n \n\nNote: See subsection 62(6).\n\n1  Conditions for supply of certain poisons included in Schedule 7\n\n  For the purposes of subsection 62(6), a poison included in Schedule 7 that is specified in column 1 of an item of the following table may be supplied:\n\n (a) only to a person who is appropriately authorised or licensed under the law of the jurisdiction where the person will receive the poison; and\n\n (b) if “a” appears in column 2 of the item—only for analytical or research purposes; and\n\n (c) if “p” appears in column 2 of the item—only to a person who is authorised or licensed, under the law of the jurisdiction where the person will receive the poison, to possess and use the poison.\n\n \n\n- Conditions for supply of certain poisons included in Schedule 7\n- Item Column 1 Poison Column 2 Condition\n- 1 ABAMECTIN\n- 2 ACIBENZOLAR‑S‑METHYL\n- 3 ACROLEIN\n- 4 ACRYLONITRILE\n- 5 ALACHLOR a\n- 6 ALLYL ALCOHOL\n- 7 4‑AMINOPROPIOPHENONE p\n- 8 4‑AMINOPYRIDINE\n- 9 ARPRINOCID a\n- 10 ARSENIC p\n- 11 AZOCYCLOTIN a\n- 12 BENZENE\n- 13 BIFLUORIDE\n- 14 BORON TRIFLUORIDE\n- 15 BRODIFACOUM\n- 16 BROMADIOLONE\n- 17 BROMINE\n- 18 BRUCINE\n- 19 CALCIFEROL\n- 20 CARBADOX\n- 21 CARBON TETRACHLORIDE\n- 22 CARBONYL SULFIDE\n- 23 CHLORDECONE a\n- 24 CHLORDIMEFORM a\n- 25 CHLORINE\n- 26 CHLOROMETHIURON a\n- 27 CHLOROPICRIN\n- 28 4‑CHLORO‑o‑TOLUIDINE a\n- 29 COLECALCIFEROL\n- 30 COUMATETRALYL\n- 31 CYANOGEN\n- 32 CYHEXATIN a\n- 33 4,4‑DIAMINODIPHENYLMETHANE\n- 34 1,2‑DIBROMO‑3‑CHLOROPROPANE a\n- 35 1,3‑DICHLOROPROPENE\n- 36 DIFENACOUM\n- 37 4‑DIMETHYLAMINOAZOBENZENE a\n- 38 DINITROCRESOLS a\n- 39 DINITROPHENOLS a\n- 40 DINOSEB a\n- 41 EPICHLOROHYDRIN\n- 42 EPIDERMAL GROWTH FACTOR\n- 43 ETACONAZOLE a\n- 44 ETHYLENE DIBROMIDE a\n- 45 ETHYLENE OXIDE\n- 46 FLUOROACETAMIDE p\n- 47 FLUOROACETIC ACID p\n- 48 FOLPET\n- 49 HALOFUGINONE\n- 50 HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS a\n- 51 HCB a\n- 52 HYDROCYANIC ACID AND CYANIDES p\n- 53 HYDROFLUORIC ACID\n- 54 HYDROSILICOFLUORIC ACID\n- 55 IODOMETHANE\n- 56 MADURAMICIN\n- 57 MERCURY\n- 58 METHACRIFOS\n- 59 METHOXYETHYLMERCURIC ACETATE a\n- 60 METHOXYETHYLMERCURIC CHLORIDE\n- 61 METHYL BROMIDE\n- 62 4,4'‑METHYLENEBIS[2‑CHLOROANILINE]\n- 63 MIREX a\n- 64 MOLINATE\n- 65 NICOTINE except when in tobacco\n- 66 NITROFEN a\n- 67 PHENYLMERCURIC ACETATE\n- 68 PHOSPHIDE, metallic\n- 69 PHOSPHINE\n- 70 PROPYLENE OXIDE\n- 71 PYRINURON a\n- 72 STRYCHNINE p\n- 73 SULCOFURON a\n- 74 TETRACHLOROETHANE\n- 75 2,2',6,6'‑TETRAISOPROPYL‑DIPHENYL‑CARBODIIMIDE\n- 76 THALLIUM p\n- 77 o‑TOLIDINE\n- 78 VINYL CHLORIDE\n\nAppendix K—Human medicines required to be labelled with a sedation warning\n\n \n\n \n\nNote: See subsection 33(2).\n\n1  Human medicines required to be labelled with a sedation warning\n\n  The following table specifies poisons for the purposes of subsection 33(2).\n\n \n\n- Human medicines required to be labelled with a sedation warning\n- Item Column 1 Poison\n- 1 ALIMEMAZINE\n- 2 ALPRAZOLAM\n- 3 AMISULPRIDE\n- 4 AMITRIPTYLINE\n- 5 AMOBARBITAL\n- 6 ARIPIPRAZOLE\n- 7 ASENAPINE\n- 8 AZATADINE\n- 9 BACLOFEN\n- 10 BENZATROPINE\n- 11 BREXPIPRAZOLE\n- 12 BRIVARACETAM\n- 13 BROMAZEPAM\n- 14 BROMPHENIRAMINE\n- 15 BUCLIZINE\n- 16 BUPRENORPHINE\n- 17 BUTOBARBITAL\n- 18 CANNABIS except cannabidiol when included in Schedule 3 or 4\n- 19 CETIRIZINE\n- 20 CHLORAL HYDRATE\n- 21 CHLORDIAZEPOXIDE\n- 22 CHLORMETHIAZOLE\n- 23 CHLORPHENAMINE\n- 24 CHLORPROMAZINE\n- 25 CLEMASTINE\n- 26 CLOMIPRAMINE\n- 27 CLONAZEPAM\n- 28 CLONIDINE\n- 29 CLORAZEPATE\n- 30 CLOZAPINE\n- 31 CODEINE.\n- 32 CYCLIZINE\n- 33 CYCLOBARBITAL\n- 34 CYCLOSERINE\n- 35 CYPROHEPTADINE\n- 36 DANTROLENE\n- 37 DESIPRAMINE\n- 38 DEUTETRABENAZINE.\n- 39 DEXCHLORPHENAMINE\n- 40 DEXTROMORAMIDE\n- 41 DEXTROPROPOXYPHENE\n- 42 DIAZEPAM\n- 43 DIFELIKEFALIN\n- 44 DIFENOXIN\n- 45 DIHYDROCODEINE\n- 46 DIMENHYDRINATE\n- 47 DIMETHINDENE\n- 48 DIPHENHYDRAMINE\n- 49 DIPHENOXYLATE\n- 50 DIPHENYLPYRALINE\n- 51 DOSULEPIN\n- 52 DOXEPIN\n- 53 DOXYLAMINE\n- 54 DRONABINOL (delta‑9‑TETRAHYDROCANNABINOL)\n- 55 DROPERIDOL\n- 56 DULOXETINE\n- 57 ESKETAMINE\n- 58 ETHYLMORPHINE\n- 59 FENFLURAMINE\n- 60 FENTANYL\n- 61 FLUNITRAZEPAM\n- 62 FLUPENTIXOL\n- 63 FLUPHENAZINE\n- 64 FLURAZEPAM\n- 65 GABAPENTIN\n- 66 GEMCITABINE\n- 67 GLUTETHIMIDE\n- 68 GUANFACINE\n- 69 HALOPERIDOL\n- 70 HYDROCODONE\n- 71 HYDROMORPHONE\n- 72 HYDROXYZINE\n- 73 IMIPRAMINE\n- 74 LAMOTRIGINE\n- 75 LEMBOREXANT.\n- 76 LEVETIRACETAM\n- 77 LEVOCABASTINE\n- 78 LEVOCETIRIZINE\n- 79 LORAZEPAM\n- 80 LURASIDONE.\n- 81 MAZINDOL\n- 82 MEBHYDROLIN\n- 83 MECLOZINE\n- 84 MEDAZEPAM\n- 85 MEPROBAMATE\n- 86 MEPYRAMINE\n- 87 MERCAPTAMINE\n- 88 METHADONE\n- 89 METHDILAZINE\n- 90 METHOCARBAMOL\n- 91 METHYLPHENOBARBITAL\n- 92 MIANSERIN\n- 93 MIDAZOLAM\n- 94 MIRTAZAPINE\n- 95 MORPHINE\n- 96 NABIXIMOLS.\n- 97 NALBUPHINE\n- 98 NITRAZEPAM\n- 99 NORMETHADONE\n- 100 NORTRIPTYLINE\n- 101 OLANZAPINE\n- 102 OPIUM in any form except the alkaloids noscapine and papaverine\n- 103 OXAZEPAM\n- 104 OXYCODONE\n- 105 PALIPERIDONE\n- 106 PAPAVERETUM\n- 107 PENTAZOCINE\n- 108 PENTOBARBITAL\n- 109 PERAMPANEL\n- 110 PERICIAZINE\n- 111 PERPHENAZINE\n- 112 PETHIDINE\n- 113 PHENELZINE\n- 114 PHENIRAMINE\n- 115 PHENOBARBITAL\n- 116 PHENOPERIDINE\n- 117 PHENYLTOLOXAMINE\n- 118 PHOLCODINE\n- 119 PIMOZIDE\n- 120 PIZOTIFEN\n- 121 PRAZEPAM\n- 122 PREGABALIN\n- 123 PROCHLORPERAZINE\n- 124 PROMAZINE\n- 125 PROMETHAZINE\n- 126 PROTRIPTYLINE\n- 127 QUETIAPINE\n- 128 RETIGABINE\n- 129 RISPERIDONE\n- 130 ROTIGOTINE\n- 131 RUFINAMIDE\n- 132 RUPATADINE\n- 133 SAFINAMIDE\n- 134 SECBUTOBARBITAL\n- 135 SECOBARBITAL\n- 136 SELETRACETAM\n- 137 SODIUM OXYBATE\n- 138 STIRIPENTOL\n- 139 SUVOREXANT\n- 140 TAPENTADOL\n- 141 TEMAZEPAM\n- 142 TETRAHYDROCANNABINOLS except cannabidiol when included in Schedule 3 or 4\n- 143 THENYLDIAMINE\n- 144 THIETHYLPERAZINE\n- 145 THIOPROPAZATE\n- 146 THIORIDAZINE\n- 147 THIOTHIXENE\n- 148 TRABECTEDIN\n- 149 TRAMADOL\n- 150 TRANYLCYPROMINE\n- 151 TRIFLUOPERAZINE\n- 152 TRIMIPRAMINE\n- 153 TRIPROLIDINE\n- 154 ZIPRASIDONE\n- 155 ZOLPIDEM\n- 156 ZONISAMIDE\n- 157 ZOPICLONE\n\nAppendix L—Requirements for dispensing labels for medicines\n\n \n\n \n\nNote: See subsection 33(1) and paragraph 40(b).\n\n1  General\n\n (1) This clause sets out requirements for the purposes of paragraph 40(b).\n\n (2) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 mm in height.\n\n (3) All symbols, numbers and words on a label must be in durable characters.\n\n (4) The label on a container of a substance for therapeutic use must contain the following details:\n\n (a) the name, address and telephone number of the dispenser supplying the substance;\n\n (b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula);\n\n (c) adequate directions for use;\n\n (d) the strength and form of the substance;\n\n (e) the total quantity of the goods in the container;\n\n (f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;\n\n (g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background;\n\n (h) if the substance is a medicine for human use, the name of the person for whom it was dispensed; and\n\n (i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.\n\n (5) The label on a container of a medicine for human use, or a veterinary chemical, that is supplied on prescription must also include:\n\n (a) the prescription reference number; and\n\n (b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and\n\n (c) the directions for use set out in the prescription.\n\n2  Additional warning statements for certain human medicines\n\n (1) For the purposes of subsection 33(1), and subject to subclause (2), the warning statement represented by each item number specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item.\n\nNote: For the warning statements represented by the item numbers, see clause 1 of Appendix F.\n\n (2) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate).\n\n \n\n- Additional warning statements for certain human medicines\n- Item Column 1 Poison Column 2 Warning statement item number\n- 1 ACITRETIN—for oral use 7, 62, 76\n- 2 ACITRETIN—for topical use 62, 77\n- 3 ADAPALENE—for oral use 7, 62, 76\n- 4 ADAPALENE—for topical use 62, 77\n- 5 AMBRISENTAN 7, 62, 76\n- 6 BELUMOSUDIL 62, 77\n- 7 BEXAROTENE—for oral use 7, 62, 76\n- 8 BEXAROTENE—for topical use 62, 77\n- 9 BOSENTAN 7, 62, 76\n- 10 DIENESTROL 67\n- 11 ETRETINATE—for oral use 7, 62, 76\n- 12 ETRETINATE—for topical use 62, 77\n- 13 ENZALUTAMIDE 7, 67, 87\n- 14 FARICIMAB 76\n- 15 FINERENONE 67, 111\n- 16 FINGOLIMOD 76\n- 17 ISAVUCONAZOLE 53\n- 18 ISOTRETINOIN—for oral use 7, 62, 76\n- 19 ISOTRETINOIN—for topical use 62, 77\n- 20 LEFLUNOMIDE 7, 62, 87\n- 21 LENALIDOMIDE—for oral use 7, 62, 76\n- 22 LENALIDOMIDE—for topical use 62, 77\n- 23 LEVOCABASTINE 62\n- 24 MACITENTAN 7, 62, 76\n- 25 MISOPROSTOL 53\n- 26 PALOVAROTENE 7, 62, 76, 111\n- 27 PLITIDEPSIN 7, 62, 63, 76, 87\n- 28 POMALIDOMIDE 7, 62, 76\n- 29 PONESIMOD 76\n- 30 RIOCIGUAT 7, 62, 76\n- 31 RUFINAMIDE 62, 76, 77\n- 32 SAFINAMIDE 62, 76, 77\n- 33 SELINEXOR 62 and 77\n- 34 SELUMETINIB. 76\n- 35 SITAXENTAN 7, 62, 76\n- 36 TERIFLUOMIDE 7, 62, 87\n- 37 THALIDOMIDE—for oral use 7, 62, 76\n- 38 THALIDOMIDE—for topical use 62, 77\n- 39 TIRZEPATIDE 67\n- 40 TRASTUZUMAB DERUXTECAN 62, 77\n- 41 TRETINOIN—for oral use 7, 62, 76\n- 42 TRETINOIN—for topical use 62, 77\n\n \n\nAppendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist\n\n \n\n   \n\nNote: Appendix M is intentionally blank. It is reserved for future use.\n\n \n\nIndex\n\n \n\n \n\nA\n\nABACAVIR\n\nABAMECTIN\n\nSchedule 7  Schedule 6  Schedule 5  Appendix J, clause 1\n\nABATACEPT\n\nABCIXIMAB\n\nABEMACICLIB\n\nABIRATERONE ACETATE\n\nABROCITINIB\n\nABRUS PRECATORIUS  cross reference: JEQUIRITY\n\nABSCISIC ACID\n\nACALABRUTINIB\n\nACAMPROSATE CALCIUM\n\nACARBOSE\n\nACEBUTOLOL\n\nACEPHATE\n\nACEPROMAZINE\n\nACEQUINOCYL\n\nACETAMIPRID\n\nACETANILIDE  cross reference: ALKYL ACETANILIDES\n\nACETARSOL\n\nACETAZOLAMIDE\n\nACETIC ACID\n\nACETIC ANHYDRIDE\n\nACETOHEXAMIDE\n\nACETONE  cross reference: DESIGNATED SOLVENT\n\nACETORPHINE\n\ncross reference: CAS No. 25333-77-1\n\nACETYL‑ALPHA‑METHYLFENTANYL\n\ncross reference: CAS No. 101860-00-8\n\nACETYLCARBROMAL\n\nACETYLCHOLINE\n\nACETYLCYSTEINE\n\nACETYLDIGITOXIN\n\nACETYLDIHYDROCODEINE\n\nACETYL ISOVALERYLTYLOSIN\n\nACETYLMETHADOL\n\nACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE\n\nACETYLMORPHINES\n\n4‑[4‑(ACETYLOXY)PHENYL]‑2‑BUTANONE\n\nACETYLSTROPHANTHIDIN\n\nACIBENZOLAR‑S‑METHYL\n\nACICLOVIR\n\nACIFLUORFEN\n\nACINITRAZOLE\n\nACIPIMOX\n\nACITRETIN\n\nACLIDINIUM BROMIDE\n\nACLONIFEN\n\nACOKANTHERA OUABAIO\n\nACOKANTHERA SCHIMPERI\n\nACONITUM spp.\n\nACORUS CALAMUS  cross reference: CALAMUS\n\nACRIFLAVINE  cross reference: ACRIFLAVINIUM CHLORIDE\n\nACRIFLAVINUM CHLORIDE\n\nACRIVASTINE\n\nACROLEIN\n\nACRYLONITRILE\n\nADALIMUMAB\n\nADAPALENE\n\nSchedule 4  Schedule 3  Appendix F, clause 4  Appendix H, clause 1  Appendix L, clause 2\n\nADEFOVIR\n\nADENOSINE\n\nADIPHENINE\n\nADONIS VERNALIS\n\nADRAFINIL\n\nADRENALINE\n\nADRENOCORTICAL HORMONES\n\nAFAMELANOTIDE  cross reference: MELANOCYTE STIMULATING HORMONE, MELANOTAN I\n\nAFATINIB DIMALEATE\n\nAFIDOPYROPEN\n\nAFLIBERCEPT\n\nAFOXOLANER\n\nAGALSIDASE\n\nAGLEPRISTONE\n\nAGOMELATINE\n\nAKLOMIDE\n\nALACHLOR\n\nALANYLGLUTAMINE\n\nALATROFLOXACIN MESILATE  cross reference: ALATROFLOXACIN MESYLATE\n\nALBENDAZOLE\n\nALCLOFENAC\n\nALCLOMETASONE\n\nALCOHOL, DEHYDRATED\n\nALCURONIUM\n\nALDESLEUKIN\n\nALDICARB\n\nALDOSTERONE\n\nALDOXYCARB\n\nALDRIN\n\nALECTINIB\n\nALEFACEPT\n\nSchedule 4  Appendix D, clause 7\n\nALEMTUZUMAB\n\nALENDRONIC ACID\n\nALFACALCIDOL\n\nALFENTANIL\n\nALFUZOSIN\n\nALGICIDES\n\nALGLUCERASE\n\nALGLUCOSIDASE\n\nALIMEMAZINE  cross reference: TRIMEPRAZINE\n\nALIROCUMAB\n\nALISKIREN\n\nALKALINE SALTS  cross reference: LYE WATER, POTASSIUM CARBONATE. POTASSIUM PHOSPHATE, POTASSIUM SALTS, POTASSIUM SILICATE, SODIUM CARBONATE, SODIUM SALTS, SODIUM SILICATE(S)\n\nALKOXYAMFETAMINES  cross reference: ALKOXYAMPHETAMINES\n\nALKOXYLATED FATTY ALKYLAMINE POLYMER\n\nALKOXYPHENYLETHYLAMINES\n\nALKYLAMINES WITH STIMULANT PROPERTIES  cross reference: 1,3‑DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1‑AMINOISOHEPTANE, DMHA, 1,5‑DIMETHYLHEXYLAMINE, 4‑METHYLHEXANE‑2‑AMINE, 1,3‑DIMETHYLAMYLAMINE, DMAA, 4‑AMINO‑2‑METHYLPENTANE CITRATE (AMP CITRATE), 1,4‑DIMETHYLPENTYLAMINE, DMPA, 1,4‑DIMETHYLAMYLAMINE, DMAA.\n\nALKYL NITRITES\n\nALKYLTHIOAMFETAMINES  cross reference: ALKYLTHIOAMPHETAMINES\n\nALLERGENS\n\nALLETHRIN\n\nALLOPURINOL\n\nALLOXYDIM\n\nALLYL ALCOHOL\n\nALLYL CYCLOHEXANEACETATE (CAS No. 4728‑82‑9)\n\nALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705‑87‑5)\n\nALLYL ESTERS (excluding derivatives)\n\nALLYLESTRENOL  cross reference: ALLYLOESTRENOL\n\nALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142‑19‑8)\n\nALLYL HEXANOATE (CAS No. 123‑68‑2)\n\nALLYL ISOVALERATE (CAS No. 2835‑39‑4)\n\nALLYL NONANOATE (CAS No. 7493‑72‑3)\n\nALLYL OCTANOATE (CAS No. 4230‑97‑1)\n\nALLYLOESTRENOL  cross reference: ALLYLESTRENOL\n\nALLYL PHENYLACETATE (CAS No. 1797‑74‑6)\n\nALLYLPRODINE\n\ncross reference: CAS No. 25384-17-2\n\nALLYL TRIMETHYLHEXANOATE (CAS No. 68132‑80‑9)\n\nALOGLIPTIN\n\nALOSETRON\n\nALOXIPRIN\n\nALPELISIB\n\nALPHACETYLMETHADOL\n\nALPHA‑CHLOROHYDRIN\n\nALPHA‑CYPERMETHRIN\n\nALPHADOLONE\n\nALPHAMEPRODINE\n\ncross reference: CAS No. 468-51-9\n\nALPHAMETHADOL\n\ncross reference: CAS No. 17199-54-1\n\nALPHA‑METHYLFENTANYL\n\ncross reference: CAS No. 79704-88-4\n\nALPHA‑METHYLTHIOFENTANYL\n\ncross reference: CAS No. 103963-66-2\n\nALPHAPRODINE\n\nALPHA‑PYRROLIDINOVALEROPHENONE *(ALPHA‑PVP).\n\ncross reference: CAS No. 14530-33-7\n\nALPHA1‑PROTEINASE INHIBITOR (HUMAN)\n\nALPHAXALONE\n\nALPRAZOLAM\n\nSchedule 8  Appendix D, clause 5 (Benzodiazepine derivatives)  Appendix K, clause 1\n\nALPRENOLOL\n\nALPROSTADIL\n\nALSEROXYLON\n\nALTEPLASE\n\nALTRENOGEST\n\nALTRETAMINE  cross reference: HEXAMETHYLMELAMINE\n\nALUM\n\nALUMINIUM AMMONIUM SULFATE\n\nALUMINIUM POTASSIUM SULFATE\n\nALUMINIUM SILICATE\n\nALUMINIUM tris (ETHYLPHOSPHONATE)\n\nAMANTADINE\n\nAMBENONIUM CHLORIDE\n\nAMBRISENTAN\n\nAMBUCETAMIDE\n\nAMBUTONIUM BROMIDE\n\nAMCINONIDE\n\nAMETOCTRADIN\n\nAMETRYN\n\nAMICARBAZONE\n\nAMIDITHION\n\nAMIDOPROPYL BETAINES\n\nAMIFAMPRIDINE\n\nAMIFOSTINE\n\nAMIKACIN\n\nAMILORIDE\n\nAMINACRINE  cross reference: AMINOACRIDINE\n\nAMINES  cross reference: CURING AGENTS FOR EPOXY RESINS\n\nAMINOACRIDINE  cross reference: AMINACRINE\n\nAMINOCAPROIC ACID\n\nAMINOCARB\n\n2‑AMINO‑6‑CHLORO‑4‑NITROPHENOL\n\n4‑AMINO‑m‑CRESOL\n\n5‑AMINO‑o‑CRESOL  cross reference: 4‑AMINO‑2‑HYDROXYTOLUENE\n\nAMINOCYCLOPYRACHLOR\n\n2‑AMINO‑1‑(2,5‑DIMETHOXY‑4‑METHYL)PHENYLPROPANE  cross reference: DOM, STP (CAS No. 15588-95-1), DOM HYDROCHLORIDE (CAS No. 15589-00-1)\n\nAMINOETHOXYVINYLGLYCINE\n\n2‑AMINO‑5‑ETHYLPHENOL\n\nAMINOGLUTETHIMIDE\n\n4‑AMINO‑2‑HYDROXYTOLUENE\n\n5‑AMINOLEVULINIC ACID\n\n1‑AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE\n\n2‑[(4‑AMINO‑2‑METHYL‑5‑NITROPHENYL)AMINO]‑ETHANOL  cross reference: HC VIOLET 1\n\n2‑AMINO‑5‑METHYLPHENOL\n\ncross reference: CAS No. 2835-98-5\n\nSchedule 10  Schedule 7\n\nAMINOMETRADINE\n\n4‑AMINO‑3‑NITROPHENOL\n\n2,2'‑[(4‑AMINO‑3‑NITROPHENYL)IMINO]BISETHANOL  cross reference: HC RED 13\n\nAMINOPHENAZONE  cross reference: AMIDOPYRINE (CAS No. 58-15-1), AMINOPHENAZONE HYDROCHLORIDE (CAS No. 6170-29-2)\n\nSchedule 10  Schedule 4\n\nm‑AMINOPHENOL\n\np‑AMINOPHENOL\n\nAMINOPHYLLINE\n\n4‑AMINOPROPIOPHENONE  cross reference: PARA‑AMINOPROPIOPHENONE (PAPP)\n\n5‑(2‑AMINOPROPYL)INDAN\n\ncross reference: CAS No. 13396-94-6\n\nAMINOPTERIN\n\nAMINOPYRALID\n\n4‑AMINOPYRIDINE  cross reference: FAMPRIDINE\n\nSchedule 7  Schedule 4  Appendix E, clause 3  Appendix J, clause 1\n\nAMINOREX\n\nAMINOSALICYLIC ACID\n\nAMIODARONE\n\nAMIPHENAZOLE\n\nAMISOMETRADINE\n\nAMISULBROM\n\nAMISULPRIDE\n\nAMITON\n\nAMITRAZ\n\nAMITRIPTYLINE\n\nAMITROLE\n\nAMLODIPINE\n\nAMMI VISNAGA\n\nAMMONIA  cross reference: AMMONIUM HYDROXIDE, CHROMATES\n\nAMMONIUM BROMIDE\n\nAMMONIUM COCOYL ISETHIONATE\n\nAMMONIUM PERSULFATE\n\nAMMONIUM PHOSPHATE\n\nAMMONIUM THIOCYANATE\n\nAMMONIUM THIOSULPHATE\n\nAMOBARBITAL\n\nAMODIAQUINE\n\nAMOROLFINE\n\nAMOXAPINE\n\nAMOXICILLIN\n\nAMOXYCILLIN  cross reference: AMOXICILLIN\n\nAMFETAMINE  cross reference: AMPHETAMINE\n\nAMPHOMYCIN\n\nAMPHOTERICIN  cross reference: AMPHOTERICIN B\n\nAMPHOTERICIN B\n\nAMPICILLIN\n\nAMPRENAVIR\n\nAMPROLIUM\n\nAMRINONE\n\nAMSACRINE\n\nAMYGDALIN  cross reference: CAS No. 29883-15-6, APRICOT KERNELS\n\nAMYL ACETATE\n\nAMYL NITRITE\n\nSchedule 4  Schedule 3  Appendix E, clause 3\n\nα‑AMYLASE derived from Aspergillus niger\n\nAMYL CINNAMALDEHYDE\n\nAMYLOBARBITAL  cross reference: AMOBARBITAL\n\nAMYLOBARBITONE  cross reference: AMOBARBITAL\n\nAMYLOCAINE\n\nANABOLIC STEROIDAL AGENTS  cross reference: ANDROSTERONE, STEROIDAL AGENTS\n\nANAGRELIDE\n\nANAKINRA\n\nANASTROZOLE\n\nANCESTIM\n\nANCHUSA OFFICINALIS\n\nANCROD\n\nANDEXANET ALFA\n\nANDROGENIC STEROIDAL AGENTS  cross reference: STEROIDAL AGENTS\n\nANDROISOXAZOLE\n\nANDROSTANOLONE\n\nANDROSTENEDIOL\n\nANDROSTENEDIONE\n\nANDROSTENEDIONE ALBUMEN\n\nANECORTAVE\n\nANGIOTENSIN AMIDE\n\nANHYDRIDES, ORGANIC ACID  cross reference: CURING AGENTS FOR EPOXY RESINS\n\nANIDULAFUNGIN\n\nANILERIDINE\n\nANILINE\n\nANIRACETAM  cross reference: RACETAMS\n\nANISE OIL\n\nSchedule 5  Appendix E, clause 3, Part 4\n\no‑ANISIDINE\n\ncross reference: CAS No. 90-04-0, o-ANISIDINE HYDROCHLORIDE (CAS No. 134-29-2)\n\nANISTREPLASE\n\nANTAZOLINE\n\nANTIBIOTIC SUBSTANCES  cross reference: NISIN\n\nANTIGENS\n\nANTIHISTAMINES  cross reference: ASTEMIZOLE, AZELASTINE, BILASTINE, CETIRIZINE, DESLORATADINE, FEXOFENADINE, LORATADINE, OLOPATADINE, TERFENADINE\n\nANTIMONY  cross reference: ANTIMONY COMPOUNDS, ANTIMONY CHLORIDE, ANTIMONY TITANATE\n\nSchedule 6  Schedule 4  Appendix E, clause 3  Appendix G, clause 1\n\nANTISERA  cross reference: IMMUNOSERA\n\nAOD‑9604 (CAS No. 221231‑10‑3)\n\nAPALUTAMIDE\n\nAPIXABAN\n\nAPOCYNUM spp.\n\nAPOMORPHINE\n\nAPRACLONIDINE\n\nAPRAMYCIN\n\nAPREMILAST\n\nAPREPITANT\n\nAPRICOT KERNELS\n\ncross reference: AMYGDALIN, HYDROCYANIC ACID\n\nAPRONAL\n\ncross reference: ALLYLISOPROPYLACETYLUREA (CAS No. 528-92-7)\n\nAPROTININ\n\nARBUTIN (ALPHA)\n\ncross reference: ARBUTIN (BETA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)\n\nARBUTIN (BETA)\n\ncross reference: ARBUTIN (ALPHA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)\n\nARBUTIN (DEOXY OR OTHER DERIVATIVES)\n\ncross reference: ARBUTIN (ALPHA); ARBUTIN (BETA)\n\nARECOLINE\n\nARIPIPRAZOLE\n\nARISTOLOCHIA spp.\n\nARISTOLOCHIC ACID(S)  cross reference: ASARUM spp, BRAGANTIA (CAS No. 313-67-7)\n\nARPRINOCID\n\nARMODAFINIL\n\nARSENIC  cross reference: ARSENIC TRIOXIDE, CACODYLIC ACID, TERMITE BARRIERS, COPPER‑CHROME‑ARSENIC, SELENIUM ARSENIDE, THIACETARSAMIDE\n\nSchedule 7  Schedule 6  Schedule 4  Appendix G, clause 1  Appendix J, clause 1\n\nARTEMETHER\n\nARTICAINE\n\nASARUM spp\n\nASCIMINIB\n\nASENAPINE\n\nASFOTASE ALFA\n\nASPARAGINASE\n\ncross reference: CRISANTASPASE\n\nASPARTIC ACID\n\nASPIRIN  cross reference: CAFFEINE, PARACETAMOL, SALICYLAMIDE\n\nSchedule 6  Schedule 5  Schedule 4  Schedule 2  Appendix F, clause 4\n\nASTEMIZOLE\n\nASTODRIMER SODIUM\n\nASULAM\n\nASUNAPREVIR\n\nATAMESTANE\n\nATAZANAVIR\n\nATENOLOL\n\nATEZOLIZUMAB\n\nATIPAMEZOLE\n\nATOMOXETINE\n\nATORVASTATIN\n\nATOSIBAN\n\nATOVAQUONE\n\nATRACURIUM BESILATE  cross reference: ATRACURIUM BESYLATE\n\nATRAZINE\n\nATROPA BELLADONNA  cross reference: BELLADONNA\n\nATROPINE\n\nATROPINE METHONITRATE\n\nAURANOFIN\n\nAUREOBASIDIUM PULLULANS (Strains DSM14940 and DSM14941)\n\nAppendix B\n\nAUROTHIOMALATE SODIUM\n\nAVACOPAN\n\nAVATROMBOPAG\n\nAVELUMAB\n\nAVILAMYCIN\n\nAVIPTADIL\n\nAVOPARCIN\n\nAXITINIB\n\nAZACITIDINE\n\nAZACONAZOLE\n\nAZACYCLONOL\n\nAZADIRACHTA INDICA  cross reference: DEBITTERISED NEEM SEED OIL, NEEM\n\nAZADIRACHTA INDICA EXTRACTS\n\nAZAFENIDIN\n\nAZAMETHIPHOS\n\nAZAPERONE\n\nAZAPROPAZONE\n\nAZARIBINE\n\nAZATADINE\n\nAZATADINE\n\nAZATHIOPRINE\n\nAZELAIC ACID\n\nAZELASTINE\n\nAZIMSULFURON\n\nAZINPHOS‑ETHYL\n\nAZINPHOS‑METHYL\n\nAZITHROMYCIN\n\nAZLOCILLIN\n\nAZOBENZENE\n\nAZOCYCLOTIN\n\nAZO DYES (derivatives by diazotisation)\n\nAZOXYSTROBIN\n\nAZTREONAM\n\nB\n\nBACAMPICILLIN\n\nBACILLUS AMYLOLIQUEFACIENS  cross reference: BACILLUS SUBTILIS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN MBI 600\n\nBACILLUS SPHAERICUS, STRAIN 2362\n\nBACILLUS SUBTILIS, STRAIN QST 713  cross reference: BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713\n\nBACILLUS THURINGIENSIS  cross reference: ENDOTOXIN\n\nBACILLUS THURINGIENSIS DELTA ENDOTOXIN\n\nBACILLUS TOYOI\n\nBACITRACIN\n\nBACLOFEN\n\nBACTERIAL CULTURE MEDIA  cross reference: ANTIBIOTIC SUBSTANCES\n\nBACTERICIDES\n\nBACULOVIRUS CYDIA POMONELLA\n\nBALOXAVIR MARBOXIL\n\nBALSALAZIDE\n\nBAMBERMYCIN  cross reference: FLAVOPHOSPHOLIPOL\n\nBAMBUTEROL\n\nBAMETHAN\n\nBAMIPINE\n\nBARBITURATES\n\nBARICITINIB\n\nBARIUM SALTS  cross reference: BARIUM METABORATE, BARIUM SULFATE\n\nBARIUM SILICOFLUORIDE\n\nBASIC BLUE 26\n\nBASIC ORANGE 31  cross reference: 2‑[(4‑AMINOPHENYL)AZO]‑1,3‑DIMETHYL‑1H‑IMIDAZOLIUM, CHLORIDE (CAS No. 97404-02-9)\n\nBASIC RED 76 (CAS No. 68391‑30‑0)  cross reference: [7‑HYDROXY‑8‑[(2‑ METHOXYPHENYL)AZO]‑2‑NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391‑30‑0)\n\nBASIL OIL  cross reference: METHYL CHAVICOL\n\nBASILIXIMAB\n\nBATTERIES\n\nBAY OIL\n\nBAZEDOXIFENE\n\nBEAUVERIA BASSIANA\n\nBECAPLERMIN\n\nBECLAMIDE\n\nBECLOMETASONE  cross reference: BECLOMETHASONE\n\nBECLOMETHASONE  cross reference: BECLOMETASONE\n\nBELATACEPT\n\nBELIMUMAB\n\nBELUMOSUDIL\n\nBELZUTIFAN\n\nBEMEGRIDE\n\nBENACTYZINE\n\nBENALAXYL\n\nBENAZEPRIL\n\nBENDAMUSTINE\n\nBENDIOCARB  cross reference: DENATONIUM BENZOATE\n\nBENDROFLUAZIDE\n\nBENETHAMINE PENICILLIN\n\nBENFLURALIN\n\nBENOMYL\n\nBENORYLATE\n\nBENOXAPROFEN\n\nBENPERIDOL\n\nBENQUINOX\n\nBENRALIZUMAB\n\nBENSERAZIDE\n\nBENSULFURON‑METHYL\n\nBENSULIDE\n\nBENTAZONE\n\nBENTONITE\n\nBENZALKONIUM CHLORIDE\n\nBENZATHINE PENICILLIN\n\nBENZENE\n\ncross reference: LIQUID HYDROCARBONS  Schedule 7  Appendix E, clause 3  Appendix F, clause 4  Appendix J, clause 1\n\n1,2‑BENZENEDIAMINE\n\ncross reference: CAS No. 95-54-5, 1,2-BENZENEDIAMINE DIHYDROCHLORIDE (CAS No. 615-28-1)\n\n1,3‑BENZENEDIAMINE\n\ncross reference: CAS No. 108-45-2\n\n1,2‑BENZENEDIOL  cross reference: CATECHOL\n\nBENZETHIDINE\n\ncross reference: CAS No. 3691-78-9\n\nBENZHEXOL  cross reference: TRIHEXYPHENIDYL\n\nBENZIDINE‑CONGENER (3,3'‑disubstituted) AZO DYES\n\nBENZIDINE‑BASED AZO DYES\n\nBENZILONIUM\n\nBENZOCAINE\n\nBENZODIAZEPINE DERIVATIVES\n\nBENZOFENAP\n\nBENZOIC ACID\n\nSchedule 5\n\nBENZOVINDIFLUPYR\n\nBENZOYL PEROXIDE\n\nSchedule 5  Schedule 4  Schedule 2  Appendix E, clause 3  Appendix F, clause 4\n\nBENZOYLINDOLES\n\nBENZPHETAMINE\n\nBENZTHIAZIDE\n\nBENZATROPINE  cross reference: BENZITROPINE\n\nBENZYDAMINE\n\n6‑BENZYLADENINE\n\nBENZYL BENZOATE\n\nBENZYLMORPHINE\n\nBENZYLPENICILLIN\n\nBENZYLPIPERAZINE  cross reference: BZP (CAS No. 2759-28-6), BENZYLPIPERAZINE TARTRATE (CAS No. 10510-56-2), BENZYLPIPERAZINE DIHYDROCHLORIDE (CAS No. 5321-63-1)\n\nBEPHENIUM SALTS\n\nBEPRIDIL\n\nBERACTANT\n\nBERGAMOT OIL\n\nBERYLLIUM\n\nBESIFLOXACIN\n\nBETACETYLMETHADOL\n\ncross reference: CAS No. 17199-59-6\n\nBETACYFLUTHRIN\n\nBETA‑CYPERMETHRIN\n\nBETA‑PHENYL‑GAMMA‑AMINOBUTYRIC ACID  cross reference: PHENIBUT\n\nBETAHISTINE\n\nBETA‑HYDROXY‑3‑METHYLFENTANYL\n\ncross reference: CAS No. 78995-14-9\n\nBETA‑HYDROXYFENTANYL\n\ncross reference: CAS No. 78995-10-5\n\nBETAINE HYDROCHLORIDE\n\nBETAMEPRODINE\n\ncross reference: CAS No. 468-50-8\n\nBETAMETHADOL\n\ncross reference: CAS No. 17199-55-2\n\nBETAMETHASONE\n\n1‑(BETA‑METHYL SULPHONAMIDOETHYL)‑ 2‑AMINO‑3\n\nBETAPRODINE\n\ncross reference: CAS No. 468-59-7\n\nBETAXOLOL\n\nBETHANECHOL CHLORIDE\n\nBETHANIDINE\n\nBEVACIZUMAB\n\nBEVANTOLOL\n\nBEXAROTENE\n\nBEZAFIBRATE\n\nBEZITRAMIDE\n\nBEZLOTOXUMAB\n\nBHC\n\nBICALUTAMIDE\n\nBICTEGRAVIR\n\nBICYCLOPYRONE\n\nBIFENAZATE\n\nBIFENTHRIN\n\nBIFLUORIDES  cross reference: AMMONIUM BIFLUORIDE, AMMONIUM SALTS, POTASSIUM SALTS, SODIUM SALTS\n\nSchedule 7  Schedule 6  Schedule 5  Appendix E, clause 3  Appendix F, clause 4  Appendix J, clause 1\n\nBIFONAZOLE\n\nBILASTINE\n\nSchedule 2  Appendix H, clause 1\n\nBIMATOPROST\n\nBINIMETINIB\n\nBIOALLETHRIN\n\nBIORESMETHRIN\n\nBIPERIDEN\n\n1,3‑BIS(2,4‑DIAMINOPHENOXY)PROPANE\n\nBIS‑ISOBUTYL PEG/PPG‑20/35/AMODIMETICONE COPOLYMER\n\nBISMUTH COMPOUNDS  cross reference: BISMUTH CITRATE, BISMUTH FORMIC IODIDE, BISMUTH OXYCHLORIDE, BISMUTH SUBIODIDE\n\nBISMUTH SUBNITRATE\n\nBISOPROLOL\n\nN,N‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,5‑DIMETHANAMINE  cross reference: N,N‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,6‑DIMETHANAMINE\n\nN,N‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,6‑DIMETHANAMINE  cross reference: N,N‑bIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,6‑DIMETHANAMINE\n\nBISPYRIBAC\n\nBISTRIFLURON\n\nBITHIONOL\n\ncross reference: CAS No. 97-18-7\n\nSchedule 10  Schedule 6  Appendix F, clause 4\n\nBIURET\n\nBIVALIRUDIN\n\nBIXAFEN\n\nBIXLOZONE\n\nBLAD (banda de Lupinus albus doce)\n\nBLEOMYCIN\n\nBLINATUMOMAB\n\nBOCEPREVIR\n\nBOLANDIOL\n\nBOLASTERONE\n\nBOLAZINE\n\nBOLDENONE  cross reference: DEHYDROTESTOSTERONE\n\nBOLENOL\n\nBOLMANTALATE\n\nBORAGO OFFICINALIS  cross reference: BORAGE\n\nBORIC ACID  cross reference: BORAX, SODIUM BORATE, POTASSIUM BORATE, MEA‑BORATE, MIPA‑BORATE\n\nSchedule 4  Appendix E, clause 3  Appendix F, clause 4\n\nBORON  cross reference: BORATES, BORAX, BORIC ACID, BORON COMPOUNDS\n\nBORON TRIFLUORIDE\n\nSchedule 7  Schedule 6  Schedule 5  Appendix E, clause 3  Appendix F, clause 4  Appendix J, clause 1\n\nBORTEZOMIB\n\nBOSCALID\n\nBOSENTAN\n\nBOSUTINIB\n\nBOTULINUM TOXINS\n\nBOVINE SOMATOTROPHIN\n\nBPC‑157\n\nAppendix D, clause 5\n\nBRAGANTIA spp\n\nBRENTUXIMAB VEDOTIN\n\nBRETYLIUM TOSILATE\n\nBRETYLIUM TOSYLATE\n\ncross reference: BRETYLIUM TOSILATE\n\nBREXPIPRAZOLE\n\nBRIGATINIB\n\nBRIMONIDINE\n\nBRINZOLAMIDE\n\nBRIVARACETAM\n\nBRODIFACOUM\n\nBROFLANILIDE\n\nSchedule 6   Schedule 5\n\nBROMACIL\n\nBROMADIOLONE\n\nBROMAZEPAM\n\nBROMETHALIN\n\nBROMHEXINE\n\nBROMIDES\n\nBROMINE\n\n1‑(8‑BROMOBENZO[1,2‑B;4,5‑B]DIFURAN‑4‑YL)‑2‑AMINOPROPANE  cross reference: BROMO‑DRAGONFLY (CAS No. 502759-67-3)\n\nBROMOCRIPTINE\n\n4‑BROMO‑2,5‑DIMETHOXYPHENETHYLAMINE   cross reference: BDMPEA (CAS No. 66142-81-2)\n\nBROMOFORM\n\nBROMOPHOS\n\nBROMOPHOS‑ETHYL\n\nBROMOPROPYLATE\n\nBROMOXYNIL\n\nBROMPHENIRAMINE\n\nBROMUCONAZOLE\n\nBROMVALETONE\n\nBROTIANIDE\n\nBRUCINE\n\nSchedule 7  Appendix E, clause 3  Appendix J, clause 1\n\nBRUGMANSIA spp.\n\nBUCLIZINE\n\nBUCLOSAMIDE\n\ncross reference: CAS No. 575-74-6\n\nBUDESONIDE\n\nBUFEXAMAC\n\nBUFOTENINE\n\ncross reference: CAS No. 487-93-4\n\nBULEVIRTIDE\n\nBUMETANIDE\n\nBUNAMIDINE\n\nBUNIODYL SODIUM\n\ncross reference: CAS No. 1923-76-8, BUNIODYL BASE (CAS No. 1233-53-0)\n\nBUPHENINE\n\nBUPIRIMATE\n\nBUPIVACAINE\n\nBUPRENORPHINE\n\nBUPROFEZIN\n\nBUPROPION  cross reference: AMFEBUTAMONE\n\nBUSERELIN\n\nBUSPIRONE\n\nBUSULPHAN\n\nBUTACAINE\n\nBUTACARB\n\nBUTAFENACIL\n\nBUTAMBEN  cross reference: BUTYL AMINOBENZOATE\n\n1,4‑BUTANEDIOL\n\ncross reference: CAS No. 110-63-4\n\nBUTHIDAZOLE\n\nBUTOBARBITAL\n\nBUTOBARBITONE  cross reference: BUTOBARBITAL\n\nBUTOCONAZOLE\n\nBUTONITAZENE\n\ncross reference: CAS No. 95810-54-1\n\nBUTORPHANOL\n\nBUTOXYCARBOXIM\n\n2‑BUTOXYETHANOL\n\nBUTOXYPOLYPROPYLENE GLYCOL\n\n2‑BUTOXY‑2'‑THIOCYANODIETHYL ETHER\n\nBUTRACONAZOLE\n\nBUTRALIN\n\nBUTROXYDIM\n\nn‑BUTYL ALCOHOL\n\nBUTYL AMINOBENZOATE  cross reference BUTAMBEN\n\nBUTYL BENZYL PHTHALATE\n\ncross reference: CAS No. 85-68-7\n\nn‑BUTYL BUTYRATE\n\nn‑BUTYL LACTATE\n\nBUTYL NITRITE\n\nBUTYLCHLORAL HYDRATE\n\nBUTYRIC ACID\n\nC\n\nCABAZITAXEL\n\nCABERGOLINE\n\nCABOTEGRAVIR\n\nCABOZANTINIB\n\nCACALIA spp.\n\nCACODYLIC ACID\n\nCADMIUM COMPOUNDS  cross reference: CADMIUM, CADMIUM ACETATE, CADMIUM CHLORIDE, CADMIUM NITRATE\n\nSchedule 6  Schedule 4  Appendix E, clause 3\n\nCADUSAFOS\n\nCAFFEINE  cross reference: PARACETAMOL, ASPIRIN, SALICYLAMIDE\n\nCAJUPUT OIL\n\nCALCIFEDIOL\n\nCALCIFEROL\n\nCALCIPOTRIOL\n\nCALCITONIN SALMON\n\nCALCITRIOL\n\nCALCIUM CARBIMIDE\n\nCALCIUM HYDROXYLAPATITE\n\nCALCIUM POLYSTYRENE SULPHONATE\n\nCALOTROPIS GIGANTEA\n\nCALOTROPIS PROCERA\n\nCALUSTERONE\n\nCAMBENDAZOLE\n\nCAMPHOR  cross reference: ESSENTIAL OILS, LAVANDIN OIL, ROSEMARY OIL, SHUI OIL\n\nCAMPHORATED OIL\n\nCAMPHOTAMIDE\n\nCANAGLIFLOZIN\n\nCANAKINUMAB\n\nCANDESARTAN CILEXETIL\n\nCANDICIDIN\n\nCANINE TICK ANTI‑SERUM\n\nCANNABICHROMENE  cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS\n\nCANNABIDIOL  cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS\n\nCANNABIDIOLIC ACID  cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS\n\nCANNABIDIVAROL  cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS\n\nCANNABIGEROL  cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS\n\nCANNABINOIDS  cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS\n\nCANNABINOL  cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS\n\nCANNABIS  cross reference: CANNABIS SATIVA, HEMP, HEMP SEED OIL, TETRAHYDROCANNABINOLS\n\nSchedule 9  Schedule 8  Appendix D, clause 1  Appendix K, clause 1\n\nCANTHARIDIN\n\nCAPECITABINE\n\nCAPREOMYCIN\n\nCAPROMORELIN\n\nAppendix D, clause 5\n\nCAPTAFOL\n\nCAPTAN\n\nCAPTODIAME\n\nCAPTOPRIL\n\nCAPURIDE\n\nCARAMIPHEN\n\nCARBACHOL\n\nCARBADOX\n\nCARBAMAZEPINE\n\nCARBAMIDE PEROXIDE\n\ncross reference: CAS No. 124-43-6\n\nCARBARYL\n\nCARBAZOCHROME\n\nCARBENDAZIM\n\nCARBENICILLIN\n\nCARBENOXOLONE\n\nCARBETAMIDE\n\nCARBETAPENTANE\n\nCARBETOCIN\n\nCARBIDOPA\n\nCARBIMAZOLE\n\nCARBOCISTEINE\n\nCARBOCROMEN\n\nCARBOFURAN\n\nCARBON DISULFIDE\n\nCARBON TETRACHLORIDE\n\nCARBONYL SULFIDE\n\nCARBOPHENOTHION\n\nCARBOPLATIN\n\nCARBOPROST\n\nCARBOSULFAN\n\nCARBOXIN\n\nCARBROMAL\n\nCARBUTAMIDE\n\nCARBUTEROL\n\nCARDARINE\n\ncross reference: CAS No. 317318-70-0\n\nCARFENTANYL\n\nCARFENTRAZONE‑ETHYL\n\nCARFILZOMIB.\n\nCARGLUMIC ACID\n\nCARINDACILLIN\n\nCARIPRAZINE\n\nCARISOPRODOL\n\nCARMUSTINE\n\nCARNIDAZOLE\n\nCARPROFEN\n\nCARVEDILOL\n\nCASIRIVIMAB\n\nCASPOFUNGIN\n\nCASSIA OIL\n\nCASTOR OIL, MONOMALEATE\n\nCATHINE\n\nCATHINONES  cross reference: SYNTHETIC CATHINONES\n\nCATUMAXOMAB\n\nCEDAZURIDINE\n\nCEFACETRILE  cross reference: CEPHACETRILE\n\nCEFACLOR\n\nCEFADROXIL\n\nCEFALEXIN  cross reference: CEPHALEXIN\n\nCEFALORIDINE  cross reference: CEPHALORIDINE\n\nCEFALOTIN  cross reference: CEPHALOTHIN, CEFALOTHIN\n\nCEFAMANDOLE  cross reference: CEPHAMANDOLE\n\nCEFAPIRIN  cross reference: CEPHAPIRIN\n\nCEFAZOLIN  cross reference: CEPHAZOLIN\n\nCEFEPIME\n\nCEFETAMET\n\nCEFIXIME\n\nCEFODIZIME\n\nCEFONICID\n\nCEFOPERAZONE\n\nCEFOTAXIME\n\nCEFOTETAN\n\nCEFOTIAM\n\nCEFOVECIN\n\nCEFOXITIN\n\nCEFPIROME\n\nCEFPODOXIME\n\nCEFQUINOME\n\nCEFSULODIN\n\nCEFTAROLINE FOSAMIL\n\nCEFTAZIDIME\n\nCEFTIBUTEN\n\nCEFTIOFUR\n\nCEFTRIAXONE\n\nCEFUROXIME\n\nCELECOXIB\n\nSchedule 4  Schedule 3  Appendix H, clause 1\n\nCELIPROLOL\n\nCELLULASE derived from Aspergillus niger\n\nCENEGERMIN\n\nCEPHAELIS ACUMINATA  cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA\n\nCEPHAELIS IPECACUANHA  cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA\n\nCEPHALEXIN  cross reference: CEFALEXIN\n\nCEPHALONIUM\n\nCEPHALOTHIN  cross reference: CEFALOTIN\n\nCEPHRADINE\n\nCERAMICS\n\nCERITINIB\n\nCERIVASTATIN\n\nCERLIPONASE ALFA\n\nCERTOLIZUMAB PEGOL\n\nCERULETIDE\n\nCETIRIZINE\n\nCETRORELIX\n\nCETUXIMAB\n\nCETYL ALCOHOL\n\nCHAMOMILE OIL\n\nCHEMISTRY SETS\n\nCHENODEOXYCHOLIC ACID\n\nCHINA CLAY\n\nCHLOPHEDIANOL\n\nCHLORAL FORMAMIDE\n\nCHLORAL HYDRATE\n\nCHLORALOSE  cross reference: ALPHA‑CHLORALOSE\n\nCHLORAMBUCIL\n\nCHLORAMPHENICOL\n\nCHLORANDROSTENOLONE\n\nCHLORANTRANILIPROLE\n\nCHLORAZANIL\n\nCHLORBUTANOL\n\nCHLORBUTOL   cross reference: CHLOROBUTANOL\n\nCHLORCYCLIZINE\n\nCHLORDANE\n\nCHLORDECONE\n\nCHLORDIAZEPOXIDE\n\nCHLORDIMEFORM\n\nCHLORFENAC\n\nCHLORFENAPYR\n\nCHLORFENETHOL\n\nCHLORFENSON\n\nCHLORFENVINPHOS\n\nCHLORFLUAZURON\n\nCHLORFLURENOL\n\nCHLORHEXIDINE\n\nCHLORIDAZON\n\nCHLORIDE\n\nCHLORINATING COMPOUNDS  cross reference: BLEACHES, BROMOCHLORODIMETHYLHYDANTOIN, TRICHLOROISOCYANURIC ACID, CALCIUM HYPOCHLORITE, CHLORINE, DICHLOROETHYL ETHER, SODIUM HYPOCHLORITE\n\nSchedule 6  Schedule 5  Appendix E, clause 3  Appendix F, clause 4  Appendix J, clause 1\n\nCHLORINE  cross reference: CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, DICHLOROISOCYANURIC ACID\n\nSchedule 7  Appendix G, clause 1  Appendix J, clause 1\n\nCHLORMEQUAT\n\nCHLORMERODRIN\n\nCHLORMETHIAZOLE\n\nCHLORMEZANONE\n\nCHLORNIDINE\n\nCHLOROACETAMIDE\n\nCHLOROCRESOL\n\n2‑CHLORO‑6‑(ETHYLAMINO)‑4‑NITROPHENOL\n\nCHLOROFORM\n\n4‑CHLOROMETHANDIENONE\n\nSchedule 4  Appendix D, clause D (Anabolic and/or androgenic steroidal agents)\n\nCHLOROMETHIURON\n\n5‑CHLORO‑3‑METHYL‑4‑NITROPYRAZOLE\n\n2‑CHLORO‑5‑NITRO‑N‑HYDROXYETHYL‑p‑PHENYLENEDIAMINE  cross reference: PHENYLENEDIAMINES\n\nCHLOROPHACINONE\n\n2‑(4‑CHLOROPHENYL)‑(1,2,4)TRIAZOLO[5,1‑A]ISOQUINOLINE\n\nCHLOROPICRIN\n\nCHLOROPICRIN\n\nCHLOROQUINE\n\nCHLOROTHALONIL\n\nCHLOROTHIAZIDE\n\n4‑CHLORO‑o‑TOLUIDINE\n\nCHLOROTRIANISENE\n\n2‑CHLORO‑6‑(TRICHLOROMETHYL)‑PYRIDINE\n\nCHLOROXYDIENONE\n\nCHLOROXYLENOLS\n\nCHLORPHENAMINE  cross reference: CHLORPHENIRAMINE\n\nCHLORPHENIRAMINE  cross reference: CHLORPHENAMINE\n\nCHLORPHENTERMINE\n\nCHLORPROMAZINE\n\nCHLORPROPAMIDE\n\nCHLORPROPHAM\n\nCHLORPROTHIXENE\n\nCHLORPYRIFOS\n\nCHLORPYRIFOS‑METHYL\n\nCHLORQUINALDOL\n\nCHLORSULFURON\n\nCHLORTALIDONE\n\nCHLORTETRACYCLINE\n\nCHLORTHAL‑DIMETHYL\n\nCHLORTHALIDONE  cross reference: CHLORTALIDONE\n\nCHLORTHIAMID\n\nCHLORTHIOPHOS\n\nCHLORZOXAZONE\n\nCHOLECALCIFEROL  cross reference: COLECALCIFEROL\n\nCHOLERA VACCINE\n\nCHOLESTYRAMINE  cross reference: COLESTYRAMINE\n\nCHOLIC ACID\n\nCHOLINE SALICYLATE\n\nCHROMATES  cross reference: AMMONIUM CHROMATE, BARIUM CHROMATE, CHROMIUM, COPPER‑CHROME‑ARSENIC, DICHROMATES, POTASSIUM CHROMATE, ZINC CHROMATE SODIUM CHROMATE, STRONTIUM CHROMATE\n\nCHROMIUM TRICHLORIDE HEXAHYDRATE\n\nCHROMIUM TRIOXIDE  cross reference: CHROMIC ACID\n\nCHRYSOIDINE BASE\n\ncross reference: CAS No. 495-54-5\n\nSchedule 10  Schedule 6  Appendix E, clause 3\n\nCHYMOPAPAIN\n\nCICLACILLIN\n\nCICLESONIDE\n\nCICLOPIROX\n\nCICLOSPORIN\n\nCIDOFOVIR\n\nCILASTATIN\n\nCILAZAPRIL\n\nCILGAVIMAB\n\nCILOSTAZOL\n\nCIMETIDINE\n\nCIMICOXIB\n\nCINACALCET\n\nCINCHOCAINE\n\nCINCHOPHEN\n\ncross reference: CAS No. 132-60-5, CINCHOPHEN HYDROCHLORIDE (CAS No. 132-58-1), CINCHOPHEN SODIUM (CAS No. 5949-18-8)\n\nCINEOLE  cross reference: CAMPHOR OIL (white), ROSEMARY OIL\n\nSchedule 7  Appendix E, clause 3\n\nCINMETHYLIN\n\nCINNAMEDRINE\n\nCINNAMON BARK OIL\n\nCINNAMON LEAF OIL\n\nCINNARIZINE\n\nCINOXACIN\n\nCIPROFLOXACIN\n\nCISAPRIDE\n\nCISATRACURIUM BESILATE   cross reference: CISATRACURIUM BESYLATE\n\nCIS‑JASMONE  cross reference: (Z)‑JASMONE\n\nCISPLATIN\n\nCITALOPRAM\n\nCITRONELLA OIL\n\nCJC‑1295 (CAS No. 863288‑34‑0)\n\nCLADRIBINE\n\nCLANOBUTIN\n\nCLARITHROMYCIN\n\nCLARY SAGE OIL\n\nCLASCOTERONE\n\nCLAVULANIC ACID\n\nCLEMASTINE\n\nCLEMIZOLE\n\nCLENBUTEROL\n\nCLETHODIM\n\nCLEVIDIPINE\n\nCLIDINIUM BROMIDE\n\nCLIMBAZOLE\n\nCLINDAMYCIN\n\nCLIOQUINOL  cross reference: OXYQUINOLINE, CHLORQUINALDOL, HALQUINOL (CAS No. 130-26-7)\n\nSchedule 10  Schedule 4\n\nCLITORIA TERNATEA EXTRACT\n\nCLOBAZAM\n\nCLOBETASOL\n\nCLOBETASONE\n\nCLOCORTOLONE\n\nCLODINAFOP‑PROPARGYL\n\nCLODRONIC ACID  cross reference: SODIUM CLODRONATE\n\nCLOFARABINE\n\nCLOFAZIMINE\n\nCLOFENAMIDE\n\nCLOFENTEZINE\n\nCLOFIBRATE\n\nCLOMAZONE\n\nCLOMIFENE  cross reference: CLOMIPHENE\n\nCLOMIPHENE  cross reference: CLOMIFENE\n\nCLOMIPRAMINE\n\nCLOMOCYCLINE\n\nCLONAZEPAM\n\nCLONAZOLAM\n\ncross reference: CAS No. 33887-02-4\n\nCLONIDINE\n\nCLONITAZENE\n\ncross reference: CAS No. 3861-76-5\n\nCLOPAMIDE\n\nCLOPIDOGREL\n\nCLOPIDOL\n\nCLOPROSTENOL\n\nCLOPYRALID\n\nCLOQUINTOCET\n\nCLORAZEPATE\n\nCLOREXOLONE\n\nCLORPRENALINE\n\nCLORSULON\n\nCLOSANTEL\n\nCLOSTEBOL  cross reference: 4‑CHLOROTESTOSTERONE\n\nCLOTHIANIDIN\n\nCLOTRIMAZOLE\n\nCLOVE OIL\n\nCLOXACILLIN\n\nCLOZAPINE\n\nSchedule 4  Appendix D, clause 1  Appendix K, clause 1\n\nCOAL TAR\n\nCOBALT  cross reference: DICOBALT EDETATE\n\nCOBALT NAPHTHENATE\n\nCOBICISTAT\n\nCOBIMETINIB\n\nCOCA LEAF\n\nCOCAINE\n\nN‑COCO‑1,3‑DIAMINOPROPANE\n\nCOCOYL GLYCINATE\n\nCOCOYL METHYL GLUCAMAIDE   cross reference: 1‑DEOXY‑1‑(METHYLAMINO)‑D‑GLUCITOL N‑COCO ACYL DERIVATIVES\n\nCODEINE\n\nCODEINE‑N‑OXIDE\n\nCO‑DERGOCRINE\n\nCODOXIME\n\ncross reference: CAS No. 7125-76-0\n\nCOLASPASE  cross reference: ASPARAGINASE\n\nCOLCHICINE\n\nCOLCHICUM AUTUMNALE\n\nCOLECALCIFEROL  cross reference: CHOLECALCIFEROL\n\nCOLESTIPOL\n\nCOLESTYRAMINE\n\nCOLFOSCERIL PALMITATE\n\nCOLISTIN\n\nCOLLAGEN\n\nCOLLAGENASE CLOSTRIDIUM HISTOLYTICUM\n\nCOLURACETAM  cross reference: RACETAMS\n\nCONCENTRATE OF POPPY STRAW\n\nCONCIZUMAB\n\nCONIUM MACULATUM  cross reference: CONIINE (CAS No. 3238-60-6), CONIINE R-ISOMER (CAS No. 5985-99-9), CONIINE S-ISOMER (CAS No. 458-88-8)\n\nCONVALLARIA KEISKI\n\nCONVALLARIA MAJALIS\n\nCOPPER ACETATE\n\nCOPPER COMPOUNDS  cross reference: COPPER\n\nSchedule 6  Schedule 5  Schedule 4  Appendix A, clause 1\n\nCOPPER HYDROXIDE\n\nCOPPER NITRATE  cross reference: COPPER CHLORIDE\n\nCOPPER OXIDES\n\nCOPPER OXYCHLORIDE\n\nCOPPER SULFATE\n\nCORIFOLLITROPIN ALFA  cross reference: FOLLICLE STIMULANT, RECOMBINANT\n\nCORONILLA spp.\n\nCORTICOSTERONE\n\nCORTICOTROPHIN\n\nCORTISONE\n\nCOTARNINE\n\ncross reference: CAS No. 82-54-2, COTARNINE HYDROCHLORIDE (CAS No. 36647-02-6), COTARNINE CHLORIDE (CAS No. 10018-19-6)\n\nCO‑TRIMOXAZOLE\n\nCOUMAPHOS\n\nCOUMARIN\n\nCOUMATETRALYL\n\nSchedule 7  Schedule 6  Schedule 5   Appendix J, clause 1\n\n4‑CPA\n\nCREOSOTE  cross reference: BEECHWOOD, PHENOL, WOOD\n\nSchedule 7  Schedule 6  Schedule 2  Appendix E, clause 3\n\nCRESOLS\n\nCRISABOROLE\n\nCRIZOTINIB\n\nCROFELEMER\n\nCROSPOVIDONE\n\nCROTALARIA spp.\n\nCROTON TIGLIUM  cross reference: CROTON OIL\n\nSchedule 10  Appendix G, clause 1\n\nCROTOXYPHOS\n\nCRUFOMATE\n\nCRYSTAL VIOLET  cross reference: METHYLROSANILINIUM CHLORIDE, GENTIAN VIOLET\n\nCULICINOMYCES CLAVOSPORUS\n\nCUPRIMYXIN\n\nCURARE\n\n13C‑UREA\n\nCYANAMIDE\n\nCYANATRYN\n\nCYANAZINE\n\nCYANIDES  cross reference: FERRICYANIDES, FERROCYANIDES\n\nCYANOACRYLATE ESTERS\n\nCYANOACRYLIC ACID ESTERS\n\n4‑CYANO‑2‑DIMETHYLAMINO‑4,4'‑DIPHENYLBUTANE  cross reference: METHADONE INTERMEDIATE (CAS No. 125-79-1)\n\nCYANOGEN  cross reference: ETHANEDINITRILE, OXALONITRILE\n\n4‑CYANO‑1‑METHYL‑4‑PHENYLPIPERIDINE  cross reference: PETHIDINE INTERMEDIATE A\n\nCYANTRANILIPROLE\n\nCYANURIC ACID\n\nCYAZOFAMID\n\nCYCLAMIC ACID\n\nCYCLANDELATE\n\nCYCLANILIDE\n\nCYCLANILIPROLE\n\nAppendix B\n\nCYCLIZINE\n\nCYCLOBARBITAL\n\nCYCLOBARBITONE  cross reference: CYCLOBARBITAL\n\nCYCLOBENZAPRINE\n\nCYCLOBUTRIFLURAM\n\nCYCLOFENIL\n\nCYCLOHEXANE\n\nCYCLOHEXANOL ACETATE\n\nCYCLOHEXANONE PEROXIDE\n\nCYCLOHEXIMIDE\n\nN‑CYCLOHEXYLDIAZENIUMDIOXY‑POTASSIUM  cross reference: K‑HDO\n\nCYCLOHEXYLPHENOLS\n\nCYCLOPENTHIAZIDE\n\nCYCLOPENTOLATE\n\nCYCLOPHOSPHAMIDE\n\nCYCLOPROPANE\n\nCYCLOPROTHRIN\n\nCYCLOSERINE\n\nSchedule 4  Appendix J, clause 1\n\nCYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2)\n\nCYCLOSPORIN  cross reference: CICLOSPORIN\n\nCYCLOTHIAZIDE\n\nCYCLOXYDIM\n\nCYCRIMINE\n\nSchedule 4  Appendix E, clause 3  Appendix F, clause 4\n\nCYFLUFENAMID\n\nCYFLUMETOFEN\n\nCYFLUTHRIN\n\nCYHALOFOP‑BUTYL\n\nCYHALOTHRIN\n\nCYHEXATIN\n\nCYMARIN\n\nCYMIAZOLE\n\nCYNOGLOSSUM spp.\n\nCYOMETRINIL\n\nCYPERMETHRIN  cross reference: ALPHA‑CYPERMETHRIN AND BETA‑CYPERMETHRIN, ZETA‑CYPERMETHRIN\n\nCYPHENOTHRIN\n\nCYPRINID HERPESVIRUS‑3\n\nCYPROCONAZOLE\n\nCYPRODINIL\n\nCYPROHEPTADINE\n\nCYPROTERONE\n\nCYROMAZINE\n\nCYSTEAMINE  cross reference: MERCAPTAMINE\n\nCYTARABINE\n\nCYTHIOATE\n\nD\n\n2,4‑D\n\nDABIGATRAN\n\nDABRAFENIB MESILATE\n\nDACARBAZINE\n\nDACLATASVIR\n\nDACLIZUMAB\n\nDACTINOMYCIN\n\nDALFOPRISTIN\n\nDALTEPARIN\n\nDAMINOZIDE\n\nDANAPAROID\n\nDANAZOL\n\nDANTHRON\n\nDANTROLENE\n\nDAPAGLIFLOZIN\n\nDAPOXETINE\n\nDAPSONE\n\nDAPTOMYCIN\n\nDARATUMUMAB\n\nDARBEPOETIN\n\nDARIFENACIN\n\nDAROLUTAMIDE\n\nDARUNAVIR\n\nDASABUVIR\n\nDASATINIB\n\nDATURA spp.\n\nDATURA STRAMONIUM  cross reference: STRAMONIUM\n\nDATURA TATULA  cross reference: STRAMONIUM\n\nDAUNORUBICIN\n\nDAZOMET\n\n2,4‑DB\n\nDEANOL  cross reference: 2‑(DIMETHYLAMINO)ETHANOL, DMEA, DIMETHYL MEA\n\nDEBRISOQUINE\n\nDECAMETHONIUM\n\nDECITABINE\n\nDECOQUINATE\n\nDEFERASIROX\n\nDEFERIPRONE\n\nDEFIBROTIDE\n\nDEFLAZACORT\n\nDEGARELIX \n\nDEHYDROCHLOROMETHYLTESTOSTERONE  cross reference: CHLOROMESTERONE\n\nDEHYDROCORTICOSTERONE\n\nDELAVIRDINE  cross reference: DELAVIRDINE MESILATE\n\nDELAVIRDINE MESILATE\n\nDELPHINIUM STAPHISAGRIA  cross reference: STAPHISAGRIA\n\nDELTAMETHRIN\n\nDEMBREXINE\n\nDEMECARIUM\n\nDEMECLOCYCLINE\n\nDEMETON\n\nDEMETON‑O‑METHYL\n\nDEMETON‑S‑METHYL\n\nDENGUE VACCINE  cross reference: LIVE ATTENUATED CHIMERIC DENGUE VIRUS (SEROTYPES 1, 2, 3 and 4)\n\nDENOSUMAB\n\nDEOXYCHOLIC ACID\n\nDEOXYCORTONE\n\n1‑DEOXY‑1‑(METHYLAMINO)‑D‑GLUCITOL N‑COCO ACYL DERIVATIVES  cross reference: COCOYL METHYL GLUCAMAIDE\n\nDEOXYRIBONUCLEASE\n\nDERACOXIB\n\nDERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT\n\nDERQUANTEL\n\n2,4‑DES\n\nDESCHLOROETIZOLAM\n\ncross reference: CAS No. 40054-73-7\n\nDESFERRIOXAMINE\n\nDESFLURANE\n\nDESIPRAMINE\n\nDESIRUDIN\n\nDESLANOSIDE\n\nDESLORATADINE\n\nDESLORELIN\n\nDESMOPRESSIN  cross reference: D.D.A.V.P.\n\nDESOGESTREL\n\nDESOMORPHINE\n\ncross reference: CAS No. 427-00-9\n\nDESONIDE\n\nDESOXYMETHASONE\n\nDESVENLAFAXINE\n\nDETOMIDINE\n\nDEUCRAVACITINIB\n\nDEUTETRABENAZINE\n\nDEXAMETHASONE\n\nDEXAMFETAMINE  cross reference: DEXAMPHETAMINE\n\nDEXCHLORPHENAMINE  cross reference: DEXCHLORPHENIRAMINE\n\nDEXCHLORPHENIRAMINE  cross reference: DEXCHLORPHENAMINE\n\nDEXFENFLURAMINE\n\nDEXMEDETOMIDINE\n\nDEXTRANS\n\nDEXTROMETHORPHAN\n\nDEXTROMORAMIDE  cross reference: MORAMIDE\n\nDEXTROPROPOXYPHENE\n\nSchedule 8  Schedule 4  Appendix D, clause 5  Appendix K, clause 1\n\nDEXTRORPHAN\n\nN,N‑DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES  cross reference: 3,4‑DICHLORO‑N‑[(1R,2R)‑2‑(DIMETHYLAMINO)CYCLOHEXYL]‑N‑METHYLBENZAMIDE *(U‑47700) (CAS No. 82657-23-6)\n\nN,N‑DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES   Cross reference: 3,4‑DICHLORO‑N‑{[1‑(DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH‑7921) (CAS No. 55154-30-8)\n\n4,4‑DIAMINODIPHENYLMETHANE  cross reference: METHYLENE DIANILINE\n\n2,4‑DIAMINO‑5‑METHYLPHENETOLE  cross reference: PHENYLENEDIAMINES\n\n2,4‑DIAMINOPHENOXYETHANOL\n\nDIAFENTHIURON\n\nDIALIFOS\n\nN,N‑DIALLYLDICHLOROACETAMIDE\n\nDIAMPROMIDE\n\ncross reference: CAS No. 552-25-0\n\nDIAMTHAZOLE\n\nDIAVERIDINE\n\nDIAZEPAM\n\nDIAZINON\n\nDIAZOXIDE\n\nDIBENZEPIN\n\nDIBENZOPYRANS\n\nDIBOTERMIN\n\n1,2‑DIBROMO‑3‑CHLOROPROPANE\n\nDIBROMOPROPAMIDINE\n\nDIBUTYL PHTHALATE\n\ncross reference: CAS No. 84-74-2\n\nDICAMBA\n\nDICLAZEPAM\n\ncross reference: CAS No. 2894-68-0\n\nDICHLOBENIL\n\no‑DICHLOROBENZENE\n\nDICHLOEOETHYL ETHER\n\nDICHLOFENTHION\n\nDICHLOFLUANID\n\nDICHLONE\n\nDICHLORALPHENAZONE\n\nDICHLOROBENZENE\n\n3,4‑DICHLORO‑N‑[(1R,2R)‑2‑(DIMETHYLAMINO)CYCLOHEXYL]‑N‑METHYLBENZAMIDE (U‑47700)  cross reference: N,N‑DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES (CAS No. 82657-23-6)\n\nDICHLOROETHYL ETHER\n\nDICHLOROETHYLENE\n\nDICHLOROISOCYANURIC ACID  cross reference: CHLORINE, CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, SODIUM DICHLOROISOCYANURATE\n\nDICHLOROMETHANE  cross reference: METHYLENE CHLORIDE\n\n3,4‑DICHLORO‑N‑{[1‑DIMETHYLAMINO)CYCLOHEXYL]METHYL}  BENZAMIDE  cross reference: AH‑7921 (CAS No. 55154-30-8)\n\n4,5‑DICHLORO‑2‑N‑OCTYL‑3(2H)‑ISOTHIAZOLONE\n\nDICHLOROPHEN\n\n2,4‑DICHLORPROP\n\n1,2‑DICHLOROPROPANE\n\n1,3‑DICHLOROPROPENE\n\nDICHLORPHENAMIDE\n\nDICHLORVOS\n\nDICHROMATES\n\nDICLAZURIL\n\nDICLOBUTRAZOL\n\nDICLOFENAC\n\nDICLOFOP‑METHYL\n\nDICLORAN\n\nDICLOXACILLIN\n\nDICOFOL\n\nDICOPHANE  cross reference: DDT (CAS No. 50-29-3)\n\nDICROTOPHOS\n\nDICYCLANIL\n\nDICYCLOMINE\n\nDIDANOSINE\n\nDIDECYLDIMETHYLAMMONIUM SALTS\n\nDIELDRIN\n\nDIENESTROL\n\nDIENOGEST\n\nDIESEL\n\nDIETHANOLAMINE\n\nDIETHAZINE\n\nDIETHYL CARBONATE\n\nDIETHYLCARBAMAZINE\n\nDIETHYLENE GLYCOL  cross reference: DENATONIUM BENZOATE (CAS No. 111-46-6)\n\nSchedule 10  Schedule 6  Schedule 5\n\nDIETHYLENE GLYCOL MONOBUTYL ETHER\n\nDIETHYLENE GLYCOL MONOMETHYL ETHER\n\ncross reference: CAS No. 111-77-3\n\nDIETHYLHEXYL PHTHALATE\n\ncross reference: DEHP (CAS No. 117-81-7)\n\nDIETHYLPHTHALATE\n\ncross reference: CAS No. 84-66-2\n\nDIETHYLPROPION\n\nDIETHYLTHIAMBUTENE\n\ncross reference: CAS No. 86-14-6, DIETHYLTHIAMBUTENE HYDROCHLORIDE (CAS No. 132-19-4)\n\nDIETHYLTOLUAMIDE (DEET)\n\nN,N‑DIETHYLTRYPTAMINE  cross reference: DET (CAS No. 61-51-8)\n\nDIFELIKEFALIN\n\nSchedule 4  Appendix K, clause 1\n\nDIFENACOUM\n\nDIFENOCONAZOLE\n\nDIFENOXIN\n\nDIFENZOQUAT\n\nDIFETHIALONE\n\nDIFLORASONE\n\nDIFLOXACIN\n\nDIFLUBENZURON\n\nDIFLUCORTOLONE\n\nDIFLUFENICAN\n\nDIFLUNISAL\n\nDIGITALIS LANATA\n\nDIGITALIS PURPUREA\n\nDIGITOXIN\n\nDIGOXIN\n\nDIGOXIN‑SPECIFIC ANTIBODY FRAGMENT F (Ab)\n\nDIHYDRALAZINE\n\nDIHYDROCODEINE\n\nSchedule 8  Schedule 4  Schedule 3  Appendix K, clause 1\n\nDIHYDROERGOTOXINE\n\nDIHYDROLONE\n\n2,5‑DIHYDRO‑2‑(1‑METHYL‑1‑PHENYLETHYL)‑5‑PENTYL‑1H‑PYRIDO[4,3‑B]INDOL‑1‑ONE (SGT‑151)  cross reference: SGT‑151, CUMYL‑PEGACLONE (CAS No. 2160555-55-3)\n\nDIHYDROMORPHINE\n\nDIHYDROSTREPTOMYCIN\n\nDIHYDROTACHYSTEROL\n\n5,6‑DIHYDROXYINDOLINE\n\ncross reference: CAS No. 29539-03-5, 5,6-DIHYDROXYINDOLINE HYDROBROMIDE (CAS No. 138937-28-7)\n\nDIIODOHYDROXYQUINOLINE   cross reference: IODOQUINOL (CAS No. 83-73-8)\n\nSchedule 10  Schedule 4  Schedule 3\n\nDI‑IODOHYDROXYQUINOLINE  cross reference: DIIODOHYDROXYQUINOLINE\n\nDIISOBUTYL PHTHALATE\n\ncross reference: CAS No. 84-69-5\n\nDIISOPROPYLAMINE DICHLOROACETATE\n\nDIKEGULAC‑SODIUM\n\nDILTIAZEM\n\nDIMEFOX\n\nDIMENHYDRINATE\n\nSchedule 4  Schedule 3  Schedule 2  Appendix H, clause 1  Appendix K, clause 1\n\nDIMENOXADOL\n\ncross reference: CAS No. 509-78-4, DIMENOXADOL HYDROCHLORIDE (CAS No. 2424-75-1)\n\nDIMEPHEPTANOL\n\ncross reference: CAS No. 545-90-4\n\nDIMERCAPROL\n\nDIMETHANDROSTANOLONE\n\nDIMETHAZINE\n\nDIMETHENAMID‑P\n\nDIMETHICODIETHYLBENZALMALONATE  cross reference: POLYSILICONE‑15\n\nDIMETHICONE  cross reference: DIMETICONE\n\nDIMETHINDENE\n\nDIMETHIPIN\n\nDIMETHIRIMOL\n\nDIMETHOATE\n\nDIMETHOMORPH\n\nDIMETHOTHIAZINE\n\nDIMETHOXANATE\n\n2,5‑DIMETHOXYAMFETAMINE  cross reference: 2,5‑DIMETHOXYAMPHETAMINE, DMA (CAS No. 2801-68-5), DMA HYDROCHLORIDE (CAS No. 24973-25-9)\n\n2,5‑DIMETHOXY‑4‑BROMOAMFETAMINE  cross reference: 2,5‑DIMETHOXY‑4‑BROMOAMPHETAMINE, DOB (CAS No. 64638-07-9)\n\n2,5‑DIMETHOXY‑4‑ETHYL‑a‑AMFETAMINE  cross reference: 2,5‑DIMETHOXY‑4‑ETHYL‑a‑AMPHETAMINE, DOET (CAS No. 22004-32-6), DOET HYDROCHLORIDE (CAS No. 22139-65-7)\n\n2,5‑DIMETHOXY‑4‑ETHYLTHIOPHENETHYLAMINE  cross reference: 2C‑T‑2 (CAS No. 207740-24-7)\n\n2,5‑DIMETHOXY‑4‑IODOPHENETHYLAMINE  cross reference: 2C‑I (CAS No. 69587-11-7)\n\n2,5‑DIMETHOXY‑4‑(N)‑PROPYLTHIOPHENETHYLAMINE  cross reference: 2C‑T‑7 (CAS No. 207740-26-9)\n\n2,6‑DIMETHOXY‑3,5‑PYRIDINEDIAMINE\n\nDIMETHYLACETAMIDE\n\nN,N‑DIMETHYLAMFETAMINE  cross reference: N,N‑DIMETHYLAMPHETAMINE, DIMETAMFETAMINE (CAS No. 4075-96-1), DIMETAMFETAMINE S-ISOMER (CAS No. 17279-39-9)\n\n4‑DIMETHYLAMINOAZOBENZENE  cross reference: MOCA, N,N‑DIMETHYL‑4‑[PHENYLAZO]‑BENZENAMINE\n\n3‑(2‑DIMETHYLAMINOETHYL)‑4‑HYDROXYINDOLE  cross reference: PSILOCINE, PSILOTSIN (CAS No. 520-53-6)\n\n1,3‑DIMETHYLAMYLAMINE  cross reference: 4‑METHYLHEXANE‑2‑AMINE, DMAA (CAS No. 105-41-9)\n\n1,3‑DIMETHYLBUTYLAMINE (DMBA)  cross reference: OCTODRINE, 1‑AMINOISOHEPTANE, DMHA, 1,5‑DIMETHYLHEXYLAMINE, 4‑METHYLHEXANE‑2‑AMINE, 1,3‑DIMETHYLAMYLAMINE, DMAA, 4‑AMINO‑2‑METHYLPENTANE CITRATE (AMP CITRATE), (CAS No. 108-09-8)\n\n4,4‑DIMETHYL‑1‑CYCLOHEXENE‑1‑PROPANAL\n\nN,N‑DIMETHYLDECANAMIDE\n\nDIMETHYL ETHER\n\n1‑(1,1‑DIMETHYLETHYL)‑2‑METHOXY‑4‑METHYL‑3,5‑DINITROBENZENE (musk ambrette)  cross reference: AMBER MUSK (CAS No. 83-66-9)\n\nDI(METHYLOXYETHYL) PHTHALATE\n\ncross reference: CAS No. 117-82-8\n\n1,4‑DIMETHYLPENTYLAMINE (DMPA)  cross reference: 1,4‑DIMETHYLAMYLAMINE (DMAA) (CAS No. 28292-43-5)\n\nDIMETHYLFORMAMIDE  cross reference: DESIGNATED SOLVENT\n\nDIMETHYL FUMARATE\n\n3‑(1,2‑DIMETHYLHEPTYL)‑1‑HYDROXY‑7,8,9,10‑TETRAHYDRO‑6,6,9‑ TRIMETHYL‑6H‑DIBENZO (b,d) PYRAN  cross reference: DMHP (CAS No. 32904-22-6)\n\n1,5‑DIMETHYLHEXYLAMINE (DMHA)  cross reference: 1,3‑DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1‑AMINOISOHEPTANE, DMHA, 4‑METHYLHEXANE‑2‑AMINE, 1,3‑DIMETHYLAMYLAMINE, DMAA, 4‑AMINO‑2‑METHYLPENTANE CITRATE (AMP CITRATE), (CAS No. 543-82-8), 1,5-DIMETHYLHEXYLAMINE HYDROCHLORIDE (CAS No. 5984-59-8), 1,5-DIMETHYLHEXYLAMINE S-ISOMER (CAS No. 70419-10-2), 1,5-DIMETHYLHEXYLAMINE R-ISOMER (CAS No. 70419-11-3)\n\nN, α ‑DIMETHYL‑3,4‑(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA)  cross reference: 3,4‑METHYLENEDIOXY‑N‑α‑DIMETHYLPHENYLETHYLAMINE, MDMA, MIDOMAFETAMINE (CAS No. 42542-10-9), MDMA HYDROCHLORIDE (CAS No. 64057-70-1)\n\nSchedule 9  Schedule 8  Appendix D, clause 5  Appendix D, clause 10\n\n3,7‑DIMETHYL‑2,6‑OCTADIENAL  cross reference: CITRAL, NERAL, GERANIAL\n\n3,7‑DIMETHYL‑2,6‑OCTADIEN‑1‑OL  cross reference: GERANIOL, NEROL, CITROL\n\nN,N‑DIMETHYLOCTANAMIDE\n\nDIMETHYLPHTHALATE\n\ncross reference: CAS No. 131-11-3\n\nDIMETHYL SULFATE\n\nDIMETHYL SULFOXIDE  cross reference: COPPER SALICYLATE, METHYL SALICYLATE\n\nDIMETHYLTHIAMBUTENE\n\ncross reference: CAS No. 524-84-5\n\nN,N‑DIMETHYLTRYPTAMINE  cross reference: DMT (CAS No. 61-50-7)\n\nDIMETICONE  cross reference: DIMETHICONE\n\nDIMETILAN\n\nDIMETRIDAZOLE\n\nDIMIRACETAM  cross reference: RACETAMS\n\nDIMPROPYRIDAZ\n\nDINICONAZOLE\n\n2,4‑DINITROCHLOROBENZENE\n\nDINITROCRESOLS\n\nSchedule 7  Schedule 6  Schedule 4  Appendix E, clause 3  Appendix J, clause 1\n\nDINITRONAPHTHOLS\n\n2,4‑DINITROPHENOL  cross reference: CAS No. 51‑28‑5  Schedule 10\n\nDINITROPHENOLS\n\nSchedule 7  Schedule 6  Schedule 4  Appendix E, clause 3  Appendix F, clause 4  Appendix J, clause 1\n\nDINITROTHYMOLS\n\nDINOCAP\n\nDINOPROST\n\nDINOPROSTONE\n\nDINOSEB\n\nDINOTEFURAN\n\nDI‑n‑PROPYL ISOCINCHOMERONATE (previously di‑N propyl isocinchomeronate)\n\nDIOXACARB\n\nDIOXANE\n\nDIOXAPHETYL BUTYRATE\n\ncross reference: CAS No. 467-86-7\n\nDIPERODON\n\nDIPHACINONE\n\nDIPHEMANIL\n\nDIPHENAMID\n\nDIPHENHYDRAMINE\n\nDIPHENIDOL\n\nDIPHENOXYLATE\n\nSchedule 8  Schedule 4  Schedule 3  Appendix F, clause 4  Appendix H, clause 1  Appendix K, clause 1\n\nDIPHENYLAMINE\n\nDIPHENYLPYRALINE\n\nDIPHTHERIA TOXOID\n\nDIPIPANONE\n\nDIPIVEFRIN\n\nDIPROPYLENE GLYCOL\n\nDIPYRIDAMOLE\n\nDIQUAT\n\nDIRECT RED 254  cross reference: 2‑NAPHTHALENESULFONIC ACID, 7‑AMINO‑4‑HYDROXY‑3‑[[p‑[(p‑SULFOPHENYL)AZO]PHENYL]AZO]‑, (3Z)‑7‑AMINO‑4‑OXO‑3‑[[4‑[(4‑SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE‑2‑SULFONIC ACID, (3Z)‑7‑AMINO‑4‑OXO‑3‑[[4‑[(4‑SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE‑2‑SULFONIC ACID BIS(TRIETHANOLAMINE) SALT, (3Z)‑7‑AMINO‑4‑OXO‑3‑[[4‑[(4‑SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE‑2‑SULFONIC ACID DISODIUM SALT\n\nDIRITHROMYCIN\n\nDIRLOTAPIDE\n\nDIROXIMEL FUMARATE\n\nDISODIUM MANGANESE EDTA\n\nDISOPHENOL\n\nDISOPYRAMIDE\n\nDISPERSE YELLOW 3\n\ncross reference: CAS No. 2832-40-8\n\nDISTIGMINE\n\nDISTILLATE\n\nDISULFIRAM\n\nDISULFOTON\n\nDISULPHAMIDE\n\nDITHIANON\n\nDITHIAZANINE\n\nDITHIOPYR\n\nDITHRANOL\n\nDITIOCARB\n\nDIUREDOSAN\n\nDIURON\n\nDOBUTAMINE\n\nDOCETAXEL\n\nDOCUSATE SODIUM  cross reference: DIOCTYL SODIUM SULFOSUCCINATE\n\nN‑(N‑DODECYL)‑2‑PYRROLIDONE  cross reference: DESIGNATED SOLVENT, N‑(N‑OCTYL)‑2‑PYRROLIDONE, N‑METHYL‑2‑PYRROLIDONE\n\nDODINE\n\nDOFETILIDE\n\nDOLASETRON\n\nDOLUTEGRAVIR\n\nDOMPERIDONE\n\nDONEPEZIL\n\nDOPAMINE\n\nDOPEXAMINE\n\nDORAMECTIN\n\nDORAVIRINE\n\nDORIPENEM\n\nDORNASE\n\nDORZOLAMIDE\n\nDOSULEPIN  cross reference: DOTHIEPIN.\n\nDOTHIEPIN  cross reference: DOSULEPIN\n\nDOXANTRAZOLE\n\nDOXAPRAM\n\nDOXAZOSIN\n\nDOXEPIN\n\nDOXORUBICIN\n\nDOXYCYCLINE\n\nDOXYLAMINE\n\n2,2‑DPA  cross reference: SODIUM 2,2‑DICHLOROPROPIONATE\n\nDROMETRIZOLE TRISILOXANE\n\nDRONABINOL  cross reference: DELTA‑9‑TETRAHYDROCANNABINOL, NABIXIMOLS\n\nSchedule 8  Appendix D, clause 3  Appendix K, clause 1\n\nDRONEDARONE\n\nDROPERIDOL\n\nDROSPIRENONE\n\nDROSTANOLONE\n\nDROTEBANOL\n\nDROTRECOGIN\n\nDSMA\n\nDUBOISIA LEICHHARDTII\n\nDUBOISIA MYOPOROIDES\n\nDUDDINGTONIA FLAGRANS, STRAIN IAH 1297\n\nDULAGLUTIDE\n\nDULCIN\n\ncross reference: CAS No. 150-69-6\n\nDULOXETINE\n\nDUPILUMAB\n\nDURVALUMAB\n\nDUTASTERIDE\n\nDYDROGESTERONE\n\nE\n\n(E)‑(S)‑1‑(4‑CHLOROPHENYL)‑4,4‑DIMETHYL‑2‑(1H‑1,2,4‑TRIAZOL‑1‑YL)PENT‑1‑EN‑3‑OL  cross reference: UNICONAZOLE‑P\n\nECGONINE\n\ncross reference: CAS No. 481-37-8, ECGONINE HYDROCHLORIDE (CAS No. 5796-31-6), ECGONINE RACEMATE (CAS No. 876657-17-9)\n\nECONAZOLE\n\nECOTHIOPATE  cross reference: ECOTHIOPATE IODIDE\n\nECTYLUREA\n\nECULIZUMAB\n\nEDARAVONE\n\nEDETIC ACID  cross reference: DICOBALT EDETATE\n\nEDOXUDINE\n\nEDROPHONIUM\n\nEFALIZUMAB\n\nEFAVIRENZ\n\nEFLORNITHINE\n\nEFORMOTEROL  cross reference: FORMOTEROL\n\nELBASVIR\n\nELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS\n\nELECTRONIC COMPONENTS\n\nELETRIPTAN\n\nELEXACAFTOR\n\nELOSULFASE ALFA\n\nELOTUZUMAB\n\nELRANATAMAB\n\nELTENAC\n\nELTROMBOPAG\n\nELUXADOLINE\n\nELVITEGRAVIR\n\nEMAMECTIN\n\nEMEPRONIUM\n\nEMETINE  cross reference: CEPHAELIS ACUMINATA\n\nEMODEPSIDE\n\nEMPAGLIFLOZIN\n\nEMTRICITABINE\n\nENALAPRIL\n\nENASIDENIB\n\nENCORAFENIB\n\nENDOSULFAN\n\nENDOTHAL\n\nENDRIN\n\nENESTEBOL\n\nENFLURANE\n\nENFORTUMAB VEDOTIN\n\nENFUVIRTIDE\n\nENHANCING AGENTS  cross reference: MAGNETIC RESONANCE IMAGING ENHANCING AGENTS, ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING\n\nENOBOSARM\n\nSchedule 4  Appendix D, clause 5 (SELECTIVE ANDROGEN RECEPTOR MODULATORS)\n\nENOXACIN\n\nENOXAPARIN\n\nENOXIMONE\n\nENPROSTIL\n\nENROFLOXACIN\n\nENTACAPONE\n\nENTECAVIR\n\nENTRECTINIB\n\nENZALUTAMIDE\n\nEPHEDRA spp.\n\nEPHEDRINE  cross reference: EPHEDRA\n\nSchedule 4  Appendix D, clause 5  Appendix F, clause 4\n\nEPICHLOROHYDRIN\n\nEPICILLIN\n\nEPIDERMAL GROWTH FACTOR  cross reference: SH‑OLIGOPEPTIDE‑1, RH‑OLIGOPEPTIDE‑1\n\nSchedule 7  Appendix G, clause 1  Appendix J, clause 1\n\nEPINASTINE\n\nEPINEPHRINE  cross reference: ADRENALINE\n\nEPIRUBICIN\n\nEPITIOSTANOL\n\nEPLERENONE\n\nEPOETINS  cross reference: METHOXY POLYETHYLENE GLYCOL‑EPOETIN BETA\n\nEPOPROSTENOL\n\nEPOXICONAZOLE\n\nEPOXY RESINS, LIQUID  cross reference: RESINS\n\nSchedule 5  Appendix E, clause 3   Appendix F, clause 4\n\nEPRINOMECTIN\n\nEPROSARTAN\n\nEPSIPRANTEL\n\nEPTC\n\nEPTIFIBATIDE\n\nEQUINE ANTI‑HUMAN THYMOCYTE IMMUNOGLOBULIN   cross reference: IMMUNOGLOBULINSERGOMETRINE\n\nERENUMAB\n\nERGOT\n\nERGOTAMINE\n\nERGOTOXINE\n\nERIBULIN MESILATE  cross reference: ERIBULIN MESYLATE\n\nERLOTINIB\n\nERTAPENEM\n\nERTUGLIFLOZIN\n\nERYSIMUM spp.\n\nERYTHRITYL TETRANITRATE\n\nERYTHROMYCIN\n\nERYTHROPOIETIN\n\nERYTHROPOIETINS\n\nESBIOTHRIN\n\nESCITALOPRAM\n\nESFENVALERATE\n\nESKETAMINE\n\nESLICARBAZEPINE ACETATE\n\nESMOLOL\n\nESOMEPRAZOLE\n\nSchedule 4  Schedule 2  Appendix H, clause 1\n\nESTETROL MONOHYDRATE\n\nESTRADIOL\n\nSchedule 5  Schedule 4  Appendix G, clause 1\n\nESTRAMUSTINE\n\nESTRIOL\n\nESTROGENS\n\nESTRONE\n\nESTROPIPATE  cross reference: PIPERAZINE ESTRONE SULFATE\n\nETACONAZOLE\n\nETACRYNIC ACID\n\nETAFEDRINE\n\nETANERCEPT\n\nETHACRYNIC ACID  cross reference: ETACRYNIC ACID\n\nETHALFLURALIN\n\nETHAMBUTOL\n\nETHAMETSULFURON‑METHYL\n\nETHAMIVAN\n\n1,2‑ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND N‑METHYLMETHANAMINE  cross reference: N‑METHYLMETHANAMINE\n\nETHANOL  cross reference: ETHYL ALCOHOL\n\nETHANOLAMINE   cross reference: MONOETHANOLAMINE\n\nETHCHLORVYNOL\n\nETHEPHON\n\nETHER\n\nSchedule 6  Schedule 5  Schedule 4  Schedule 2  Appendix E, clause 3  Appendix F, clause 4\n\nETHERIFIED STARCHES\n\nETHINAMATE\n\nETHINYLESTRADIOL\n\nETHINYLOESTRADIOL  cross reference: ETHINYLESTRADIOL\n\nETHIOFENCARB\n\nETHION\n\nETHIONAMIDE\n\nETHISTERONE\n\nETHOATE‑METHYL\n\nETHOFUMESATE\n\nETHOGLUCID\n\nETHOHEPTAZINE\n\nETHOPABATE\n\nETHOPROPAZINE\n\nETHOPROPHOS  cross reference: LINSEED OIL\n\nETHOSUXIMIDE\n\nETHOTOIN\n\n2‑ETHOXYETHANOL\n\nETHOXYETHYLMERCURIC CHLORIDE\n\nETHOXYQUIN\n\nETHOXYSULFURON\n\nETHOXZOLAMIDE\n\nETHYL ACETATE\n\nETHYL ALCOHOL\n\nETHYL BROMIDE\n\nETHYL BUTYRATE\n\nETHYL CHLORIDE\n\nETHYL FORMATE\n\nETHYL LACTATE\n\nETHYL METHACRYLATE\n\nETHYLAMFETAMINE  cross reference: ETHYLAMPHETAMINE\n\nETHYLBUTYLACETYL‑\n\nETHYLDIENOLONE\n\nETHYLENE CHLOROHYDRIN\n\nETHYLENE DIBROMIDE\n\nETHYLENE DICHLORIDE\n\nETHYLENE GLYCOL  cross reference: DENATONIUM BENZOATE (CAS No. 107-21-1)\n\nSchedule 10  Schedule 6  Schedule 5  Appendix E, clause 3\n\nETHYLENE GLYCOL MONOALKYL ETHERS\n\nETHYLENE OXIDE\n\nETHYLESTRENOL  cross reference: ETHYLOESTRENOL\n\nETHYLHEXANEDIOL\n\ncross reference: ETHOHEXADIOL  Schedule 6  Appendix E, clause 3  Appendix F, clause 4\n\n2‑ETHYLHEXANOIC ACID\n\nETHYLMERCURIC CHLORIDE\n\nN‑ETHYL‑α‑METHYL‑3,4‑(METHYLENEDIOXY)PHENETHYLAMINE  cross reference: N‑ETHYL MDA (CAS No. 82801-81-8), N-ETHYL MDA HYDROCHLORIDE (CAS No. 74341-78-9)\n\nETHYLMETHYLTHIAMBUTENE\n\ncross reference: CAS No: 441-61-2\n\nETHYLMORPHINE\n\nSchedule 8  Schedule 4  Schedule 2  Appendix K, clause 1\n\nETHYLOESTRENOL  cross reference: ETHYLESTRENOL\n\nETHYNODIOL  cross reference: ETYNODIOL\n\nETICYCLIDINE  cross reference: PCE (CAS No. 2201-15-2)\n\nETIDOCAINE\n\nETIDRONIC ACID  cross reference: ETIDRONATE DISODIUM\n\nETILEFRIN\n\nETIPROSTON\n\nETODESNITAZENE\n\ncross reference: CAS No. 14030-76-3, ETAZENE\n\nETODOLAC\n\nETOFENAMATE\n\nETOFENPROX\n\nETONITAZENE\n\ncross reference: CAS No. 911-65-9\n\nETONITAZEPIPNE\n\ncross reference: CAS No. 734496-28-7, N-PIPERIDINO ETONITAZENE\n\nETONITAZEPYNE\n\ncross reference: CAS No. 2785346-75-8, N-PYRROLIDINO ETONITAZENE\n\nETONOGESTREL\n\nETOPOSIDE\n\nETORICOXIB\n\nETORPHINE\n\ncross reference: CAS No. 14521-96-1\n\nETOXAZOLE\n\nETOXERIDINE\n\ncross reference: CAS No. 469-82-9\n\nETRANACOGENE DEZAPARVOVEC\n\nETRASIMOD\n\nETRAVIRINE\n\nETRETINATE\n\nSchedule 4  Appendix D, clause 5  Appendix F, clause 4  Appendix L, clause 2\n\nETRIDIAZOLE\n\nETRIMFOS\n\nETYNODIOL  cross reference: ETHYNODIOL\n\nEUBACTERIUM sp. strain DSM11798\n\nEUCALYPTUS OIL\n\nEUGENOL\n\nEUPATORIUM CANNABINUM  cross reference: HEMP AGRIMONY\n\nEVEROLIMUS\n\nEXEMESTANE\n\nEXENATIDE\n\nEXPLOSIVES\n\nEXTRACT OF LEMON EUCALYPTUS  cross reference: CORYMBIA CITRIODORA, OIL OF LEMON EUCALYPTUS\n\nEZETIMIBE\n\nF\n\nFAMCICLOVIR\n\nFAMOTIDINE\n\nFAMOXADONE\n\nFAMPHUR\n\nFARFUGIUM JAPONICUM\n\nFARICIMAB\n\nSchedule 4  Appendix L, clause 2\n\nFASORACETAM  cross reference: RACETAMS\n\nFEBANTEL\n\nFEBUXOSTAT\n\nFELBINAC\n\nFELODIPINE\n\nFELYPRESSIN\n\nFENAMIPHOS\n\nFENARIMOL\n\nFENAZAFLOR\n\nFENBENDAZOLE\n\nFENBUCONAZOLE\n\nFENBUFEN\n\nFENBUTATIN OXIDE\n\nFENCAMFAMIN\n\nFENCHLORAZOLE‑ETHYL\n\nFENCHLORPHOS\n\nFENCLOFENAC\n\nFENETYLLINE\n\ncross reference: CAS No. 3736-08-1, FENETYLLINE HYDROCHLORIDE (CAS No. 1892-80-4)\n\nFENFLURAMINE\n\nFENFURAM\n\nFENHEXAMID\n\nFENITROTHION\n\nFENNEL OIL\n\nFENOFIBRATE\n\nFENOLDOPAM\n\nFENOPROFEN\n\nFENOPROP\n\nFENOTEROL\n\nFENOXACRIM\n\nFENOXAPROP‑ETHYL\n\nFENOXAPROP‑p‑ETHYL\n\nFENOXYCARB\n\nFENPIPRAMIDE\n\nFENPIPRANE\n\nFENPROPIDIN\n\nFENPROPOREX\n\nFENPROSTALENE\n\nFENPYRAZAMINE\n\nFENPYROXIMATE\n\nFENSON\n\nFENSULFOTHION\n\nFENTANYL\n\nFENTEROL\n\nFENTHION\n\nFENTHION‑ETHYL\n\nFENVALERATE\n\nFERRIC DERISOMALTOSE\n\nFEXOFENADINE\n\nFEZOLINETANT\n\nFIBRINOLYSIN\n\nFIBROBLAST GROWTH FACTORS\n\nFIDAXOMICIN\n\nFILGOTINIB\n\nFILGRASTIM\n\nFINASTERIDE\n\nFINERENONE\n\nFINGOLIMOD\n\nFIPRONIL\n\nFIROCOXIB\n\nFLAMPROP‑METHYL\n\nFLAMPROP‑M‑METHYL\n\nFLAVOXATE\n\nFLAZASULFURON\n\nFLECAINIDE\n\nFLEROXACIN\n\nFLOCOUMAFEN\n\nFLOCTAFENINE\n\nFLONICAMID\n\nFLORASULAM\n\nFLORFENICOL\n\nFLORPYRAUXIFEN‑BENZYL\n\nFLORYLPICOXAMID\n\nFLUANISONE\n\nFLUAZAINDOLIZINE\n\nFLUAZIFOP‑BUTYL\n\nFLUAZIFOP‑p‑BUTYL\n\nFLUAZINAM\n\nFLUAZURON\n\nFLUBENDAZOLE\n\nFLUBENDIAMIDE\n\nFLUBROMAZEPAM\n\ncross reference: CAS No. 2647-50-9\n\nFLUBROMAZOLAM\n\ncross reference: CAS No. 612526-40-6\n\nFLUCHLORALIN\n\nFLUCLOROLONE\n\nFLUCLOXACILLIN\n\nFLUCOFURON\n\nFLUCONAZOLE\n\nSchedule 4  Schedule 3  Appendix F, clause 4  Appendix H, clause 1\n\nFLUCYTHRINATE\n\nFLUCYTOSINE\n\nFLUDARABINE\n\nFLUDIOXONIL\n\nFLUDROCORTISONE\n\nFLUENSULFONE\n\nFLUFENAMIC ACID\n\nFLUFENOXURON\n\nFLUMAZENIL\n\nFLUMETASONE  cross reference: FLUMETHASONE\n\nFLUMETHASONE  cross reference: FLUMETASONE\n\nFLUMETHIAZIDE\n\nFLUMETHRIN\n\nFLUMETSULAM\n\nFLUMICLORAC PENTYL\n\nFLUMIOXAZIN\n\nFLUNISOLIDE\n\nFLUNITAZENE\n\ncross reference: CAS No. 2249-36-7, FLUNITAZENE HYDROCHLORIDE (CAS No. 2728-91-8)  Schedule 9\n\nFLUNITRAZEPAM\n\nSchedule 8  Appendix D, clause 5 (Benzodiazepine derivatives)  Appendix K, clause 1\n\nFLUNIXIN MEGLUMINE\n\nFLUOCINOLONE\n\nFLUOCINONIDE\n\nFLUOCORTIN\n\nFLUOCORTOLONE\n\nFLUOMETURON\n\nFLUOPICOLIDE\n\nFLUOPYRAM\n\nFLUORESCEIN\n\nFLUORIDES  cross reference: SILICOFLUORIDES\n\nSchedule 6  Schedule 5  Schedule 4  Schedule 3  Schedule 2  Appendix E, clause 3  Appendix F, clause 4\n\nFLUOROACETAMIDE\n\nFLUOROACETIC ACID\n\nFLUOROMETHOLONE\n\n4‑FLUORO‑N‑METHYLAMFETAMINE  cross reference: 4‑FLUORO‑N‑METHYLAMPHETAMINE, 4‑FLUORO‑N‑METHAMFETAMINE (CAS No. 351-03-1)\n\n1‑(5‑FLUOROPENTYL)‑3‑(2‑IODOBENZOYL)INDOLE  cross reference: AM‑694 (CAS No. 335161-03-0)\n\nFLUOROURACIL\n\nFLUOXETINE\n\nFLUOXYMESTERONE\n\nFLUPENTIXOL  cross reference: FLUPENTHIXOL\n\nFLUPHENAZINE\n\nFLUPROPANATE  cross reference: TETRAPION\n\nFLUPROSTENOL\n\nFLUPYRADIFURONE\n\nFLUQUINCONAZOLE\n\n \n\nFLURALANER  cross‑reference: CARBAMOYL BENZAMIDE, PHENYL ISOXAZOLINE\n\nFLURANDRENOLONE\n\nFLURAZEPAM\n\nFLURBIPROFEN\n\nFLUOROACETAMIDE\n\nFLUOXAPIPROLIN\n\nFLUROXENE\n\nFLUROXYPYR\n\nFLUSILAZOL\n\nFLUSPIRILENE\n\nFLUTAMIDE\n\nFLUTICASONE  cross reference: FLUTICASONE FUROATE, FLUTICASONE PROPIONATE\n\nFLUTICASONE FUROATE  cross reference FLUTICASONE\n\nFLUTICASONE PROPIONATE\n\ncross reference: FLUTICASONE\n\nFLUTOLANIL\n\nFLUTRIAFOL\n\nFLUVALINATE\n\nFLUVASTATIN\n\nFLUVOXAMINE\n\nFLUXAPYROXAD\n\nFOLIC ACID\n\nFOLINIC ACID  cross reference: CALCIUM FOLINATE\n\nFOLLICLE‑STIMULATING HORMONE\n\nFOLLISTATIN\n\nFOLLITROPIN ALFA  cross reference: FOLLICLE‑STIMULATING HORMONE, RECOMBINANT HUMAN\n\nFOLLITROPIN BETA  cross reference: FOLLICLE‑STIMULATING HORMONE, RECOMBINANT HUMAN\n\nFOLLITROPIN DELTA  cross reference: FOLLICLE‑STIMULATING HORMONE, RECOMBINANT HUMAN\n\nFOLPET\n\nFOMEPIZOLE\n\nFOMESAFEN SODIUM\n\nFOMIVIRSEN\n\nFONDAPARINUX\n\nFOOD\n\nFORAMSULFURON\n\nFORCHLORFENURON\n\nFORMALDEHYDE  cross reference: FORMALDEHYDE CONDENSATION PRODUCT, FREE FORMALDEHYDE, METACRESOLSULPHONIC ACID, METHYLENE GLYCOL (CAS No. 50-00-0)\n\nSchedule 10  Schedule 6  Schedule 2  Appendix E, clause 3  Appendix F, clause 4\n\nFORMALDEHYDE CONDENSATION PRODUCT\n\nFORMEBOLONE\n\nFORMESTANE\n\nFORMETANATE\n\nFORMIC ACID\n\nFORMOTEROL\n\nFORMOTHION\n\nFOSAMPRENAVIR\n\nFOSAPREPITANT\n\nFOSCARNET\n\nFOSFESTROL  cross reference: DIETHYLSTILBESTROL DIPHOSPHATE\n\nFOSFOMYCIN\n\nFOSINOPRIL\n\nFOSNETUPITANT\n\nFOSPHENYTOIN\n\nFOSPIRATE\n\nFOSTEMSAVIR\n\nFOSTHIAZATE\n\nFOTEMUSTINE\n\nFRAMYCETIN\n\nFRITTED GLAZING OR ENAMELLING PREPARATIONS\n\nFULLERS EARTH\n\nFULVESTRANT\n\nFUMAGILLIN\n\nFUNGAL PROTEASE derived from Aspergillus niger\n\nFURALAXYL\n\nFURALTADONE\n\nFURATHIOCARB\n\nFURAZABOL\n\nFURAZOLIDONE\n\nFURETHIDINE\n\ncross reference: CAS No. 2385-81-1\n\nFURFURAL  cross reference: 2‑FURANCARBOXALDEHYDE\n\nFUROSEMIDE  cross reference: FRUSEMIDE\n\nFUSIDIC ACID\n\nG\n\nGABAPENTIN\n\nGALANTAMINE\n\nGALANTHUS spp.\n\nGALCANEZUMAB\n\nGALLAMINE\n\nGALSULFASE\n\nGAMMA BUTYROLACTONE\n\ncross reference: CAS No. 96-48-0\n\nGAMMA HYDROXYBUTYRATE  cross reference: 4‑HYDROXYBUTANOIC ACID, GHB, SODIUM OXYBATE\n\nGAMMA‑CYHALOTHRIN\n\nGANCICLOVIR\n\nGANIRELIX\n\nGATIFLOXACIN\n\nGEFITINIB\n\nGELATIN – SUCCINYLATED\n\nGELSEMIUM SEMPERVIRENS\n\nSchedule 2  Appendix G, clause 1\n\nGEMCITABINE\n\nGEMEPROST\n\nGEMFIBROZIL\n\nGEMIFLOXACIN\n\nGEMTUZUMAB OZOGAMICIN\n\nGENTAMICIN\n\nGENTIAN VIOLET  cross reference: METHYLROSANILINIUM CHLORIDE, CRYSTAL VIOLET\n\nGERANIUM OIL\n\nGESTODENE\n\nGESTONORONE\n\nGESTRINONE\n\nGHRH INJECTABLE PLASMID\n\nGIBBERELLIC ACID\n\nGILTERITINIB\n\nGITALIN\n\nGIVOSIRAN\n\nGLASS  cross reference: CRYSTAL WARE\n\nGLATIRAMER ACETATE\n\nGLAZED POTTERY\n\nGLECAPREVIR\n\nGLIBENCLAMIDE\n\nGLIBORNURIDE\n\nGLICLAZIDE\n\nGLIMEPIRIDE\n\nGLIPIZIDE\n\nGLIPTINS\n\ncross reference: DIPEPTIDYL PEPTIDASE-4 (DDP-4) INHIBITORS  Schedule 4\n\nGLISOXEPIDE\n\nGLOFITAMAB\n\nGLUCAGON\n\nSchedule 3  Appendix G, clause 1\n\nα‑GLUCANASE derived from Aspergillus niger\n\nGLUFOSINATE‑AMMONIUM\n\nGLUTARAL\n\nGLUTARALDEHYDE  cross reference: GLUTARAL\n\nGLUTATHIONE\n\nGLUTETHIMIDE\n\nSchedule 4  Appendix D, clause 5  Appendix K, clause 1\n\nGLYCERYL THIOGLYCOLLATE\n\nGLYCERYL TRINITRATE\n\nSchedule 4  Schedule 3  Appendix G, clause 1  Appendix H, clause 1\n\nGLYCOLIC ACID\n\nGLYCOPYRRONIUM\n\nGLYCOSYLATED HYDROQUINONE  cross reference: HYDROQUINONE\n\nGLYMIDINE\n\nGLYPHOSATE\n\nGnRH VACCINE\n\nGOLIMUMAB\n\nGONADORELIN\n\nGONADOTROPHIC HORMONES\n\nGOSERELIN\n\nGRAMICIDIN\n\nGRANISETRON\n\nGRAPIPRANT\n\nGRAZOPREVIR\n\nGREPAFLOXACIN\n\nGRISEOFULVIN\n\nGROWTH HORMONE RELEASING HORMONES *(GHRHs)\n\nGROWTH HORMONE RELEASING PEPTIDE‑6 (GHRP‑6)\n\nGROWTH HORMONE RELEASING PEPTIDE *(GHRPs)\n\nGROWTH HORMONE SECRETAGOGUES *(GHSs)\n\nGUAIFENESIN   cross reference: PARACETAMOL\n\nGUAIPHENESIN  cross reference: GUAIFENESIN\n\nGUANABENZ\n\nGUANACLINE\n\nGUANETHIDINE\n\nGUANFACINE\n\nGUANIDINE\n\nSchedule 6  Schedule 4  Appendix E, clause 3\n\nGUAZATINE\n\nGUSELKUMAB\n\nH\n\nHACHIMYCIN\n\nHAEMATIN\n\nHAEMOPHILUS INFLUENZAE VACCINE\n\nHALAUXIFEN METHYL\n\nHALCINONIDE\n\nHALOFANTRINE\n\nHALOFENATE\n\nHALOFUGINONE\n\nSchedule 7  Schedule 4  Appendix J, clause 1\n\nHALOGENATED DIBENZODIOXINS AND DIBENZOFURANS  cross reference: DIBENZODIOXINS, HALOGENATED ‑ DIBENZOFURANS, HALOGENATED, DIOXINS\n\nHALOPERIDOL  cross reference: BUTYPHENONES\n\nSchedule 4  Appendix G, clause 1  Appendix K, clause 1\n\nHALOSULFURON‑METHYL\n\nHALOTHANE\n\nHALOXON\n\nHALOXYFOP\n\nHARMALA ALKALOIDS\n\nHC RED 13  cross reference: 2,2'‑[(4‑AMINO‑3‑NITROPHENYL)IMINO]BISETHANOL\n\nHC VIOLET 1   cross reference: 2‑[(4‑AMINO‑2‑METHYL‑5‑NITROPHENYL)AMINO]‑ETHANOL\n\nHCB\n\nHELIONAL\n\nAppendix B, Part 3\n\nHELIOTROPIUM spp.\n\nHEMEROCALLIS\n\nHEMP SEED OIL  cross reference: CANNABIDIOL, CANNABIS, TETRAHYDROCANNABINOLS\n\nHEPARINS\n\nHEPATITIS A VACCINE\n\nHEPATITIS B VACCINE\n\nHEPTACHLOR\n\nHEROIN\n\ncross reference: CAS No. 561-27-3, HEROIN HYDROCHLORIDE (CAS No. 1502-95-0)\n\nHETACILLIN\n\nHEXACHLOROPHANE  cross reference: HEXACHLOROPHENE\n\nHEXACHLOROPHENE   cross reference: HCB\n\nHEXACONAZOLE\n\nHEXAFLURON\n\nHEXAMETHONIUM\n\nHEXARELIN\n\nHEXAZINONE\n\nHEXETIDINE\n\nHEXLOXYETHANOL\n\nHEXOBENDINE\n\nHEXOCYCLIUM\n\nHEXOPRENALINE\n\nHEXYL ACETATE\n\nHEXYL AMINOLEVULINATE (AS HYDROCHLORIDE)\n\nHEXYL CINNAMALDEHYDE\n\n3‑HEXYL‑1‑HYDROXY‑7,8,9,10‑TETRAHYDRO‑6,6,9‑TRIMETHYL‑6H‑DIBENZO (b,d) PYRAN  cross reference: PARAHEXYL (CAS No. 117-51-1)\n\nHEXYLOXYETHANOL\n\nHEXYTHIAZOX\n\nHISTAMINE\n\nHMG‑CoA REDUCTASE INHIBITORS  cross reference: STATINS\n\nHOMATROPINE\n\nHUMAN BLOOD PRODUCTS  cross reference: ALBUMIN, ANTICOAGULATION COMPLEX, C1 ESTERASE INHIBITORS, CLOTTING FACTORS, CRYOPRECIPITATE, FIBRINOGEN, PLASMA, PLATELETS, PROTEIN C, PROTHROMBIN COMPLEX CONCENTRATE (PCC), RED CELLS, THROMBIN, WHOLE BLOOD, STEM CELLS\n\nHUMAN CHORIONIC GONADOTROPHIN\n\nHUMAN OSTEOGENIC PROTEIN‑1 (OP‑1)\n\nHUMAN PAPILLOMAVIRUS VACCINE\n\nHYALURONIC ACID\n\nHYALURONIC ACID AND ITS POLYMERS\n\nHYDRALAZINE\n\nHYDRAMETHYLNON\n\nHYDRARGAPHEN\n\nHYDRAZINE\n\nHYDROCARBONS LIQUID AROMATIC  cross reference: AROMATIC EXTRACT OILS,\n\nHYDROCARBONS, LIQUID   cross reference: BENZENE, DESIGNATED SOLVENT, DIESEL (DISTILLATE), DRY CLEANING FLUID, KEROSENE, LAMP OIL, LIGHT MINERAL OILS, LIQUID HYDROCARBONS, MINERAL OILS, MINERAL TURPENTINE, NAPHTHALENE, PARAFFIN OILS, PETROL, PETROLEUM OILS, REDUCERS, THINNERS, TOLUENE, WHITE SPIRIT, WHITE PETROLEUM SPIRIT, WHITE MINERAL OILS, XYLENE\n\nHYDROCHLORIC ACID\n\nHYDROCHLOROTHIAZIDE\n\nHYDROCODONE\n\nHYDROCORTISONE\n\nHYDROCORTISONE ACETATE\n\nHYDROCYANIC ACID  cross reference: CYANIDES, APRICOT KERNELS\n\nSchedule 7  Schedule 4  Appendix F, clause 4  Appendix G, clause 1  Appendix J, clause 1\n\nHYDROFLUMETHIAZIDE\n\nHYDROFLUORIC ACID  cross reference: HYDROGEN FLUORIDE\n\nAppendix F, clause 4  Appendix J, clause 1\n\nHYDROGEN PEROXIDE\n\ncross reference: CAS No. 7722-84-1\n\nHYDROGEN SULFIDE\n\nHYDROMORPHINOL\n\nHYDROMORPHONE\n\nHYDROPRENE\n\nHYDROQUINONE  cross reference: ARBUTIN, GLYCOSYLATED HYDROQUINONE, MONOBENZONE\n\nHYDROSILICOFLUORIC ACID  cross reference: FLUOROSILICIC ACID, HEXAFLUOROSILIC ACID, HYDROFLUOSILICIC ACID, SILICOFLUORIC ACID\n\nSchedule 7  Schedule 6  Schedule 5  Appendix E, clause 3  Appendix F, clause 4\n\n4‑HYDROXYBUTANOIC ACID\n\ncross reference: CAS No. 591-81-1, SODIUM OXYBATE (CAS No. 502-85-2)\n\nHYDROXYCARBAMIDE\n\nHYDROXYCHLOROQUINE\n\nSchedule 4  Appendix D, clause 8\n\n2‑[(1R,3S)‑3‑HYDROXYCYCLOHEXYL]‑5‑(2‑METHYLNONAN‑2‑YL)PHENOL                cross reference: CANNABICYCLOHEXANOL (CAS No. 70434-92-3), CP 47,497 C8 HOMOLOGUE, CP 47,497 (CAS No. 70434-82-1)\n\nHYDROXYEPHEDRINE\n\n4‑[(2‑HYDROXYETHYL)AMINO]‑3‑NITROPHENOL  cross reference: 3‑NITRO‑p‑HYDROXYETHYLAMINOPHENOL\n\n2‑HYDROXYETHYL METHACRYLATE\n\nHYDROXYETHYL‑3,4‑METHYLENEDIOXYANILINE\n\n[7‑HYDROXY‑8‑[(2‑ METHOXYPHENYL)AZO]‑2‑NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391‑30‑0)  cross reference: BASIC RED 76 (CAS No. 68391‑30‑0)\n\nHYDROXYPETHIDINE\n\ncross reference: CAS No. 468-56-4\n\nHYDROXYPHENAMATE\n\nHYDROXYPROGESTERONE\n\nHYDROXYPROPYL CELLULOSE\n\n2‑HYDROXYPROPYL METHACRYLATE\n\n8‑HYDROXYQUINOLINE  cross reference: OXYQUINOLINE\n\nHYDROXYSTENOZOL\n\nHYDROXYUREA  cross reference: HYDROXYCARBAMIDE\n\nHYDROXYZINE\n\nHYGROMYCIN\n\nHYOSCINE  cross reference: HYOSCINE BUTYLBROMIDE\n\nHYOSCINE BUTYLBROMIDE\n\nHYOSCYAMINE\n\nHYOSCYAMUS NIGER\n\nHYPOTHALAMIC RELEASING FACTORS\n\nHYPROMELLOSE\n\nI\n\nIBAFLOXACIN\n\nIBANDRONIC ACID\n\nIBOGAINE\n\nIBOTENIC ACID\n\ncross reference: MUSCIMOL\n\nIBRITUMOMAB\n\nIBRUTINIB\n\nIBUFENAC\n\nIBUPROFEN  cross reference: PARACETAMOL\n\nIBUTAMOREN  cross reference: MK‑677, NUTROBAL\n\nIBUTEROL\n\nIBUTILIDE\n\nICATIBANT\n\nICODEXTRIN\n\nIDARUBICIN\n\nIDARUCIZUMAB\n\nIDEBENONE\n\nIDOXURIDINE\n\nIDURSULFASE\n\nIFOSFAMIDE\n\nILOPROST\n\nIMATINIB\n\nIMAZALIL  cross reference: ENILCONAZOLE\n\nIMAZAMOX\n\nIMAZAPIC\n\nIMAZAPYR\n\nIMAZETHAPYR\n\nIMDEVIMAB\n\nIMEPITOIN\n\nIMIDACLOPRID\n\nIMIDAPRIL\n\nIMIDOCARB\n\nIMIGLUCERASE\n\nIMINOCTADINE TRIALBESILATE\n\nIMIPENEM\n\nIMIPRAMINE\n\nIMIPROTHRIN\n\nIMIQUIMOD\n\nIMLIFIDASE\n\nIMMUNOGLOBULINS  cross reference: EQUINE ANTI‑HUMAN THYMOCYTE IMMUNOGLOBULIN, POLYCLONAL ANTIBODIES\n\nIN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS\n\nINCLISIRAN\n\nINDACATEROL\n\nINDANAZOLINE\n\nINDAPAMIDE\n\nINDAZIFLAM\n\nINDINAVIR\n\nINDOLE‑3‑ACETIC ACID\n\nINDOMETACIN\n\nINDOMETHACIN  cross reference: INDOMETACIN\n\nINDOPROFEN\n\nINDORAMIN\n\nINDOXACARB\n\nINFIGRATINIB\n\nINFLIXIMAB\n\nINFLUENZA AND CORYZA VACCINES  cross reference: H5N1 INFLUENZA VIRUS HAEMAGGLUTININ\n\nINGENOL MEBUTATE\n\nINOTUZUMAB OZOGAMICIN\n\nINOSITOL NICOTINATE\n\nINPYRFLUXAM\n\nINSULIN DEGLUDEC\n\nINSULIN GLARGINE\n\nINSULIN‑LIKE GROWTH FACTOR I\n\nINSULIN‑LIKE GROWTH FACTORS\n\nINSULINS\n\nINTERFERONS\n\nINTERLEUKINS\n\nINTRAOCULAR VISCOELASTIC PRODUCTS\n\nIODINE  cross reference: IODOPHORS\n\nSchedule 6  Schedule 2  Appendix E, clause 3  Appendix F, clause 4\n\nIODOMETHANE\n\nIODOPHORS  cross reference: IODINE\n\n3‑IODO‑2‑PROPYNYL BUTYL CARBAMATE  cross reference: IODOCARB\n\nIODOSULFURON‑METHYL‑SODIUM\n\nIODOTHIOURACIL\n\nIOXYNIL\n\nIPAMORELIN\n\nSchedule 4,  Appendix D, clause 5\n\nIPCONAZOLE\n\nIPFLUFENOQUIN\n\nAppendix B, Part 3\n\nIPILIMUMAB\n\nIPRATROPIUM\n\nIPRATROPIUM BROMIDE\n\nIPRIFLAVONE\n\nIPRINDOLE\n\nIPRODIONE\n\nIPRONIAZID\n\nIRBESARTAN\n\nIRINOTECAN\n\nIRON COMPOUNDS  cross reference: IRON OXIDES\n\nSchedule 6  Schedule 5  Schedule 4  Schedule 2\n\nISAVUCONAZOLE\n\nISETHIONATE\n\nISOAMINILE\n\nISOAMYL NITRITE\n\nISOBUTYL NITRITE\n\nISOCARBOPHOS\n\nISOCARBOXAZID\n\nISOCONAZOLE\n\nSchedule 6  Schedule 4  Schedule 3  Schedule 2  Appendix H, clause 1\n\nISOCYANATES\n\nISOCYCLOSERAM\n\nISOETARINE\n\nISOEUGENOL\n\nISOFENPHOS\n\nISOFETAMID\n\nISOFLURANE\n\nISOMETHADONE\n\ncross reference: CAS No. 466-40-0\n\nISOMETHEPTENE\n\nISONIAZID\n\nISOPHORONE\n\nISOPRENALINE\n\nISOPRENE ALCOHOL\n\nISOPRINOSINE\n\nISOPROPAMIDE\n\nISOPROPYL NITRITE\n\ncross reference: CAS No. 541-42-4\n\nISOPROTURON\n\nISOPYRAZAM\n\nISOSORBIDE DINITRATE\n\nISOSORBIDE MONONITRATE\n\nISOSTEARYL ALCOHOL ETHOXYLATE\n\nISOTIANIL\n\nISOTONITAZENE\n\ncross reference: CAS No. 14188-81-9\n\nISOTRETINOIN\n\nSchedule 4  Appendix D, clause 5  Appendix F, clause 4  Appendix L, clause 2\n\nISOXABEN\n\nISOXAFLUTOLE\n\nISOXICAM\n\nISOXSUPRINE\n\nISRADIPINE\n\nITRACONAZOLE\n\nIVABRADINE\n\nIVACAFTOR\n\nIVERMECTIN\n\nSchedule 7  Schedule 5  Schedule 4\n\nIVOSIDENIB\n\nIXABEPILONE\n\nIXAZOMIB\n\nIXEKIZUMAB\n\nJ\n\nJAPANESE ENCEPHALITIS VACCINE\n\nJUNIPERUS SABINE  cross reference: SAVIN(E)\n\nK\n\nKAMBO  cross reference: Secretion of the South American Giant Leaf Frog or Giant Monkey Frog (Phyllomedusa bicolor)\n\nKANAMYCIN\n\nKAOLIN\n\nKEROSENE\n\nKETAMINE\n\nKETANSERIN\n\nKETAZOLAM\n\nKETOBEMIDONE\n\ncross reference: CAS No. 469-79-4, KETOBEMIDONE HYDROCHLORIDE (CAS No. 5965-49-1)\n\nKETOCONAZOLE\n\nKETOPROFEN\n\nKETOROLAC\n\nKETOTIFEN\n\nKHELLIN\n\nKINETIN\n\nKITASAMYCIN\n\nKRATOM\n\ncross reference: MITRAGYNA SPECIOSA, MITRAGYNINE\n\nKRESOXIM‑METHYL\n\nKUNZEA OIL\n\nL\n\nLABETALOL\n\nLACIDIPINE\n\nLACOSAMIDE\n\nLAMBDA‑CYHALOTHRIN\n\nLAMIVUDINE\n\nLAMOTRIGINE\n\nLANADELUMAB\n\nLANATOSIDES\n\nLANREOTIDE\n\nLANSOPRAZOLE\n\nLANTHANUM\n\nLAPATINIB\n\nLARONIDASE\n\nLAROPIPRANT\n\nLAROTRECTINIB\n\nLASALOCID\n\nLASIODIPLODIA PSEUDOTHEOBROMAE\n\nLATAMOXEF\n\nLATANOPROST\n\nLAUDEXIUM\n\nLAURETH CARBOXYLIC ACIDS\n\nLAURIC ACID\n\nLAUROMACROGOLS  cross reference: LAURETH‑9\n\nLAURYL ALCOHOL  cross reference: 1‑DODECANOL\n\nLAURYL ISOQUINOLINIUM BROMIDE\n\nLAURYL SULFATE SALTS  cross reference: SODIUM LAURYL SULPHATE, DODECYL SULFATES\n\nLAVANDIN OIL  cross reference: CAMPHOR\n\nLAVENDER OIL\n\nLEAD COMPOUNDS  cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES, SELENIUM\n\nSchedule 10  Schedule 6  Appendix E, clause 3  Appendix F, clause 4 (in glazing preparations)  Appendix F, clause 4\n\nLEAD METALLIC\n\nLEBRIKIZUMAB\n\nLECANEMAB\n\nLEDIPASVIR\n\nLEFETAMINE\n\nLEFLUNOMIDE\n\nLEMBOREXANT\n\nLEMON OIL\n\nLEMONGRASS OIL\n\nLENACAPAVIR\n\nLENALIDOMIDE\n\nLENOGRASTIM\n\nLENVATINIB\n\nLEPIDOPTEROUS SEX PHEROMONES\n\nLEPIRUDIN\n\nLEPTAZOL\n\nLEPTOPHOS\n\nLEPTOSPERMUM SCOPARIUM OIL  cross reference: MANUKA OIL\n\nLERCANIDIPINE\n\nLESINURAD\n\nLETERMOVIR\n\nLETROZOLE\n\nLEUPRORELIN\n\nLEVALLORPHAN\n\nLEVAMISOLE\n\nLEVAMFETAMINE  cross reference: LEVAMPHETAMINE\n\nLEVETIRACETAM\n\nLEVOBUNOLOL\n\nLEVOBUPIVACAINE\n\nLEVOCABASTINE\n\nSchedule 4  Schedule 2  Appendix F, clause 4  Appendix L, clause 2\n\nLEVOCETIRIZINE\n\nLEVODOPA\n\nLEVOMEPROMAZINE  cross reference: METHOTRIMEPRAZINE\n\nLEVOMETHAMFETAMINE  cross reference: LEVOMETHAMPHETAMINE\n\nLEVOMETHORPHAN\n\ncross reference: CAS No. 125-70-2\n\nLEVOMILNACIPRAN\n\nLEVOMORAMIDE\n\nLEVONORGESTREL\n\nLEVOPHENACYLMORPHAN\n\ncross reference: CAS No. 10061-32-2\n\nLEVORPHANOL\n\nLEVOSIMENDAN\n\nLIDOCAINE\n\nSchedule 5  Schedule 4  Schedule 2\n\nLIDOFLAZINE\n\nLIFITEGRAST\n\nLIGNOCAINE  cross reference: LIDOCAINE\n\nLIGULARIA DENTATA\n\nLIME OIL\n\nLIMONENE  cross reference: DIPENTENE\n\nLINACLOTIDE\n\nLINAGLIPTIN\n\nLINCOMYCIN\n\nLINDANE  cross reference: BHC\n\nSchedule 6  Schedule 5  Schedule 4  Schedule 2\n\nLINEZOLID\n\nLINOLEIC ACID\n\nLINSEED FATTY ACIDS\n\nLINURON\n\nLIOTHYRONINE  cross reference: TRIIODOTHYRONINE\n\nLIPEGFILGRASTIM\n\nLIQUORICE, DEGLYCYRRHISINISED\n\nLIRAGLUTIDE\n\nLISDEXAMFETAMINE\n\nLISINOPRIL\n\nLISURIDE\n\nLITHIUM\n\nLITHIUM PERFLUOROOCTANE SULFONATE\n\nLIXISENATIDE\n\nLOBELIA INFLATA\n\nLOBELINE\n\nLODOXAMIDE\n\nLOFEXIDINE\n\nLOGIPARIN\n\nLOMEFLOXACIN\n\nLOMUSTINE\n\nLOPERAMIDE\n\nLOPINAVIR\n\nLOPRAZOLAM\n\nLORACARBEF\n\nLORATADINE\n\nLORAZEPAM\n\nLORLATINIB\n\nLORMETAZEPAM\n\nLOSARTAN\n\nLOTEPREDNOL\n\nLOTILANER\n\nLOXAPINE\n\nLUBRICANTS\n\nLUFENURON\n\nLUMACAFTOR\n\nLUMEFANTRINE\n\nLUMIRACOXIB\n\nLURASIDONE\n\nLURBINECTEDIN\n\nLUSPATERCEPT\n\nLUTEINISING HORMONE\n\nLYMECYCLINE\n\nLYSERGIC ACID\n\ncross reference: CAS No. 82-58-6\n\nLYSERGIDE\n\ncross reference: CAS No. 50-37-3\n\nM\n\nMACITENTAN\n\nSchedule 4  Appendix D, clause 6  Appendix L, clause 2\n\nMACROGOLS\n\nMACROPHOMINA PHASEOLINA\n\nMADURAMICIN\n\nSchedule 7  Schedule 5  Appendix J, clause 1\n\nMAFENIDE\n\nMAGNESIUM CHLORATE\n\nMAGNESIUM HYDROXIDE\n\nMAGNESIUM SULFATE\n\nMALACHITE GREEN\n\nMALATHION  cross reference: MALDISON, ORGANOPHOSPHORUS COMPOUNDS\n\nSchedule 6  Schedule 5  Schedule 3  Appendix E, clause 3\n\nMALEIC HYDRAZIDE\n\nMANCOZEB\n\nMANDESTROBIN\n\nMANDIPROPAMID\n\nMANDRAGORA OFFICINARUM\n\nMANGANESE DIOXIDE\n\nMANNITYL HEXANITRATE\n\nMANNOMUSTINE\n\nMAPROTILINE\n\nMARAVIROC\n\nMARBOFLOXACIN\n\nMARIBAVIR\n\nMARJORAM OIL\n\nMAROPITANT\n\nMATCHES\n\nMAVACAMTEN\n\nMAVACOXIB\n\nMAZIDOX\n\nMAZINDOL\n\nMCPA\n\nMCPB  cross reference: (4‑(4‑CHLORO‑2‑METHYLPHENOXY)BUTANOIC ACID\n\nMEASLES VACCINE\n\nMEBANAZINE\n\nMEBENDAZOLE\n\nSchedule 6  Schedule 5  Schedule 2\n\nMEBEVERINE\n\nMEBHYDROLIN\n\nMEBOLAZINE\n\nMEBUTAMATE\n\nMECAMYLAMINE\n\nMECARBAM\n\nMECASERMIN\n\nMECILLINAM\n\nMECLOCYCLINE\n\nMECLOFENAMATE\n\nMECLOFENAMIC ACID\n\nMECLOFENOXATE\n\nMECLONAZEPAM\n\ncross reference: CAS No. 58662-84-3\n\nMECLOQUALONE\n\ncross reference: CAS No. 340-57-8\n\nMECLOZINE  cross reference: MECLIZINE\n\nMECOPROP\n\nMECOPROP‑P\n\nMEDAZEPAM\n\nMEDETOMIDINE\n\nMEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS\n\nMEDICAL DEVICES  cross reference: ANTICOAGULANT MEDICAL DEVICES, ARTIFICIAL TEARS, COLLAGEN, INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS, INTRA‑ARTICULAR FLUIDS, URINARY CATHETERS\n\nMEDIGOXIN  cross reference: METHYLDIGOXIN\n\nMEDROXYPROGESTERONE\n\nMEDRYSONE\n\nMEFENAMIC ACID\n\nMEFENOREX\n\nMEFENPYR‑DIETHYL\n\nMEFENTRIFLUCONAZOLE\n\nMEFLOQUINE\n\nMEFLUIDIDE\n\nMEFRUSIDE\n\nMEGASPHAERA ELSDENII strain 41125\n\nMEGESTROL\n\nMELAGATRAN\n\nMELALEUCA OIL  cross reference: TEA TREE OIL\n\nMELANOTAN II  cross reference: α–MELANOCYTE STIMULATING HORMONE\n\nMELATONIN\n\nMELENGESTROL\n\nMELENGESTROL ACETATE\n\nMELIA AZEDARACH\n\nMELOXICAM\n\nMELPHALAN\n\nMEMANTINE\n\nMENAZON\n\nMENINGOCOCCAL VACCINE\n\nMENINGOCOCCAL GROUP B VACCINE  cross reference: Neisseria Meningitidis Serogroup B Recombinant LP2086 (MnB rLP2086) Subfamily A Protein and Subfamily B Protein\n\nMENOTROPHIN\n\ncross reference: HUMAN MENOPAUSAL GONADOTROPHIN\n\nMEPACRINE\n\nMEPENZOLATE\n\nMEPHENESIN\n\nMEPHENTERMINE\n\nMEPINDOLOL\n\nMEPIQUAT\n\nMEPITIOSTANE\n\nMEPIVACAINE\n\nMEPROBAMATE\n\nMEPTAZINOL\n\nMEPYRAMINE\n\nSchedule 4  Schedule 3   Schedule 2  Appendix K, clause 1\n\nMEQUITAZINE\n\nMERCAPTAMINE  cross reference: CYSTEAMINE\n\nSchedule 6  Schedule 5  Schedule 4  Appendix K, clause 1\n\nMERCAPTOACETIC ACID  cross reference: THIOGLYCOLIC ACID\n\n2‑MERCAPTOETHANOL\n\nMERCAPTOMERIN\n\nMERCAPTOPURINE\n\nMERCURIC CHLORIDE  cross reference: CALOMEL\n\nSchedule 7  Appendix E, clause 3\n\nMERCURIC IODIDE\n\nMERCURIC NITRATE\n\nMERCURIC OXIDE\n\nMERCURIC POTASSIUM IODIDE\n\nMERCURIC THIOCYANATE\n\nMERCUROCHROME\n\nSchedule 6  Schedule 4  Schedule 2  Appendix E, clause 3\n\nMERCUROUS CHLORIDE  cross reference: CORROSIVE SUBLIMATE\n\nMERCURY  cross reference: ETHOXYETHYLMERCURIC CHLORIDE, ETHOXYQUIN, PHENYL MERCURIC CHLORIDE\n\nSchedule 7  Schedule 4  Schedule 2  Appendix G, clause 1  Appendix J, clause 1\n\nMERCURY metallic\n\nMERCURY, organic compounds\n\nMEROPENEM\n\nMERSALYL\n\nMESABOLONE\n\nMESALAZINE\n\nMESNA\n\nMESOSULFURON‑METHYL\n\nMESOTRIONE\n\nMESTANOLONE  cross reference: ANDROSTALONE\n\nMESTEROLONE\n\nMESTRANOL\n\nMETACRESOLSULPHONIC ACID\n\nMETAFLUMIZONE\n\nMETALAXYL\n\nMETALDEHYDE\n\nMETAMFETAMINE  cross reference: METHAMFETAMINE, METHAMPHETAMINE, METHYLAMFETAMINE, METHYLAMPHETAMINE\n\nMETAMITRON\n\nMETANDIENONE\n\nMETARAMINOL\n\nMETARHIZIUM ANISOPLIAE\n\nMETAZACHLOR\n\nMETAZOCINE\n\ncross reference: CAS No. 3734-52-9, METAZOCINE RACEMATE CIS-FORM (CAS No. 25144-79-0)\n\nMETCAMIFEN\n\nMETENOLONE\n\nMETERGOLINE\n\nMETFORMIN\n\nMETHABENZTHIAZURON\n\nMETHACHOLINE\n\nMETHACRIFOS\n\nMETHACYCLINE\n\nMETHADONE\n\nMETHALLENESTRIL  cross reference: METHALLENOESTRIL\n\nMETHAM  cross reference: METHAM SODIUM\n\nMETHAMIDOPHOS\n\nMETHANDRIOL\n\nMETHANOL\n\ncross reference: CAS No. 67-56-1\n\nMETHANTHELINIUM\n\nMETHAPYRILENE\n\nMETHAQUALONE\n\ncross reference: CAS No. 72-44-6, METHAQUALONE HYDROCHLORIDE (CAS No. 340-56-7)\n\nMETHAZOLAMIDE\n\nMETHAZOLE\n\nMETHCATHINONE\n\ncross reference: CAS No. 5650-44-2, METHCATHINONE HYDROCHLORIDE (CAS No. 49656-78-2)\n\nMETHDILAZINE\n\nMETHENAMINE  cross reference: 1,3,5,7‑TETRAAZATRICYLO[3.3.1.13,7] DECANE, HEXAMINE, HEXAMETHYLENETETRAMINE\n\nMETHENOLONE\n\nMETHICILLIN\n\nMETHIDATHION\n\nMETHIMAZOLE  cross reference: THIAMAZOLE\n\nMETHIOCARB\n\nMETHISAZONE\n\nMETHIOZOLIN\n\nMETHIXENE\n\nMETHOCARBAMOL\n\nMETHOFLUTHRIN\n\nMETHOHEXITONE\n\nMETHOIN\n\nMETHOMYL  cross reference: DENATONIUM BENZOATE\n\nMETHOPRENE\n\nMETHOTREXATE\n\nMETHOXAMINE\n\nMETHOXSALEN\n\nMETHOXYCHLOR\n\n2‑METHOXYETHANOL\n\nMETHOXYETHYLMERCURIC ACETATE\n\nMETHOXYETHYLMERCURIC CHLORIDE\n\nMETHOXYFENOZIDE\n\nMETHOXYFLURANE\n\n5‑METHOXY‑3,4‑METHYLENEDIOXYAMFETAMINE  cross reference: 5‑METHOXY‑3,4‑METHYLENEDIOXYAMPHETAMINE, MMDA (CAS No. 13674-05-0), MMDA HYDROCHLORIDE (CAS No. 60676-84-8)\n\n4‑METHOXY‑ α –METHYLPHENYLETHYLAMINE  cross reference: PMA (CAS No. 64-13-1), PMA HYDROCHLORIDE (CAS No. 3706-26-1)\n\n5‑METHOXY‑ α –METHYLTRYPTAMINE  cross reference: 5‑MeO‑AMT (CAS No. 1137-04-8)\n\n6‑METHOXY‑N2‑METHYL‑2,3‑PYRIDINEDIAMINE\n\n2‑METHOXY‑5‑NITROPHENOL\n\nSchedule 6\n\nMETHOXYPHENAMINE\n\n2‑(2‑METHOXYPHENYL)‑1‑(1‑PENTYLINDOL‑3‑YL)ETHANONE  cross reference: JWH‑250 (CAS No. 864445-43-2)\n\nMETHSUXIMIDE\n\nMETHYCLOTHIAZIDE\n\nMETHYL ACETATE\n\nMETHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)‑9‑ACETOXY‑6a,10b‑DIMETHYL‑4,10‑DIOXO‑DODECAHYDRO‑2‑(3‑FURYL)‑2H‑NAPHTHO[2,1‑c]PYRAN‑7‑CARBOXYLATE  cross reference: SALVINORIN A (CAS No. 83729-01-5)\n\nMETHYL AMINOLEVULINATE\n\np‑METHYLAMINOPHENOL\n\n4‑METHYLAMINOREX\n\ncross reference: CAS No. 3568-94-3\n\nMETHYLANDROSTANOLONE\n\nMETHYLATED SPIRIT(S)  cross reference: DENATONIUM BENZOATE, ETHANOL, FLUORESCEIN\n\nMETHYL BENZOQUATE\n\nMETHYL BROMIDE\n\nMETHYL CHLORIDE\n\nMETHYLCHLOROISOTHIAZOLINONE   cross reference: METHYLISOTHIAZOLINONE\n\nMETHYLCLOSTEBOL\n\nMETHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL\n\n1‑METHYLCYCLOPROPENE\n\nMETHYLDESORPHINE\n\ncross reference: CAS No. 16008-36-9\n\nMETHYLDIBROMO GLUTARONITRILE\n\ncross reference: CAS No. 35691-65-7\n\nSchedule 10  Schedule 6  Appendix F, clause 4\n\nMETHYLDIHYDROMORPHINE\n\nMETHYLDOPA\n\n4,4'‑METHYLENEBIS[2‑CHLOROANILINE]\n\nMETHYLENE BISTHIOCYANATE\n\nMETHYLENE BLUE\n\nSchedule 7  Schedule 5  Schedule 4\n\n3,4‑METHYLENEDIOXYAMFETAMINE  cross reference: 3,4‑METHYLENEDIOXYAMPHETAMINE, MDA, TENAMFETAMINE (CAS No. 4764-17-4)\n\n3,4‑METHYLENEDIOXYPYROVALERONE  cross reference: MDPV (CAS No. 687603-66-3)\n\nMETHYLEPHEDRINE\n\nMETHYLERGOMETRINE\n\nMETHYL ETHYL KETONE  cross reference: DESIGNATED SOLVENT\n\nMETHYL ETHYL KETONE OXIME\n\nMETHYL ETHYL KETONE PEROXIDE\n\nMETHYLEUGENOL\n\nSchedule 6  Appendix E, clause 3,  Appendix F, clause 4\n\n3‑METHYLFENTANYL\n\ncross reference: CAS No. 42045-86-3\n\nMETHYLPHENYLPIRACETAM  cross reference: RACETAMS\n\nMETHYL p‑HYDROXYBENZOATE\n\nMETHYL ISOAMYL KETONE  cross reference: DESIGNATED SOLVENT\n\nMETHYL ISOBUTYL KETONE  cross reference: DESIGNATED SOLVENT, METHYLATED SPIRIT(S)\n\nMETHYL ISOTHIOCYANATE\n\nMETHYLISOTHIAZOLINONE  cross reference: METHYLCHLOROISOTHIAZOLINONE\n\nMETHYLMERCURY\n\nMETHYL METHACRYLATE\n\ncross reference: CAS No. 80-62-6\n\nSchedule 10  Schedule 6   Appendix F, clause 4\n\n4‑METHYLMETHCATHINONE  cross reference: MEPHEDRONE (CAS No. 1189805-46-6)\n\nN‑METHYL‑1‑(3,4‑METHYLENEDIOXYPHENYL)‑2‑BUTANAMINE  cross reference: MBDB (CAS No. 135795-90-3)\n\nN‑ α ‑[METHYL‑3,4‑(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE  cross reference: N‑HYDROXY MDA (CAS No. 74698-47-8)\n\n2‑METHYL‑3‑MORPHOLINO‑1, 1‑DIPHENYLPROPANE CARBOXYLIC ACID                cross reference: MORAMIDE INTERMEDIATE (CAS No. 3626-55-9)\n\nMETHYLNALTREXONE\n\nMETHYL NEODECANAMIDE\n\nMETHYLNORBORNYLPYRIDINE\n\nMETHYLONE *(MDMC)\n\ncross reference: CAS No. 186028-79-5, MDMC HYDROCHLORIDE (CAS No. 186028-80-8)\n\nMETHYLPENTYNOL\n\nMETHYLPHENIDATE\n\nMETHYLPHENOBARBITAL  cross reference: BARBITURATE METHYLPREDNISOLONE\n\nMETHYLPHENOBARBITONE  cross reference: METHYLPHENOBARBITAL, BARBITURATE METHYLPREDNISOLONE\n\n1‑METHYL‑4‑PHENYL‑4‑PIPERIDINOL PROPIONATE  cross reference: ACIDMPPP (CAS No. 13147-09-6), MPPP HYDROCHLORIDE (CAS No. 4968-48-3)\n\n1‑METHYL‑4‑PHENYLPIPERIDINE‑4‑CARBOXYLIC ACID  cross reference: PETHIDINE INTERMEDIATE C\n\nMETHYLPREDNISOLONE\n\nN‑METHYL‑2‑PYRROLIDONE\n\n2‑METHYLRESORCINOL\n\nMETHYLROSANILINIUM CHLORIDE   cross reference: CRYSTAL VIOLET (CAS No. 548-62-9), GENTIAN VIOLET, ACID VIOLET 49 (CAS No. 1694-09-3), ETHYL VIOLET (CAS No. 2390-59-2), BASIC BLUE 7 (CAS No. 2390-60-5), BASIC BLUE 26 (CAS No. 2580-56-5)\n\nSchedule 10  Schedule 6  Schedule 4\n\nMETHYL SALICYLATE\n\nMETHYL SALICYLATE LIQUID\n\nMETHYLTESTOSTERONE\n\n4‑METHYLTHIOAMFETAMINE  cross reference: 4‑METHYLTHIOAMPHETAMINE (CAS No. 14116-06-4)\n\n3‑METHYLTHIOFENTANYL\n\ncross reference: CAS No. 86052-04-2\n\n2‑METHYLTHIO‑4‑(2‑METHYLPROP‑2‑YL) AMINO‑6‑CYCLOPROPYLAMINO‑5‑ TRIAZINE\n\nMETHYLTHIOURACIL\n\nMETHYLTRIENOLONE\n\nMETHYPRYLONE\n\nMETHYSERGIDE\n\nMETIRAM\n\nMETOBROMURON\n\nMETOCLOPRAMIDE\n\nMETODESNITAZENE\n\ncross reference: CAS No. 14030-77-4, METAZENE\n\nMETOFLUTHRIN\n\nMETOLACHLOR\n\nMETOLAZONE\n\nMETONITAZENE\n\ncross reference: CAS No. 14680-51-4\n\nMETOPON\n\ncross reference: CAS No. 143-52-2\n\nMETOPROLOL\n\nMETOSULAM\n\nMETRAFENONE\n\nMETRIBOLONE\n\nMETRIBUZIN\n\nMETRIFONATE  cross reference: TRICHLORFON\n\nMETRONIDAZOLE  cross reference: BENZOYL METRONIDAZOLE\n\nMETSULFURONMETHYL\n\nMETYRAPONE\n\nMEVINPHOS\n\nMEXILETINE\n\nMEZLOCILLIN\n\nMIANSERIN\n\nMIBEFRADIL\n\nMIBOLERONE\n\nMICAFUNGIN\n\nMICONAZOLE\n\nMIDAZOLAM\n\nMIDODRINE\n\nMIDOSTAURIN\n\nMIFEPRISTONE\n\nMIGALASTAT\n\nMIGLITOL\n\nMIGLUSTAT\n\nMILBEMECTIN\n\nMILNACIPRAN\n\nMILBEMYCIN OXIME\n\nMILRINONE\n\nMINOCYCLINE\n\nMINOXIDIL\n\nMIPAFOX\n\nMIRABEGRON\n\nMIREX\n\nMIRIKIZUMAB\n\nMIRTAZAPINE\n\nMISOPROSTOL\n\nMITOBRONITOL\n\nMITOMYCIN\n\nMITOTANE\n\nMITOXANTRONE\n\nMITRAGYNA SPECIOSA  cross reference: KRATOM; MITRAGYNINE (CAS No. 4098-40-2)  Schedule 9\n\nMITRAGYNINE  cross reference: (CAS No. 4098-40-2), KRATOM; MITRAGYNA SPECIOSA\n\nMITRATAPIDE\n\nMIVACURIUM CHLORIDE\n\nMOBOCERTINIB\n\nMOCLOBEMIDE\n\nMODAFINIL\n\nMOLGRAMOSTIM\n\nMOLINATE\n\nMOLINDONE\n\nMOLNUPIRAVIR\n\nMOMETASONE\n\nMOMFLUOROTHRIN\n\nMONENSIN\n\nMONEPANTEL\n\nMONOBENZONE  cross reference: HYDROQUINONE\n\nMONOCLONAL ANTIBODIES\n\nMONOCROTOPHOS\n\nMONOETHANOLAMINE\n\nSchedule 6  Schedule 5  Schedule 4  Appendix E, clause 3  Appendix F, clause 4\n\nMONTELUKAST\n\nMOPERONE\n\nMORANTEL\n\nMORAZONE\n\nMORICIZINE\n\nMORPHERIDINE\n\ncross reference: CAS No. 469-81-8\n\nMORPHINE\n\nMORPHINE METHOBROMIDE\n\nMORPHINE‑N‑OXIDE\n\n(1‑(2‑MORPHOLIN‑4‑YLETHYL)INDOL‑3‑YL)‑NAPTHALEN‑1‑ YLMETHANONE  cross reference: JWH‑200 (CAS No. 103610-04-4)\n\nMOTOR, HEATING or FURNACE FUELS  cross reference: FUELS, FUELS, HOBBY ‑ FUELS, TOY, KEROSENE, METHANOL, PETROL\n\nMOTRAZEPAM\n\nMOTRETINIDE\n\nMOXIDECTIN\n\nSchedule 7  Schedule 6  Schedule 5  Schedule 4\n\nMOXIFLOXACIN\n\nMOXONIDINE\n\nMSMA\n\nMUMPS VACCINE\n\nMUPIROCIN\n\nMURAGLITAZAR\n\nMUROMONAB\n\nMUSCIMOL\n\ncross reference: CAS No. 2763-96-4, MUSCIMOL HYDROBROMIDE (CAS No. 18174-72-6)\n\nMUSTINE  cross reference: NITROGEN MUSTARD\n\nMYCLOBUTANIL\n\nMYCOPHENOLIC ACID  cross reference: MYCOPHENOLATE MOFETIL\n\nMYRISTIC ACID\n\nMYROPHINE\n\ncross reference: CAS No. 467-18-5\n\nN\n\nNAA  cross reference: NAPTHALENEACETIC ACID\n\nNABILONE\n\nNABIXIMOLS  cross reference: CANNABICHROMENE, CANNABIDIOL, CANNABIDIOLIC ACID, CANNABIDIVAROL, CANNABIGEROL, CANNABINOIDS, CANNABINOL, CANNABIS SATIVA, TETRAHYDROCANNABINOLIC ACID, TETRAHYDROCANNABINOLS, TETRAHYDROCANNABIVAROL\n\nSchedule 8  Appendix D, clause 1  Appendix K, clause 1\n\nNABUMETONE\n\nNADOLOL\n\nNADROPARIN\n\nNAFARELIN\n\nNAFTIDROFURYL\n\nNALBUPHINE\n\nNALED\n\nNALIDIXIC ACID\n\nNALMEFENE\n\nNALORPHINE\n\nNALOXEGOL\n\nNALOXONE\n\nNALTREXONE\n\nNANDROLONE\n\nNAPHAZOLINE\n\nNAPHTHALENE\n\ncross reference: CAS No. 91-20-3\n\nSchedule 10  Schedule 6   Appendix E, clause 3   Appendix F, clause 4   Appendix G, clause 1\n\n1,5‑NAPHTHALENEDIOL\n\n2,7‑NAPTHALENEDIOL\n\nNAPHTHALEN‑1‑YL‑(1‑BUTYLINDOL‑3‑YL)METHANONE  cross reference: JWH‑073 (CAS No. 208987-48-8)\n\nNAPHTHALOPHOS\n\n1‑NAPHTHOL\n\nNAPHTHOYLINDOLES\n\nNAPHTHOYLPYRROLES\n\nNAPHTHYLMETHYLINDENES\n\nNAPHTHYLMETHYLINDOLES\n\nNAPROPAMIDE\n\nNAPROXEN\n\nNAPTALAM\n\nNAPTHYL ACETAMIDE\n\nNARASIN\n\nNARATRIPTAN\n\nSchedule 3\n\nAppendix H, clause 1\n\nNATALIZUMAB\n\nNATAMYCIN  cross reference: PIMARCIN\n\nNATEGLINIDE\n\nNEBACUMAB\n\nNEBIVOLOL\n\nNEBRACETAM  cross reference: RACETAMS\n\nNEDOCROMIL\n\nNEFAZODONE\n\nNEFIRACETAM  cross reference: RACETAMS\n\nNEFOPAM\n\nNELARABINE\n\nNELFINAVIR\n\nNEOMYCIN\n\nNEOSCYTALIDIUM NOVAEHOLLANDIAE\n\nNEOSTIGMIN\n\nNEPAFENAC\n\nNERATINIB\n\nNERIUM OLEANDER\n\nNEROLI OIL\n\nNESIRITIDE\n\nNETILMICIN\n\nNETOBIMIN\n\nNETUPITANT\n\nNEVIRAPINE\n\nNIALAMIDE\n\nNICARBAZIN\n\nNICARDIPINE\n\nNICERGOLINE\n\nNICKEL SULFATE\n\nNICLOSAMIDE\n\nNICOCODINE\n\ncross reference: CAS No. 3688-66-2, NICOCODINE HYDROCHLORIDE (CAS No. 58263-01-7)\n\nNICODICODINE\n\ncross reference: CAS No. 808-24-2\n\nNICOFURANOSE\n\nNICOMORPHINE\n\ncross reference: CAS No. 639-48-5, NICOMORPHINE HYDROCHLORIDE (CAS No. 12040-41-4)\n\nNICORANDIL\n\nNICOTINE\n\nSchedule 7  Schedule 4  Appendix D, clause 5  Appendix F, clause 4  Appendix J, clause 1\n\nNICOTINIC ACID  cross reference: NICOTINAMIDE\n\nNICOTINYL ALCOHOL\n\nNICOUMALONE\n\nNIFEDIPINE\n\nNIFENAZONE\n\nNIFOXIPAM\n\ncross reference: CAS No. 74723-10-7\n\nNIKETHAMIDE\n\nNILOTINIB\n\nNILUTAMIDE\n\nNIMESULIDE\n\nNIMIDANE\n\nNIMODIPINE\n\nNIMORAZOLE\n\nNINTEDANIB\n\nNIRAPARIB\n\nNIRIDAZOLE\n\nNIRMATRELVIR\n\nNIRSEVIMAB\n\nNISIN\n\nNISOLDIPINE\n\nNITENPYRAM\n\nNITISINONE\n\nNITRAZEPAM\n\nNITRENDIPINE\n\nNITRIC ACID\n\nNITRIC OXIDE\n\nNITROBENZENE\n\nNITROFEN\n\nNITROFURANTOIN\n\nNITROFURAZONE\n\n3‑NITRO‑p‑HYDROXYETHYLAMINOPHENOL  cross reference: 4‑[(2‑HYDROXYETHYL)AMINO]‑3‑NITROPHENOL\n\nNITROPHENOLS\n\nNITROPRUSSIDES\n\nNITROSCANATE\n\n2‑NITROTOLUENE\n\nNITROUS OXIDE\n\nSchedule 6\n\nAppendix E, clause 3\n\nAppendix F, clause 4\n\nNITROXOLINE\n\nNITROXYNIL\n\nNIVOLUMAB\n\nNIZATIDINE\n\nNOMEGESTROL\n\nNOMIFENSINE\n\nNONANOIC ACID\n\nNONOXINOL 9\n\nNORACYMETHADOL\n\ncross reference: CAS No. 1477-39-0, NORACYMETHADOL HYDROCHLORIDE (CAS No. 5633-25-0)\n\nNORADRENALINE\n\n19‑NORANDROSTENEDIOL\n\n19‑NORANDROSTENEDIONE\n\nNORANDROSTENOLONE\n\nNORBOLETHONE\n\nNORBORMIDE\n\nNORCLOSTEBOL\n\nNORCODEINE\n\nNORELGESTROMIN\n\nNOREPINEPHRINE   cross reference: NORADRENALINE\n\nNORETHANDROLONE\n\nNORETHISTERONE\n\nNORFLOXACIN\n\nNORFLURAZON\n\nNORGESTREL\n\nNORIBOGAINE\n\nNORLEVORPHANOL\n\ncross reference: CAS No. 1531-12-0, NORLEVORPHANOL HYDROBROMIDE (CAS No. 63732-85-4), NORLEVORPHANOL RACEMATE (CAS No. 39131-41-4)\n\nNORMAL HUMAN IMMUNOGLOBULIN\n\nNORMETHADONE\n\nNORMETHANDRONE\n\nNORMORPHINE\n\ncross reference: CAS No. 466-97-7, NORMORPHINE HYDROCHLORIDE (CAS No. 3372-02-9)\n\nNORPIPANONE\n\ncross reference: CAS No. 561-48-8, NORPIPANONE HYDROCHLORIDE (CAS No. 6033-41-6), NORPIPANONE HYDROBROMIDE (CAS No. 6033-42-7)\n\nNORTRIPTYLINE\n\nNOSCAPINE\n\nNOVALURON\n\nNOVOBIOCIN\n\nNOXIPTYLINE\n\nNUCLEAR POLYHEDROSIS VIRUS OF Helicoverpa armigera occlusion bodies\n\nNUSINERSEN\n\nNUTMEG OIL\n\nNUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION\n\nNYSTATIN\n\nO\n\nOBETICHOLIC ACID\n\nOCLACITINIB\n\nOCRELIZUMAB\n\nOCRIPLASMIN\n\nOCTAMYLAMINE\n\nOCTATROPINE\n\n1‑OCTEN‑3‑OL\n\nOCTHILINONE\n\nOCTREOTIDE\n\nOCTYL ALCOHOLS\n\nN‑OCTYL BICYCLOHEPTENE DICARBOXIMIDE\n\ncross reference: OCTYLBICYCLOHEPTENEDICARBOXIMIDE\n\nOCTYL NITRITE\n\nN‑(N‑OCTYL)‑2‑PYRROLIDONE  cross reference: DESIGNATED SOLVENT, N‑(N‑DODECYL)‑2‑PYRROLIDONE, N‑METHYL‑2‑PYRROLIDONE\n\nOESTRADIOL  cross reference: ESTRADIOL\n\nOESTRIOL  cross reference: ESTRIOL\n\nOESTROGENS  cross reference: ESTROGENS\n\nOESTRONE  cross reference: ESTRONE\n\nOFATUMUMAB\n\nOFLOXACIN\n\nOLANZAPINE\n\nOLAPARIB\n\nOLAQUINDOX\n\nOLARATUMAB\n\nOLEANDOMYCIN\n\nOLEANDRIN\n\nOLEIC ACID\n\nN‑OLEYL‑1,3‑DIAMINOPROPANE\n\nOLIPUDASE ALFA\n\nOLMESARTAN\n\nOLODATEROL\n\nOLOPATADINE\n\nOLSALAZINE\n\nOMBERACETAM  cross reference: RACETAMS, NOOPEPT, N‑PHENYLACETYL‑L‑PROLYLGLYCINE ETHYL ESTER\n\nOMBITASVIR\n\nOMALIZUMAB\n\nOMEGA‑3‑ACID ETHYL ESTERS\n\nOMEPRAZOLE\n\nOMETHOATE\n\nONASEMNOGENE ABEPARVOVEC\n\nONDANSETRON\n\nOPICAPONE\n\nOPIPRAMOL\n\nOPIUM  cross reference: NOSCAPINE, PAPAVERINE\n\nORANGE OIL (BITTER)\n\nORANGE OIL, SWEET\n\nORBIFLOXACIN\n\nORCIPRENALINE\n\nORGANOPHOSPHORUS COMPOUNDS  cross reference: MALATHION\n\nORLISTAT\n\nORNIDAZOLE\n\nORNIPRESSIN\n\nORPHENADRINE\n\nORTHOPTERIN\n\nOSELTAMIVIR\n\nOSILODROSTAT\n\nOSIMERTINIB\n\nOUABAIN\n\nOVANDROTONE\n\nOXABETRINIL\n\nOXABOLONE\n\nOXACILLIN\n\nOXADIARGYL\n\nOXADIAZON\n\nOXADIXYL\n\nOXALATES\n\nOXALIC ACID\n\nOXALIPLATIN\n\nOXAMYL\n\nOXANDROLONE\n\nOXANTEL EMBONATE\n\nOXAPROZIN\n\nOXAZEPAM\n\nOXCARBAZEPINE\n\nOXATHIAPIPROLIN\n\nOXEDRINE  cross reference: SYNEPHRINE\n\nOXETACAINE  cross reference: OXETHAZAINE\n\nOXFENDAZOLE\n\nOXIBENDAZOLE\n\nOXICONAZOLE\n\nOXIRACETAM  cross reference: RACETAMS\n\nOXITROPIUM\n\nOXOLAMINE\n\nOXOLINIC ACID\n\nOXPENTIFYLLINE  cross reference: PENTOXIFYLLINE\n\nOXPRENOLOL\n\nOXYBUPROCAINE\n\nOXYBUTYNIN\n\nOXYCARBOXIN\n\nOXYCLOZANIDE\n\nOXYCODONE\n\nOXYDEMETON METHYL\n\nOXYFLUORFEN\n\nOXYMESTERONE\n\nOXYMETAZOLINE\n\nOXYMETHOLONE\n\nOXYMORPHONE\n\nOXYPHENBUTAZONE\n\nOXYPHENCYCLIMINE\n\nOXYPHENISATIN\n\ncross reference: CAS No. 125-13-3\n\nOXYPHENONIUM\n\nOXYQUINOLINE\n\nOXYTETRACYCLINE\n\nOXYTHIOQUINOX\n\nOXYTOCIN\n\nOZANIMOD\n\nP\n\nPACLITAXEL\n\nPACLOBUTRAZOL\n\nPAECILOMYCES LILACINUS STRAIN 251\n\nPAINT\n\nPALBOCICLIB\n\nPALIFERMIN\n\nPALIPERIDONE\n\nPALIVIZUMAB\n\nPALMAROSA OIL\n\nPALMITIC ACID\n\nPALONOSETRON\n\nPALOVAROTENE\n\nSchedule 4  Appendix F, clause 4  Appendix L, clause 2\n\nPAMAQUIN\n\nPAMIDRONIC ACID  cross reference: PAMIDRONATE DISODIUM\n\nPANCREATIC ENZYMES  cross reference: LIPASE\n\nPANCURONIUM\n\nPANITUMUMAB\n\nPANOBINOSTAT\n\nPANTOPRAZOLE\n\nPAPAVERETUM\n\nPAPAVERINE  cross reference: OPIUM\n\nPAPER\n\nPARA‑AMINOPROPIOPHENONE (PAPP)  cross reference: 4‑AMINOPROPIOPHENONE\n\nPARACETAMOL  cross reference: ASPIRIN, IBUPROFEN, METOCLOPRAMIDE, SALICYLAMIDE, CAFFEINE\n\npara‑DICHLOROBENZENE  cross reference: PDB\n\nPARA‑FLUOROFENTANYL\n\ncross reference: CAS No. 90736-23-5\n\nPARAFORMALDEHYDE  cross reference: FREE FORMALDEHYDE (CAS No. 30525-89-4)\n\nSchedule 10  Schedule 6  Schedule 2  Appendix E, clause 3\n\nPARALDEHYDE\n\nPARAMETHADIONE\n\nPARAMETHASONE\n\nPARAQUAT\n\nPARATHION\n\nPARATHION‑METHYL\n\nPARBENDAZOLE\n\nPARECOXIB\n\nPARICALCITOL\n\nPARITAPREVIR\n\nPAROMOMYCIN\n\nPAROXETINE\n\nPASIREOTIDE\n\nPATCHOULI OIL\n\nPATIROMER SORBITEX CALCIUM\n\nPATISIRAN\n\nPAZOPANIB\n\nPEBULATE\n\nPECAZINE\n\nPECTINASE derived from Aspergillus niger\n\nPEFLOXACIN\n\nPEGAPTANIB\n\nPEGASPARGASE\n\nPEGBOVIGRASTIM\n\nPEGCETACOPLAN\n\nPEGFILGRASTIM\n\nPEGINTERFERON\n\nPEGVALIASE\n\nPEGVISOMANT\n\nPEMIGATINIB\n\nPERAMIVIR\n\nPHENOLS\n\nPEMBROLIZUMAB\n\nPEMETREXED\n\nPEMOLINE\n\nPEMPIDINE\n\nPENBUTOLOL\n\nPENCICLOVIR\n\nPENCONAZOLE\n\nPENCYCURON\n\nPENDIMETHALIN\n\nPENETHAMATE\n\nPENFLUFEN\n\nPENICILLAMINE\n\nPENNYROYAL OIL\n\nPENTACHLOROPHENOL\n\nSchedule 7  Schedule 6  Appendix F, clause 4\n\nPENTADECANOIC ACID\n\nPENTAERYTHRITYL TETRANITRATE\n\nPENTAGASTRIN\n\nPENTAMETHONIUM\n\nPENTAMIDINE\n\nPENTAZOCINE\n\nPENTHIENATE\n\nPENTHIOPYRAD\n\nPENTOBARBITONE   cross reference: PENTOBARBITAL\n\nPENTOBARBITAL\n\nSchedule 8  Schedule 4  Appendix D, clause 9  Appendix K, clause 1\n\nPENTOLINIUM\n\nPENTOSAN POLYSULFATE SODIUM\n\nPENTOXIFYLLINE\n\n1‑PENTYL‑3‑(1‑NAPHTHOYL)INDOLE  cross reference: JWH‑018 (CAS No. 209414-07-3)\n\n1‑PENTYL‑3‑(4‑METHYL‑1‑NAPTHOYL)INDOLE  cross reference: JWH‑122 (CAS No. 619294-47-2)\n\nPEPPERMINT OIL\n\nPERACETIC ACID\n\nPERAMPANEL\n\nSchedule 4  Appendix D, clause 5  Appendix K, clause 1\n\nPERFLUIDONE\n\nPERGOLIDE\n\nPERHEXILINE\n\nPERICIAZINE\n\nPERICYAZINE  cross reference: PERICIAZINE\n\nPERINDOPRIL\n\nPERMANGANATES  cross reference: POTASSIUM PERMANGANATE\n\nPERMETHRIN\n\nPERPHENAZINE\n\nPERTUSSIS ANTIGEN\n\nPERTUZUMAB\n\nPETASITES spp.\n\nPETHIDINE\n\nPETROL\n\nPHEDRAZINE\n\nPHENACEMIDE\n\nPHENACETIN\n\nPHENADOXONE\n\ncross reference: CAS No. 467-84-5, PHENADOXONE HYDROCHLORIDE (CAS No. 545-91-5)\n\nPHENAGLYCODOL\n\nPHENAMPROMIDE\n\ncross reference: CAS No. 129-83-9\n\nPHENAZOCINE\n\ncross reference: CAS No. 127-35-5, PHENAZOCINE RACEMATE (CAS No. 58073-76-0), PHENOAZOCINE HYDROBROMIDE (CAS No. 1239-04-9)\n\nPHENAZONE\n\nSchedule 5  Schedule 4  Schedule 2\n\nPHENAZOPYRIDINE\n\nPHENCYCLIDINE  cross reference: PCP (CAS No. 77-10-1), PHENCYCLIDINE HYDROCHLORIDE (CAS No. 956-90-1)\n\nPHENDIMETRAZINE\n\nPHENELZINE\n\nN‑PHENETHYL‑4‑PIPERIDONE\n\ncross reference: CAS No. 39742-60-4\n\nPHENETICILLIN\n\nPHENFORMIN\n\nPHENGLUTARIMIDE\n\nPHENIBUT  cross reference: BETA‑PHENYL‑GAMMA‑AMINOBUTYRIC ACID (CAS No. 1078-21-3), PHENIBUT HYDROCHLORIDE (CAS No. 3060-41-1), PHENIBUT HYDROBROMIDE (CAS No. 103095-38-1)\n\nPHENINDIONE\n\nPHENIRAMINE\n\nPHENISATIN\n\nPHENISOPHAM\n\nPHENMEDIPHAM\n\nPHENMETRAZINE\n\nPHENOBARBITAL\n\nPHENOBARBITONE  cross reference: PHENOBARBITAL\n\nPHENOL  cross reference: CREOSOTE, PHENOLS, TAR, XYLENOLS\n\nSchedule 6  Schedule 5  Schedule 4  Schedule 2  Appendix E, clause 3  Appendix F, clause 4\n\nPHENOLPHTHALEIN\n\nPHENOMORPHAN\n\ncross reference: CAS No. 468-07-5\n\nPHENOPERIDINE\n\nPHENOTHIAZINE\n\nd‑PHENOTHRIN\n\nPHENOXYBENZAMINE\n\n2‑PHENOXYETHANOL\n\nPHENOXYMETHYL OXIRANE\n\nPHENOXYMETHYLPENICILLIN\n\nPHENPROMETHAMINE\n\ncross reference: CAS No. 93-88-9\n\nPHENSUXIMIDE\n\nPHENTERMINE\n\nPHENTHIMENTONIUM\n\nPHENTOLAMINE\n\nPHENYLACETYLINDOLES\n\nPHENYLBUTAZONE\n\nPHENYLENEDIAMINES  cross reference: ALKYLATED, ARYLATED, HALOGENATED and NITRO‑PHENYLENEDIAMINES, DIETHYL‑PARA‑PHENYLENEDIAMINE, DIMETHYL‑PARA‑PHENYLENEDIAMINE\n\nPHENYLEPHRINE  cross reference: CODEINE, IBUPROFEN, PARACETAMOL\n\n1‑PHENYLETHYL‑4‑PHENYL‑4‑PIPERIDINOL ACETATE  cross reference: PEPAP (CAS No. 64-52-8)\n\nPHENYLMERCURIC ACETATE  cross reference: MERCURY\n\nPHENYL METHYL KETONE  cross reference: DESIGNATED SOLVENT\n\no‑PHENYLPHENOL\n\n4‑PHENYLPIPERIDINE‑4‑CARBOXYLIC ACID ETHYL ESTER  cross reference: PETHIDINE INTERMEDIATE B\n\nPHENYL METHYL PYRAZOLONE\n\nPHENYLPIRACETAM  cross reference: RACETAMS\n\nPHENYLPROPANOLAMINE\n\nPHENYLTOLOXAMINE\n\nPHENYTOIN\n\nPHLEUM PRATENSE POLLEN EXTRACT (Timothy‑grass pollen extract)\n\nPHOLCODINE\n\nSchedule 8  Schedule 4  Schedule 2  Appendix K, clause 1\n\nPHORATE\n\nPHOSALONE\n\nPHOSFOLAN\n\nPHOSMET\n\nPHOSPHIDES, METALLIC  cross reference: ALUMINIUM PHOSPHIDE, MAGNESIUM PHOSPHIDE, ZINC PHOSPHIDE\n\nPHOSPHINE\n\nPHOSPHODIESTERASE TYPE 5 INHIBITORS\n\nPHOSPHONIC ACID  cross reference: PHOSPHOROUS ACID\n\nPHOSPHORIC ACID\n\nPHOSPHORUS\n\nPHOSPHORUS, YELLOW\n\nPHOTOGRAPHIC PAPER or FILM\n\nPHOXIM\n\no‑PHTHALADEHYDE\n\no‑PHTHALALDEHYDE\n\nPHTHALALDEHYDE\n\nPHTHALYLSULFATHIAZOLE\n\nPHYSOSTIGMINE\n\nPHYTASE\n\nPIBRENTASVIR\n\nPICARIDIN\n\nPICLORAM\n\nPICOLINAFEN\n\nPICRAMIC ACID (including its salts)  cross reference: 2‑AMINO‑4,6‑DINITROPHENOL\n\nPICRIC ACID\n\nPICROTOXIN\n\nPIGMENTS\n\nPILOCARPINE\n\nPIMECROLIMUS\n\nPIMELIC ACID\n\nPIMINODINE\n\ncross reference: CAS No. 13495-09-5, PIMINODINE DIHYDROCHLORIDE (CAS No. 113862-30-9). PIMINODINE ESILATE (CAS No. 7081-52-9)\n\nPIMOBENDAN\n\nPIMOZIDE\n\nPINACIDIL\n\nPINDOLOL\n\nPINDONE\n\nPINE OILS\n\nPINOXADEN\n\nPIOGLITAZONE\n\nPIPECURONIUM\n\nPIPEMIDIC ACID\n\nPIPENZOLATE\n\nPIPER METHYSTICUM  cross reference: KAVA, KAVALACTONES\n\nPIPERACILLIN\n\nPIPERAZNE\n\nPIPERIDINE\n\nPIPERIDOLATE\n\nPIPERONYL BUTOXIDE\n\nPIPEROPHOS\n\nPIPOBROMAN\n\nPIPOTHIAZINE\n\nPIPRADROL\n\nPIRACETAM\n\nPIRBUTEROL\n\nPIRENOXINE  cross reference: CATALIN\n\nPIRENZEPINE\n\nPIRETANIDE\n\nPIRFENIDONE\n\nPIRIMICARB\n\nPIRIMIPHOS‑ETHYL\n\nPIRIMIPHOS‑METHYL\n\nPIRITRAMIDE\n\nPIROXICAM\n\nPIRPROFEN\n\nPITAVASTATIN\n\nPITUITARY HORMONES\n\nPIVAMPICILLIN\n\nPIZOTIFEN\n\nPLASMID DNA (rE. coli DH5α pINGhT)  cross reference: VACCINES – PLASMID DNA\n\nPLERIXAFOR\n\nPLICAMYCIN\n\nPLITIDEPSIN\n\nPNEUMOCOCCAL VACCINE\n\nPODOPHYLLOTOXIN  cross reference: PODOPHYLLIN\n\nPODOPHYLLUM EMODI   cross reference: PODOPHYLLIN\n\nPODOPHYLLUM PELTATUM  cross reference: PODOPHYLLIN\n\nPODOPHYLLUM RESIN  cross reference: PODOPHYLLIN\n\nPOLIHEXANIDE\n\ncross reference: 1‑(DIAMINOMETHYLIDENE)‑2‑HEXYLGUANIDINE, POLY (IMINOCARBONIMIDOYLIMINOCARBONIMIDOYL IMINO‑1,6‑HEXANEDIYL), POLYHEXAMETHYLENE BIGUANIDE (PHMB)\n\nPOLIOMYELITIS VACCINE\n\nPOLIXETONIUM SALTS\n\nPOLOXALENE\n\nPOLY (GNRF) OVALBUMIN\n\nPOLY DIALLYL DIMETHYL AMMONIUM CHLORIDE  cross reference: POLYDADMAC\n\nPOLY(OXY‑1,2‑ETHANEDIYL), α ‑[2‑[(2‑HYDROXYETHYL)AMINO]‑2‑OXOETHYL]‑ α ‑HYDROXY‑,MONO‑C13‑15‑ALKYL ETHERS\n\nPOLYACRYLAMIDE\n\nPOLYCAPROLACTONE\n\nPOLYESTRADIOL\n\nPOLYETHANOXY (15) TALLOW AMINE\n\nPOLYHEDROSIS VIRUS of Helico zea occlusion bodies\n\nPOLYLACTIC ACID\n\nPOLYMYXIN\n\nPOLYOXIN D ZINC SALT\n\nPOLYSORBATE 20\n\nPOLYSULFATED GLYCOSAMINOGLYCANS\n\nPOLYTHIAZIDE\n\nPOMALIDOMIDE\n\nPONATINIB\n\nPONESIMOD\n\nPORACTANT\n\nPORCELAIN\n\nPORCINE SOMATOTROPHIN\n\nPOSACONAZOLE\n\nPOTASSIUM AZELOYL DIGLYCINATE\n\nPOTASSIUM BICARBONATE\n\nPOTASSIUM BROMATE\n\nPOTASSIUM BROMIDE\n\nPOTASSIUM CHLORATE\n\nSchedule 5  Schedule 2  Appendix E, clause 3\n\nPOTASSIUM CHLORIDE\n\nPOTASSIUM CYANATE\n\nPOTASSIUM HYDROXIDE\n\ncross reference: CAS No. 1310-58-3\n\nPOTASSIUM METABISULPHITE\n\nPOTASSIUM NITRITE\n\nSchedule 7  Schedule 6  Schedule 5  Appendix E, clause 3  Appendix F, clause 4\n\nPOTASSIUM PERCHLORATE\n\nPOTASSIUM PEROXOMONOSULFATE TRIPLE SALT\n\nPOTASSIUM PERSULFATE\n\nPOTASSIUM SORBATE\n\nPOTASSIUM SULFIDE\n\nPRACTOLOL\n\nPRADOFLOXACIN\n\nPRALATREXATE\n\nPRALIDOXIME\n\nPRALLETHRIN\n\nPRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE‑2) (GHRP‑2)\n\nPRALSETINIB\n\nPRAMIPEXOLE\n\nPRAMIRACETAM\n\nPRAMOCAINE\n\nPRAMPINE\n\nPRASTERONE  cross reference: DEHYDROEPIANDROSTERONE, DEHYDROISOANDROSTERONE\n\nPRASUGREL\n\nPRAVASTATIN\n\nPRAZEPAM\n\nPRAZIQUANTEL\n\nPRAZOSIN\n\nPREDNISOLONE\n\nPREDNISONE\n\nPREGABALIN\n\nPREGNENOLONE\n\nPRENALTEROL\n\nPRENYLAMINE\n\nPRILOCAINE\n\nPRIMAQUINE\n\nPRIMIDONE\n\nPRINTING INKS or INK ADDITIVES\n\nPROBENECID\n\nPROBUCOL\n\nPROCAINAMIDE\n\nPROCAINE\n\nPROCAINE BENZYLPENICILLIN\n\nPROCAINE PENICILLIN  cross reference: PROCAINE BENZYLPENICILLIN\n\nPROCARBAZINE\n\nPROCHLORAZ\n\nPROCHLORPERAZINE\n\nPROCYCLIDINE\n\nPROCYMIDONE\n\nPROFENOFOS\n\nPROFOXYDIM\n\nPROGESTERONE\n\nSchedule 5  Schedule 4  Appendix G, clause 1\n\nPROGESTOGENS\n\nPROGLUMIDE\n\nPROGUANIL\n\nPROHEPTAZINE\n\ncross reference: CAS No. 77-14-5\n\nPROHEXADIONE CALCIUM\n\nPROLINTANE\n\nPROMACYL\n\nPROMAZINE\n\nPROMETHAZINE\n\nPROMETRYN\n\nPROMOXOLANE\n\nPROPACHLOR\n\nPROPAFENONE\n\nPROPAMIDINE\n\nPROPAMOCARB\n\nPROPANIDID\n\nPROPANIL\n\nPROPANTHELINE\n\nPROPAQUIZAFOP\n\nPROPARGITE\n\nPROPENTOFYLLINE\n\nPROPERIDINE\n\ncross reference: CAS No. 561-76-2\n\nPROPETAMPHOS\n\nPROPETANDROL\n\nPROPICONAZOLE\n\nPROPINEB\n\nPROPIONIBACTERIUM ACNES\n\nPROPIONIC ACID\n\nPROPIRAM\n\nPROPOFOL\n\nPROPOXUR\n\nPROPRANOLOL\n\nPROPYL ACETATES\n\nn‑PROPYL ALCOHOL\n\nn‑PROPYL NITRITE\n\ncross reference: CAS No. 543-67-9\n\nPROPYLENE GLYCOL\n\n2‑PROPYLENE GLYCOL 1‑MONOMETHYL\n\nPROPYLENE OXIDE\n\nPROPYLHEXEDRINE\n\nPROPYLTHIOURACIL\n\nPROPYPHENAZONE\n\nPROPYZAMIDE\n\nPROQUAZONE\n\nPROQUINAZID\n\nPROSCILLARIDIN\n\nPROSTAGLANDINS\n\nPROSTIANOL\n\nPROSULFOCARB\n\nPROSULFURON\n\nPROTAMINE\n\nPROTHIOCONAZOLE\n\nPROTHIOCONAZOLE‑DESCHLORO\n\nPROTHIOCONAZOLE‑TRIAZOLIDINETHIONE\n\nPROTHIOFOS\n\nPROTHIONAMIDE\n\nPROTHIPENDYL\n\nPROTIRELIN\n\nPROTONITAZENE\n\ncross reference: CAS No. 95958-84-2\n\nPROTOVERATRINES\n\nPROTRIPTYLINE\n\nPROTRIPTYLINE\n\nPROXYMETACAINE\n\nPRUCALOPRIDE\n\nPSEUDOEPHEDRINE\n\nPSEUDOMONAS FLUORESCENS\n\nPSILOCYBINE\n\ncross reference: PSILOCYBIN, CAS No. 520-52-5\n\nSchedule 9  Schedule 8  Appendix D, clause 5  Appendix D, clause 10\n\nPTERIDIUM spp.\n\nd‑PULEGONE\n\nPULMONARIA spp.\n\nPYDIFLUMETOFEN\n\nPYMETROZINE\n\nPYRACLOFOS\n\nPYRACLOSTROBIN\n\nPYRAFLUFEN‑ETHYL\n\nPYRANTEL\n\nPYRASULFOTOLE\n\nPYRAZINAMIDE\n\nPYRAZOLAM\n\ncross reference: CAS No. 39243-02-2\n\nPYRAZOPHOS\n\nPYRETHRINS  cross reference: CHRYSANTHEMIC ACID ESTERS, CINEROLONE, JASMOLONE, PYRETHRIC ACIDS, PYRETHROLONE\n\nPYRIDABEN\n\nPYRIDALYL\n\nPYRIDATE\n\nPYRIDINOLCARBAMATE\n\nPYRIDOSTIGMINE\n\nPYRIDOXAL\n\nPYRIDOXAMINE\n\nPYRIDOXINE\n\nPYRIFENOX\n\nPYRIMETHAMINE\n\nPYRIMETHANIL\n\nPYRINURON\n\nPYRIOFENONE\n\nPYRIPROLE\n\nPYRIPROXYFEN\n\nPYRITHIOBAC SODIUM\n\nPYRITHIONE COPPER\n\nPYRITHIONE ZINC\n\nSchedule 6  Schedule 5  Schedule 2  Appendix E, clause 3\n\nPYROVALERONE\n\nPYROXASULFONE\n\nPYROXSULAM\n\nPYRVINIUM  cross reference: VIPRYNIUMA\n\nQ\n\nQUASSIA\n\nQUATERNARY AMMONIUM COMPOUNDS  cross reference: BENZALKONIUM CHLORIDE, DIALKYL and DIALKOYL QUATERNARY AMMONIUM COMPOUNDS\n\nQUAZEPAM\n\nQUETIAPINE\n\nQUINAGOLIDE\n\nQUINALBARBITONE  cross reference: SECOBARBITAL\n\nQUINAPRIL\n\nQUINBOLONE\n\nQUINCLORAC\n\nQUINETHAZONE\n\nQUINIDINE\n\nQUININE  cross reference: QUININE (CAS No. 130‑95‑0), QUININE SULFATE (1:1) (CAS No. 549‑56‑4), QUININE SULFATE (2:1) (CAS No. 804‑63‑7), QUININE SULFATE (2:1) DIHYDRATE (CAS No. 6119‑70‑6), QUININE SULFATE (1:1) HEPTAHYDRATE (CAS No. 6183‑68‑2), QUININE DIHYDROCHLORIDE (CAS No. 60‑93‑5), QUININE MONOHYDROCHLORIDE (CAS No. 130‑89‑2), QUININE HYDROCHLORIDE DIHYDRATE (CAS No. 6119‑47‑7), QUININE HYDROCHLORIDE (UNSPECIFIED) (CAS No. 7549‑43‑1)\n\nSchedule 7  Schedule 6  Schedule 5  Schedule 4  Appendix F, clause 4\n\nQUINISOCAINE  cross reference: DIMETHISOQUINE\n\nQUINOLINE  cross reference: 2,3‑BENZAPYRIDINE\n\nQUINOXYFEN\n\nQUINTOZENE  cross reference: PENTACHLORONITROBENZENE\n\nQUINUPRISTIN\n\nQUIZALOFOP ETHYL  cross reference: QUIZALOFOP ETHYL (D + ISOMER)\n\nQUIZALOFOP‑p‑ETHYL\n\nQUIZALOFOP‑p‑TEFURYL\n\nR\n\nRABEPRAZOLE\n\nRABIES VACCINE\n\nRACEMETHORPHAN\n\ncross reference: CAS No. 510-53-2\n\nRACEMORAMIDE\n\nRACEMORPHAN\n\ncross reference: CAS No. 297-90-5\n\nRACETAMS\n\nRACTOPAMINE\n\nRADIOGRAPHIC CONTRAST MEDIA  cross reference: RADIOPAQUES\n\nRADIOISOTOPES\n\nRALOXIFENE\n\nRALTEGRAVIR\n\nRALTITREXED\n\nRAMIPRIL\n\nRAMUCIRUMAB\n\nRANIBIZUMAB\n\nRANITIDINE\n\nRANOLAZINE\n\nRAPACURONIUM\n\nRASAGILINE\n\nRASBURICASE\n\nRAUWOLFIA SERPENTINA\n\nRAUWOLFIA VOMITORIA\n\nRAZOXANE\n\nREBOXETINE\n\nRECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN\n\nRED YEAST RICE\n\nREGDANVIMAB\n\nREGORAFENIB\n\nRELUGOLIX\n\nREMIFENTANIL\n\nREMDESIVIR\n\nREMOXIPRIDE\n\nREPAGLINIDE\n\nRESCALURE\n\ncross reference: (3S,6R)‑(3S,6S)‑6‑isopropenyl‑3‑methyldec‑9‑en‑1‑yl acetate\n\nRESERPINE\n\nRESLIZUMAB\n\nRESMETHRIN\n\nRESORCINOL  cross reference: 1,3‑BENZENEDIOL\n\nRETAPAMULIN\n\nRETEPLASE\n\nRETIGABINE\n\nRHIZOBIUM RHIZOGENES\n\nRIBAVIRIN\n\nRIBOCICLIB\n\nRIDAFOROLIMUS\n\nRIFABUTIN\n\nRIFAMPICIN\n\nRIFAMYCIN\n\nRIFAPENTINE\n\nRIFAXIMIN\n\nRILPIVIRINE\n\nRILUZOLE\n\nRIMEGEPANT\n\nRIMEXOLONE\n\nRIMITEROL\n\nRIMONABANT\n\nRIMSULFURON\n\nRIOCIGUAT\n\nSchedule 4  Appendix D, clause 4  Appendix L, clause 2\n\nRIPRETINIB\n\nRISANKIZUMAB\n\nRISDIPLAM\n\nRISEDRONIC ACID\n\nRISPERIDONE\n\nRITODRINE\n\nRITONAVIR\n\nRITUXIMAB\n\nRIVAROXABAN\n\nRIVASTIGMINE\n\nRIZATRIPTAN\n\nROBENACOXIB\n\nROBENIDINE\n\nROFECOXIB\n\nROFLUMILAST\n\nROLICYCLIDINE  cross reference: PCPY, PHP (CAS No. 2201-39-0)\n\nROLITETRACYCLINE\n\nROLZIRACETAM\n\nROMIDEPSIN\n\nROMIFIDINE\n\nROMIPLOSTIM\n\nROMOSOZUMAB\n\nRONIDAZOLE\n\nROPINIROLE\n\nROPIVACAINE\n\nROSEMARY OIL\n\nROSIGLITAZONE\n\nROSIN  cross reference: COLOPHONY\n\nROSOXACIN\n\nROSUVASTATIN\n\nROTENONE  cross reference: CUBE\n\nROTIGOTINE\n\nROXIBOLONE\n\nROXITHROMYCIN\n\nRUBELLA VACCINE\n\nRUBOXISTAURIN\n\nRUFINAMIDE\n\nSchedule 4  Appendix K, clause 1  Appendix L, clause 2\n\nRUPATADINE\n\nRUXOLITINIB\n\nS\n\nSACITUZUMAB GOVITECAN\n\nSACUBITRIL\n\nSAFINAMIDE\n\nSAFLUFENACIL\n\nSAFROLE  cross reference: CAS No. 94-59-7, SASSAFRAS OIL\n\nSAGE OIL  cross reference: DALMATIAN, THUJONE\n\nSAGE OIL (Spanish)  cross reference: CAMPHOR\n\nSALBUTAMOL\n\nSALCATONIN  cross reference: CALCITONIN SALMON\n\nSALICYLAMIDE  cross reference: ASPIRIN, CAFFEINE, PARACETAMOL\n\nSALICYLANILIDE\n\nSALICYLIC ACID  cross reference: CHOLINE SALICYLATE\n\nSALINOMYCIN\n\nSALMETEROL\n\nSALVIA DIVINORUM\n\nSANDALWOOD OIL\n\nSANGUINARIA CANADENSIS (bloodroot)\n\nSANGUINARINE  cross reference: CAS No. 2447-54-3, SANGUINARIA CANADENSIS (bloodroot)\n\nSANTONIN\n\nSAPROPTERIN\n\nSAQUINAVIR\n\nSARILUMAB\n\nSAROLANER\n\nSARS‑COV‑2 (COVID‑19) VACCINE\n\nSASSAFRAS OIL  cross reference: SAFROLE\n\nSAXAGLIPTIN\n\nSCHOENOCAULON OFFICINALE  cross reference: SABADILLA\n\nSCHRADAN\n\nSCOPOLIA CARNIOLICA\n\nSEAWEED\n\nSEBELIPASE ALFA\n\nSECBUTOBARBITAL\n\nSECBUTOBARBITONE  cross reference: SECBUTOBARBITAL\n\nSECOBARBITAL\n\nSECUKINUMAB\n\nSEDAXANE\n\nSEEDS\n\nSELAMECTIN\n\nSELECTIVE ANDROGEN RECEPTOR MODULATORS  cross reference: SARM\n\nSELEGILINE\n\nSELENIUM  cross reference: BARIUM SELENATE, SELENIUM COMPOUNDS, SELENIUM ARSENIDE, SELENIUM SULFIDE\n\nSchedule 7  Schedule 6  Schedule 4  Schedule 2  Appendix E, clause 3  Appendix F, clause 4  Appendix G, clause 1\n\nSELETRACETAM\n\nCross reference RACETAMS\n\nSELEXIPAG\n\nSELINEXOR\n\nSELPERCATINIB\n\nSELUMETINIB\n\nSEMAGLUTIDE\n\nSEMDURAMICIN\n\nSENECIO spp.\n\nSERELAXIN\n\nSERMORELIN\n\nSERTINDOLE\n\nSERTRALINE\n\nSETHOXYDIM\n\nSEVELAMER\n\nSEVOFLURANE\n\nSEX HORMONES\n\nSH‑OLIGOPEPTIDE‑1, RH‑OLIGOPEPTIDE‑1  cross reference: EPIDERMAL GROWTH FACTOR\n\nSIBUTRAMINE\n\nSIDURON\n\nSILANDRONE\n\nSchedule 4  Appendix D, clause 5 (Anabolic steroidal agent)\n\nSILDENAFIL\n\nSILICOFLUORIDES  cross reference: BARIUM SILICOFLUORIDE, FLUORIDES, FLUOROSILICATES, HEXAFLUOROSILICATES MAGNESIUM FLUOSILICATE,\n\nSILICONES\n\nSchedule 10  Schedule 4  Appendix F, clause 4\n\nSILODOSIN\n\nSILTUXIMAB\n\nSILVER\n\nSILVER NITRATE  cross reference: SILVER SALTS\n\nSILVER OXIDE\n\nSILVER SULFADIAZINE\n\nSIMAZINE\n\nSIMEPREVIR\n\nSIMVASTATIN\n\nSINBIOALLETHRIN\n\nSINGLE‑USE TUBES\n\nSIPONIMOD\n\nSIROLIMUS\n\nSISOMICIN\n\nSITAGLIPTIN\n\nSITAXENTAN\n\nSLIMICIDES\n\nSODIUM ALUMINATE\n\nSODIUM BICARBONATE\n\nSODIUM BROMATE\n\nSODIUM BROMIDE\n\nSODIUM CELLULOSE PHOSPHATE\n\nSODIUM CHLORATE\n\nSODIUM CROMOGLYCATE\n\nSODIUM DIACETATE\n\nSODIUM DICHLOROISOCYANURATE\n\nSODIUM DODECYLBENZENE SULFONATE\n\nSchedule 5  Appendix E, clause 3, Part   Appendix F, clause 4\n\nSODIUM FLUORIDE\n\nSODIUM GLYCEROPHOSPHATE HYDRATE\n\nSODIUM HYDROGEN SULFATE\n\nSODIUM HYDROSULFITE\n\nSODIUM HYDROXIDE  cross reference: CAS No. 1310-73-2, LYE WATER\n\nSODIUM LAURETH‑6 CARBOXYLATE\n\nSODIUM METABISULPHITE\n\nSODIUM MORRHUATE\n\nSODIUM NITRITE\n\nSchedule 7  Schedule 6  Schedule 5  Schedule 2  Appendix E, clause 3  Appendix F, clause 4\n\nSODIUM NITROPRUSSIDE\n\nSODIUM OXYBATE\n\nSchedule 8  Appendix D, clause 1  Appendix K, clause 1\n\nSODIUM PERCARBONATE\n\nSODIUM PERSULFATE\n\nSODIUM PHENYLBUTYRATE\n\nSODIUM PHOSPHATE\n\nSODIUM PICOSULFATE\n\nSODIUM POLYSTYRENE SULPHONATE\n\nSODIUM PROPIONATE\n\nSODIUM SALICYLATE\n\nSODIUM STANNATE\n\nSchedule 5,   Appendix E, clause 3\n\nSODIUM SULFIDE\n\nSODIUM TETRADECYLSULFATE\n\nSODIUM TRICHLOROACETATE\n\nSODIUM ZIRCONIUM CYCLOSILICATE.\n\nSODIUMHYDROSULFITE\n\nSOFOSBUVIR\n\nSOLASODINE\n\nSOLIFENACIN\n\nSOMAPACITAN\n\nSOMATOSTATIN\n\nSOMATOTROPIN EQUINE\n\nSOMATROPIN  cross reference: HUMAN GROWTH HORMONE\n\nSONIDEGIB\n\nSONTOQUINE\n\nSORAFENIB\n\nSOTALOL\n\nSOTORASIB\n\nSOTROVIMAB\n\nSPARFLOXACIN\n\nSPARTEINE\n\nSPECTINOMYCIN\n\nSPESOLIMAB\n\nSPINETORAM\n\nSPINOSAD\n\nSPIRAMYCIN\n\nSPIRAPRIL\n\nSPIROMESIFEN\n\nSPIRONOLACTONE\n\nSPIROPIDION\n\nSPIROTETRAMAT\n\nSPIROXAMINE\n\nSQUILL\n\nSTANOLONE\n\nSTANOZOLOL\n\nSTAR ANISE OIL\n\nSTAVUDINE\n\nSTENABOLIC (SR9009) and other synthetic REV‑ERB agonists  cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667\n\nSTENBOLONE\n\nSTERIC ACID\n\nSTEROID HORMONES\n\nSTILBESTROL  cross reference: STILBOESTROL, DIETHYLSTILBESTROL\n\nSTIRIPENTOL\n\nSTREPTODORNASE\n\nSTREPTOKINASE\n\nSTREPTOMYCES LYDICUS WYEC 108\n\nSTREPTOMYCIN\n\nSTRONTIUM RANELATE\n\nSTROPHANTHINS\n\nSTROPHANTHUS spp.\n\nSTRYCHNINE  cross reference: NUX VOMICA\n\nSchedule 7  Schedule 4  Appendix E, clause 3  Appendix G, clause 1  Appendix J, clause 1\n\nSTRYCHNOS spp.\n\nSTYRAMATE\n\nSTYRENE  cross reference: DESIGNATED SOLVENT\n\nSUCCIMER\n\nSUCRALFATE\n\nSUCROFERRIC OXYHYDROXIDE\n\nSUFENTANIL\n\nSUGAMMADEX\n\nSULBACTAM\n\nSULCOFURON\n\nSchedule 7  Schedule 6  Appendix E, clause 3  Appendix J, clause 1\n\nSULCONAZOLE\n\nSULESOMAB\n\nSULFACETAMIDE\n\nSchedule 5  Schedule 4  Schedule 3\n\nSULFADIAZINE\n\nSULFADIMETHOXINE\n\nSULFADIMIDINE\n\nSULFADOXINE\n\nSULFAFURAZOLE\n\nSULFAGUANIDINE\n\nSULFAMERAZINE\n\nSULFAMETHIZOLE\n\nSULFAMETHOXAZOLE\n\nSULFAMETHOXYDIAZINE\n\nSULFAMETHOXYPYRIDAZINE\n\nSULFAMETROLE\n\nSULFAMIC ACID\n\nSULFAMONOMETHOXINE\n\nSULFAMOXOLE\n\nSULFAPHENAZOLE\n\nSULFAPYRIDINE\n\nSULFAQUINOXALINE\n\nSULFASALAZINE\n\nSULFATHIAZOLE\n\nSULFATROXAZOLE\n\nSULFENTRAZONE\n\nSULFINPYRAZONE\n\nSULFLURAMID\n\nSULFOMETURON‑METHYL\n\nSULFOMYXIN\n\nSULFONAMIDES  cross reference: SULFACETAMIDE, SULPHANILAMIDE\n\nSULFONMETHANE  cross reference: ALKYL SULFONALS, SULFONAL\n\nSULFOSULFURON\n\nSULFOTEP\n\nSULFOXAFLOR\n\nSULFURIC ACID\n\nSULFURYL FLUORIDE\n\nSULINDAC\n\nSULPHATED POLYSACCHARIDES\n\nSULPROFOS\n\nSULTAMICILLIN\n\nSULTHIAME\n\nSUMATRIPTAN\n\nSUNIFIRAM\n\nSUNITINIB\n\nSUPROFEN\n\nSUTILAINS\n\nSUVOREXANT\n\nSUXAMETHONIUM\n\nSUXETHONIUM\n\nSYMPHYTUM spp.  cross reference: COMFREY\n\nSchedule 10  Schedule 5  Appendix F, clause 4\n\nSYNTHETIC CANNABINOMIMETICS\n\nT\n\n2,4,5‑T\n\nTACRINE\n\nTACROLIMUS\n\nTADALAFIL\n\nTAFAMIDIS\n\nTAFASITAMAB\n\nTAFENOQUINE SUCCINATE\n\nTAFLUPROST\n\nTAGRAXOFUSP\n\nTALAZOPARIB\n\nTALIGLUCERASE ALFA\n\nTALIMOGENE LAHERPAREPVEC\n\nTALLOW ALKYLAMINE ACETATES\n\nN‑TALLOW ALKYL‑1,3‑PROPANEDIAMINE DIACETATE\n\nTAMOXIFEN\n\nTAMSULOSIN\n\nTANACETUM VULGARE  cross reference: OIL OF TANSY, TANSY OIL\n\nTANNIC ACID\n\nTANNIC ACID/BENZYL ALCOHOL PRODUCT\n\nTAPENTADOL\n\nTAR ACIDS\n\nTASONERMIN\n\nTAZAROTENE\n\nTAZOBACTAM\n\nTB‑500\n\nSchedule 4   Appendix D, clause 5\n\n2,3,6‑TBA\n\nT‑CELL RECEPTOR ANTIBODY\n\nTCMTB  cross reference: 2‑[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE\n\nTDE   cross reference: 1,1‑DICHLORO‑2,2‑BIS[4‑CHLOROPHENYL]ETHANE\n\nTEBENTAFUSP\n\nTEBUCONAZOLE  cross reference: TERBUCONAZOLE\n\nTEBUFENOZIDE\n\nTEBUFENPYRAD\n\nTEBUTHIURON\n\nTECLISTAMAB\n\nTEDUGLUTIDE\n\nTEFLUTHRIN\n\nTEGAFUR\n\nTEGASEROD\n\nTEICOPLANIN\n\nTELAPREVIR\n\nTELBIVUDINE\n\nTELITHROMYCIN\n\nTELMISARTAN\n\nTELOTRISTAT ETHYL\n\nTEMAZEPAM\n\nTEMEPHOS\n\nTEMOZOLOMIDE\n\nTEMSIROLIMUS\n\nTENECTEPLASE\n\nTENIPOSIDE\n\nTENOCYCLIDINE  cross reference: TCP (CAS No. 21500-98-1)\n\nTENOFOVIR\n\nTENOXICAM\n\nTEPOTINIB\n\nTEPOXALIN\n\nTEPP\n\nTEPRALOXYDIM\n\nTERAZOSIN\n\nTERBACIL\n\nAppendix B, clause 3,Part 3\n\nTERBINAFINE\n\nTERBUFOS\n\nTERBUTALINE\n\nTERBUTHYLAZINE\n\nTERBUTRYN\n\nTERFENADINE\n\nTERIFLUNOMIDE\n\nTERIPARATIDE\n\nTERLIPRESSIN\n\nTERMITE BARRIERS\n\nTERODILINE\n\nTEROPTERIN\n\nTERPENES, CHLORINATED  cross reference: CHLORINATED TERPENES\n\nTESTOLACTONE\n\nTESTOSTERONE\n\nSchedule 6  Schedule 4  Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)  Appendix G, clause 1\n\nTETANUS ANTITOXIN\n\nTETANUS TOXOID\n\n1,3,5,7‑TETRAAZATRICYLO[3.3.1.13,7] DECANE  cross reference: HEXAMINE, HEXAMETHYLENETETRAMINE, METHENAMINE\n\nTETRABENAZINE\n\nTETRACAINE   cross reference: AMETHOCAINE\n\nSchedule 4   Schedule 2\n\nTETRACHLOROETHANE\n\nTETRACHLOROETHYLENE  cross reference: DESIGNATED SOLVENT\n\nTETRACHLORVINPHOS\n\nTETRACONAZOLE\n\nTETRACOSACTIDE\n\nTETRACOSACTRIN  cross reference: TETRACOSACTIDE\n\nTETRACYCLINE\n\nTETRADIFON\n\nTETRAETHYLAMMONIUM\n\nTETRAHYDROCANNABINOLIC ACID  cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS\n\nTETRAHYDROCANNABINOLS  cross reference: CANNABIS, HEMP SEED OIL, NABIXIMOLS\n\nSchedule 9  Schedule 8  Appendix D, clause 1  Appendix K, clause 1\n\nTETRAHYDROCANNABIDIVAROL  cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS\n\nTETRAHYDROFURFURYL ALCOHOL\n\nTETRAHYDROZOLINE  cross reference: TETRYZOLINE\n\n2,2',6,6'‑TETRAISOPROPYL‑DIPHENYL‑CARBODIIMIDE  cross reference: STABAXOL\n\nSchedule 6  Appendix J, clause 1\n\nTETRAMETHRIN\n\nTETRAMISOLE\n\nTETRANILIPROLE\n\nTETROXOPRIM\n\nTETRYZOLINE  cross reference: TETRAHYDROZOLINE\n\nTEZACAFTOR\n\nTHALIDOMIDE\n\nTHALLIUM  cross reference: THALLIUM SULFATE\n\nTHAUMATIN\n\nTHEBACON\n\nTHEBAINE\n\nTHENYLDIAMINE\n\nTHEOPHYLLINE\n\nTHEVETIA PERUVIANA\n\nTHEVETIN\n\nTHIABENDAZOLE\n\nTHIACETARSAMIDE\n\nTHIACLOPRID\n\nTHIAMBUTOSINE\n\nTHIAMETHOXAM\n\nTHIAZAFLURON\n\nTHIAZOPYR\n\nTHIAZOSULFONE\n\nTHIDIAZURON\n\nTHIETHYLPERAZINE\n\nTHIFENSULFURON\n\nTHIOACETAZONE\n\nTHIOBENCARB\n\nTHIOCARLIDE\n\nTHIODICARB\n\nTHIOFANOX\n\nTHIOFENTANYL\n\ncross reference: CAS No. 1165-22-6\n\nTHIOGUANINE  cross reference: TIOGUANINE\n\nTHIOMESTERONE  cross reference: TIOMESTERONE\n\nTHIOMETON\n\nTHIOPENTAL\n\nTHIOPENTONE  cross reference: THIOPENTAL\n\nTHIOPHANATE‑METHYL\n\nTHIOPROPAZATE\n\nTHIOPROPERAZINE\n\nTHIORIDAZINE\n\nTHIOSTREPTON\n\nTHIOTEPA  cross reference: TRIETHYLENE THIOPHOSPHORAMIDE\n\nTHIOTHIXENE\n\nTHIOURACIL\n\nTHIOUREA  cross reference: ALKYL THIOUREAS\n\nTHIRAM\n\nTHUJONE\n\nTHYME OIL\n\nTHYMOL\n\nTHYMOSIN BETA 4 (THYMOSIN β4)\n\nTHYMOXAMINE\n\nTHYROID\n\nTHYROTROPHIN  cross reference: TSH\n\nTHYROXINE\n\nTIAFENACIL\n\nTIAGABINE\n\nTIAMULIN\n\nTIANEPTINE\n\nTIAPROFENIC ACID\n\nTIARAMIDE\n\nTIBOLONE\n\nTICAGRELOR\n\nTICARCILLIN\n\nTICLOPIDINE\n\nTIEMONIUM\n\nTIENILIC ACID\n\nTIGECYCLINE\n\nTIGILANOL TIGLATE\n\nTIGLOIDINE\n\nTIGOLANER\n\nTILDIPIROSIN\n\nTILETAMINE\n\nTILIDINE\n\nTILMANOCEPT\n\nTILMICOSIN\n\nTILUDRONIC ACID  cross reference: DISODIUM TILUDRONATE\n\nTIMBER  cross reference: WALLBOARD\n\nTIMOLOL\n\nTIMOTHY‑GRASS POLLEN EXTRACT   cross reference: PHLEUM PRATENSE POLLEN EXTRACT\n\nTIN ORGANIC COMPOUNDS  cross reference: DIALKYL TIN COMPOUNDS, DIBUTYL TIN COMPOUNDS, DIETHYL TIN COMPOUNDS, DIMETHYL TIN DICHLORIDE, DIMETHYL TIN COMPOUNDS, DIPROPYL TIN COMPOUNDS, FENBUTATIN OXIDE, ORGANO TIN‑COMPOUNDS, TBTO, TRIALKYL TIN COMPOUNDS, TRIBUTYL TIN COMPOUNDS, TRIETHYL TIN COMPOUNDS, TRIMETHYL TIN COMPOUNDS, TRIPHENYL TIN COMPOUNDS, TRIPROPYL TIN COMPOUNDS\n\nTINIDAZOLE\n\nTINZAPARIN\n\nTIOCARBAZIL\n\nTIOCONAZOLE\n\nSchedule 4  Schedule 3  Schedule 2\n\nTIOGUANINE  cross reference: THIOGUANINE\n\nTIOTROPIUM\n\nTIPEPIDINE\n\nTIPIRACIL\n\nTIPRANAVIR\n\nTIRBANIBULIN\n\nTIRILAZAD\n\nTIROFIBAN\n\nTIRZEPATIDE\n\nTISLELIZUMAB\n\nTIXAGEVIMAB\n\nTOBRAMYCIN\n\nTOCAINIDE\n\nTOCERANIB\n\nTOCILIZUMAB\n\nTOFACITINIB\n\nTOLAZAMIDE\n\nTOLAZOLINE\n\nTOLBUTAMIDE\n\nTOLCAPONE\n\nTOLCLOFOS‑METHYL\n\nTOLFENAMIC ACID\n\no‑TOLIDINE\n\nSchedule 7  Appendix E, clause 3  Appendix J, clause 1\n\nTOLMETIN\n\nTOLONIUM\n\nTOLPROPAMINE\n\nTOLRESTAT\n\nTOLTERODINE\n\nTOLTRAZURIL\n\nTOLUENE  cross reference: XYLENE\n\n2,4‑TOLUENEDIAMINE\n\ncross reference: CAS No. 95-80-7\n\nTOLUENEDIAMINES\n\no‑TOLUIDINE\n\ncross reference: CAS No. 95-53-4\n\nTOLVAPTAN\n\nTOLYLFLUANID\n\nTOPIRAMATE\n\nTOPOTECAN\n\nTOPRAMEZONE\n\nTORASEMIDE\n\nTOREMIFENE\n\nTOXOIDS\n\nTRABECTEDIN\n\nTRALKOXYDIM\n\nTRAMADOL\n\nTRAMAZOLINE\n\nTRAMETINIB DIMETHYL SULFOXIDE\n\nTRANDOLAPRIL\n\nTRANEXAMIC ACID   cross reference: CETYL TRANEXAMATE\n\nTRANSFLUTHRIN\n\nTRANYLCYPROMINE\n\nTRASTUZUMAB\n\nTRASTUZUMAB DERUXTECAN\n\nTRASTUZUMAB EMTANSINE\n\nTRAVOPROST\n\nTRAZODONE\n\nTRENBOLONE  cross reference: TRIENBOLONE, TRIENOLONE\n\nSchedule 5  Schedule 4  Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)\n\nTREOSULPHAN\n\nTREPROSTINIL\n\nTRESTOLONE\n\nSchedule 4  Appendix D, clause 5 (androgenic steroidal agents)\n\nTRETAMINE\n\nTRETINOIN\n\nTRIACETYLOLEANDOMYCIN\n\nTRIADIMEFON\n\nTRIADIMENOL\n\nTRI‑ALLATE\n\nTRIAMCINOLONE\n\nSchedule 4  Schedule 3  Schedule 2  Appendix F, clause 4, Part 2\n\nTRIAMIPHOS\n\nTRIAMTERENE\n\nTRIASULFURON\n\nTRIAZBUTIL\n\nTRIAZIQUONE\n\nTRIAZOLAM\n\nTRIBENURON‑METHYL\n\nTRIBUFOS  cross reference: s,s,s‑TRIBUTYLPHOSPHOROTRITHIOATE\n\nTRICHLORFON  cross reference: METRIFONATE\n\nTRICHLORMETHIAZIDE\n\nTRICHLOROACETIC ACID\n\nSchedule 6  Schedule 5  Schedule 4  Appendix E, clause 3  Appendix F, clause 4\n\nTRICHLOROACETIC ACID ALKALI SALTS\n\n1,1,1‑TRICHLOROETHANE   cross reference: CAS No. 71-55-6, DESIGNATED SOLVENT\n\nSchedule 10  Schedule 5  Appendix E, clause 3  Appendix F, clause 4\n\nTRICHLOROETHYLENE  cross reference: TRICHLOROETHENE\n\nTRICHLOROISOCYANURIC ACID  cross reference: CHLORINATING COMPOUNDS\n\nTRICHLOROPHENOL\n\nTRICHODERMA HARZIANUM\n\nTRICHODESMA AFRICANA\n\nTRICLABENDAZOLE\n\nTRICLOFOS\n\nTRICLOPYR\n\nTRICLOSAN\n\nTRICYCLAMOL\n\nTRIDEMORPH\n\nTRIDIHEXETHYL\n\nTRIDIPHANE\n\nTRIENTINE\n\nTRIETAZINE\n\nTRIETHANOLAMINE  cross reference: TROLAMINE\n\nTRIETHYL PHOSPHATE\n\nTRIETHYLENE GLYCOL\n\nTRIFAROTENE\n\nTRIFLOXYSTROBIN\n\nTRIFLOXYSULFURON\n\nTRIFLUDIMOXAZIN\n\nTRIFLUMIZOLE\n\nTRIFLUMURON\n\nTRIFLUOPERAZINE\n\nTRIFLUOROMETHANESULFONIC ACID\n\n1‑(3‑TRIFLUOROMETHYLPHENYL)PIPERAZINE  cross reference: TFMPP (CAS No. 15532-75-9), TFMPP HYDROCHLORIDE (CAS No. 16015-69-3)\n\nTRIFLUPERIDOL\n\nTRIFLUPROMAZINE\n\nTRIFLURALIN\n\nTRIFLURIDINE\n\nTRIFORINE\n\nTRIHEXYPHENIDYL  cross reference: BENZHEXOL\n\nTRIISOPROPANOLAMINE LAURYL ETHER SULFATE\n\nTRILOSTANE\n\nTRIMEPERIDINE\n\ncross reference: CAS No. 29606-10-8\n\nTRIMEPRAZINE  cross reference: ALIMEMAZINE\n\nTRIMETAPHAN\n\nTRIMETHOPRIM\n\n3,4,5‑TRIMETHOXY‑ α –METHYLPHENYLETHYLAMINE  cross reference: TMA (CAS No. 1082-88-8), TMA HYDROCHLORIDE (CAS No. 5688-80-2)\n\n3,4,5‑TRIMETHOXYPHENETHYLAMINE  cross reference: MESCALINE, METHOXYPHENAMINE, METHOXY‑PHENYLETHYLAMINE (CAS No. 54-04-6), MESCALINE HYDROCHLORIDE (CAS No. 832-92-8), MESCALINE HYDROGEN SULFATE (CAS No. 5967-42-0), MESCALINE HEMISULFATE (CAS No. 642-73-9)\n\n1‑(3,4,5‑TRIMETHOXYPHENYL)‑2‑AMINOBUTANE\n\ncross reference: CAS No. 17097-73-3\n\nTRIMIPRAMINE\n\nTRIMUSTINE\n\nTRINEXAPAC‑ETHYL\n\nTRINITROPHENOL\n\n3,6,9‑TRIOXAUNDECANEDIOIC ACID\n\nTRIOXYSALEN\n\nTRIPARANOL\n\ncross reference: CAS No. 78-41-1\n\nTRIPELENNAMINE\n\nTRIPLE ANTIGEN VACCINE\n\ncross reference: DIPHTHERIA TOXOID, PERTUSSIS ANTIGEN, TETANUS TOXOID\n\nTRIPROLIDINE\n\nTRIPTORELIN\n\nTRISODIUM NITRILOTRIACETATE\n\nTRITICONAZOLE\n\nTROGLITAZONE\n\nTROLAMINE\n\nSchedule 5  Schedule 4  Appendix E, clause 3  Appendix F, clause 4\n\nTROMETAMOL\n\nTROPICAMIDE\n\nTROPISETRON\n\nTROVAFLOXACIN\n\nTROXIDONE\n\nTRYPTOPHAN\n\nTUAMINOHEPTANE\n\nTUCATINIB\n\nTUBERCULIN\n\nTUBOCURARINE\n\nTULATHROMYCIN\n\nTULOBUTEROL\n\nTURPENTINE OIL  cross reference: OIL OF TURPENTINE\n\nTUSSILAGO FARFARA  cross reference: COLTSFOOT\n\nTYLOSIN\n\nTYMAZOLINE\n\nTYPHOID VACCINE\n\nU\n\nULIPRISTAL\n\nULOCLADIUM OUDEMANSII\n\nUMECLIDINIUM\n\nUNIFIRAM\n\nUNOPROSTONE\n\nUPADACITINIB\n\nURACIL\n\nURAPIDIL\n\nUREA\n\nURETHANE\n\nUROFOLLITROPIN  cross reference: FOLLICLE‑STIMULATING HORMONE, HUMAN\n\nUROKINASE\n\nURSODEOXYCHOLIC ACID\n\nUSTEKINUMAB\n\nV\n\nVACCINES\n\nVACCINES – PLASMID DNA  cross reference: PLASMID DNA (rE. coli DH5α pINGhT)\n\nVACCINIA VIRUS VACCINE\n\nVADADUSTAT\n\nSchedule 4  Appendix D, clause 5\n\nVALACICLOVIR\n\nVALDECOXIB\n\nVALGANCICLOVIR\n\nVALNOCTAMIDE\n\nVALPROIC ACID\n\nVALSARTAN\n\nVAMIDOTHION\n\nVANCOMYCIN\n\nVANDETANIB\n\nVARDENAFIL\n\nVARENICLINE\n\nVARICELLA VACCINE\n\nVARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN (RECOMBINANT)\n\ncross reference: RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN\n\nVASOPRESSIN\n\nVECURONIUM\n\nVEDAPROFEN\n\nVEDOLIZUMAB\n\nVELAGLIFLOZIN\n\nVELAGLUCERASE ALFA\n\nVELPATASVIR\n\nVEMURAFENIB\n\nVENETOCLAX\n\nVENLAFAXINE\n\nVERAPAMIL\n\nVERATRUM\n\nVERICIGUAT\n\nVERNAKALANT\n\nVERNOLATE\n\nVERTEPORFIN\n\nVETIVER OIL\n\nVIDARABINE\n\nVIGABATRIN\n\nVILANTEROL\n\nVILDAGLIPTIN\n\nVILOXAZINE\n\nVINBLASTINE\n\nVINCAMINE\n\nVINCLOZOLIN\n\nVINCRISTINE\n\nVINDESINE\n\nVINFLUNINE\n\nVINORELBINE\n\nVINYL ACETATE MONOMER\n\nVINYL CHLORIDE\n\nVINYL ETHER\n\nVIRGINIAMYCIN\n\nVISMODEGIB\n\nVISNADINE\n\nVITAMIN A\n\nVITAMIN D  cross reference: COLECALCIFEROL, ERGOCALCIFEROL\n\nVITAMIN K  cross reference: PHYTOMENADIONE\n\nVITREOUS ENAMELS\n\nVORAPAXAR\n\nVORETIGENE NEPARVOVEC\n\nVORICONAZOLE\n\nVORINOSTAT\n\nVORTIOXETINE\n\nVOSORITIDE\n\nVOXILAPREVIR\n\nW\n\nWALLBOARD  cross reference: TIMBER\n\nWARFARIN\n\nWRITING CORRECTION PENS\n\nX\n\nXAMOTEROL\n\nXANTHINOL NICOTINATE\n\nXANTHOPHYLL  cross reference: LUTEIN\n\nXIMELAGATRAN\n\nXIPAMIDE\n\nXYLANASE derived from Aspergillus niger\n\nXYLAZINE\n\nXYLENE  cross reference: TOLUENE\n\nXYLOMETAZOLINE\n\nY\n\nYLANG YLANG OIL\n\nYOHIMBINE  cross reference: ASPIDOSPERMA QUEBRACHO\n\nZ\n\n(Z)‑9‑TRICOSENE  cross reference: TRICOSENE\n\nZAFIRLUKAST\n\nZALCITABINE\n\nZALEPLON\n\nZANAMIVIR\n\nZANUBRUTINIB\n\nZERANOL\n\nZETA‑CYPERMETHRIN\n\nZIDOVUDINE\n\nZILPATEROL\n\nZILUCOPLAN\n\nZIMELDINE\n\nZINC BORATE\n\nZINC CHLORIDE\n\nZINC COMPOUNDS\n\nZINC LACTATE\n\nZINC NAPHTHENATE\n\nZINC para‑PHENOLSULFONATE\n\nZINC SULFATE\n\nZINEB  cross reference: DITHIOCARBAMATES, MANCOZEB, PROPINEB, THIRAM\n\nZIPRASIDONE\n\nZIRAM\n\nZOLAZEPAM\n\nZOLEDRONIC ACID\n\nZOLMITRIPTAN\n\nZOLPIDEM\n\nZONISAMIDE\n\nZOPICLONE\n\nZOXAZOLAMINE\n\nZUCLOPENTHIXOL\n\n---\n\n[[1]](#_ftnref1) “Cultivation”, “production” and “manufacture” have the same meaning as in the Narcotic Drugs Act 1967\n","sortOrder":85}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":2311},"content_quality":"ok","complexity_score":9,"scope_assessment":{"changed":false,"description":"This instrument maintains the existing comprehensive poisons classification framework established under the Therapeutic Goods Act 1989. It represents a routine update to the Poisons Standard (replacing the February 2024 version) and does not expand beyond the original legislative intent of providing uniform national scheduling of medicines and poisons."},"complexity_factors":["10 hierarchical schedules with distinct regulatory controls that interact with each other","13 appendices (A-M) containing specific exemptions, additional restrictions, and technical specifications","Over 50 defined terms in section 6, including complex chemical classifications and cross-references to external standards","Thousands of substance-specific entries with varying concentration thresholds (e.g., 'containing 2% or less' vs 'containing 10 mg or less per dosage unit')","Nested conditional logic with multiple layers of exceptions ('except when included in Schedule X', 'unless in preparations containing Y%')","Detailed technical specifications for labelling (letter heights, font types, colour contrasts) and packaging (child-resistant closure standards)","Different regulatory treatment for human therapeutic use, veterinary use, and agricultural/industrial use for the same substance","Integration with multiple external legislative schemes (Therapeutic Goods Orders, Agricultural and Veterinary Chemicals Code, Australian Standards)"],"plain_english_summary":"The Poisons Standard is Australia’s national rulebook that classifies chemicals, medicines and pesticides into schedules to set how they’re labelled, packaged, stored, supplied and advertised. It determines who may sell or prescribe substances and what safety controls apply.\n\nIt affects pharmacists, doctors, vets, manufacturers, farmers and retailers. The Standard reduces accidental poisoning, limits misuse of addictive drugs, and keeps highly toxic substances restricted while allowing legitimate access."}},"importantCases":[],"_links":{"self":"/api/acts/therapeutic-goods-poisons-standard-june-2024-instrument-2024","history":"/api/acts/therapeutic-goods-poisons-standard-june-2024-instrument-2024/history","analysis":"/api/acts/therapeutic-goods-poisons-standard-june-2024-instrument-2024/analysis","conflicts":"/api/acts/therapeutic-goods-poisons-standard-june-2024-instrument-2024/conflicts","importantCases":"/api/acts/therapeutic-goods-poisons-standard-june-2024-instrument-2024/important-cases","documents":"/api/acts/therapeutic-goods-poisons-standard-june-2024-instrument-2024/documents"}}